{"title": "Clinical Trials", "author": null, "url": "https://www.mayo.edu/research/clinical-trials/tests-procedures/cancer-treatment/", "hostname": "mayo.edu", "description": null, "sitename": null, "date": "2019-06-19", "cleaned_text": "- [Institutional Analysis of Non-metastatic Pancreatic Adenocarcinoma Outcomes from 2011-2016](/research/clinical-trials/cls-20506984) No Locations The purpose of this study is to evaluate survival of patients with resectable, borderline resectable pancreatic cancer (BRPC) and locally advanced pancreatic cancer (LAPC) separately and as a group. - [A Study to See if the Depth of Tumor Invasion of Esophageal Carcinoma Predicts Lymph Node Involvement and Cancer Free Survival](/research/clinical-trials/cls-20502362) Rochester, MN The purpose of this study is to see if different depths of submucosal tumor invasion in esophageal cancer can predict lymph node involvement and survival. - [A Study to Evaluate Intravenous Ascorbic Acid (Vitamin C) as an Adjunct to Pazopanib in the First-Line or Post-immunotherapy Setting for Metastatic or Unresectable Clear Cell Renal Cell Carcinoma (ccRCC)](/research/clinical-trials/cls-20425295) Rochester, MN This randomized phase II trial studies how well pazopanib hydrochloride with or without ascorbic acid work in treating patients with kidney cancer that has spread to other places in the body or cannot be removed by surgery. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ascorbic acid may help pazopanib hydrochloride stop tumor growth and improve treatment survival. Giving pazopanib hydrochloride and ascorbic acid may work better in treating patients with kidney cancer. - [Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients EGFR Wild-type Advanced Non-small Cell Lung Cancer](/research/clinical-trials/cls-20260186) Rochester, MN A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280. - [A Study of X4P-001 in Patients with Advanced Renal Cell Carcinoma](/research/clinical-trials/cls-20193947) Scottsdale/Phoenix, AZ The purpose of the study is to test different doses of X4P-001 given alone and in combination with axitinib in patients diagnosed with advanced renal cell carcinoma. The goals of the study are to determine the safety and tolerability of X4P-001, as well as the potential effect it may have on the body and the cancer tumor. - [A Study to Assess Dynamic Changes in Plasma Proteome to Identify Early Detection and Treatment Response Biomarkers for HGSOC](/research/clinical-trials/cls-20523448) Rochester, MN This study aims to identify candidate High Grade Serous Cancer (HGSC) early detection and chemotherapy treatment response biomarkers. For the purpose of this study we define high grade serous cancers to include invasive cancers arising in the ovary and/or fallopian tubes (FT). Using mass spectrometry we will deeply profile and quantitate dynamic changes in the plasma proteome and N-gylcocapture sub-proteome that occur as a consequence of surgical debulking and platinum-based chemotherapy. - [Study of Oral LOXO-338 in Patients With Advanced Blood Cancers](/research/clinical-trials/cls-20525382) Jacksonville, FL; Rochester, MN The purpose of this study is to find out whether the study drug, LOXO-338, is safe and effective in patients with advanced blood cancer. Patients must have already received standard therapy. The study may last up to approximately 3 years. - [A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression](/research/clinical-trials/cls-20116719) Rochester, MN The purpose of this study is to obtain an estimate of the biochemical response rate as determined by CA125 response using the Gynecologic Cancer Intergroup (GCIG) response criteria of PD0332991 in patients with recurrent ovarian epithelial carcinoma. CA125 response is defined as 50% decrease from the baseline CA125 level and confirmed 21 days after initial evaluation (baseline is defined as the higher value of 2 pre-treatment CA125 assessments). - [A Study to Explore Cancer Patient Experiences and Their Decisions About Sharing Genetic Cancer Screening Information with Family Members](/research/clinical-trials/cls-20509124) Rochester, MN The purpose of this study is to characterize the beliefs and attitudes of cancer patients who received a positive result from a genetic cancer screen as part of the Mayo Clinic Intercept study (IRB#18-000326, PI: Samadder). This data will be collected using semi-structured, one-on-one interviews. - [A Study of SC-007 in Subjects With Advanced Cancer](/research/clinical-trials/cls-20400608) No Locations This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC followed by Part A in participants with gastric cancer. Part B (dose expansion) will enroll participants into separate disease specific cohorts of CRC or gastric cancer. - [Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)](/research/clinical-trials/cls-20529145) Rochester, MN The purpose of this study is to evaluate the safety and effectiveness of MK-1026 (formerly ARQ 531) in participants with hematologic BMF-219, in Adult Patients With Acute Leukemia (AL), Diffuse Large B-cell Lymphoma (DLBCL), Multiple Myeloma Lymphocytic Lymphoma (SLL)](/research/clinical-trials/cls-20538770) Jacksonville, FL The purpose of this study is to determine the optimal biologic dose (OBD) and recommended Phase 2 dose (RP2D) of BMF-219 monotherapy (Cohorts 1, 2, 3, and 4). - [BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Rochester, MN The purpose of this study is to test the safety and tolerability of a drug called BAY 1895344 in combination with irinotecan or topotecan at different doses. Irinotecan has already been approved by the FDA to treat pancreatic cancer while topotecan has already been approved by the FDA to treat small cell lung cancer. Another purpose of the study is to check the level of the study drugs in your blood called pharmacokinetics or PK and to see if there are changes in levels of circulating tumor cells in your blood. To assess what effect the study ... - [ALPN-202 With PD-1 Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate ALPN-202 with PD-1 inhibition to treat adults with advanced solid tumors or lymphoma. - [Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial](/research/clinical-trials/cls-20366167) Scottsdale/Phoenix, AZ The purpose of the study is to provide access to continued treatment for subjects who participated in other Astellas sponsored ASP2215 trials that completed the primary analysis and for whom the Investigator feels may have potential to continue to derive clinical benefit from the treatment with ASP2215, and who did not meet any of the study discontinuation criteria in the present study. - [Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor](/research/clinical-trials/cls-20492350) Jacksonville, FL The purpose of this study is to evaluate the safety and tolerability of DCC-3014 in patients with solid tumors including, but not limited to, prostate, breast, gastric, ovarian, and non-small cell lung cancer, as well as tumor types with high macrophage content or high expression of CSF-1 such as tenosynovial giant cell tumor. There will be an Escalation Phase and an Expansion Phase in this study. - [A Study to Analyze Symptoms and Quality of Life Issues in Women Living with Metastatic Breast Cancer](/research/clinical-trials/cls-20477023) Jacksonville, FL The purpose of this study is to gain an understanding of the lived experiences of symptoms and quality of life issues experienced by women with metastatic breast cancer. - [Project Survival-Prospective Biomarker Discovery](/research/clinical-trials/cls-20320333) Scottsdale/Phoenix, AZ sample-collection study is open to participants in several categories: healthy volunteers (with or without a family history of pancreatic cancer) and individuals diagnosed with pancreatitis or any stage of pancreatic cancer. All participants will submit urine, saliva and blood samples; pancreatitis and pancreatic cancer patients will also submit tissue samples if biopsy/ies or surgery is part of the care being provided by their doctor. In partnership with Berg Health, LLC, biomarkers will be investigated for potential use in early detection of pancreatic cancer, to determine prognosis of patients, and to find the most appropriate treatments for patients. - [Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma](/research/clinical-trials/cls-20536237) Rochester, MN The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD7789 in patients with relapsed/refractory classical Hodgkin Lymphoma (r/r cHL). - [A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)](/research/clinical-trials/cls-20538369) Jacksonville, FL The purpose of this study is to compare the effectiveness and safety of unesbulin plus dacarbazine versus placebo plus dacarbazine in participants with unresectable or metastatic, relapsed or refractory Leiomyosarcoma (LMS) who have received at least 1 prior line of systemic therapy. - [A Study to Evaluate Personalized Molecular Marker and Immunoprofiling to Transform Hepatocellular Carcinoma Treatment](/research/clinical-trials/cls-20509128) Jacksonville, FL The purpose of this study is to evaluate whether profiling aggressive tumors for molecular alterations, together with drug testing in patient-derived 3D models, can provide crucial information for the identification of specific therapeutic targets. Additionally, immunoprofiling of microcancer model systems is crucially necessary data to enable prediction of immunotherapeutic efficacy. We postulate that our innovative approach will establish much needed immune microenvironment information and facilitate the identification of specific sensitivity profiles and biomarker signatures that correlate response to targeted agents (or combinations) with particular tumor profiles. - [The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer](/research/clinical-trials/cls-20111930) Scottsdale/Phoenix, AZ The proposed clinical trial will study the effects of 12 months of therapy with ARN-509 alone, or in combination with an LHRH agonist (LHRHa), each compared to LHRHa alone, in men with a rapidly rising serum PSA after prior definitive local therapy for prostate cancer. The endpoints selected reflect measurable short term effects of androgen deprivation therapy (ADT), including quality of life and several metabolic parameters. In addition, the relative effect of each treatment strategy on PSA suppression as well as testosterone recovery (and subsequent PSA progression) after 12 months of therapy will be evaluated. - [A Drug-drug Interaction Study of Avapritinib and Midazolam to Treat Unresectable or Metastatic Gastrointestinal Stromal Tumors and Other Advanced Solid Tumors](/research/clinical-trials/cls-20534746) Jacksonville, FL The purpose of this study is to investigate the effect of Avapritinib on the pharmacokinetics of Midazolam in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST) or other advanced solid tumors. - [A Study to Evaluate AZD1775 in Women with Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma](/research/clinical-trials/cls-20511180) Rochester, MN The purpose of this study is to evaluate an investigational drug as a possible treatment for uterine cancer, AZD1775. - [A Study to Evaluate Zanubrutinib to Treat Patients with B-cell Malignancies](/research/clinical-trials/cls-20508601) Rochester, MN The purpose of this study is to evaluate the long-term safety and effectiveness of zanubrutinib in participants with B-cell malignancies who were previously enrolled in an eligible BeiGene study. - [Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) Pragmatic Clinical Trial ](/research/clinical-trials/cls-20445691) Rochester, MN The Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) Pragmatic Clinical Trial will determine whether systematically assessing patient reported outcomes for sleep disturbance, pain, anxiety, depression, and fatigue among patients with solid and liquid malignancies and using these data to increase the frequency of guideline-concordant care by: 1) reporting these data to their clinical teams, 2) providing patients with needs-matched symptom self-management education, and 3) suggesting evidence-based symptom management strategies to their care teams improves patients' quality of life, symptoms, and adherence to cancer treatment, while reducing their unplanned use of healthcare resources. - [First-in-Human Study of FLX925 in Subjects with Relapsed or AZ; Jacksonville, FL; a Phase 1/1b, open-label, sequential-group, dose-escalation and cohort expansion study evaluating the safety, and antitumor activity of FLX925 in people with relapsed or refractory Acute Myeloid Leukemia. - [A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma](/research/clinical-trials/cls-20150037) Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety and tolerability of ASP4132 and to determine the maximum tolerated dose and recommended phase 2 dose of ASP4132. The study will also determine the pharmacokinetics (PK) of ASP4132 and evaluate the preliminary antitumor activity. - [Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas](/research/clinical-trials/cls-20133374) Rochester, MN This is a Phase 1b/2 open-label to evaluate the safety/efficacy of MEDI-551 + MEDI0680 (AMP-514) in participants with relapsed or refractory aggressive B-cell lymphomas who have failed 1-2 prior lines of therapy. The primary objectives are to determine the maximum tolerated dose (MTD) or highest protocol-defined dose (HPDD); in the absence of exceeding the MTD of MEDI-551 in combination with MEDI0680 (AMP-514); and to evaluate the safety, tolerability, and clinical activity of MEDI-551 in combination with MEDI0680 (AMP-514). - [Safety and Tolerability Study of Oral NS-018 in Patients With Jacksonville, FL The purpose of this study is to determine the safety and tolerability of orally administered NS-018 in patients with with Myeloproliferative Neoplasms](/research/clinical-trials/cls-20115538) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to determine a dose of LY2784544 that may be safely administered to participants with myeloproliferative neoplasms. - [A Randomized, Double-blind, Phase 3 With Castrate-Resistant Prostate Cancer](/research/clinical-trials/cls-20209368) Rochester, MN The purpose of this study is to determine whether PROSTVAC alone or in combination with GM-CSF is effective in prolonging overall survival in men with few or no symptoms from metastatic, castrate-resistant prostate cancer. - [A Study of STRO-001 in Patients with Advanced B-Cell Malignancies](/research/clinical-trials/cls-20542550) Jacksonville, FL The purpose of this first-in-human study is to evaluate the safety, pharmacokinetics and preliminary effectiveness of STRO-001 given intravenously every 2 weeks to patients with advanced b-cell malignancies. - [An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Soc, Versus SoC Alone, in Adult Male Patients With mHSPC](/research/clinical-trials/cls-20538061) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the effectiveness and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with mHSPC. In this study, the SoC is defined as a combination of Androgen Receptor Directed Therapy + Androgen Deprivation Therapy. - [A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma](/research/clinical-trials/cls-20129258) Scottsdale/Phoenix, AZ Phase 1b: To evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose axitinib in patients with advanced renal cell carcinoma. Phase 2: To estimate the PFS of patients with advanced or metastatic RCC by RECIST 1.1 criteria in patients treated with axitinib and TRC105 compared to those treated with axitinib alone, following failure of one prior VEGF TKI - [A Study to Estimate the Clinical Benefit of REGN2810 for Patients with Advanced Squamous Cell Skin Cancer](/research/clinical-trials/cls-20265558) Scottsdale/Phoenix, AZ The purpose of this study is to estimate the clinical benefit of REGN2810 for patients who have metastatic (in lymph nodes or distant) squamous cell skin cancer or locally advanced squamous cell skin cancer that cannot be removed with surgery. - [Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1](/research/clinical-trials/cls-20149947) Rochester, MN This is a Phase 1b, open CMB305 (sequentially recombinant protein plus GLA-SE]) in patients with melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1. - [Cancer screening practices of individuals with Lynch Syndrome](/research/clinical-trials/cls-20509685) Rochester, MN This is a survey study to describe how women with Lynch syndrome are being screened for gynecologic cancer risk, their perception of cancer risk, and uptake of risk reducing surgery. - [Study of rSIFN-co for Patients with Advanced Solid Tumors](/research/clinical-trials/cls-20201667) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety, disease response, and drug /body interactions of rSIFN-co at different dose levels to demonstrate optimal dosage for patients with advanced solid tumors. - [Evaluation of the Value of Exosomal DEL-1 and miRNA Levels as Biomarkers for Breast Cancer](/research/clinical-trials/cls-20506103) Jacksonville, FL The purpose of this study is to measure DEL-1 levels and develop and validate methods for measurement of the exosomal T-RNAs( miR 1274b and mirR 720) as well as four miRs ( miR 21, let-7a, miR 125b and miR 100) in pre and post tumor resection plasma samples from women with newly diagnosed localized breast cancer. - [A Study to Evaluate the Impact of a Pharmacist-led Oral Anticancer Medication (OAM) Program on Patient Outcomes](/research/clinical-trials/cls-20509334) La Crosse, WI The purpose of this study is to evaluate the impact of integrating a pharmacist-led OAM education program within the interdisciplinary oncology team at the Stephen and Barbara Slaggie Family Cancer Center and Blood Disorders Center within Mayo Clinic Health System - La Crosse. - [Financial Toxicity Among Patients in Phase I Clinical Trials](/research/clinical-trials/cls-20531435) Rochester, MN As medical care in the United States becomes increasingly expensive, cost stewardship is a necessary component of delivering high value care. Cancer patients require additional protection from unmanageable costs, as the average out of pocket (OOP) cost during the first month of diagnosis is as high as $2900. Financial toxicity (FT) describes the adverse impact that the cost of treatment imposes upon our patients. Over the last five years, FT has become a well-recognized adverse impact of a cancer diagnosis. FT not only decreases the patient's quality of life, but also patients who file bankruptcy during cancer treatment ... - [Study of MK-8242 Alone and in Combination with Cytarabine in Participants with Acute Myelogenous Leukemia (P07649)](/research/clinical-trials/cls-20115805) Scottsdale/Phoenix, AZ; Rochester, MN This is a study of MK-8242 alone and in combination with cytarabine in adult participants with refractory or recurrent acute myelogenous leukemia (AML). The study will have 2 Arms. Arm A is for participants with refractory or recurrent AML who are considered ineligible for standard chemotherapy. In Part 1 of Arm A, participants will receive MK-8242 monotherapy in escalating doses to determine the recommended phase 2 dose [RP2D]. In Part 2, participants will receive monotherapy with MK-8242 to confirm the RP2D and assess preliminary efficacy. Arm B is for participants with recurrent AML following an initial complete remission (CR) or ... - [Collection and Storage of Tissue and Blood Samples From Patients With Cancer](/research/clinical-trials/cls-20493015) Rochester, MN This research trial collects and stores tissue and blood samples from patients with cancer. Collecting and storing samples of tissue and blood from patients with cancer to study in the laboratory may help scientists create new and better models to learn about cancer and to test new cancer drugs. - [Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies](/research/clinical-trials/cls-20412972) Jacksonville, FL; Rochester, doubleblind, international, multicenter study comparing the efficacy of DCC-2618 to placebo in patients who have received treatment with prior anticancer therapies. Prior anticancer therapies must include imatinib, sunitinib, and regorafenib (3 prior therapies). Approximately 120 patients will be randomized in a 2:1 ratio to DCC2618 150 mg QD or placebo - [A Study to Explore Tumor Biology in Metastatic Esophageal and Gastric Cancer Patients](/research/clinical-trials/cls-20506298) Rochester, MN The purpose of this study is to explore various biomarkers in the post-treatment tissue of patients who have responded to cancer therapy and compare it to the biopsy performed prior to cancer treatment. - [A Study to Evaluate the Safety and Tolerability of HMPL-306 to Treat Advanced or Metastatic Solid Tumors with IDH Mutations](/research/clinical-trials/cls-20533343) Rochester, MN The purpose of this study is to evaluate the safety, tolerability, and preliminary effectiveness of HMPL-306 in advanced or metastatic solid tumors with IDH mutation. - [Study of Single Agent CJM112, and PDR001 in Combination With or CJM112 in Patients With Multiple Myeloma](/research/clinical-trials/cls-20392041) Scottsdale/Phoenix, AZ The purpose of this study is to assess the safety, tolerability, and identify the recommended doses of single agent CJM112, and of CJM112 or LCL161 in combination with PDR001, in patients with relapsed and/or refractory multiple myeloma. - of INBRX-109 in Conventional Chondrosarcoma](/research/clinical-trials/cls-20528564) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to evaluate INBRX-109 in unresectable or metastatic conventional chondrosarcoma patients. - [Phase 2 Study with TTI-622 and TTI-621 in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL)](/research/clinical-trials/cls-20535900) Rochester, MN The purpose of ths study is to find out more about the side effects of two new drug combinations for lymphoma, TTI-621 and pembrolizumab and TTI-622 and pembrolizumab, and what doses of TTI-621 and TTI-622 are safe for people to take. In addition, we want to learn if the drug combinations help your cancer. - [A Study to Assess Metformin Hydrochloride in Patients With Atypical Hyperplasia or In Situ Breast Cancer to Placebo in Decreasing Atypical Cells in Patients With Atypical Hyperplasia or in Situ Breast Cancer](/research/clinical-trials/cls-20143931) Rochester, MN The purpose of this research study is to test whether metformin, a drug commonly used to treat diabetes, is able to get rid of atypia (early cell changes that are thought to be a marker of breast cancer risk) in women at increased risk for breast cancer. There will be testing for the presence of atypia in the breast after metformin is given to see if it can get rid of atypia. The study will compare the effects, good and/or bad, of metformin or placebo on atypia to find out which is better. Note: The standard drug used for the ... - [A Study to Evaluate AL102 to Treat Patients Progressing Desmoid Tumors](/research/clinical-trials/cls-20525451) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the effectiveness and safety of AL102 in patients with progressive desmoid tumors. - [Iberdomide in Combination with Daratumumab, Bortezomib, and in Patients with Newly-diagnosed Multiple Myeloma (IDEAL)](/research/clinical-trials/cls-20529818) Rochester, MN The purpose of this study is to find the maximum tolerated dose of iberdomide for patients newly diagnosed with multiple myeloma, and to determine response rate during induction treatment when combined with daratumumab, bortezomib and dexamethansone. - [A Study to Evaluate Gleolan to Enhance Tumor Visualization in Patients with Newly-diagnosed or Recurrent Meningioma](/research/clinical-trials/cls-20509118) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to investigate the safety, diagnostic performance, and clinical usefulness of the imaging agent Gleolan (Aminolevulinic Acid Hydrochloride, ALA HCl, ALA, 5-ALA), an orally administered imaging agent for the real-time detection and visualization of meningiomas during tumor resection surgery. ALA is a prodrug that is metabolized intracellularly to form the fluorescent molecule Protoporphyrin IX (PpIX). - [Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors](/research/clinical-trials/cls-20536231) Scottsdale/Phoenix, AZ The purpose of this research is to see how well fruquintinib works in combination with tislelizumab in participants with metastatic colorectal cancer (mCRC). - [Study of Cell-surface Proteins in Renal Tumors for Future Exploration of New Anticancer Therapies](/research/clinical-trials/cls-20526727) Rochester, MN In this study, we propose to use a combination of cell-surface capture and mass spectrometry on patient tumors to identify tumor-associated cell-surface proteins that are targetable with next-generation immunotherapies. These therapeutic antibodies and their derivatives have transformed the therapeutic landscape of cancer patients. Only 20% of cell-surface proteins have been investigated so far for drug development. Untargeted proteomics has been the gold standard to identify tumor-associated proteins. However, it suffers from low sensitivity for cell-surface proteins. Cytosolic proteins are much more abundant and soluble than cell-surface proteins which results in limited resolution of the entire cell-surface proteome. - [A Study to Analyze the Safety and Effectiveness of the NanoKnife\u00ae System in Unresectable Stage 3 Pancreatic Adenocarcinom Patients](/research/clinical-trials/cls-20502316) Jacksonville, FL The purpose of this study is to evaluate the safety and effectiveness of the NanoKnife System for the ablation of unresectable Stage 3 pancreatic adenocarcinoma (Stage 3 pancreatic cancer). - [JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations](/research/clinical-trials/cls-20533790) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation. - [A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (KarMMa-4)](/research/clinical-trials/cls-20486467) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety and to determine the optimal dose of bb2121 in subjects with high risk, (HR) newly -diagnosed multiple myeloma (NDMM). - [A Study to Evaluate the Effectiveness and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects with Mycosis Fungoides](/research/clinical-trials/cls-20467305) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The primary purpose of this study is to evaluate the effectiveness and safety of cobomarsen (also known as MRG-106) for the (MF) subtype. Cobomarsen is to inhibit the activity of a molecule called miR-155 that may be important to the growth and survival of MF cancer cells. The study will compare the effects of cobomarsen to vorinostat, a drug that has been approved for the treatment of CTCL in the United States and several other countries. - [SAR650984, Pomalidomide and Dexamethasone in Primary Objectives: Part A: To evaluate the safety and determine the recommended dose of SAR650984 in combination with pomalidomide (P) and dexamethasone (d), in patients with Relapsed/Refractory Multiple Myeloma (RRMM). Part B: To evaluate the feasibility of isatuximab administered from a fixed infusion volume in combination with Pd as assessed by occurrence of grade 3 infusion associated reactions (IAR). Secondary Objectives: - To evaluate the infusion duration (Part B). - To evaluate the safety profile of the combination with isatuximab administration from fixed volume (Part B). - To evaluate immunogenicity of SAR650984 in combination with Pd (Part A and B). ... - [A Study to Evaluate Oncologic Outcomes and Quality of Life in Sinonasal Cancer Patients](/research/clinical-trials/cls-20507410) Rochester, MN This is a multi-site study with several other leading centers studying sinonasal cancers. The purpose of this study is to gain a better understanding of the treatment and significant morbidity associated with sinonasal cancer and identify the impact this disease has on quality of life. In addition, several additional endpoints will focus on survival and optimal treatment strategies. Additional components will also included genomic and molecular analysis of tumor tissue as we search for novel targets for therapy. - [Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score](/research/clinical-trials/cls-20526729) Albert Lea, MN; Rochester, MN The puporse of this trial is to compare less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Abiraterone acetate may help fight prostate cancer by lowering the amount of testosterone made by the body. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses ... - [Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma](/research/clinical-trials/cls-20201832) Rochester, MN This phase II trial studies how well glembatumumab vedotin works in treating patients with middle layer of the wall of the eye (uveal) melanoma that has spread to other parts of the body (metastatic) or has returned at or near the same place after a period of time during which the cancer could not be detected (locally recurrent). Glembatumumab vedotin may shrink the tumor by binding to tumor cells and delivering tumor-killing substances to them. - [Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer](/research/clinical-trials/cls-20264710) Scottsdale/Phoenix, AZ This study consists of two phases: Dose Escalation (Phase 1b) and Dose Expansion (Phase 2) The Dose Escalation phase will evaluate the safety and tolerability of GS-5829 as a single agent and in combination with enzalutamide, as well as determine the maximum tolerated dose (MTD) of GS-5829 as a single agent and in combination with enzalutamide in participants with metastatic castrate-resistant prostate cancer (mCRPC). The Dose Expansion phase will evaluate the following: - In group 1, the efficacy of GS-5829 as a single agent in participants with mCRPC who have progressed while receiving enzalutamide (may have also received abiraterone) - ... - [A Study to Evaluate the Effectiveness and Safety of Cobomarsen (MRG-106) in Subjects with Mycosis Fungoides Who Have Completed the SOLAR Study](/research/clinical-trials/cls-20480288) Scottsdale/Phoenix, AZ The main purpose of this study is to evaluate the effectiveness and safety of cobomarsen (also known as MRG-106) for the lymphoma (CTCL), mycosis fungoides (MF) subtype in subjects who have confirmed disease progression following treatment with vorinostat in the SOLAR clinical study (MRG106-11-201). Cobomarsen is designed to inhibit the activity of a molecule called miR-155 that may be important to the growth and survival of MF cancer cells. The effects of treatment will be measured based on changes in skin lesion severity, disease-associated symptoms, and quality of life, as well as the length of time ... - [Establishing a Platform for Personalized Approach to the Management of Rectal Adenocarcinoma Using Patient-Derived Tumoroids and Organoids](/research/clinical-trials/cls-20516417) Jacksonville, FL The purpose of this study is to create a database of rectal cancer cells that can be studied outside of the patient's body. - [Topical Cannabidiol (CBD) for the Treatment MN; Albert Lea, MN; Mankato, MN The primary purpose of this study is to evaluate whether topical CBD improves chemotherapy-induced peripheral neuropathy (CIPN), compared to placebo, and to evaluate side effects from topical CBD cream use, compared to placebo. - [Phase III Copanlisib in Rituximab-refractory iNHL](/research/clinical-trials/cls-20169975) Rochester, MN Assess the efficacy and safety of copanlisib monotherapy - [Immune Control of Breast Cancer Tumor Dormancy](/research/clinical-trials/cls-20310392) Rochester, MN The Primary Aim of this study is to quantify BDTC in breast cancer patients at different stages of cancer. As part of this aim we will establish the proliferation status of the tumor cells. We will in parallel examine CTC to determine the correlation between BDTC and CTC. The Second Aim is to determine role of tumor associated immune responses in maintaining tumor dormancy. Knowledge gained will provide the rationale for an in depth study of breast cancer tumor dormancy and immune response. Ultimately, the information gained will help us to design of immune intervention strategies that prevent cancer recurrence. - [A Prospective Ocular Tumor Study](/research/clinical-trials/cls-20502635) Rochester, MN The purpose of this study is to use clinical, imaging, molecular, and epidemiological investigation toward the goal of providing new knowledge about ocular tumors that will be useful in understanding, diagnosing, monitoring, and suggesting new avenues of treatment. This study does not involve experimental treatment of any ocular tumor, but rather observation of tumor natural history or outcomes following standard of care therapy, associated systemic and ocular conditions, and basic research investigations to better understand tumor biomarkers and pathophysiology. - [A Study to Evaluate the DermaSensor Tool on Skin Lesions Suggestive of Skin Cancer](/research/clinical-trials/cls-20517097) Rochester, MN The objective of this study is to investigate the sensitivity and specificity of the DermaSensor device in evaluating skin lesions suggestive of melanoma, basal cell carcinoma, and squamous cell carcinoma, and to compare the sensitivity of DermaSensor to that of dermatopathology and primary care physicians' empiric diagnosis. - [A Study Comparing Gemcitabine with or without AZD 1775 in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer](/research/clinical-trials/cls-20260172) Rochester, MN The purpose of this study is to compare gemcitabine hydrochloride in combination with AZD 1775 to gemcitabine hydrochloride given alone to treat patients with ovarian, primary peritoneal, or fallopian tube cancer that has returned after a period of time. Gemcitabine hydrochloride may prevent tumor cells from multiplying by damaging their deoxyribonucleic acid (DNA) molecules that contain instructions for the proper development and functioning of cells, which in turn stops the tumor from growing. AZD 1775 may block specific protein activity and may increase the effectiveness of gemcitabine hydrochloride by preventing the protein from repairing damaged tumor cells without causing harm to normal cells. It ... - [A Study to Evaluate Plasma and Sputum As Noninvasive Biomarkers for Bronchial Dysplasia Progression/Regression](/research/clinical-trials/cls-20504065) No Locations This study is designed to determine whether or not plasma and sputum microRNA might be an effective, non-invasive biomarker for lung cancer risk. - [Retrospective Study of Adult Acute Myeloid Leukemia and the Impact on Clinical Characteristics & Outcomes After Therapy](/research/clinical-trials/cls-20506874) Jacksonville, FL The purpose of this study is to perform a retrospective review of adult patients diagnosed with AML at all 3 Mayo Clinic sites over the past 25 years in order to identify prior exposures documented at presentation. - [The Captivator EMR Registry](/research/clinical-trials/cls-20491135) Rochester, MN; Jacksonville, FL The purpose of this study is to confirm the performance of the Captivator endoscopic mucosal resection device for resection of early tumor growth in Barrett's Esophagus. - [A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke (EAISE)](/research/clinical-trials/cls-20505706) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to assess the effectiveness, safety, tolerability, and pharmacokinetics (PK) of elezanumab in subjects with acute ischemic stroke to potentially accelerate recovery and/or provide more complete recovery by decreasing neuronal damage and enhancing restoration of neuronal activity. - [Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy](/research/clinical-trials/cls-20509817) Rochester, MN The purpose of this study is to determine safety and measure biodistribution of two imaging agents in patients with refractory or metastatic melanoma. This study will use [203Pb]VMT01 Tomography (SPECT) imaging for Positron Tomography imaging. - [A Study to Evaluate TAB006, as Monotherapy and in Combination with Toripalimab, in Patients with Previously Treated, Advanced Malignancies](/research/clinical-trials/cls-20529820) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to assess the safety and tolerability of multiple doses of TAB006 as monotherapy and in combination with toripalimab to treat advanced malignancies. - [Cancer of the Uterus and Treatment of Stress Urinary Incontinence](/research/clinical-trials/cls-20306806) Rochester, MN Concurrent treatment of endometrial cancer and SUI may improve QOL, emotional and physical health and decrease costs for both patients and the health care system. At the time of endometrial cancer diagnosis, not only are women evaluated by a gynecologist and/or a gynecologic oncologist, but the majority will undergo surgery within weeks of their diagnosis. Thus, urinary incontinence could easily be identified, a referral made, and concurrent surgery performed. This would spare the patient two surgeries, decrease the emotional distress associated with SUI symptoms, decrease the costs associated with SUI for the patient and possibly improve overall quality of life. ... - [A Study of SC004 in Subjects With Advanced Solid Tumors](/research/clinical-trials/cls-20400609) Rochester, MN This is a two-part study consisting of Part A (dose regimen finding) followed by Part B (dose expansion). Part A (dose regimen finding) will allow definition of the maximum tolerated dose (MTD) through dose escalation and possible dose interval modification. In Part B (dose expansion), potential therapeutic doses may be studied with SC-004 as monotherapy and SC-004 in combination with ABBV-181 in disease-specific cohorts. - [Circulating Tumor DNA (cTDNA) Based in NGS (Next Generation Sequencing) Assays for Oncology Patients With Solid Tumors](/research/clinical-trials/cls-20539339) Rochester, MN The purpose of this study is to design, develop and assess the performance characteristics of NGS assays using circulating tumor DNA for the detection of mutations associated solid tumors. The performance characteristics of these assays for detecting ctDNA mutation in oncology patients will be assessed by comparing the mutation results obtained from these assays to those obtained by orthogonal methods, including tissue-based assays and results from a ctDNA assay by Guardant on blood. - [A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM](/research/clinical-trials/cls-20537823) Jacksonville, FL The purpose of this study is to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent glioblastoma (GBM). - [A Study of Enfortumab Vedotin for Advanced or Metastatic Urothelial Bladder Cancer](/research/clinical-trials/cls-20397710) Scottsdale/Phoenix, AZ This is a study that will test how an experimental drug (enfortumab vedotin) affects patients with cancer of the urinary system (urothelial cancer). This type of cancer includes cancer of the bladder, renal pelvis, ureter or urethra that has spread to nearby tissues or to other areas of the body. This clinical trial will enroll patients who were previously treated with a kind of anticancer drug called an immune checkpoint inhibitor (CPI). Some CPIs have been approved for the treatment of urothelial cancer. This study will test if the cancer shrinks with treatment. This study will also look at the ... - [Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as Treatment in Participants With PD-L1-Positive (CPS 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck](/research/clinical-trials/cls-20540336) Jacksonville, FL The purpose of this study is to evaluate the safety and effectiveness of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). - [Study to Assess Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20537620) Jacksonville, FL The purpose of this trial is to identify the RP2D of STI-6129 by assessing the safety, preliminary effectiveness and pharmacokinetics in treating subjects with relapsed/refractory multiple myeloma (RRMM). - [A Study to Evaluate DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study](/research/clinical-trials/cls-20526826) Rochester, MN The purpose of this study is train and test classifiers for lung cancer detection using the DELFI assay and other biomarker and clinical features. - [Oxybutynin Chloride in Managing Hot Flashes](/research/clinical-trials/cls-20463111) Rochester, MN This randomized phase III trial studies how well oxybutynin chloride works in managing hot flashes in patients who are not candidates for, or not interested in hormone replacement therapy. Previous studies have shown that oxybutynin is effective in managing hot flashes, however doses used in prior studies have resulted in side effects. This trial is evaluating lower doses of oxybutynin with the goal of determining if they are efficacious with less side effects. - [A Study of Single Patient Investigational Drug CPI-613 for Use in Treatment-Refractory, Metastatic Prostate Cancer](/research/clinical-trials/cls-20305172) Rochester, MN This is a single patient study of an investigational drug CPI-613 for treatment of metastatic prostate cancer. - [Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal ER/PR+ Metastatic Breast Rochester, MN; Rochester, MN This is a phase 1b/2 study of the safety and efficacy of MLN0128 in combination with exemestane or fulvestrant therapy in women with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced or metastatic breast cancer that has progressed on treatment with everolimus in combination with exemestane or fulvestrant. - [Consent Forms in Cancer Research: Examining the Effect of Length on Readability](/research/clinical-trials/cls-20493190) Rochester, MN The objectives of this study are to determine whether cancer patients report that shorter, or less wordy, consent forms are helpful to them as they decide about whether or not to enroll in a cancer clinical trial, and to determine whether shorter consent forms result in a greater percentage of patients' enrolling in a cancer clinical trial, based on whether or not the patient has signed a mock consent form. - [A Study to Assess Myocardial Blood Flow Changes in Oncology Patients](/research/clinical-trials/cls-20475821) Rochester, MN The primary purpose of this study is to determine if ICI administration causes microvascular damage/endothelial function. - [A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies](/research/clinical-trials/cls-20111774) Rochester, MN The purpose of this study is to determine the maximum tolerated dose of this drug (MEDI-551) in subjects with advanced B-cell malignancies. Expansion to occur at maximum tolerated dose (MTD), or if not reached, at optimal biologic dose Scottsdale/Phoenix, AZ Many tumor cells, in contrast to normal cells, have been shown to require the amino acid glutamine to produce energy for growth and survival. To exploit the dependence of tumors on glutamine, CB-839, a potent and selective inhibitor of the first enzyme in glutamine utilization, glutaminase, will be tested in this Phase 1 study in patients with advanced hematologic malignancies. This study is an open-label Phase 1 evaluation of CB-839 in subjects with hematological tumors. Patients will receive CB-839 capsules orally three times daily. The study will be conducted in 2 parts. Part 1 is a dose escalation study ... - [Escalating Dose Study in Subjects with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia](/research/clinical-trials/cls-20115774) Jacksonville, FL The purpose of this study is to evaluate the safety and tolerability of AVL-292 as monotherapy in subjects with relapsed or B 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With AZ; Rochester, MN Primary Objective: Phase 1: To determine the maximum tolerated dose (MTD)/maximum administered dose (MAD) of SAR650984 (Isatuximab). Phase 2 (stage 1): To evaluate the activity of single-agent Isatuximab at different doses/schedules and to select dose and regimen to further evaluate the overall response rate (ORR) of Isatuximab as single agent or in combination with dexamethasone. Phase 2 (stage 2): To evaluate the activity in terms of overall response rate (ORR) of Isatuximab at the selected dose/schedule from stage1, as single agent (ISA arm) and in combination with dexamethasone (ISAdex arm). Secondary Objectives: Phase 1: - To characterize the global safety ... - [Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer](/research/clinical-trials/cls-20467292) Eau Claire, WI; Scottsdale/Phoenix, AZ; La Crosse, WI This randomized phase III trial studies how well pembrolizumab works in treating patients with bladder cancer that has spread from where it started to nearby tissue or lymph nodes. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. - [A Study of Nirogacestat for Adults With 3, double-blind, placebo-controlled study is being conducted to determine the efficacy, safety, and tolerability of nirogacestat in participants with progressing desmoid tumors. - [A Study Evaluating the Safety and Effectiveness of Therapies in Patients with Metastatic Colorectal Cancer](/research/clinical-trials/cls-20521138) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN this study for the Inavo + Cetux Arm (A): To evaluate the effectiveness of Inavo + Cetux in PIK3CA-mutated colorectal cancer (CRC) with no detected RAS (KRAS, NRAS) or BRAFV600E mutations. The purpose of this study for the Inavo + Bev Arm (B_: To evaluate the Bev in PIK3CA-mutated, RAS (KRAS, NRAS)-mutated CRC. The purpose of this study for the Atezo+SY-5069 Arm (C): To evaluate the effectiveness of atezolizumab and SY-5609 treatment combination on patients with mCRC. The purpose of this study for the GDC-6036+cetuzimab+FOLFOX Arm (E): To evaluate the effectivenss of GDC-6036 plus cetuximab plus FOLFOX on patients with mCRC. The purpose of this study ... - [A Study Of AL101 In Patients with Adenoid Cystic Carcinoma Bearing Activating Notch Mutations](/research/clinical-trials/cls-20477732) Rochester, MN The primary purpose of this study is to assess the clinical activity of AL101 using radiographic assessments and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Adenoid Cystic Carcinoma (ACC) patients with activating Notch mutations. - [A Study Of AL101 In Patients with Adenoid Cystic Carcinoma Bearing Activating Notch Mutations](/research/clinical-trials/cls-20477732) Rochester, MN The primary purpose of this study is to assess the clinical activity of AL101 using radiographic assessments and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in Adenoid Cystic Carcinoma (ACC) patients with activating Notch mutations. - [Study of a Triple Combination Therapy, DTRM-555, in MN Targeted drug therapies have greatly improved outcomes for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma. However, single drug therapies have limitations, therefore, the current study is evaluating a novel oral combination of targeted drugs as a way of overcoming these limitations. This study will determine the effectiveness of the triple combination therapy, DTRM-555, in patients with R/R CLL Sorafenib in Patients With HCC](/research/clinical-trials/cls-20179465) No Locations The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose sorafenib in patients with hepatocellular carcinoma. Up to 18 patients will be treated. The purpose of the phase 2 portion is to estimate the ORR of patients with hepatocellular carcinoma by RECIST 1.1. Up to 21 patients will be treated in phase 2. - [IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome](/research/clinical-trials/cls-20385841) Rochester, MN The primary objective of this study is to determine the safety and tolerability of utilizing the insulin-like growth factor-1-methotrexate conjugate, 765IGF-MTX for the treatment of advanced, previously treated myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia leukemia (oligoblastic AML or O-AML), including determining the maximum tolerated dose (MTD). - [Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia](/research/clinical-trials/cls-20261271) Rochester, MN The purpose of this study is to evaluate the safety of alisertib and its effect, bad and/or good, on acute megakaryoblastic leukemia (AMKL) or myelofibrosis (MF). The study drug, alisertib, is an investigational drug. An investigational drug is one that has not been approved by the U.S. Food and Drug Administration (FDA). Alisertib has shown evidence in the lab that it may have an effect on a type of cell that produces platelets. This cell is called a megakaryocyte and it is known to be defective (doesn't work well) in both AMKL and MF. - [Colorectal Cancer and Peripheral Neuropathy Study](/research/clinical-trials/cls-20521242) Jacksonville, FL The purpose of this study is to prospectively evaluate the development of neuropathy symptoms and corresponding changes in physical function in persons receiving oxaliplatin based chemotherapy. - [A Study to Evaluate Combination Therapy to Treat Newly-diagnosed Diffuse Anaplastic Wilms Tumors and Relapsed Favorable Histology Wilms Tumors A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT](/research/clinical-trials/cls-20520090) Rochester, MN The purpose of this study is to evaluate how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 ... - [A Study of Rose Geranium in Sesame Oil Nasal Spray for Treating Established Chemotherapy and Targeted Therapy-Related Nasal Vestibulitis](/research/clinical-trials/cls-20379678) Rochester, MN The purpose of this study is to - Explore the efficacy of rose geranium in sesame oil nasal spray in treating nasal vestibulitis related to cancer-directed therapy. - [A Study of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment for Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20228038) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of the study is to evaluate progression free survival, using independent radiologic review, of ASP8273 compared to erlotinib or gefitinib in patients with locally advanced, metastatic or unresectable stage IIIB/IV adenocarcinoma non-small cell lung cancer that has epidermal growth factor receptor (EGFR) activating mutations. This study will also assess overall survival, overall response rate, progression free survival assessed by the investigator, disease control rate, duration of response, safety of ASP8273, quality of life, and patient-reported outcome parameters. - [A Study to Collect Surgical Tumor Samples for Prostate Cancer-derived Tissue Graft](/research/clinical-trials/cls-20480304) Rochester, MN The purposes of this study are to collect prostate surgical samples from metastatic patients to establish xenograft tumor lines for future testing of potential therapies and for understanding mechanisms of therapy resistance via DNA/RNA sequencing, to collect patient blood samples for future DNA/RNA sequencing , and to collect patient urine samples for future prostate cancer related biomarker detection and DNA/RNA sequencing. - [Study to Evaluate the Safety and Effectiveness of Localizing Biopsy-Proven Metastatic Axillary Lymph Nodes in Women with Breast Cancer Using Magseed Markers as an Alternative to the Current Practice of Placing Radioactive Seed Markers](/research/clinical-trials/cls-20441688) Rochester, MN The purpose of this study is to evaluate if Magseed is a viable alternative to radioactive seed as a localization method for biopsy proven metastatic breast carcinoma following neoadjuvant chemotherapy. - [A Study of Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma](/research/clinical-trials/cls-20260185) Rochester, MN The main purpose of this study is to assess the effectiveness and safety of treatment with anetumab ravtansine versus vinorelbine for progression free survival in patients with stage IV mesothelin overexpressing type of malignant pleural mesothelioma. Radiological tumor assessments will be performed at defined time points until the patient's disease progresses. Blood samples will be collected for safety, pharmacokinetic and biomarker analysis. Archival or fresh biopsy tissue may also be collected for central pathology review and biomarkers. - [Defibrotide for Patients with Hepatic Scottsdale/Phoenix, Single arm, open-label study to provide Defibrotide to patients diagnosed with VOD. Defibrotide is no longer available though the Emergency Use IND mechanism (also known as compassionate use, or single patient named use). This protocol is the only mechanism by which Defibrotide can be made available to patients in the U.S. - [A Study to Assess the Effectiveness, Safety, and Drug/Body Interactions of Rovalpituzumab for Third-Line and Later Treatment of Patients with Small Cell Lung Cancer that has Returned or is Resistant to Treatment](/research/clinical-trials/cls-20306080) Rochester, MN The purpose of this study is to determine the effectiveness, safety, and drug/body interactions of rovalpituzumab tesirine as a third-line or later treatment for patients who have small cell lung cancer that has returned or is resistant to other treatments. - [First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients AZ; FL; Rochester, MN oral inhibitor that targets AXL kinase. Preclinical studies have shown promising antitumor activity of TP-0903 as a single agent against a variety of tumor types in both in vitro and in vivo studies. This first-in-human study is conducted to identify the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of TP-0903 administered orally to patients with advanced solid tumors. The study will investigate the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity profiles. - [Response Adapted Combination Therapy Approaches for High-Risk Multiple Myeloma](/research/clinical-trials/cls-20535686) Jacksonville, FL; Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to estimate the rate of sustained MRD negativity (MRD negative status at any point, with a repeated MRD negative status one year later) in subjects with high-risk multiple myeloma. - [A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas](/research/clinical-trials/cls-20507607) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate CC-220 alone, as well as in combination with an anti-CD20 mAb (rituximab or obinutuzumab) in subjects with relapsed or refractory (R/R) lymphoma. Subjects must have received at least 2 prior lines of therapy, and have at least one measurable lesion according to Lugano 2014 classification. Study will consist of two parts: Part 1 (Dose Escalation) which will be followed by Part 2 (Dose Expansion). - [A Study of Personalized Molecular Markers to Transform Treatment of High Grade Endometrial Cancer](/research/clinical-trials/cls-20467891) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to characterize a landscape of DNA alterations, RNA transcripts, and microbiome changes in resected tumors and body fluids of patients that have been diagnosed with aggressive endometrial cancer (Grade 3 and Type II) in order to identify molecular targets for which therapeutic drugs may exist. - [University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities](/research/clinical-trials/cls-20509335) Jacksonville, FL The purpose of this study is to establish at least 200 patient-derived cancer xenografts (PDXs), and to utilize these PDXs in preclinical testing of single agents and drug combinations to guide precision cancer medicine decision-making with a focus upon the predominant racial/ethnic minority populations residing in California. - [A Study to Evaluate Outpatient Blinatumomab in Subjects with Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)](/research/clinical-trials/cls-20509430) Jacksonville, FL The purpose of this study is to determine the safety and feasibility of complete outpatient blinatumomab administration for subjects with minimal residual disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL). - [Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed By Surgery](/research/clinical-trials/cls-20111911) Scottsdale/Phoenix, AZ; Rochester, MN This randomized phase II trial studies how well cetuximab with or without tivantinib works in treating patients with head and neck cancer that is recurrent, metastatic, or cannot be removed by surgery. Monoclonal antibodies, such as cetuximab, can interfere with tumor growth by blocking the ability of tumor cells to grow and spread. Tivantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cetuximab is more effective with or without tivantinib in treating patients with head and neck cancer. - [A Study of the Safety, Tolerability, Drug/Body Interactions, Biological and Clinical Activity of MSB0011359C (M7824) in Metastatic or Locally Advanced Solid Tumors](/research/clinical-trials/cls-20304530) Scottsdale/Phoenix, AZ The purpose of this study is to assess the safety, tolerability, drug/body interactions, and the biological and clinical activities of MSB0011359C (M7824) at different dose levels given to patients who have metastatic or locally advanced solid tumors. - [Phase 1/2, Open-label, Dose-escalation Study of ISIS-STAT3Rx, Administered to Patients with Advanced Cancers](/research/clinical-trials/cls-20115513) Scottsdale/Phoenix, AZ; Rochester, MN This is a Phase 1/2, open-label, dose-escalation, dose-expansion study for the treatment of patients with advanced cancers. Eligible patients with DLBCL or other advanced lymphomas will be enrolled into the dose-expansion cohort. - [Needle-based Confocal Laser Endomicroscopy Guided For Lung Diagnosis: A Randomized Controlled Trial](/research/clinical-trials/cls-20536824) Jacksonville, FL; Rochester, MN The purpose of this study is to compare per pass diagnostic yield of different numbers of sequential needle passes (ROSE) and the procedure duration needed to obtain a contributive TBNA sample with ROBOTIC-guided TBNA to that of ROBOTIC-guided nCLE in PPNs. - [Testing for Spread of Stomach Cancer to Abdominal Cavity](/research/clinical-trials/cls-20539922) Rochester, MN The purpose of this study is to establish a clinical useful gene expression panel for detecting and predicting peritoneal relapse and survival to address the unmet clinical need for a simple and accurate staging of the peritoneum in gastric cancer. - [Immune Response to Antigens](/research/clinical-trials/cls-20528818) Jacksonville, FL The purpose of this study is to sequence patient germline and tumor samples, and nominate top neoantigen candidates using an in-house developed bioinformatics pipeline, and to validate the neoantigen candidates by laboratory assays using patient peripheral blood immune cells or serum. - [Patient Perspectives on Bladder Cancer Care](/research/clinical-trials/cls-20529027) Jacksonville, FL; Rochester, MN The purpose of this study is to explore thoughts and experiences of bladder cancer patients who underwent radical cystectomy at Mayo Clinic Florida through qualitative interviews. - [Team Based Psychosocial Care to Promote, Maintain and Restore Wellness of Breast Cancer Patients](/research/clinical-trials/cls-20434445) No Locations The purpose of this study is: - To assess whether a team based care model applied to distressed breast cancer patients will result in lower distress at 3, 6, 9 & 12 months compared to treatment as usual. - To assess whether health promotion tools such as psychoeducation applied to non-distressed breast cancer patients will result in lower distress at 3, 6, 9 & 12 months compared to treatment as usual. - [Female Patients and Female Partners of Patients With Confirmed HPV Associated Oropharyngeal Carcinoma (Pap-Op): Prospective Assessment of HPV Associated Anogenital Pathology](/research/clinical-trials/cls-20536451) Rochester, MN The purpose of this study is to determine the incidence of anogenital infection with high-risk HPV serotypes and HPV-associated anogenital lesions in female patients with newly diagnosed HPV(+)OPSCC and female partners of patients with HPV(+)OPSCC, and compare this with retrospective review of exams and paps obtained during routine well woman checks in Rochester MN. - [A Study to Provide Expanded Access for the Treatment of Cancers with Rearranged During Transfection (RET) Activation](/research/clinical-trials/cls-20470856) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to provide expanded access for patients with cancer with RET activation who are ineligible for an ongoing LOXO-292 clinical trial or have other considerations that prevent access to LOXO-292 through an existing clinical trial. - [Investigating Magnesium Glycinate in Structure/Function Role of Hot Flashes.](/research/clinical-trials/cls-20424755) Jacksonville, FL The goal of this study is to further evaluate the effect of magnesium on the symptoms of menopause, specifically vasomotor symptoms (VMS) in breast cancer patients and/or women at an elevated risk of breast cancer. - [A Study to Evaluate Infigratinib to Treat Subjects with Invasive Urothelial Carcinoma with Susceptible FGFR3 Genetic Alterations (PROOF 302)](/research/clinical-trials/cls-20509120) Jacksonville, FL The purpose of this study is to evaluate the effectiveness of infigratinib in approximately 218 adult subjects with invasive urothelial carcinoma with susceptible FGFR3 genetic alterations (mutations, and gene fusions or translocations [ie, rearrangements]; hereafter referred to collectively as \"FGFR3 alterations\") who are within 120 days following nephroureterectomy, distal ureterectomy, or cystectomy and ineligible for cisplatin-based (neo)adjuvant chemotherapy or with residual disease after neoadjuvant therapy. - [177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer](/research/clinical-trials/cls-20532384) Rochester, MN The purpose of this study is to determine whether 177Lu-PSMA-617 improves the rPFS or death compared to a change in ARDT in mCRPC participants that were previously treated with an alternate ARDT and not exposed to a taxane-containing regimen in the CRPC or mHSPC settings. - [Lutetium 177Lu-Edotreotide Versus Best Standard Care Well-differentiated (COMPOSE)](/research/clinical-trials/cls-20532370) Rochester, MN The purpose of the study is to evaluate the effectiveness, safety and patient-reported outcomes of peptide receptor radionuclide therapy (PRRT) with 177Lu-Edotreotide as 1st or 2nd line of treatment compared to best standard of care in patients with well-differentiated aggressive grade 2 and grade 3, somatostatin receptor-positive (SSTR+), neuroendocrine tumours of gastroenteric or pancreatic origin. to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Patients with Solid Tumors](/research/clinical-trials/cls-20467347) Scottsdale/Phoenix, AZ; Rochester, MN The study is an open-label, dose escalation clinical trial to evaluate the safety, tolerability, and PK of fruquintinib in patients with advanced solid tumors. - [A Study to Evaluate the Safety, Effectiveness and Tolerability of APG-2575 in Patients with Waldenstr\u00f6m Macroglobulinemia](/research/clinical-trials/cls-20508015) Jacksonville, FL The purpose of this study is to assess the safety and tolerability, identify dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of APG-2575, alone or in combination with other therapeutic agents (ibrutinib or rituximab), in patients with Waldenstr\u00f6m Macroglobulinemia (WM). - [A Study to Assess LXH254 in with Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma](/research/clinical-trials/cls-20507935) Rochester, MN The purpose of this study is to evaluate combinations, using LXH254 as a backbone, which may help overcome intrinsic and acquired resistance to BRAF targeted therapy as well as offer new treatment options for NRAS melanoma patients. - [Utility of Gallium-68-DOTA-Octreotat PET/CT in the Characterization of Pediatric Neuroendocrine Tumors](/research/clinical-trials/cls-20463890) Rochester, MN The purpose of this pilot study is to assess the efficacy of the Federal Drug Administration approved 68Ga-DOTATATE PET/CT in the radiotherapeutic target volume definition of metastatic neuroendocrine tumors as compared to MIBG scintigraphy. Secondary - Function After Treatment Malignancy](/research/clinical-trials/cls-20425261) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate cognitive function and to determine neurocognitive assessment using a select CogState test battery in patients with primary intracranial malignancies receiving photon- or proton-based cranial irradiation with curative - [Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study](/research/clinical-trials/cls-20461994) Jacksonville, FL The purpose of this study is to provide continuing availability to tazemetostat as a single agent to subjects who have completed their participation in an antecedent tazemetostat study (either with monotherapy or combination therapy). In addition, long-term safety and overall survival will be collected. - [Study of Efficacy and Safety of CTL019 in Adult ALL Patients](/research/clinical-trials/cls-20460826) Scottsdale/Phoenix, AZ The purpose of this study is to determine the effectiveness and safety of CTL019 in adult patients with r/r B-cell ALL. The study will have the following sequential phases: Screening, Pre-Treatment, Treatment and Primary Follow-up, Secondary Follow-up (Relapse Follow-up) and Survival Follow-up. The total duration of the primary follow-up is 1 year from cell infusion. Safety will be assessed until the end of the treatment and primary follow-up phase. - [A Study to Determine the Effectiveness and Safety of Luspatercept in Patients with Myelodysplastic/ Myeloproliferative FL; Rochester, MN The purpose of this study is to document the erythroid response rate assessed as per the 2015 International Working Group (IWG) MDS/MPN response criteria. In this study we want to find out more about the side effects of a new drug combination for MDS/MPN-RS-T and MDS/MPN-U with RS, luspatercept with or without hydroxyurea and what doses of this combination are safe for people to take and how the disease responds to the treatment. There are 2 groups of patients being studied in this trial. One group of patients will receive luspatercept. The other group will receive luspatercept and hydroxyurea. ... - [Alisertib in Treating Young Patients with Recurrent or Refractory Solid Tumors or Leukemia](/research/clinical-trials/cls-20115762) No Locations This phase II trial is studying the side effects of and how well alisertib works in treating young patients with relapsed or refractory solid tumors or leukemia. Alisertib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. - [Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients with Relapsed or Relapsed/Refractory Multiple Myeloma](/research/clinical-trials/cls-20145339) Rochester, MN This phase I/II trial studies the side effects and best dose of ixazomib and to see how well it works when given together with pomalidomide and dexamethasone in treating patients with relapsed or relapsed/refractory multiple myeloma. Ixazomib may stop the growth of cancer by interfering with proteasomes (the protein breakdown mechanism in the cells). Pomalidomide and dexamethasone can modify and regulate the immune system and may stop cancer cells from growing. Giving ixazomib with pomalidomide and dexamethasone may be an effective treatment for relapsed or relapsed/refractory multiple myeloma. - [Phase IIa Study Evaluating Safety of BL-8040 in Relapsed/Refractory AML Patients](/research/clinical-trials/cls-20131487) Jacksonville, FL The goal of this clinical research study is to learn if BL-8040 in combination with cytarabine (Ara-C) can help to control the disease in patients with Acute Myeloid Leukemia (AML) that has relapsed or did not respond adequately to previous treatment. The safety of the study drug combination will also be studied. - [A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Effectiveness of AMG 397 in Subjects With Multiple Myeloma, NHL, and AML](/research/clinical-trials/cls-20455986) Jacksonville, FL The purpose of this study is to evaluate the safety and tolerability of AMG 397 by estimating the maximum tolerated doses (MTDs) and/or biologically active doses. - [A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma](/research/clinical-trials/cls-20467357) Rochester, MN The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with metastatic merkel cell carcinoma (MCC). - [Efficacy and Safety of COVID-19 Vaccine in Cancer Patients](/research/clinical-trials/cls-20509687) Jacksonville, FL We hypothesize that cancer patients on cytotoxic chemotherapy which affect immune response may not mount adequate immune response to COVID-19 vaccines. Aims, purpose, or objectives: - To determine the antibody response to COVID-19 vaccine after vaccination. - To assess the adverse events of COVID-19 vaccines in cancer patients. - To determine the incidence and severity of COVID-19 infection after the vaccination. - [Long-term Safety and Efficacy of Momelotinib in MN This open-label study is to determine the long-term safety and tolerability of momelotinib in previously enrolled study participants essential thrombocythemia (ET), who have tolerated and achieved stable disease or better with momelotinib treatment while enrolled in a previous clinical trial. - [Methylene Blue Mouthwash for Oral Mucositis Pain in Cancer](/research/clinical-trials/cls-20541617) Rochester, MN Evaluate the efficacy of methylene blue mouth wash for increasing oral intake and relieving pain in patients with oral mucositis related to cancer and/or cancer treatments. Oral intake will improve after six doses of methylene blue mouthwash compared to usual care. Usual care is defined as the institutional standard of care at the study site which includes magic mouthwash (lidocaine/diphenhydramine/Maalox) and sodium bicarbonate oral rinse. - [A Study to Evaluate TAK-981 Given With Monoclonal Antibodies In Adults With Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20517037) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The primary purpose of this study is to evaluate the safety and effectiveness of TAK-981 in combination with anti-CD38 monoclonal antibodies. TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies to treat participants who have relapsed or refractory multiple myeloma. - [Breath Condensate of Lung Cancer Patients and Healthy Controls to Measure RNA Species in Exhaled Breath Condensate](/research/clinical-trials/cls-20542945) Rochester, MN The purpose of this study is to develop tests for early detection of lung cancer (LC) based on multiomics analyses of patients' breath condensates. - After in Patients With Osteosarcoma](/research/clinical-trials/cls-20517178) Jacksonville, FL; Rochester, MN This study is evaluating whether administration of glucarpidase will allow faster clearance of high-dose methotrexate and thus fewer side effects related to methotrexate therapy. - [Study of Lenzilumab (KB003) in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)](/research/clinical-trials/cls-20157195) Rochester, MN This is a multicenter, open-label, repeat-dose, Phase 1 Dose Escalation Study to evaluate safety, pharmacokinetics, and clinical activity. - [Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)](/research/clinical-trials/cls-20203536) Rochester, MN The purpose of this study is to evaluate the efficacy and safety of imetelstat in transfusion dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to erythropoiesis-stimulating agent (ESA) treatment. - [Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors](/research/clinical-trials/cls-20385842) Rochester, MN Tinostamustine (EDO-S101) is a new chemical entity, an AK-DAC (a first-in-class alkylating deacetylase inhibiting molecule) that, in preclinical studies, has been shown to simultaneously improve access to the DNA strands within cancer cells, break them and block damage repair. This Phase 1/2 study will enroll patients with various advanced solid tumors. - [In Vitro 3D Cell Culture Models Validation for Tumor Drug Sensitivity after Tissue Removal](/research/clinical-trials/cls-20539163) Rochester, MN The purpose of this study is to validate that tumor organoid drug sensitivity is representative of patient treatment outcomes. - [A Study of ABBV-085, an Antibody Drug Conjugate, for Patients with Advanced Solid Cancer Tumors](/research/clinical-trials/cls-20263280) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety and drug/body interactions of ABBV-085, and to determine the recommended future study dose (alone or in combination with standard therapies) for people who have advanced solid tumors. - [Alisertib in Treating Patients With Advanced or Metastatic Sarcoma](/research/clinical-trials/cls-20112306) Scottsdale/Phoenix, AZ; Rochester, MN This phase II trial studies how well alisertib works in treating patients with advanced or metastatic sarcoma. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. - [A Study to Examine Financial Distress in Patients Undergoing Treatment of Locally-advanced Rectal Cancer](/research/clinical-trials/cls-20467510) Scottsdale/Phoenix, AZ The purpose of this study is to examine the needs and gap in our understanding of financial burden experienced by rectal cancer patients from a patient perspective to help provide patient centered care and improve psychosocial outcomes of this group. - [A Study of BBI608 in Adult Patients With Advanced Colorectal Cancer](/research/clinical-trials/cls-20111770) Scottsdale/Phoenix, AZ; Rochester, MN This is an open label study of BBI608 in combination with cetuximab, panitumumab or capecitabine in patients with advanced colorectal cancer. - [Safety and Efficacy of VB-111 in Subjects with Advanced Differentiated Thyroid Cancer](/research/clinical-trials/cls-20116769) Jacksonville, FL; Rochester, MN The purpose of this study is to examine the safety and evaluate the response of VB-111 on DTC. - [Safety and Tolerability of TAR-200 in Subjects With Muscle-Invasive Bladder Cancer Who Are Unfit for Radical Cystectomy](/research/clinical-trials/cls-20417921) Scottsdale/Phoenix, AZ The purpose of this study is to determine if TAR-200, an investigational drug-delivery system, is safe and tolerable in patients with muscle-invasive bladder cancer (MIBC) who are unfit for radical cystectomy (RC) during an 84-day induction period comprised of four consecutive 21-day dosing cycles. - [A Study to Assess a New Personalized Tool for Colorectal Cancer Peritoneal Disease Treatment](/research/clinical-trials/cls-20467370) Rochester, MN The objectives of this study are to genomically characterize patient-derived organoids (PDOs) and primary tissues from colorectal peritoneal cancer (CRC) disease, to evaluate the use of PDOs as a new personalized therapy selection tool for intraperitoneal therapy in CRC peritoneal disease, and to evaluate the use of PDOs as a new personalized therapy selection tool for systemic therapy in CRC peritoneal disease. - [Patient and Caregiver Perspective About Financial Distress of Cancer Treatment](/research/clinical-trials/cls-20411779) Scottsdale/Phoenix, AZ The purpose of this study is to understand the need and gap in interventions addressing financial burden from a patient perspective, and develop a psychoeducational intervention directed towards decreasing financial distress in patients undergoing cancer treatment based on the knowledge gained. - [A Study of RLY-4008 in Patients with Intrahepatic Cholangiocarcinoma and Advanced Solid Tumors](/research/clinical-trials/cls-20504322) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to define the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), safety profile, pharmacokinetics (PK), pharmacodynamics and preliminary anti-tumor activity of RLY-4008 in patients with ICC and other advanced solid tumors. - [Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade, Non-muscle Invasive Bladder Cancer](/research/clinical-trials/cls-20535937) Jacksonville, FL; Rochester, MN The primary objective of this study is to characterize the safety and toxicity profile of TARA-002 administered intravesically. - [A Study to Evaluate HH2853 in Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (how a drug moves within the body) and clinical activity of HH2853, an EZH1/2 Inhibitor, in patients with relapsed/refractory Non-Hodgkin's lymphomas or advanced solid tumors. - [A Study of Selpercatinib Following Definitive Locoregional Treatment in Participants with Non-small Cell Lung Cancer](/research/clinical-trials/cls-20528570) Rochester, MN The purpose of this study is to compare Event-Free Survival (EFS) of participants in the primary analysis population with Stage II-IIIA RET fusion-positive Non-small Cell Lung Cancer (NSCLC) treated with selpercatinib versus placebo. - [Phase II with Cetuximab ](/research/clinical-trials/cls-20506803) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to assess the preliminary anti-tumor activity, safety, and tolerability, and to explore the pharmacokinetics (PK) of tepotinib in combination with oncogene wild-type left-sided metastatic colorectal cancer (mCRC) having acquired resistance to anti-epidermal growth factor receptor (EGFR) antibody targeted therapy due to mesenchymal epithelial transition factor (MET) amplification. - [Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients With Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma](/research/clinical-trials/cls-20506436) Rochester, MN Despite recent improvements in outcome for children with newly diagnosed high-risk neuroblastoma, cure rates remain unsatisfactory.Further, these gains have been the result of interventions during the Consolidation (tandem autologous stem cell transplant) and Post-Consolidation (dinutuximab immunotherapy) phases of treatment, while rates of disease control during Induction have not improved in recent COG trials. The current phase 3 trial seeks to improve the event-free survival (EFS) for children with high-risk neuroblastoma through early integration of promising novel targeted therapies: targeted radiopharmaceutical therapy with 131I-MIBG or the ALK inhibitor, crizotinib. After enrollment, patients will receive one cycle of Induction chemotherapy. ... - [A Study to Evaluate Belinostat and AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to assess how well belinostat and SGI-110 (guadecitabine) or ASTX727 work in treating patients with conventional chondrosarcoma that cannot be removed by surgery (unresectable) and has spread to other places in the body (metastatic). Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as guadecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving belinostat and guadecitabine may lower the chance of chondrosarcoma growing or ... - [Dynamics of Clinical Trial Discussions in Oncology to Identify Patient Barriers and Help Develop a Patient-centered Intervention to Increase Participation in Clinical Trials](/research/clinical-trials/cls-20540922) Rochester, MN The purposes of this study are to richly describe the content and dynamics of clinical trial discussions in oncology and compare the knowledge, beliefs, and attitudes of oncology patients, caregivers, and clinicians related to clinical trials, and to develop a multifaceted, patient-centered intervention for increasing patient understanding of and participation in clinical trials in oncology. - [Placebo Controlled Study of VS-6063 in Subjects with Malignant Pleural Mesothelioma](/research/clinical-trials/cls-20116723) Rochester, MN This study is a double-blind, placebo-controlled, multicenter study of defactinib (VS-6063) in subjects with malignant pleural mesothelioma (MPM) who have not progressed (confirmed partial response or stable disease) following 4 cycles of treatment with pemetrexed/cisplatin or pemetrexed/carboplatin. Prior to entry and randomization to the study, each subject must have tumor Merlin status(high or low) established by immunohistochemistry performed at a central laboratory. Subjects will be randomized in a 1:1 ratio to receive oral VS-6063 400 mg twice per day, or matched placebo. Randomization will be stratified by tumor Merlin status (high versus low). Progression will be ... - [Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas](/research/clinical-trials/cls-20491128) Rochester, MN The purpose of this study is to determine the safety profile and the maximum dose of Debio 1143 (AT-406) that can be given to humans. This study is also designed to measure how much Debio 1143 (AT-406) gets into the blood stream (pharmacokinetics), and how Debio 1143 (AT-406) interacts with proteins related to cancer that the drug is targeted to affect (pharmacodynamics). - [A Study Evaluating AMG 424 in Subjects With Multiple Myeloma](/research/clinical-trials/cls-20463522) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN Prior clinical experience with CD38-targeting antibodies, including daratumumab, establish this molecule as an important therapeutic target in multiple myeloma. CD38 is a type II transmembrane glycoprotein with both ectoenzymatic and signal transductionfunctions. CD38 dimerization is required for its catalytic activity the latter CD38-mediated cADPR generation enables calcium release from intracellular stores, leading to a variety of cell type-specific physiological outcomes (Schuber and und, 2004; Lee and Aarhus, 1991). A distinct mode of CD38-dependent signal ... - [ALEX Study: A Randomized, randomized, active controlled, multicenter Phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with critozinib treatment in patients with treatment-naive ALK-positive advanced NSCLC. Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive treatment until disease progression, unacceptable toxicity, consent withdrawal or death occurs. The study is expected to last approximately 42 months. - [Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma](/research/clinical-trials/cls-20453010) No Locations RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the signaling molecules needed for cell growth. Monoclonal antibodies, such as alemtuzumab, can bind to and kill malignant lymphocytes. PURPOSE: This phase I/II trial is studying the side effects and best dose of everolimus when given together with alemtuzumab and will see how well they work in treating patients with recurrent chronic lymphocytic and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving aurora A kinase inhibitor MLN8237 together with bortezomib and to see how well they work in treating patients with relapsed or refractory multiple myeloma. - [A Study of Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with MCL-1 Dependence 40%](/research/clinical-trials/cls-20438953) Jacksonville, FL; Rochester, MN The purpose of this two-stage Phase 2 study is to assess the clinical response (Complete Remission) to FLAM compared to AM treatment in refractory or relapsed AML patients with demonstrated NOXA BH3 priming of 40% by mitochondrial profiling in bone Study to Evaluate AVID200 in Myelofibrosis Patients](/research/clinical-trials/cls-20480294) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety and effectiveness of AVID200. Increased levels of TGF-1 were detected in serum, plasma and BM and positively correlated with both grade of BMF and extent of leukemic cell infiltration in the marrow. TGF- likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. AVID200 is a drug that targets TGF-1 and TGF-3. The study team hypothesizes that inhibiting the TGF- signaling pathway in MF will decrease the fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation and restore normal hematopoiesis. ... Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 30% mutation to any of be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a greater than 30% mutation to the genes listed can be enrolled to a non-actionable treatment arm. The genetic sequencing of ... - [A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer](/research/clinical-trials/cls-20525151) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety and tolerability of AMG 757, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). - [Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia](/research/clinical-trials/cls-20111783) Scottsdale/Phoenix, AZ The primary hypothesis of the study is that treatment with either once-daily or twice-daily pacritinib results in a greater proportion of patients with thrombocytopenia and myelofibrosis achieving 35% reduction in spleen volume from baseline to Week 24 than treatment with Best Available Therapy, and a greater proportion of patients achieving a 50% reduction in total symptom score from baseline to Week 24 as measured by the Myeloproliferative Neoplasm Symptom Assessment Form 2.0. - [Breast Cancer Biomarker Sample Collection for the dtectDx of Concept Protocol](/research/clinical-trials/cls-20145189) Scottsdale/Phoenix, AZ; Rochester, MN The major purpose of this study is to evaluate a laboratory developed test that measures multiple breast cancer-specific biomarker proteins and multiple antibodies in your blood samples. The biomarker and antibody results along with your personal medical profile will be evaluated to determine your risk for the presence of a malignancy in the breast as compared to your breast evaluation assessment conducted by your physician. - [A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Participants With Prostate Cancer](/research/clinical-trials/cls-20467336) Scottsdale/Phoenix, AZ The purpose of this study is to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. - [Hereditary Cancer Registry](/research/clinical-trials/cls-20503445) Jacksonville, FL The purpose of this study is to develop and maintain a clinical registry database of all patients seen at Mayo Clinic Florida who have completed genetic testing through Mayo Clinic Florida or are seen due to a previously identified hereditary cancer risk. - [Developing Criteria for Treatment of Neurofibromatosis Type 1 Associated Optic Pathway Glioma](/research/clinical-trials/cls-20313409) Rochester, MN The purpose of this research study is to understand the natural history of vision in patients with OPG and determine if there are factors (e.g. age at diagnosis, male/female, tumor location, features of the MRI exam, etc) that predict future vision loss or change in tumor size. Another purpose of the study is to collect and store blood and tissue samples to use for future research to evaluate if there are certain variations in DNA, RNA, or proteins that predict the likelihood of an OPG to grow or cause vision loss. - [A Study of Leukemia Inhibitory Factor Biomarker Monitoring Progression and Treatment Response of Locally-advanced Unresectable and Metastatic Pancreatic Cancer Therapies](/research/clinical-trials/cls-20541866) Jacksonville, FL The purpose of this study is to determine if LIF (Leukemia Inhibitory Factor) level is positively correlated with disease progression and CA19-9 level in Pancreatic Ductal Adenocarcinoma (PDAC) patients and is a reliable biomarker of response. - [Longterm Follow-up of Subjects Treated With bb2121](/research/clinical-trials/cls-20258278) Rochester, MN This is a multi-center, non-randomized, open label, longterm safety and efficacy follow-up study for subjects who have been treated with bb2121 in the Phase 1 clinical parent study, that evaluated the safety and efficacy of bb2121 in subjects with relapsed or refractory B cell maturation antigen (BCMA)-expressing multiple myeloma. bb2121 is defined as autologous T cells) transduced ex vivo with anti-BCMA02 CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA suspended in cryopreservative solution. bb2121 is administered in subjects 1 time (or retreated if retreatment criteria are met) in parent clinical study. No ... - [International Precision Medicine Consortium for Neurooncology Research](/research/clinical-trials/cls-20438529) Rochester, MN The purpose of this study is to collect minimal risk normal samples, both prospectively collected and those stored at the patient's home institution and any outside institutions, along with clinical data. For this same end, the study provides for a wide scope of research, including detailed genetic analysis, and provides mechanisms for reporting of results back to participants and/or their treating physicians. - [Study of Tipifarnib in Subjects With Relapsed or Refractory Peripheral T-Cell Lymphoma](/research/clinical-trials/cls-20203469) Rochester, MN This Phase II studyis designed to investigate the antitumor activity in terms of objective response rate (ORR) of tipifarnib in 18 subjects with advanced Peripheral T-Cell Lymphoma (PTCL). The total number of patients could be extended to 30 pending on the degree of response observed at an interim analysis. Tipifarnib will be administered until disease progression then followed approximately every 12 weeks for survival until either death or 12 months after accrual of the last study subject, whichever occurs first. - [NLA101 in Adults Receiving High Dose Chemotherapy for AML](/research/clinical-trials/cls-20411781) Jacksonville, FL; Rochester, MN Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML. - [Caris Biorepository Research Protocol](/research/clinical-trials/cls-20148442) Scottsdale/Phoenix, AZ The Biorepository for Caris Life Sciences is designed for the purpose of making quality biospecimens and associated clinical data available for research studies related to advancing precision medicine and improving care for patients. The Caris Biorepository is a repository of prospectively collected biological specimens and associated clinical and demographic data gathered from multiple sources to be stored, used and shared for research. Caris Life Sciences will maintain the data and specimens and will control access to and use of the information and specimens by multiple individuals for multiple purposes which may evolve over time. - [Electronic Patient Reporting of Symptoms During Cancer Treatment](/research/clinical-trials/cls-20463517) La Crosse, WI; Eau Claire, WI; Mankato, MN The current study is designed to test nationally whether patients' outcomes and utilization of services can be improved through symptom monitoring via patient-reported outcomes between visits. - [Risk Factors for Recurrence in Endometrial Cancer Patients](/research/clinical-trials/cls-20506956) Rochester, MN The purpose of this study is to identify those clinical, immunochemical, or molecular risk factors associated with an increased risk of distant recurrence in \"high-intermediate\" risk endometrial cancer patients. - [A Study of BBI503 in Adult Patients With Advanced Solid Tumors](/research/clinical-trials/cls-20145321) Scottsdale/Phoenix, AZ; Rochester, MN This is an open label, single arm dose escalation study of BBI503 in adult patients with advanced solid tumors. - [A Study to Evaluate INSTILADRIN\u00ae in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC](/research/clinical-trials/cls-20267890) Rochester, MN Previous multi-dose Phase I and Phase II clinical studies have demonstrated that Instiladrin nadofaragene firadenovec is a safe and effective treatment for BCG-refractory and recurrent NMIBC. This Phase III study is designed to expand those observations using a high dose of Instiladrin in patients that are \"BCG Unresponsive\" which refers to patients with high grade NMIBC who are unlikely to benefit from and should not receive further intravesical BCG. - [A Study to Evaluate AL101 Monotherapy in Patients with Notch Activated Triple Negative Breast Cancer](/research/clinical-trials/cls-20506804) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is designed to evaluate the effectiveness and safety of AL101 monotherapy in subjects with Notch-activated recurrent or metastatic Triple Negative Breast Cancer (TNBC); Notch activation will be determined by a Next Generation Sequencing (NGS) test. - [Study of SBP-101 in Pancreatic Cancer](/research/clinical-trials/cls-20198324) Scottsdale/Phoenix, AZ This first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD). In addition, this study will also assess the pharmacokinetic (PK) profile and preliminary efficacy of SBP-101. - [A Study to Evaluate INSTILADRIN\u00ae in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC](/research/clinical-trials/cls-20267890) Rochester, MN Previous multi-dose Phase I and Phase II clinical studies have demonstrated that Instiladrin nadofaragene firadenovec is a safe and effective treatment for BCG-refractory and recurrent NMIBC. This Phase III study is designed to expand those observations using a high dose of Instiladrin in patients that are \"BCG Unresponsive\" which refers to patients with high grade NMIBC who are unlikely to benefit from and should not receive further intravesical BCG. - [A Study to Evaluate AL101 Monotherapy in Patients with Notch Activated Triple Negative Breast Cancer](/research/clinical-trials/cls-20506804) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is designed to evaluate the effectiveness and safety of AL101 monotherapy in subjects with Notch-activated recurrent or metastatic Triple Negative Breast Cancer (TNBC); Notch activation will be determined by a Next Generation Sequencing (NGS) test. - [Study of SBP-101 in Pancreatic Cancer](/research/clinical-trials/cls-20198324) Scottsdale/Phoenix, AZ This first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD). In addition, this study will also assess the pharmacokinetic (PK) profile and preliminary efficacy of SBP-101. - [Plasma Proneurotensin as a Predictive Biomarker for Breast Cancer in Genetically Predisposed Patients](/research/clinical-trials/cls-20391803) Rochester, MN The purpose of this study is to assess whether elevated fasting plasma proneurotensin levels are common in patients genetically predisposed to breast cancer. - [Metastatic Non-Small Cell Lung Cancer Insomnia](/research/clinical-trials/cls-20539192) Rochester, MN The purpose of this study is to evaluate the frequency of insomnia in patients with metastatic non-small cell lung cancer. - [Financial Difficulty in Patients With Blood Cancer](/research/clinical-trials/cls-20539926) Scottsdale/Phoenix, AZ The purpose of this study is to analyze the financial difficulties experienced by patients undergoing treatment for multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). It is composed of a patient survey (n=250), a physician survey (n=100), and a practice survey completed by each site enrolling patients onto this study. A subset of enrolled patients (n=35) will be invited to participate in an optional second telephone interview (Appendix D). This study will measure the prevalence of patient-reported financial difficulty, specific financial burdens and resources currently available to patients and from practices to assist with patient financial navigation. - [A Study to Evaluate Ulixertinib to Treat Patients with Rochester, MN The purpose of this study is to evaluate the safety and clinical activity experience of previous studies that have evaluated ulixertinib as a novel targeted cancer treatment in cohorts of patients with specific genetic alterations and tumor histologies that result in aberrant MAPK pathway signaling. Early clinical data have demonstrated anti-tumor activity with ulixertinib treatment and have identified specific groups of patients for whom additional development is warranted. - [A Study of LNK01002 in Patients With Primary (PMF) or Myelofibrosis or Acute Myeloid Leukemia](/research/clinical-trials/cls-20534337) Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (MF), or due to polycythemia vera (PV-MF), or essential thrombocythemia (ET-MF), or with acute myeloid leukemia (AML). - [A Study to Establish a Research Tissue Bank for Myeloproliferative Neoplasms](/research/clinical-trials/cls-20526483) Scottsdale/Phoenix, AZ The purpose of this study is to credential novel therapeutic approaches which can then be transitioned to the clinic for near-term mechanism based clinical trials in this research consortium. There is a need for new treatments for myelofibrosis (MF) patients based on laboratory insight into disease pathogenesis. We will use primary patient samples to understand how different genetic mutations contribute to MF development and to test novel treatment approaches. - [Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant](/research/clinical-trials/cls-20535259) Jacksonville, FL; Rochester, MN The purpose of this trial is to assess the safety and effectiveness of the combination of dapagliflozin plus metformin extended release (XR) compared with metformin XR during treatment with alpelisib plus fulvestrant in participants with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation following progression on or after endocrine-based therapy. - [A Study of Poziotinib in Patients Rochester, MN The purpose of this study is to evaluate the efficacy and the safety/tolerability of poziotinib in patients with NSCLC exon 20 insertion mutations. - [A Study to Evaluate FL; Rochester, MN The purpose of this study is to evaluate the safety and to determine the recommended phase 2 dose (RP2D) of Lutetium Lu 177 Dotatate in combination with triapine. - [A Study to Evaluate Dabrafenib and Trametinib With or Without Hydroxychloroquine in Advanced Melanoma](/research/clinical-trials/cls-20526650) Rochester, MN The purpose of this study is to investigate how well adding hydroxychloroquine to the standard treatment of dabrafenib and trametinib works to overcome resistance and delay disease progression in treating patients with stage IIIC or IV BRAF V600E/K melanoma. Hydroxychloroquine may cause cell death in tumor cells that rely on a process called \"autophagy\" for survival. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine together with dabrafenib and trametinib may work better than dabrafenib and trametinib alone to shrink and stabilize the cancer. - [A Study to Evaluate Maximizing Anti-PD-1 Therapy By Monitoring T Cell Responses In Melanoma, Lung and Other Cancer Types](/research/clinical-trials/cls-20435265) Rochester, MN The purpose of this study is to monitor T cell responses from patients with advanced cancer who are being treated with an anti-PD (programmed death)-1 monoclonal antibody, and compare them with clinical outcomes. - [Ph 1b Study to Evaluate GSK2110183 in Combination with Bortezomib and Dexamethasone in Subjects with Multiple Myeloma](/research/clinical-trials/cls-20115785) Scottsdale/Phoenix, AZ (PD) and clinical combination with bortezomib and dexamethasone in multiple myeloma (MM) subjects who have failed at least one line of systemic treatment. Part 1 will identify the maximum tolerated dose(s) (MTD) of the combination regimen. Schedule A - GSK2110183 administered once daily with bortezomib (1.3 mg/m2) and dexamethasone (20 mg) given biweekly. Part 2 will further explore the safety, tolerability and clinical activity of the MTD(s) identified in Part 1, including a pharmacokinetic cohort. - [Study Evaluating ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20115565) Scottsdale/Phoenix, AZ; Rochester, MN The phase 1 primary objectives of this study are to assess the safety profile, characterize pharmacokinetics (PK) and determine the dosing schedule, maximum tolerated dose (MTD), and recommended phase 2 dose (RPTD) of ABT-199 (venetoclax) when administered in subjects with relapsed or refractory multiple myeloma. This study will also assess the safety profile and PK of venetoclax in combination with dexamethasone in subjects with t(11;14)-positive multiple myeloma. The phase 2 primary objective is to further evaluate the objective response rate (ORR) and very good partial response or better rate (VGPR+) in subjects with t(11;14)-positive multiple myeloma and to evaluate patient ... - [A Study to Evaluate Safety of Enapotamab Vedotin in Patients with Solid Tumors](/research/clinical-trials/cls-20424752) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of the trial is to establish the tolerability of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors. - [A Study of the Safety and Drug/Body Interactions of BGB-3111 for Patients with B-Cell Lymphoid Malignancies](/research/clinical-trials/cls-20301416) Rochester, MN The purpose of this study is to evaluate the safety, tolerability, drug/body interactions, and treatment effects of a new drug known as BGB-3111 in patients who have B-cell lymphoid malignancies. - [A Study of the Effectiveness and Safety of CTL019 in Adult Patients with Diffuse Large B-Cell Lymphoma](/research/clinical-trials/cls-20200128) Scottsdale/Phoenix, AZ The purpose of this study is to determine the efficacy and safety of CTL019 in adult patients with relapsed or resistant diffuse large B-cell lymphoma. - [A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma](/research/clinical-trials/cls-20150031) Scottsdale/Phoenix, AZ Primary Objective: - Part A: To evaluate the safety of SAR650984 (isatuximab) in patients with relapsed/refractory multiple myeloma (RRMM). - Part B: To evaluate the activity of SAR650984 (isatuximab) as assessed by overall response rate (ORR) in RRMM patients previously treated with daratumumab. Secondary Objectives: - Part A: - To determine the pharmacokinetics (PK) of SAR650984 (isatuximab) in patients with RRMM. - Part B: - To evaluate the safety of SAR650984 (isatuximab). - To evaluate the efficacy of SAR650984 (isatuximab) as assessed by duration of response (DOR), clinical benefit rate (CBR) and progression free survival (PFS). - To assess the ... - [DS-8201a in Human Growth Factor Receptor2 (HER2)-Expressing Colorectal Cancer (DESTINY-CRC01)](/research/clinical-trials/cls-20463520) Jacksonville, FL The main objective of this study is to test the safety and effectiveness of DS-8201a for participants with HER2-expressing advanced colorectal cancer. - [A Study to Evaluate the Safety and Effectiveness of Intratumoral and Intravenous Injection of Vesicular Stomatitis Virus Expressing Human Interferon Beta, and Tyrosinase Related Protein 1 (VSV-IFNb-TYRP1) in Patients with Metastatic Ocular Melanoma and Previously with Unresectable Stage III/IV Cutaneous Melanoma](/research/clinical-trials/cls-20455118) Rochester, MN The purpose of this study is to determine the safety profile and maximum tolerated dose (MTD) of VSV-IFN\u00df-TYRP1 therapy when administered by IV and IT injection in patients with previously treated metastatic melanoma. - [A Study of Androgen Annihilation in High-Risk Scottsdale/Phoenix, AZ This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time 9 months at the time of study entry. - [64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)](/research/clinical-trials/cls-20539096) Rochester, MN The purpose of this study is to evaluate 64Cu-SAR-bisPSMA and 67Cu-ARbisPSMA administered to participants with metastatic castrate resistant prostate cancer (mCRPC). This study is to be conducted in 3 phases: a Dosimetry Phase, a Dose Escalation Phase and a Cohort Expansion Phase. - [Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory/Intolerant Failing 3 Prior Chronic Myeloid Leukemia Therapies](/research/clinical-trials/cls-20522394) Jacksonville, FL The purpose of this study is determine the safety, tolerability, pharmacokinetics and activity of K0706. A 'Multi-Omics' Approach](/research/clinical-trials/cls-20502720) Rochester, MN The purpose of this research is to determine whether circulating tumor DNA, RNA or proteins can be detected in the blood of patients with sarcoma. We are also interested in learning if these levels change over time while receiving chemotherapy. Patients with advanced sarcoma who will receive chemotherapy will be asked to participate. Study participation involves blood-draws of approximately 4 tablespoons of blood at each of 4 separate time-points as well as access to archived tumor tissue, or fresh tumor tissue at the time of clinically indicated biopsy or surgery. We hypothesize that circulating tumor DNA, RNA and/or proteins ... - [INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)](/research/clinical-trials/cls-20426328) Rochester, MN This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : - Abemaciclib - Temozolomide (temodar) - Neratinib - CC115 - [A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FR)](/research/clinical-trials/cls-20523168) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The primary purpose of Part 1 (dose escalation) of this study is to establish the MTD and/or RP2D of ELU001 in subjects who have advanced, recurrent or refractory FR overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive. The primary purpose of Part 2 (Tumor Group Expansion Cohorts) of this study is to evaluate anti-tumor activity of ELU001 in subjects who have moderate or high FR overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive. - [Phase Ib Study of PDR001 in Combination With Regorafenib in Patients With Previously Treated Metastatic Colorectal Cancer](/research/clinical-trials/cls-20542521) Scottsdale/Phoenix, AZ This is a phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer. The study will assess primarily the safety and tolerability and then the efficacy of PDR001 in combination with regorafenib. Particular attention will be paid to the level of activity of study drug combinations in CMS4 patients (retrospective analysis). - [A Study of SGN-B7H4V in Advanced Solid Tumors](/research/clinical-trials/cls-20534788) Jacksonville, FL The purpose of this study is to test the safety and side effects of a drug called SGN-B7H4V in participants with solid tumors. A side effect is anything a drug does to the body besides treating the disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). This study will have three parts. Parts A and B of the study will find out how much SGN-B7H4V should be given to participants. Part C will use the dose found in Parts A ... - [A Study Evaluating the Effectiveness of Oral Vismodegib in Various Histologic Subtypes of High Risk or Locally Advanced Basal Cell Carcinoma](/research/clinical-trials/cls-20463507) Jacksonville, FL The purpose of this study is to investigate the safety and effectiveness of oral vismodegib therapy in the treatment of different 'histologic subtypes' of basal cell skin cancer (BCC). The term 'histologic subtype' refers to how the cells and tumor tissue looks under the microscope. Three different 'histologic subtypes' of basal cell skin cancer (infiltrative/morpheaform, nodular and superficial) will be examined in this study. - [Study of AMG 650 in Adult Participants With Advanced Solid Tumors](/research/clinical-trials/cls-20509256) Rochester, MN To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D). - [Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG](/research/clinical-trials/cls-20232529) Scottsdale/Phoenix, AZ Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy. Vicinium is an experimental agent that may provide an alternative to cystectomy - [A Phase 1B Dose-escalation Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma](/research/clinical-trials/cls-20111959) Jacksonville, FL; Rochester, MN The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose pazopanib in patients with advanced soft tissue sarcoma. The purpose of the phase 2 portion is to estimate the PFS of patients with advanced soft tissue sarcoma by RECIST 1.1. - [A Study of MK-1026 with Selected Hematologic Malignancies](/research/clinical-trials/cls-20492363) Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to evaluate MK-1026 in patients with selected hematologic FL This study is being done to: 1. Create a registry of patients having or at risk for cancer of the liver or bile ducts (also known as hepatocellular carcinoma or cholangiocarcinoma), or gallbladder cancer, and those individuals who have normal risk factors in order to improve the ability to diagnose and treat these cancers. We will use information in the medical record in this registry including how far advanced the cancer is (stage) and what treatments are used to treat the cancer. 2. A second purpose of this study is to obtain blood and tissue samples from participants ... - [A Study to Analyze the Association Between Financial and Health Insurance Literacy and Financial Distress in Patients Being Treated for Cancer](/research/clinical-trials/cls-20506117) Scottsdale/Phoenix, AZ The purpose of this study is to assess the level of financial and health insurance literacy and financial distress in cancer patients coming to the infusion center by analyzing the correlation amongst these outcomes, as well assessing their association with baseline sociodemographic and disease/ treatment factors. - [A Study of Cemiplimab in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy](/research/clinical-trials/cls-20403055) Scottsdale/Phoenix, AZ The primary objective is to estimate the overall response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with Cemiplimab as a monotherapy. - [A Study of XmAb \u00ae18087 Subjects and GIST](/research/clinical-trials/cls-20428801) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine the safety and tolerability profile of XmAb18087 in subjects with advanced, well-differentiated neuroendocrine tumors (NET) of pancreatic, gastrointestinal, lung, and undetermined origin, and subjects with advanced gastrointestinal stromal tumors (GIST), and to identify the maximum tolerated dose (MTD) and/or recommended dose (RD) and schedule of XmAb18087 administered by intravenous (IV) dosing on Days 1, 8, 15, and 22 of each 28-day cycle in subjects with advanced NET and advanced GIST, separately. - [A Study to Assess the Effectiveness and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer](/research/clinical-trials/cls-20509167) Rochester, MN The purpose of this study is to assess the effectiveness and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in patients with recurrent or metastatic head and neck cancer. - [A First-in-Human, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BJ-005 in Patients With Advanced Solid Tumor or Lymphoma](/research/clinical-trials/cls-20531161) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of BJ-005 in patients with advanced solid tumor or lymphoma. BJ-005 is a recombinant bifunctional molecule, composed of a humanized anti-PD-L1 IgG1 monoclonal antibody (mAb) fused with a portion of the extracellular domain of human TGF- receptor II (TGF-RII). - [A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets](/research/clinical-trials/cls-20539268) Rochester, MN The purpose of this study is to characterize the safety and toxicity profiles of ABBV-453 in subjects with Relapsed/Refractory Multiple Myeloma (R/R MM). Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. - [PLX038 for the Treatment of Metastatic Ovarian, Peritoneal, and Fallopian Tube Cancers](/research/clinical-trials/cls-20533409) Rochester, MN The purpose of this study is to determine the response rate to PLX-038 in patients with metastatic ovarian, primary peritoneal, and fallopian tube cancers that are resistant to platinum drugs. - [Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients Mucosal Melanoma](/research/clinical-trials/cls-20535898) Jacksonville, FL; Rochester, MN The purpose of this study is to observe the antitumor activity, safety, tolerability, PK, and pharmacodynamics in patients with inoperable and/or metastatic melanoma following prior anti-PD-[L]-1 therapy. - [HeadStart4: Newly and Other CNS Embryonal Tumors](/research/clinical-trials/cls-20533479) Rochester, MN The purpose of this study is to determine whether dose-intensive tandem Consolidation, in a randomized comparison with single cycle Consolidation, provides an event-free survival (EFS) and overall survival (OS). The study population will be high-risk patients (non-Wnt and non-Shh sub-groups) with medulloblastoma, and for all patients with central nervous system (CNS) embryonal tumors completing \"Head Start 4\" Induction. This study will further determine whether the additional labor intensity (duration of hospitalizations and short-term and long-term morbidities) associated with the tandem treatment is justified by the improvement in outcome. It is expected that the tandem (3 cycles) Consolidation regimen will produce a ... - [A Study to Evaluate KO-539 to Treat Relapsed Myeloid Leukemia](/research/clinical-trials/cls-20506805) Jacksonville, FL; Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to determine the maximum tolerated dose (MTD) of KO-539, a menin-MLL(KMT2A) inhibitor, in patients with refractory or relapsed acute myeloid leukemia (AML) who have failed or are ineligible for any approved standard of care therapies, including hematopoietic stem cell transplantation (HSCT). - [Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients](/research/clinical-trials/cls-20529868) Albert Lea, MN; Eau Claire, WI; Rochester, MN This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss. - [Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer that has been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)](/research/clinical-trials/cls-20145568) Scottsdale/Phoenix, AZ; Rochester, MN This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Tumors with this mutation may respond to treatments that target the mutation, such as crizotinib. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. It is not yet known if crizotinib may be an effective treatment ... - [A Trial to Assess Effectiveness and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET](/research/clinical-trials/cls-20531304) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated Gastroenteropancreatic-Neuroendocrine Tumors (GEP-NET). Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029. - [Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast](/research/clinical-trials/cls-20433157) No Locations This randomized phase IIB trial studies how well tamoxifen or afimoxifene works in treating patients with estrogen receptor positive breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate or afimoxifene may fight breast cancer by blocking the use of estrogen by the tumor cells. - [Adrenocortical Carcinoma in Children](/research/clinical-trials/cls-20309323) Rochester, MN Adrenocortical carcinoma (ACC) is an aggressive, rare childhood cancer. Limited evidence exists on a definite histopathological criterion to differentiate ACC from adrenocortical adenomas. Early diagnosis and management is the key. Surgery is the mainstay of treatment. Even after complete resection, a high risk of recurrence of ACC remains. Despite multi-modality treatment strategies, ACC is associated with poor survival. Due to the rarity of pediatric ACC, limited evidence exists on morbidity and mortality of these patients as well as prognostic factors for survival. The aim of this study is to document morbidity and mortality of children with adrenocortical carcinoma (ACC) and ... - [Biomarkers to Predict for and Monitor Response to PD-1/PD-L1 Inhibitors](/research/clinical-trials/cls-20492001) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The primary objective of this collaborative study is to collect biospecimens for the evaluation of internally developed assays designed to predict for and monitor response to currently available PD-1/PD-L1 inhibitors. - [A Study of CC-90002 in Subjects With Acute Myeloid Leukemia and High-risk Syndrome (MDS)](/research/clinical-trials/cls-20209356) Scottsdale/Phoenix, AZ Study CC-90002-AML-001 is an open-label, Phase 1 dose escalation (Part A) and expansion (Part B), clinical study of CC-90002, administered by intravenous (IV) infusion, in subjects with relapsed and/or primary refractory AML and high-risk MDS. The study will explore escalating doses of CC-90002 using a 3 + 3 dose escalation design in Part A, followed by dose expansion in Part B. The primary objective is to determine the safety and tolerability of CC-90002 and also to define the non-tolerated dose (NTD), the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-90002. - [Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma](/research/clinical-trials/cls-20442764) Jacksonville, FL The purpose of this study is to evaluate the safety and preliminary anti-tumor activity of INCB059872 in participants with Ewing sarcoma who are refractory or relapsed from prior standard therapy and not eligible for further standard systemic therapy. - [Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation](/research/clinical-trials/cls-20192979) Rochester, Phase 1/2, multicenter, open-label, dose-escalation, safety, PK/PD, and clinical activity evaluation of orally administered AG-221 in subjects with advanced hematologic malignancies that harbor an IDH2 mutation. The study includes a dose escalation phase to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) and an expansion phase to further evaluate the safety, tolerability and clinical activity of AG-221 in select populations. - [A Study to Evaluate the Effectiveness, Safety, Pharmacokinetics and Pharmacodynamics Vera](/research/clinical-trials/cls-20463514) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety and effectiveness of idasanutlin monotherapy in participants with Treating Patients with Stage II-IV Melanoma that has been Removed by Surgery](/research/clinical-trials/cls-20116091) Rochester, MN This pilot clinical trial studies vaccine therapy and resiquimod in treating patients with stage II-IV melanoma that has been removed by surgery. Vaccines made from peptides may help the body build an effective immune response to kill tumor cell tumor cells. Biological therapies, such as resiquimod, may stimulate the immune system in different ways and stop tumor cells from growing. It is not yet known whether Gag:267-274 peptide vaccine and resiquimod are more effective when given together or separately. - [A Study to Evaluate Feasibility of In Vivo Sensitivity Screen Using Direct Tumor Microinjection and FDG-PET in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer](/research/clinical-trials/cls-20401443) Rochester, MN The purpose of this study is to assess the safety of in vivo in host drug sensitivity testing in patients with breast cancer and patients with lymphoma (nodal, extranodal masses, or cutaneous lesions). - [A Study of Oral LOXO-305 in Patients With Previously MN The purpose of this study is to evaluate oral LOXO-305 in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL) who have failed or are intolerant to standard of care. - [FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical a topical photosensitizing agent, to (mycosis fungoides). - or Refractory Chronic Myelomonocytic Leukemia](/research/clinical-trials/cls-20540775) Rochester, MN This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia that has come back (recurrent) or that does not respond to treatment (refractory). Onvansertib is a drug that binds to and inhibits an enzyme called PLK1, preventing cancer cell proliferation and causing cell death. - [INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors](/research/clinical-trials/cls-20201669) Rochester, MN This is an open-label, Phase 1b, platform study in subjects with advanced or metastatic solid tumors. The study will be divided into 2 parts (Part 1a and Part 1b). Part 1a will evaluate a JAK inhibitor with combination (epacadostat; and INCB039110 in combination with a PI3K-delta inhibitor (INCB050465; Group B) to determine the MTD or PAD and the recommended Part 1b doses for each combination. Once the recommended dose has been identified for each treatment group in Part 1a, subjects with advanced solid tumors will be enrolled into expansion ... - [A Study of MM-111 and Paclitaxel With Positive Esophagus, Gastroesophageal (GE) Junction and Stomach](/research/clinical-trials/cls-20111915) Rochester, MN To determine whether the combination of MM-111 plus paclitaxel and trastuzumab is more effective than paclitaxel and trastuzumab alone - [A Study to Assess Financial Burden and Its Impact on Quality of Life in Patients with Plasma Cell Disorders](/research/clinical-trials/cls-20482123) Rochester, MN The purpose of this study is to evaluate the magnitude of financial toxicity in newly diagnosed and relapsed multiple myeloma (MM) and amyloidosis (AL) patients. - [Profiling of Lung Cancer for Identification of Treatment Targets and Strategies](/research/clinical-trials/cls-20492433) Jacksonville, FL The purpose of this research trail is to study the genetic alteration/mutation and immune profiling in surgical resected Non-small Cell Lung Cancer (NSCLC) tumor samplesand to investigate the correlation between genetic alteration/mutation status and tumor immune micro-environment. - [A Safety Study of SEA-TGT (SGN-TGT) in Patients With Advanced Cancer](/research/clinical-trials/cls-20491268) Rochester, MN This trial will look at a drug called SGN-TGT (an anti-TIGIT antibody) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SGN-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. It will also study whether SGN-TGT works to treat solid tumors and lymphomas. The study will have four groups or \"parts.\" Part A of the study will find out how much SGN-TGT should be given to patients. Part B will use the dose found in Part A to find out how safe SGN-TGT is ... - [A Study of LOXO-292 in Patients with Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer](/research/clinical-trials/cls-20463112) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of LOXO-292 administered orally to patients with advanced solid tumors, including RET-fusion-positive solid tumors, medullary thyroid cancer (MTC) and other tumors with RET activation. - [A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme](/research/clinical-trials/cls-20541355) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The primary objective of this study is to assess the effect of berubicin compared with lomustine on overall survival (OS) in adult patients with Glioblastoma Multiforme (GBM) (WHO Grade IV) that has recurred after standard initial therapy. - [Safety Study of VAL-083 in Patients with Recurrent Malignant Glioma](/research/clinical-trials/cls-20143580) Rochester, MN The purpose of this Phase 1/2, open-label, single-arm study is to determine the safety and the maximal tolerated dose (MTD) of VAL-083 in patients with recurrent malignant glioma. Pharmacokinetic (PK) properties will be explored and tumor responses to treatment will be evaluated. - [Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma](/research/clinical-trials/cls-20392183) Rochester, MN; Jacksonville, FL This phase II trial studies how well vemurafenib and cobimetinib work in treating patients with BRAF V600E mutation positive craniopharyngioma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. - [Study of Pembrolizumab (MK-3475) in MN This is a non-randomized, open-label study evaluating the safety and efficacy of pembrolizumab (MK-3475) used in combination with dinaciclib (MK-7965) in the treatment of relapsed or refractory chronic lymphocytic leukemia (rrCLL), multiple myeloma (rrMM), or diffuse large B-cell lymphoma (rrDLBCL) in up to 138 participants from multiple sites. During an initial Dose Evaluation phase (first 2 cycles) to determine Dose Limiting Toxicities (DLTs), dose combinations of pembrolizumab 200 mg followed by dinaciclib 7 mg/m^2, pembrolizumab 200 mg followed by dinaciclib 10 mg/m^2, and pembrolizumab 200 mg followed by dinaciclib 14 mg/m^2 will be evaluated. Following safety review of the Dose ... - [A Trial of TTI-621 for Patients With Hematologic open-label, phase 1a/1b subjects with relapsed or refractory hematologic malignancies and selected solid tumors. - [Ovarian and Uterine Cancer Patients' Cancer Diagnosis and Treatment-Related Characteristics from Medical Records](/research/clinical-trials/cls-20506881) Rochester, MN The purpose of this study is to extract ovarian and uterine cancer patients' phenotypes at diagnosis and cancer treatments (side-effects, symptoms and clinical test values) from medical records using medical informatics approaches. - [MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01)](/research/clinical-trials/cls-20504259) Scottsdale/Phoenix, AZ The primary purpose of this study for Step 1: - To determine the RP2D of MEN1611 when administered orally in combination with cetuximab to patients with PIK3CA mutated colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens. The primary purpose of this study for Step 2: - To assess the anti-tumour activity of MEN1611 in combination with cetuximab in patients PIK3CA - [GEN3013, Lymphoma EPCORE NHL-1](/research/clinical-trials/cls-20507296) Scottsdale/Phoenix, AZ The purpose of the trial is to determine the maximum tolerated dose and the recommended phase 2 dose as well as to establish the safety profile of GEN3013 (DuoBody\u00ae-CD3xCD20) in patients with Relapsed, Progressive or Refractory B-Cell Lymphoma. - [A Study With Polycythemia Vera](/research/clinical-trials/cls-20510274) Scottsdale/Phoenix, AZ The purpose of this study is to test different doses of PTG-300 to identify a dose that is safe and is possibly effective for reducing the need for phlebotomies in patients with Polycythemia vera who require routine phlebotomies. [PLX3397 Phase 3 Study for Pigmented Villonodular Synovitis (PVNS) or Cell (GCT-TS)](/research/clinical-trials/cls-20146667) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This is a Phase 3 clinical study, which aims to evaluate the effectiveness of an investigational drug PLX3397 in the treatment of tumour of pigmented villonodular synovitis or giant cell tumor of the tendon sheath in subjects, for whom surgical removal of the tumour would cause more harm than good. The main purpose of this study is to gather information about the investigational drug PLX3397, which may help to treat these tumours. The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either PLX3397 or matching placebo for 24 weeks. A number of ... - [A Study to Evaluate Immune-related AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate invasive disease-free survival (iDFS) of multi-epitope HER2 vaccine vs. placebo in combination with ado-trastuzumab emtansine (TTT-DM1) in patients with stage II-III HER2+ breast cancer with residual disease post-neoadjuvant chemotherapy, and to evaluate the safety of multi-epitope HER2 vaccine given concurrently with T-DM1 maintenance therapy. - [A Study to Assess the Safety and Preliminary Effectiveness of OBT076 in Recurrent and/or Metastatic CD205-positive Solid Tumors and with CD205-positive HER2-negative Metastatic Breast Cancer](/research/clinical-trials/cls-20535258) Scottsdale/Phoenix, AZ The purpose of this study is to determine the safety and tolerability of OBT076, and to define the maximum tolerated dose (MTD) and/or the RP2D of OBT076. - [A Patient Access Program of Olaratumab for the Continued Treatment of Soft Tissue Sarcoma](/research/clinical-trials/cls-20469380) Jacksonville, FL The purpose of this study is to continue to provide olaratumab to eligible patients who are currently receiving olaratumab commercially for the treatment of soft tissue sarcoma (STS). - [A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies](/research/clinical-trials/cls-20115980) Rochester, MN This is an open label, single arm phase 1 dose escalation study and phase 2 study of BBI608 in combination with paclitaxel in patients with advanced malignancies. - [A Phase I Study of TAS-102 in Patients with Advanced Solid Tumors with Renal Impairment](/research/clinical-trials/cls-20145347) Scottsdale/Phoenix, AZ Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of renal impairment. - [Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients with Refractory Advanced Solid Tumors](/research/clinical-trials/cls-20145336) Rochester, MN The purpose of this study is to evaluate the safety and tolerability of the investigational drug VLX600 in patients with refractory advanced solid tumors. - [Acetylsalicylic Acid and Eflornithine in Treating Patients at High Risk for Colorectal Cancer](/research/clinical-trials/cls-20116763) Rochester, MN This phase II trial is studying how well giving acetylsalicylic acid together with eflornithine works in treating patients at high risk for colorectal cancer. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of acetylsalicylic acid and eflornithine may prevent colorectal cancer. - [Appointment Companion Tool](/research/clinical-trials/cls-20528750) Rochester, MN The purpose of this study is to pilot the patient appointment companion (PAC) tool in use with patients with amyloidosis and multiple myeloma (MM). Patients with hematologic malignancies have unique information and communication needs compared to those with solid tumors. The internet has shifted the dynamics of the patient-doctor relationship, toward one of more mutual participation whereby power and responsibility are shared. The PAC was designed as a patient-centered, user-friendly platform that aids patients' preparation for their visits with clinicians. PAC provides an online tool that empowers patients to direct their treatment preferences and care alongside their physician teams per the provisions ... - [MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery](/research/clinical-trials/cls-20143938) Rochester, MN This randomized pilot clinical trial studies melanoma antigen recognized by T-cells 1 (MART-1) antigen with or lipid with stage II-IV melanoma that has been removed by surgery. Vaccines made from MART-1a peptide or antigen may help the body build an effective immune response to kill tumor cells. Giving TLR4 agonist GLA-SE with MART-1 antigen may help increase the immune response to MART-1a antigen. - [A Study of the Safety and Effectiveness of TH-302 Combined with Gemcitabine and Compared with Gemcitabine Alone for Previously Untreated Patients with Pancreatic Adenocarcinoma](/research/clinical-trials/cls-20314156) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to determine if TH-302 combined with Gemcitabine versus Gemcitabine alone is as safe and effective in the treatment of patients who have first-line metastatic pancreatic adenocarcinoma. - [Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)](/research/clinical-trials/cls-20509814) Rochester, MN; Jacksonville, FL The purpose of this study is to compare the effectiveness of AG-881 to placebo in participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation who have undergone surgery as their only treatment. Participants will be required to have central confirmation of IDH mutation status prior to randomization. - [A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)](/research/clinical-trials/cls-20527460) Rochester, MN; Jacksonville, FL The purpose of this study is to evaluate safety and determine the RP2D of 177Lu-FAP-2286 in patients with an advanced or metastatic solid tumor expressing FAP who have relapsed following prior treatment. - [A Study to Evaluate KIN-3248 in Participants With Advanced Tumors FGFR2 Alterations](/research/clinical-trials/cls-20535563) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary effectiveness of KIN-3248, an oral small molecule FGFR inhibitor, in adults with advanced tumors harboring FGFR2 and/or FGFR3 gene alterations. - [A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML](/research/clinical-trials/cls-20493092) Rochester, MN The purpose of this study is to determine the safety and preliminary efficacy of voruciclib as monotherapy in subjects with relapsed or refractory B-cell malignancies or AML, and in combination with venetoclax in subjects with relapsed or refractory AML after treatment with standard therapy. - [Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer and Cervical Cancer: a Phase II Clinical Study ](/research/clinical-trials/cls-20521077) Rochester, MN The purpose of this study is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. - [Remote Monitoring for Lifestyle Changes in Patients with Lung Cancer Related Fatigue](/research/clinical-trials/cls-20534428) Rochester, MN The purpose of this study is to test the effectiveness of a remote monitoring program with health coaching for patients with cancer related fatigue. The primary objective is to assess the effect of the remote-monitoring program on patient reported fatigue by administering the Brief Fatigue Inventory and the Cancer Fatigue Scale/ MFSI-SF. Secondary objective is to assess the effect of the program on quality of life by administering the LASA questionnaire. - [Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations](/research/clinical-trials/cls-20504326) Scottsdale/Phoenix, is open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with IDH1 R132-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma. - [Study of GBR 1342, a Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma](/research/clinical-trials/cls-20507130) Rochester, MN The purpose of this study is to determine the safety profile, maximum tolerable dose (MTD) and cohort expansion of single-agent GBR 1342 in subjects with multiple myeloma who have received prior therapies. - [A Study to Evaluate the Safety and Effectiveness of TT-00420 in Adults with Advanced Cholangiocarcinoma](/research/clinical-trials/cls-20524434) Rochester, MN The purpose of this trial is to evaluate the effectiveness and safety of TT-00420 in patients with advanced/metastatic and surgically unresectable cholangiocarcinoma (CCA) with 1) FGFR 2 who failed prior FGFR inhibitor treatment, 2) FGFR2 fusions who responded on prior FGFR inhibitor treatment and discontinued due to disease progression, 3) with other FGFR alterations, or 4) whose tumors do not contain a detectable FGFR alteration. - [Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients With Non-Hodgkin Lymphoma or Histiocytic/Dendritic Cell Neoplasms](/research/clinical-trials/cls-20508603) Rochester, MN The purpose of this study is to learn about the combination of choline salicylate and selinexor. We want to find out more about the side effects of the combination, what doses are safe for patients, and to collect information on how lymphoma responds to the drug combination. The doses of both drugs received will depend on when the patient is enrolled on to the study. The drug combination of selinexor and choline salicylate is experimental and isn't approved by the U.S. Food and Drug Administration (FDA). Selinexor is FDA approved when given with dexamethasone for previously treated relapsed multiple myeloma. Selinexor [A Scottsdale/Phoenix, AZ The main purpose of this study is to assess the maximal dose of ICP-022 that can be safely administered. - [MRD Guided, Fixed Duration Therapy With Loxo-305 and Venetoclax for Previously Untreated Chronic Lymphocytic Leukemia](/research/clinical-trials/cls-20540183) Rochester, MN The purpose of this study is to determine if a new drug combination, pirtobrutinib and venetoclax, will help Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) cancer, as well as learn more about the side effects of this drug combination. Everyone in this study will receive pirtobrutinib and venetoclax. Venetoclax is U.S. Food and Drug Administration (FDA) approved for the treatment of CLL and SLL. Pirtobrutinib is currently being studied in patients with CLL but it is not FDA approved yet. This drug combination is still experimental and is not approved by the FDA. Discontinuation of pirtobrutinib ... - [Valemetostat Tosylate T-Cell Lymphoma (VALENTINE-PTCL01)](/research/clinical-trials/cls-20522385) Rochester, MN The purpose of this study is to characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory adult T-cell leukemia/lymphoma. - [A Study to Develop Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Mortality](/research/clinical-trials/cls-20475814) Jacksonville, FL The purpose of this study is to reduce disparities in endometrial cancer (EC) mortality among African American women (AAW) by developing an understanding of what may be needed to increase awareness of signs of EC and advance efforts to introduce early detection of EC using a novel tampon based test. - [A Study to Evaluate Circulating Tumor Cells from Patients with Treatment-Refractory Advanced Solid Tumors Managed in the Early Cancer Therapeutics Program](/research/clinical-trials/cls-20312022) No Locations The overall objective of this research is to evaluate and define the molecular and biological characteristics of CTCs from advanced solid tumor patients who have progressed on standard therapy. - [A Study to Evaluate Telisotuzumab Vedotin (ABBV-399) in Subjects Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpse of this study is to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for Telisotuzumab Vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate effectiveness in the selected population(s) (Stage 2). - [A Study to Evaluate the Effectiveness and Safety of rAd-IFN Administered With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma](/research/clinical-trials/cls-20469678) Rochester, MN The purpose of this study is to evaluate intrapleural administration of Adenovirus-Delivered Interferon Alpha-2b (rAd-IFN) in combination with Celecoxib and Gemcitabine in patients with histologically confirmed Malignant Pleural Mesothelioma (MPM) who have failed a minimum of 1 treatment regimen and a maximum of 2 treatment regimens, 1 of which must have been an anti-folate and platinum combination regimen. - [A Study of DFRF4539A in Patients with Relapsed or Jacksonville, FL This multicenter, open-label, study will assess the safety and efficacy of DFRF4539A in patients with relapsed or refractory multiple myeloma. Cohorts of patients will receive multiple ascending doses of intravenous DFRF4539A every 3 weeks or weekly. Patients exhibiting acceptable safety and evidence of clinical benefit may receive DFRF4539A for up to 17 cycles. Anticipated time on study treatment is 1 year or until disease progression or unacceptable toxicity occurs. - [Study to Investigate the Safety and Effectiveness of Two Doses of the Antibody Drug GSK2857916 in Relapsed/Refractory Multiple Myeloma Patients](/research/clinical-trials/cls-20442763) Rochester, MN The purpose of this study is to investigate the safety and effectiveness of two doses of the antibody drug GSK2857916 in multiple myeloma patients who had 3 or more prior lines of treatment, are refractory to a proteasome inhibitor and an immunomodulatory agent and failed an Anti-CD38 Antibody (DREAMM 2). - [A Follow-Up Study of Subjects With ACTR T Cell Product](/research/clinical-trials/cls-20459860) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to follow subjects who were treated with ACTR after the completion of the final scheduled visit in the parent clinical study or other investigational setting, such as compassionate use, named patient Investigational New Drug application, expanded access program, or equivalent setting. These subjects will be followed for safety monitoring on a schedule of decreasing frequency through 15 years post-ACTR treatment, in accordance with US FDA Regulatory guidance pertaining to long-term safety follow-up for study subjects receiving recombinant DNA-containing investigational products. - [Buparlisib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma](/research/clinical-trials/cls-20118592) Rochester, MN This pilot clinical trial studies how well buparlisib works in treating patients with non-Hodgkin lymphoma that has returned or does not respond to treatment. Buparlisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. - [Study to Investigate the Safety, Pharmacokinetic Profiles and the Efficacy of Tinostamustine, a Jacksonville, FL The purpose of this study is to evaluate the effectiveness, safety and drug/body interactions of EDO-S101 in patients with relapsed or resistant hematologic cancers. - [Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib](/research/clinical-trials/cls-20115750) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. - [A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 Positive, Metastatic Pancreatic Adenocarcinoma](/research/clinical-trials/cls-20467337) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment. This study will also evaluate other anti-tumor effects, tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM. - [Safety and of bb2121 (Ide-cel) Combinations in Multiple Myeloma](/research/clinical-trials/cls-20519543) Jacksonville, FL The purpose of this study is to determine the safety and effectiveness of bb2121 (Ide-Cel) combinations in subjects with relapsed/refractory multiple myeloma. It also aims to evaluate different agents and their doses/schedules to improve clinical effectiveness in combination with bb2121. - [Venetoclax and Vincristine Liposomal in Treating Patients T-cell B-cell Acute Lymphoblastic Leukemia](/research/clinical-trials/cls-20446031) Rochester, MN This phase Ib/II clinical trial studies the side effects and best dose of venetoclax and how well it works when given together with vincristine liposomal in treating patients with T-cell or B-cell acute lymphoblastic leukemia that has come back or does not respond to treatment. Venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as vincristine liposomal, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax ... - [A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Hematologic Malignancies](/research/clinical-trials/cls-20403518) open-label trial of orally administered CA-4948 monotherapy in adult patients with Relapsed or Refractory NHL. The trial will be conducted in 2 parts: an initial Dose Escalation Phase (Part A) of CA-4948 in patients with Relapsed or Refractory Non-Hodgkin Lymphoma, (RR NHL) and a Dose Expansion Phase (Part B) of CA-4948 in patients with RR NHL with and without myeloid differentiation primary response 88 (MYD88) mutations. During Part B, patients will be enrolled regardless of MYD88 mutation status. - [Phase I Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients](/research/clinical-trials/cls-20115498) Rochester, MN The small molecule, CWP232291, by binding Sam68 promotes apoptosis in selective cancer cells through 1)induction of the TNF- apoptotic pathway, 2)alternative splicing, tipping the balance towards pro-apoptotic as opposed to anti-apoptotic isoforms, and 3)inhibition of the Wnt driven [A Phase 2, Multicenter, Study of Ficlatuzumab Plus Erlotinib Versus Placebo Plus Erlotinib in Subjects Who Have Previously Untreated Metastatic, EGFR-mutated Non-small Cell Lung Cancer (NSCLC) and MN Phase 2 multicenter, controlled, randomized, double-blind study to evaluate the efficacy and safety of ficlatuzumab versus placebo when administered with erlotinib in subjects with previously untreated metastatic EGFR-mutated NSCLC and BDX004 Positive Label. - [Trastuzumab Emtansine in Treating Older Patients With Human Epidermal Growth Factor Receptor 2-Positive Stage I-III Breast Cancer](/research/clinical-trials/cls-20148997) Rochester, MN This phase II trial studies how well trastuzumab emtansine works in treating older patients with human epidermal growth factor receptor 2 (HER2)-positive stage I-III breast cancer. HER2 is a protein found on the surface of cancer cells that helps them to grow and spread. Trastuzumab emtansine may kill cancer cells by binding to HER2-positive on the surface of the tumor cells and blocking their ability grow and spread. - [A Pilot Study to Evaluate the Molecular and Biological Phenotype of Peripheral Immune Cells in Solid Tumor Patients](/research/clinical-trials/cls-20502633) Rochester, MN The purpose of this study is to investigate for potential mechanisms underlying the sensitivity and resistance to immune checkpoint modulating agents that lead to the identification of sensitivity/resistance biomarkers and development of novel immunotherapeutic approaches. - [A Phase 1 in Patients WT1+ Recurrent/Metastatic Cancers](/research/clinical-trials/cls-20541944) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of Part A of this study is to characterize the safety, tolerability, and biological effects of CUE-102. The goal of Part B is to expand the safety and immune activity data at the RP2D identified in Part A, and to evaluate antitumor activity at this dose. - [A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma](/research/clinical-trials/cls-20541771) Rochester, MN The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary effectiveness of AZD0466 as monotherapy or in combination with other anticancer agents in patients with advanced Non-Hodgkin Lymphoma (NHL). - [Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorder](/research/clinical-trials/cls-20438533) Rochester, MN The purpose of this Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for ... - [A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin's Lymphoma](/research/clinical-trials/cls-20404929) Rochester, MN Despite strong evidence suggesting that vitamin D deficiency is associated with undesirable outcomes in patients with numerous cancers, there has never been a thorough study of vitamin D treatment in subjects undergoing treatment for cancer. The purpose of this study is to evaluate whether modification of vitamin D levels in the blood, through supplementation, can improve outcomes. - [An Open Label Extension Study of BMS-911543 In Subjects With Myelofibrosis](/research/clinical-trials/cls-20320106) Rochester, MN The purpose of this study is to provide patients with myleofibrosis (MF) who participated in study CA215001 access to BMS-911543. - [Tipifarnib in Subjects With Chronic Leukemia, FL A Phase 2 study to investigate the antitumor activity in terms of overall response rate (ORR) of tipifarnib in approximately 20 eligible subjects with CMML. Subjects will receive tipifarnib administered orally, twice a day (bid) for 7 days in alternating weeks (Days 1-7 and 15-21) in 28 day cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment until disease progression. If a complete response is observed, therapy with tipifarnib will be maintained for at least 6 months beyond the start of response. - [A Phase 2, Multicenter, Randomized Study of AP26113](/research/clinical-trials/cls-20142985) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of AP26113 in patients advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on therapy with crizotinib. - [Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments](/research/clinical-trials/cls-20524003) Jacksonville, FL The objectives of this study are to create a proteomic profile (Host Response) using plasma from patients before and after anti-cancer therapy, and to associate the changes in the levels of plasma proteins with response to treatment (ORR) as defined by RECIST 1.1 /other validated clinical scale to assess response. - [A Study to Evaluate Hemorrhage and Thrombosis in Hematology Malignancies](/research/clinical-trials/cls-20507930) Scottsdale/Phoenix, AZ The purpose of this study is to determine: the incidence of hemorrhage in the 3 months following deep vein thrombosis diagnosis in hospitalized malignant hematology patients, based on anticoagulant use and presence of thrombocytopenia, and recurrent or progressive venous thromboembolism in the 3 months following deep vein thrombosis diagnosis in hospitalized malignant hematology patients, based on anticoagulant use and presence of thrombocytopenia. - [Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy](/research/clinical-trials/cls-20508008) Albert Lea, MN; Mankato, MN; Rochester, MN This trial will be an evaluation of rose geranium in sesame oil nasal spray versus nasal saline. Rose geranium in sesame oil nasal spray is a compounded preparation, containing 0.2 mL (4 drops) of pharmaceutical grade rose geranium oil to 119.8 mL of pharmaceutical grade sesame oil and then put into 30mL bottles. This is the same compound that was used in the aforementioned study of patients with hereditary hemorrhagic telangiectasia (2). Isotonic benzalkonium chloride, as a preservative, in a 30 mL bottle. Treatment duration The therapy will ... - [A Study of the Expression and Frequency of Tissue Biomarker Mutations in Breast Cancer that is Resistant or Refractory to Treatment with Trastuzumab and/or Pertuzumab](/research/clinical-trials/cls-20301163) Jacksonville, FL The purpose of this study is to measure the expression and frequency of the tumor tissue biomarkers (the genetics) of breast cancer, specifically the decreased presence and amount of a specific protein (Human epidermal growth factor receptor-2 [HER2]), how often genetic mutations occur, and why the cancer might or might not respond to monoclonal antibody therapy, such as trastuzumab emtansine (T-DM1) and/or pertuzumab. [A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Jacksonville, FL This is a multicenter, open-label, Phase 1 study evaluating the anti-TIM-3 (T cell immunoglobulin and mucin containing protein-3) antibody TSR-022, as a monotherapy and in combination with an anti-PD-1 antibody, in patients with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts: dose escalation and cohort expansion. - [A Study of CMB305 and Atezolizumab in Patients with Sarcoma](/research/clinical-trials/cls-20200131) Jacksonville, FL; Rochester, MN The purpose of this study is to examine the use of CMB305 in combination with atezolizumab or atezolizumab alone, in patients with locally advanced, relapsed or metastatic sarcoma (synovial or myxoid/round cell liposarcoma) expressing the NY-ESO-1 protein. CMB305 is a novel approach designed to stimulate the body's immune system to fight the spread and growth of cancer in patients whose tumors express the NY-ESO-1 protein. - [A Study of Contribution of 3D Models in Resection of Renal Cell Cancer](/research/clinical-trials/cls-20493017) Rochester, MN The purpose of this study is to evaluate the impact on surgical planning and patient acceptance and understanding of 3D kidney tumor models prior to surgery. - [Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery](/research/clinical-trials/cls-20115812) Scottsdale/Phoenix, AZ; Rochester, MN RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth by blocking blood flow to the tumor. Drugs used in chemotherapy, such as hypoxia-activated prodrug TH-302, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib tosylate together with hypoxia-activated prodrug TH-302 may kill more tumor cells. PURPOSE: This phase I/II trial studies the side effects and best dose of giving sorafenib tosylate together with hypoxia-activated prodrug TH-302 and to see how well they work in ... - [Breast Cancer Genome Guided Therapy Study (BEAUTY)](/research/clinical-trials/cls-20116513) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this research study is to better understand the reasons why or why not breast cancers are destroyed by standard chemotherapy. This information will be used to develop new and better cancer therapies. - [Do patients diagnosed with cancer suffer from \"scan-itis\"?](/research/clinical-trials/cls-20509808) Rochester, MN The purpose of this study is to determine what patients experience when they return for scans or other testing during their oncology follow-up visits after their initial cancer diagnosis. - [A Study of the Safety and Effectiveness of HBI-8000 with Nivolumab to Treat Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20233410) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety, tolerability and effectiveness of HBI-8000 when combined with a standard dose and regimen of nivolumab. - [Preclinical drug testing and assay development for lung adenocarcinoma characterized by the expression of ASCL1](/research/clinical-trials/cls-20503161) Rochester, MN The purpose of this study is to perform preclinical testing in patient samples and experimental models. - [A Study to Examine the Effect of Ginger on the Gut Microbiome](/research/clinical-trials/cls-20442902) Mankato, MN The purpose of this study is to estimate the impact of a 6week daily intake of 2000 mg of ginger extract on the composition of the gut microbiome using a randomized placebo-controlled double-blinded design, i.e. examine the change of microbiome over time within and between the subjects.. - [A Study of Prostate Cancer Care and Survivorship Among Sub-Saharan African Immigrant Impacted by Social Determinants of Migrant Health Factors](/research/clinical-trials/cls-20540772) Rochester, MN The primary objective of this study is to employ the social determinant of migrant health framework (International Organization for Migration, n.d.) to examine the impact of immigration on the health-seeking behaviors of Sub-Saharan African Immigrant (SSAI) including informed-decision making, psychosocial effects and coping mechanisms. - [S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer](/research/clinical-trials/cls-20396302) Scottsdale/Phoenix, AZ This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning. - [STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS](/research/clinical-trials/cls-20524801) Scottsdale/Phoenix, AZ The main objective of this study is to describe and evaluate safety and effectiveness of MBG453 (sabatolimab) in combination with FDA approved Hypomethylating Agents and Tolerability FL; Rochester, MN The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered once a day (QD) as a single agent and in combination with dexamethasone. - [Safety and Immunogenicity of PolyPEPI1018 Vaccine in of Metastatic Colorectal Cancer (OBERTO)](/research/clinical-trials/cls-20415509) Rochester, MN TREOS' Phase I clinical trial will investigate the safety, tolerability, and immunogenicity of a single dose of PolyPEPI1018 CRC Vaccine as an add-on treatment to the standard-of-care maintenance therapy in patients with metastatic colorectal cancer. This study will also explore the accuracy of prediction of pre-existing and newly induced CD8+ T cell responses in each patient using the PEPI Test and T lymphocyte infiltration detected in accessible biopsy sites. - [A Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST](/research/clinical-trials/cls-20509322) Jacksonville, FL The purpose of this study is to evaluate the effect of Ripretinib on the pharmacokinetics of a CYP2C8 Substrate. - [A Study of Intravital Microscopy (IVM) in Human Solid Tumors](/research/clinical-trials/cls-20453746) Jacksonville, FL The purpose of this study is to determine the feasibility of performing HIVM in patients with deep space solid tumors during standard course of surgical resection. - [Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors](/research/clinical-trials/cls-20471254) No Locations This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. - [A Global, Randomized, Placebo-controlled Phase 3 Study MN; Jacksonville, FL The purpose of this study is to compare the effectiveness and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). Approximately 687 subjects will be randomized to one of the following treatment arms in a 2:1 ratio, fruquintinib plus BSC or placebo plus BSC. - [A Study to Evaluate the Safety and Effectiveness of Metformin and Nelfinavir with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma](/research/clinical-trials/cls-20463512) Jacksonville, FL; Rochester, MN The purpose of this study is to assess the maximum tolerated dose (MTD) of administering metformin in combination with nelfinavir in patients with relapsed/refractory multiple myeloma. - [A Study to Evaluate Whether Probiotics for Gut Microbiome Will Target Cancer Immune Microenvironment in Breast and Lung Cancer](/research/clinical-trials/cls-20510641) Jacksonville, FL The purpose of this study is to evaluate whether engineering gut microbiome using probiotics will alter host immunological response to breast and lung cancers. - [A Study of Safety, Tolerability, Pharmacokinetic Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the safety and tolerability of APG-2575 as well as dose escalation and dose expansion stages. - [A Study to Evaluate AMG 701 in Subjects with Multiple Myeloma](/research/clinical-trials/cls-20391801) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine (during the escalation portion) if AMG 701 given as weekly short term IV infusions is safe and tolerable followed by a dose expansion part to gain further efficacy and safety experience with AMG 701 in adult subjects with relapsed / refractory multiple myeloma. - [Expanded Access Ga68 PSMA PET Imaging](/research/clinical-trials/cls-20509688) Rochester, MN The primary objective of this study is to provide access to [Ga-68] PSMA-11 imaging (PET/CT or PET/MR) for patients diagnosed with untreated high-risk prostate cancer or biochemically recurrent prostate cancer. - [Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms AZ This multi-center, double-blind, vehicle-controlled, randomized crossover evaluate the safety and efficacy of topically applied naloxone lotion, 0.5%, for the treatment of pruritus in patients with the mycosis fungoides (MF) or S\u00e9zary syndrome (SS) Forms of Cutaneous T-cell Lymphoma (CTCL). This study will also determine if there is systemic absorption of the drug in a subset of subjects and if so, describe the range and mean plasma levels reached after two weeks of three time daily (TID) dosing. Funding Source - FDA OOPD - [Dietary and Topical Magnesium Replacement or Supplementation in Patients with Lymphoma](/research/clinical-trials/cls-20526480) Rochester, MN The purpose of this research study is to find out if being on a magnesium rich diet and using a magnesium lotion on the skin will help to keep the magnesium blood level in a normal range or increase the magnesium level if it is slightly below the normal range or in the low end of the normal range. We also want to learn about the side effects and quality of life when patients are receiving different forms of magnesium. Ancient Minerals Magnesium Lotion is an over-the-counter lotion that can be bought at a drug store or ... - [GB5121 in Adult Subjects FL; Rochester, MN of this 3-part study, comprising a phase 1b dose escalation, dose expansion, and a phase 2, is to assess the safety, tolerability, dose-limiting toxicity(ies), maximum tolerated dose, and/or optimal biological dose, determine the recommended phase 2 dose, preliminary anti-tumor activity and efficacy of the recommended phase 2 dose of GB5121. - [A Study of Rociletinib (CO-1686) for Patients with a Mutant form of Non-Small Cell Lung Cancer.](/research/clinical-trials/cls-20154283) Scottsdale/Phoenix, AZ To provide access to rociletinib for patients with advanced or metastatic EGFR-mutant NSCLC who have been treated previously with EGFR directed therapy and have evidence of a T790M mutation (T790M+). - [Randomized, Double-blind Study Comparing Tremelimumab in Subjects With Unresectable Malignant Mesothelioma](/research/clinical-trials/cls-20111954) This is study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, a 90-day follow-up period for safety, and a long-term survival follow-up period. - [Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20460827) Scottsdale/Phoenix, AZ; Jacksonville, FL This is a 1, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory Multiple Myeloma. - [An Open-label, Phase 2 Basket Study of Neratinib in Patients with Solid Tumors with Somatic Activating HER Mutations](/research/clinical-trials/cls-20440734) Scottsdale/Phoenix, AZ; Jacksonville, FL This is an open-label, non-randomized, multicenter, multinational, Phase 2 study exploring the effectiveness and safety of neratinib as monotherapy or in combination with other therapies in patients with ERBB mutation-positive or EGFR gene-amplified solid tumors. - [A Study to Assess the Safety, Tolerability, and Effectiveness of KPT-9274 to Treat Patients who have Advanced Solid Malignancies or Non-Hodgkin's Lymphoma](/research/clinical-trials/cls-20260196) No Locations The purpose of this study is to evaluate the safety, tolerability, and effectiveness of oral KPT-9274 for the treatment of patients who have advanced solid malignancies or non-Hodgkin's lymphoma. - [A Study of MT-0169 in With or Refractory Multiple Myeloma or non-Hodgkin Lymphoma](/research/clinical-trials/cls-20470628) Jacksonville, FL; Rochester, MN The main purpose of this study is to evaluate the safety and tolerability of MT-0169 and establish the MTD (maximum tolerated dose)/ RP2D (recommended phase 2 dose). Maximum tolerated dose means the highest dose of a study drug that can be given with acceptable side effects. Recommended phase 2 dose means that dose is judged to be the most optimal for future study in patients with your disease. The study will also examine how the body handles MT-0169. This will be done by looking at the pharmacokinetics of MT-0169after a single dose and after repeat doses in people ... - [A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics Intravenous TKM 080301 Patients](/research/clinical-trials/cls-20116101) Scottsdale/Phoenix, AZ; Rochester, MN be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid tumors or lymphomas that are refractory to standard therapy or for whom there is no standard therapy. After the determination of the maximum tolerated dose this dose will be utilized in an expansion cohort or subjects with refractory neuroendocrine tumors (NET) or adrenocortical carcinoma (ACC) of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer](/research/clinical-trials/cls-20115798) Rochester, MN Dabrafenib is a potent and selective inhibitor of BRAF kinase activity. This is a Phase II, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib administered as a single agent and in combination with trametinib in stage IV disease to subjects with BRAF mutant advanced non-small cell lung cancer. Subjects will receive dabrafenib 150 mg twice daily (BID) in monotherapy treatment and dabrafenib 150 mg bid and trametinib 2 mg once daily in combination therapy and continue on treatment until disease progression, death, or unacceptable adverse event. - [A Study of AO-176 as Monotherapy Combinated with Bortezomib and Multiple Myeloma](/research/clinical-trials/cls-20492005) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to evaluate the safety and tolerability of AO-176, including dose-limiting toxicities (DLT), maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) when administered as monotherapy, and in combination with dexamethasone (AO-176+DEX) in adult patients with Relapsed/Refractory Multiple Myleoma (R/R MM). - [Study of Orally Administered AG-120 in Advanced with an IDH1 Mutation](/research/clinical-trials/cls-20152430) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where three cohorts of patients will receive AG-120 to further evaluate the safety, tolerability, and clinical activity of the recommended Phase II dose. Study will not ... - [A Trial of ZL-1201 in Subjects with Advanced Cancer](/research/clinical-trials/cls-20490387) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL First in Human, Phase I Trial of Anti-CD47 Antibody ZL-1201 in Subjects with Advanced Cancer - [An Open-label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in or Refractory B-cell Non-Hodgkin Lymphoma](/research/clinical-trials/cls-20467355) Rochester, MN The primary objective of this study is to assess the anti-tumor activity of single agent REGN1979 as measured by the objective response rate (ORR) according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) non-Hodgkin lymphoma (B-NHL) subgroups. - [A Study of the Safety and Tolerability of MEDI1873 for Treating Adult Subjects with Select Advanced Solid Tumors](/research/clinical-trials/cls-20251483) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate the safety and tolerability of MEDI1873 for the treatment of adult subjects who have selected advanced solid tumors. - [Study of E7386 in Participants With Selected Advanced Neoplasms](/research/clinical-trials/cls-20542131) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386. - [I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)](/research/clinical-trials/cls-20509336) Rochester, MN The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success. - [Study to Test the Safety and Tolerability of PF-07257876 in Participants with Selected Advanced Tumors](/research/clinical-trials/cls-20523802) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this FIH study is to assess the safety and tolerability, effectiveness, pharnacokinetcs (PK), and pharmacodynamics (PD) of increasing dose levels of PF-07257876; to identify the MTD and potential RP2D of PF-07257876; and to select the RP2D for further studies in development. This study will enroll patients with advanced cancers with no curative therapy (NSCLC, SCCHN, and OvCa) whose tumors have either failed prior PD-1 or PD-L1 therapies (NSCLC or SCCHN); or platinum-based chemotherapy (OvCa). In addition, patients' tumors must have demonstrated PD-L1 expression > 1%. - [Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies](/research/clinical-trials/cls-20542552) Scottsdale/Phoenix, AZ This clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA 2416 in patients with relapsed/refractory solid tumor malignancies or lymphoma - [Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA](/research/clinical-trials/cls-20199635) Rochester, MN Will rigosertib, with an aggressive infusion dose, improve overall survival of MDS better than the treatments available today? - [Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Leukemia](/research/clinical-trials/cls-20143399) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The objective of this study is to assess the safety and tolerability, including the maximum tolerated dose, of ASP2215 in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML). This study will also determine the pharmacokinetic (PK) parameters of ASP2215. - [XmAb18968 (CD3-CD38) in Relapsed Acute T Cell Lymphoblastic Leukemia](/research/clinical-trials/cls-20532368) Scottsdale/Phoenix, AZ; Jacksonville, FL This is a phase 1, dose-escalation study (using 3 + 3 dose-limiting toxicity (DLT) criteria) evaluating the safety and tolerability of XmAb18968, as well as establishing a recommended phase II dose (RP2D) in subjects with T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic (lymphoma) T-LBL (Group A) and acute myeloid leukemia (AML) (Group B). - [A Study of PROQOL (Patient Reported Outcome Quality of Life) Tool in the Hematology and Oncology Population](/research/clinical-trials/cls-20304025) Rochester, MN The purpose of this study is to assess if the electronic patient reported outcome quality of life (PROQOL) tool will be beneficial to hematology and oncology patients, helping to improve their quality of life by communicating symptoms and needs to busy clinicians. - [A Study of the Safety and Effectiveness of HBI-8000 with Nivolumab to Treat Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20233410) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety, tolerability and effectiveness of HBI-8000 when combined with a standard dose and regimen of nivolumab. - [Preclinical drug testing and assay development for lung adenocarcinoma characterized by the expression of ASCL1](/research/clinical-trials/cls-20503161) Rochester, MN The purpose of this study is to perform preclinical testing in patient samples and experimental models. - [A Phase 2, Multicenter, Randomized Study of AP26113](/research/clinical-trials/cls-20142985) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate the efficacy and safety of two different dosing regimens of AP26113 in patients advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on therapy with crizotinib. - [Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments](/research/clinical-trials/cls-20524003) Jacksonville, FL The objectives of this study are to create a proteomic profile (Host Response) using plasma from patients before and after anti-cancer therapy, and to associate the changes in the levels of plasma proteins with response to treatment (ORR) as defined by RECIST 1.1 /other validated clinical scale to assess response. - [A Study to Evaluate Hemorrhage and Thrombosis in Hematology Malignancies](/research/clinical-trials/cls-20507930) Scottsdale/Phoenix, AZ The purpose of this study is to determine: the incidence of hemorrhage in the 3 months following deep vein thrombosis diagnosis in hospitalized malignant hematology patients, based on anticoagulant use and presence of thrombocytopenia, and recurrent or progressive venous thromboembolism in the 3 months following deep vein thrombosis diagnosis in hospitalized malignant hematology patients, based on anticoagulant use and presence of thrombocytopenia. - [Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy](/research/clinical-trials/cls-20508008) Albert Lea, MN; Mankato, MN; Rochester, MN This trial will be an evaluation of rose geranium in sesame oil nasal spray versus nasal saline. Rose geranium in sesame oil nasal spray is a compounded preparation, containing 0.2 mL (4 drops) of pharmaceutical grade rose geranium oil to 119.8 mL of pharmaceutical grade sesame oil and then put into 30mL bottles. This is the same compound that was used in the aforementioned study of patients with hereditary hemorrhagic telangiectasia (2). Isotonic benzalkonium chloride, as a preservative, in a 30 mL bottle. Treatment duration The therapy will ... - [A Study of the Expression and Frequency of Tissue Biomarker Mutations in Breast Cancer that is Resistant or Refractory to Treatment with Trastuzumab and/or Pertuzumab](/research/clinical-trials/cls-20301163) Jacksonville, FL The purpose of this study is to measure the expression and frequency of the tumor tissue biomarkers (the genetics) of breast cancer, specifically the decreased presence and amount of a specific protein (Human epidermal growth factor receptor-2 [HER2]), how often genetic mutations occur, and why the cancer might or might not respond to monoclonal antibody therapy, such as trastuzumab emtansine (T-DM1) and/or pertuzumab. [A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Jacksonville, FL This is a multicenter, open-label, Phase 1 study evaluating the anti-TIM-3 (T cell immunoglobulin and mucin containing protein-3) antibody TSR-022, as a monotherapy and in combination with an anti-PD-1 antibody, in patients with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts: dose escalation and cohort expansion. - [A Study of CMB305 and Atezolizumab in Patients with Sarcoma](/research/clinical-trials/cls-20200131) Jacksonville, FL; Rochester, MN The purpose of this study is to examine the use of CMB305 in combination with atezolizumab or atezolizumab alone, in patients with locally advanced, relapsed or metastatic sarcoma (synovial or myxoid/round cell liposarcoma) expressing the NY-ESO-1 protein. CMB305 is a novel approach designed to stimulate the body's immune system to fight the spread and growth of cancer in patients whose tumors express the NY-ESO-1 protein. - [A Study of Contribution of 3D Models in Resection of Renal Cell Cancer](/research/clinical-trials/cls-20493017) Rochester, MN The purpose of this study is to evaluate the impact on surgical planning and patient acceptance and understanding of 3D kidney tumor models prior to surgery. - [Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery](/research/clinical-trials/cls-20115812) Scottsdale/Phoenix, AZ; Rochester, MN RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth by blocking blood flow to the tumor. Drugs used in chemotherapy, such as hypoxia-activated prodrug TH-302, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib tosylate together with hypoxia-activated prodrug TH-302 may kill more tumor cells. PURPOSE: This phase I/II trial studies the side effects and best dose of giving sorafenib tosylate together with hypoxia-activated prodrug TH-302 and to see how well they work in ... - [Breast Cancer Genome Guided Therapy Study (BEAUTY)](/research/clinical-trials/cls-20116513) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this research study is to better understand the reasons why or why not breast cancers are destroyed by standard chemotherapy. This information will be used to develop new and better cancer therapies. - [Do patients diagnosed with cancer suffer from \"scan-itis\"?](/research/clinical-trials/cls-20509808) Rochester, MN The purpose of this study is to determine what patients experience when they return for scans or other testing during their oncology follow-up visits after their initial cancer diagnosis. - [S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer](/research/clinical-trials/cls-20396302) Scottsdale/Phoenix, AZ This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning. - [STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS](/research/clinical-trials/cls-20524801) Scottsdale/Phoenix, AZ The main objective of this study is to describe and evaluate safety and effectiveness of MBG453 (sabatolimab) in combination with FDA approved Hypomethylating Agents [A Study to Examine the Effect of Ginger on the Gut Microbiome](/research/clinical-trials/cls-20442902) Mankato, MN The purpose of this study is to estimate the impact of a 6week daily intake of 2000 mg of ginger extract on the composition of the gut microbiome using a randomized placebo-controlled double-blinded design, i.e. examine the change of microbiome over time within and between the subjects.. - [Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Metastatic Colorectal Cancer (OBERTO)](/research/clinical-trials/cls-20415509) Rochester, MN TREOS' Phase I clinical trial will investigate the safety, tolerability, and immunogenicity of a single dose of PolyPEPI1018 CRC Vaccine as an add-on treatment to the standard-of-care maintenance therapy in patients with metastatic colorectal cancer. This study will also explore the accuracy of prediction of pre-existing and newly induced CD8+ T cell responses in each patient using the PEPI Test and T lymphocyte infiltration detected in accessible biopsy sites. - [A Study of Prostate Cancer Care and Survivorship Among Sub-Saharan African Immigrant Impacted by Social Determinants of Migrant Health Factors](/research/clinical-trials/cls-20540772) Rochester, MN The primary objective of this study is to employ the social determinant of migrant health framework (International Organization for Migration, n.d.) to examine the impact of immigration on the health-seeking behaviors of Sub-Saharan African Immigrant (SSAI) including informed-decision making, psychosocial effects and coping mechanisms. - [A Study to Assess the Safety and Tolerability of FL; Rochester, MN The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) administered once a day (QD) as a single agent and in combination with dexamethasone. - [A Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST](/research/clinical-trials/cls-20509322) Jacksonville, FL The purpose of this study is to evaluate the effect of Ripretinib on the pharmacokinetics of a CYP2C8 Substrate. - [A Study of Intravital Microscopy (IVM) in Human Solid Tumors](/research/clinical-trials/cls-20453746) Jacksonville, FL The purpose of this study is to determine the feasibility of performing HIVM in patients with deep space solid tumors during standard course of surgical resection. - [Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors](/research/clinical-trials/cls-20471254) No Locations This phase II trial is studying the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. - [A Global, Randomized, Placebo-controlled Phase 3 Study MN; Jacksonville, FL The purpose of this study is to compare the effectiveness and safety of fruquintinib plus best supportive care (BSC) versus placebo plus BSC in patients with refractory metastatic colorectal cancer (mCRC). Approximately 687 subjects will be randomized to one of the following treatment arms in a 2:1 ratio, fruquintinib plus BSC or placebo plus BSC. - [A Study to Evaluate the Safety and Effectiveness of Metformin and Nelfinavir with Bortezomib in Patients with Relapsed and/or Refractory Multiple Myeloma](/research/clinical-trials/cls-20463512) Jacksonville, FL; Rochester, MN The purpose of this study is to assess the maximum tolerated dose (MTD) of administering metformin in combination with nelfinavir in patients with relapsed/refractory multiple myeloma. - [Randomized, Double-blind Study Comparing Tremelimumab in Subjects With Unresectable Malignant Mesothelioma](/research/clinical-trials/cls-20111954) This is study. Subjects with unresectable pleural or peritoneal malignant mesothelioma will be randomized in a 2:1 ratio to receive either tremelimumab or placebo. Approximately 564 subjects will be enrolled at study centers in multiple countries. The study consists of a screening period, a treatment period, a 90-day follow-up period for safety, and a long-term survival follow-up period. - [A Study to Determine Safety, Pharmacokinetics and Pharmacodynamics of Intravenous TKM 080301 Patients](/research/clinical-trials/cls-20116101) Scottsdale/Phoenix, AZ; Rochester, MN be a Phase I/II, open-label, non-randomized, dose-finding trial conducted at multiple clinical centers. The study is designed to determine the safety, tolerability and PK of TKM-080301 in adult patients with solid tumors or lymphomas that are refractory to standard therapy or for whom there is no standard therapy. After the determination of the maximum tolerated dose this dose will be utilized in an expansion cohort or subjects with refractory neuroendocrine tumors (NET) or adrenocortical carcinoma (ACC) tumors. - [Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20460827) Scottsdale/Phoenix, AZ; Jacksonville, FL This is a 1, single-arm, open-label study evaluating the safety, tolerability, and anti-myeloma activity of ACTR087 (an autologous T cell product) in combination with SEA-BCMA (a monoclonal antibody) in subjects with relapsed or refractory Multiple Myeloma. - [An Open-label, Phase 2 Basket Study of Neratinib in Patients with Solid Tumors with Somatic Activating HER Mutations](/research/clinical-trials/cls-20440734) Scottsdale/Phoenix, AZ; Jacksonville, FL This is an open-label, non-randomized, multicenter, multinational, Phase 2 study exploring the effectiveness and safety of neratinib as monotherapy or in combination with other therapies in patients with ERBB mutation-positive or EGFR gene-amplified solid tumors. - [A Study to Assess the Safety, Tolerability, and Effectiveness of KPT-9274 to Treat Patients who have Advanced Solid Malignancies or Non-Hodgkin's Lymphoma](/research/clinical-trials/cls-20260196) No Locations The purpose of this study is to evaluate the safety, tolerability, and effectiveness of oral KPT-9274 for the treatment of patients who have advanced solid malignancies or non-Hodgkin's lymphoma. - [A Study of MT-0169 in With or Refractory Multiple Myeloma or non-Hodgkin Lymphoma](/research/clinical-trials/cls-20470628) Jacksonville, FL; Rochester, MN The main purpose of this study is to evaluate the safety and tolerability of MT-0169 and establish the MTD (maximum tolerated dose)/ RP2D (recommended phase 2 dose). Maximum tolerated dose means the highest dose of a study drug that can be given with acceptable side effects. Recommended phase 2 dose means that dose is judged to be the most optimal for future study in patients with your disease. The study will also examine how the body handles MT-0169. This will be done by looking at the pharmacokinetics of MT-0169after a single dose and after repeat doses in people ... - [A Study of AO-176 as Monotherapy Combinated with Bortezomib and Multiple Myeloma](/research/clinical-trials/cls-20492005) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to evaluate the safety and tolerability of AO-176, including dose-limiting toxicities (DLT), maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) when administered as monotherapy, and in combination with dexamethasone (AO-176+DEX) in adult patients with Relapsed/Refractory Multiple Myleoma (R/R MM). - [Study of Orally Administered AG-120 in Advanced with an IDH1 Mutation](/research/clinical-trials/cls-20152430) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where three cohorts of patients will receive AG-120 to further evaluate the safety, tolerability, and clinical activity of the recommended Phase II dose. Study will not ... - [A Trial of ZL-1201 in Subjects with Advanced Cancer](/research/clinical-trials/cls-20490387) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL First in Human, Phase I Trial of Anti-CD47 Antibody ZL-1201 in Subjects with Advanced Cancer - [An Open-label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 X Anti-CD3 Bispecific Antibody, in or Refractory B-cell Non-Hodgkin Lymphoma](/research/clinical-trials/cls-20467355) Rochester, MN The primary objective of this study is to assess the anti-tumor activity of single agent REGN1979 as measured by the objective response rate (ORR) according to the Lugano Classification of response in malignant lymphoma (Cheson, 2014) non-Hodgkin lymphoma (B-NHL) subgroups. - [A Study of the Safety and Tolerability of MEDI1873 for Treating Adult Subjects with Select Advanced Solid Tumors](/research/clinical-trials/cls-20251483) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate the safety and tolerability of MEDI1873 for the treatment of adult subjects who have selected advanced solid tumors. - [Study of E7386 in Participants With Selected Advanced Neoplasms](/research/clinical-trials/cls-20542131) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386. - [I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer (I-SPY)](/research/clinical-trials/cls-20509336) Rochester, MN The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success. - [Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients With Advanced Malignancies](/research/clinical-trials/cls-20542552) Scottsdale/Phoenix, AZ This clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA 2416 in patients with relapsed/refractory solid tumor malignancies or lymphoma - [Study to Test the Safety and Tolerability of PF-07257876 in Participants with Selected Advanced Tumors](/research/clinical-trials/cls-20523802) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this FIH study is to assess the safety and tolerability, effectiveness, pharnacokinetcs (PK), and pharmacodynamics (PD) of increasing dose levels of PF-07257876; to identify the MTD and potential RP2D of PF-07257876; and to select the RP2D for further studies in development. This study will enroll patients with advanced cancers with no curative therapy (NSCLC, SCCHN, and OvCa) whose tumors have either failed prior PD-1 or PD-L1 therapies (NSCLC or SCCHN); or platinum-based chemotherapy (OvCa). In addition, patients' tumors must have demonstrated PD-L1 expression > 1%. - [Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA](/research/clinical-trials/cls-20199635) Rochester, MN Will rigosertib, with an aggressive infusion dose, improve overall survival of MDS better than the treatments available today? - [Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Leukemia](/research/clinical-trials/cls-20143399) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The objective of this study is to assess the safety and tolerability, including the maximum tolerated dose, of ASP2215 in subjects with relapsed or treatment-refractory acute myeloid leukemia (AML). This study will also determine the pharmacokinetic (PK) parameters of ASP2215. - [XmAb18968 (CD3-CD38) in Relapsed Acute T Cell Lymphoblastic Leukemia](/research/clinical-trials/cls-20532368) Scottsdale/Phoenix, AZ; Jacksonville, FL This is a phase 1, dose-escalation study (using 3 + 3 dose-limiting toxicity (DLT) criteria) evaluating the safety and tolerability of XmAb18968, as well as establishing a recommended phase II dose (RP2D) in subjects with T cell acute lymphoblastic leukemia (T-ALL) and T cell lymphoblastic (lymphoma) T-LBL (Group A) and acute myeloid leukemia (AML) (Group B). - [A Study of PROQOL (Patient Reported Outcome Quality of Life) Tool in the Hematology and Oncology Population](/research/clinical-trials/cls-20304025) Rochester, MN The purpose of this study is to assess if the electronic patient reported outcome quality of life (PROQOL) tool will be beneficial to hematology and oncology patients, helping to improve their quality of life by communicating symptoms and needs to busy clinicians. - [A Study of Vulvovaginal Symptoms in Premenopausal Stage 0-III Breast Cancer Patients Treated on Aromatase Inhibitors and Ovarian Suppression](/research/clinical-trials/cls-20453745) Jacksonville, FL The purpose of this study is to evaluate the change of vulvovaginal symptoms score from baseline to 6 months in premenopausal women with stage 0-III breast cancer treating with ovarian suppression in combination with aromatase inhibitors. - [The Young Women's Breast Cancer Study](/research/clinical-trials/cls-20491214) Rochester, MN The investigators are conducting a longitudinal cohort study of young women with breast cancer. The investigators identify women age 40 and younger with newly-diagnosed breast cancer from academic and community healthcare institutions. After women consent to the study, they fill-out surveys and give blood samples, and the investigators collect tissue from their breast cancer tumor after it is removed. Women are surveyed every 6 months for the first 3 years after diagnosis, then yearly thereafter for an additional 7 years (for a total follow-up of at least 10 years following diagnosis). The study investigates short and long-term disease and treatment ... - [Surface Oncology RCC Sample project of archived serum and plasma samples from Renal Cell Carcinoma (RCC patients)and healthy patients, for use by Surface Oncology to investigate the role of IL-27 in patients with Renal Cell Carcinoma and its potential as a therapeutic target. - [A Study to Investigate Blood-derived Circulating Tumor DNA, Circulating Tumor RNA, and Circulating Tumor miRNA in Pancreatic Cancer Patients](/research/clinical-trials/cls-20503210) Jacksonville, FL The purpose of this study is to establish a cohort of 200 patients receiving definitive radiotherapy at Mayo Clinic Florida for locally advanced pancreatic cancer (T3-4NxM0; TxN+M0), and establish a biobank of 10 ml of plasma (frozen at -80o C) for each patient at baseline (prior to starting radiation treatment), week 2 of radiation treatment and 4-8 weeks following radiation treatment. - [Cediranib Maleate and Selumetinib in Treating Patients With Solid Malignancies](/research/clinical-trials/cls-20318343) Jacksonville, FL; Rochester, MN This phase I trial studies the side effects and best dose of cediranib maleate and selumetinib in treating patients with solid malignancies. Cediranib maleate and selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may also stop the growth of tumor cells by blocking blood flow to the tumor. - [A Study to Evaluate ctDNA Diagnostics in Recurrent Breast Cancer Patients](/research/clinical-trials/cls-20518197) Rochester, MN The purpose of this study is to to establish a minimally-invasive blood based test for the detection of clinically actionable genetic changes in breast cancer patients. - [Shared Decision-Making Encounter Tool for Decisions of Adjuvant Treatment in Patients with Resected Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20528847) Rochester, MN The purpose of this study is to develop, in close collaboration with stakeholders, an evidence-based decision aid to inform discussions regarding options for adjuvant treatment in patients with resected Non-Small Cell Lung Cancer. - [Cardio-Oncology Clinic Registry](/research/clinical-trials/cls-20534744) Rochester, MN The purpose of this study is to establish a retrospective and prospective clinical registry of patients seen in the cardio-oncology clinic to characterize trends in the composition and outcomes of the population seen in the clinic, as well as initial clinical analyses on cardiovascular toxicities. - [A Study to Assess the Effectiveness and Safety of UGN-102 as a Primary Chemoablation Agent in Patients with Low Grade Non-Muscle-Invasive Bladder Cancer (LG NMIBC) at Intermediate Risk of Recurrence](/research/clinical-trials/cls-20450259) Scottsdale/Phoenix, AZ The purpose of this study is to investigate the effectiveness and safety of UroGen's UGN-102 to treat patients with Low Grade (LG) Non Muscle Invasive Bladder Cancer (NMIBC) at intermediate risk of recurrence. - [OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer](/research/clinical-trials/cls-20421998) Rochester, MN; Scottsdale/Phoenix, AZ This is a phase 3, randomized, multi-center, single dose, open label, pivotal study in patients diagnosed with, or with high clinical suspicion of, ovarian cancer scheduled to undergo primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery. - [A Study to Evaluate the Venn Ovarian CAncer Liquid Biopsy](/research/clinical-trials/cls-20472107) Jacksonville, FL The primary purpode of this study is to determine the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the InterVenn Ovarian Cancer Liquid Biopsy among women with ovarian adnexal mass for which a surgery is planned. - [A Study to Determine Baseline Levels for Prostate Cancer-Derived Particles Containing Cellular Matter (Extracellular Vesicles) After Local Treatment](/research/clinical-trials/cls-20502007) Rochester, MN The purposes of this study are to determine the levels of prostate cancer-derived extracellular vesicles pre- and post-local therapy (radical prostatectomy or radiation therapy), to correlate analysis for PSA levels and prostate cancer-derived extracellular vesicles, and to determine baseline levels of prostate cancer-derived extracellular vesicles in patients undergoing different lines of primary local treatment. - [Dose-Escalation Study of cevostamab (BFCR4350A) in Participants Multiple Myeloma study of cevostamab (BFCR4350A) administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM). - [A First-in-Human Phase 1 and Expanded Cohort Study of EPZ-5676 in Advanced Hematologic Malignancies, Including Acute Leukemia With Rearrangement of the MLL Gene](/research/clinical-trials/cls-20111976) Scottsdale/Phoenix, AZ The purpose of this study is to determine the safe dose of EPZ-5676, to evaluate the safety of EPZ-5676 in patients with advanced hematologic malignancies, and to conduct a preliminary assessment of the anti-leukemia activity of EPZ-5676 in patients with acute leukemias bearing rearrangements of the MLL gene. Currently this study is in the MLL-r restricted/expansion phase and is only enrolling patients with rearrangements involving the MLL gene, including 11q23 or partial tandem duplications (PTD). - [Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer](/research/clinical-trials/cls-20115482) Rochester, MN This phase I trial studies the side effects and the best dose of viral therapy in treating patients with squamous cell carcinoma of the head and neck that has returned (come back) after a period of improvement or has spread to other parts of the body or breast cancer that has spread to other parts of the body. A virus called encoding thyroidal sodium iodide symporter, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells. - [Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash](/research/clinical-trials/cls-20416406) Rochester, MN This early phase I trial studies the side effects of ketoconazole and how well it works in treating participants with ongoing EGFR inhibitor-induced rash. Ketoconazole may reduce the symptoms related to EGFR inhibitor therapy and improve EGFR inhibitor-induced rash. We would like to see if use of topical ketoconazole will improve rashes in patients with EGFR inhibitor-induced rash. - [Study Using Chromogranin A as Surveillance Biomarker in Patients with cARcinoids](/research/clinical-trials/cls-20447457) Rochester, MN The purpose of this study is to monitor and validate the performance and stability of the BRAHMS Chromogranin A (CgA) II KRYPTOR Assay tumors Pain Management and Patient Habit Survey](/research/clinical-trials/cls-20509813) Scottsdale/Phoenix, AZ This study aims to evaluate the complexities of Myeloproliferative neoplasms (MPN) pain and review current treatment strategies through an online survey of MPN patients. The results of this preliminary investigation will provide the groundwork for future prospective studies addressing the MPN symptom burden. - [Addressing Breast Cancer Equity](/research/clinical-trials/cls-20529056) Jacksonville, FL The purpose of this study is to test if a culturally tailored virtual navigation program (Second-Life) meet the needs of Black women in learning more about breast health and care for cancer prevention, and mammography screening. We are asking for feedback on the Second-Life experience to determine if the information is easy to understand, relevant, and valuable to the community. The goal is to develop virtual community navigation that helps Black women make informed decisions about their breast healthcare since Black women have high mortality rates from breast cancer compared to other races or ethnicities. - [A Study of TAS-120 in Patients Cancer](/research/clinical-trials/cls-20502725) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to assess the antitumor activity of TAS-120 as monotherapy or in combination with Fulvestrant in the treatment of patients with metastatic breast cancer harboring fibroblast growth factor receptor (FGFR) amplifications. - [Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men](/research/clinical-trials/cls-20536049) Jacksonville, FL The objective of this pilot stdy is to plan, develop and establish the acceptance and usability of a Point of Prostate Cancer Diagnosis (PPCD) iCCaRE Virtual Robot Assistant (ViRA). The specific aims of this study are to plan and develop a PPCD iCCaRE ViRA model that will provide social determinants of health (SDOH) navigation services, psycho-oncology support and emotional support using qualitative formative research, and to establish the acceptance and usability of the iCCaRE ViRA at a urology clinic among 50 Black men (BM). - [Study of Ociperlimab in Combination With Tislelizumab in Advanced Solid Tumors](/research/clinical-trials/cls-20523442) Scottsdale/Phoenix, AZ; Rochester, MN The primary objectives of this study are to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD), and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217 (known as Ociperlimab) in combination with tislelizumab in participants with advanced solid tumors in phase 1. Primary objective of Phase 1b is to assess overall response rate (ORR) determined by Investigator per RECIST v1.1 for patients in each dose- expansion. - [A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation](/research/clinical-trials/cls-20143158) Rochester, MN The purpose of this study is to determine whether oral rucaparib is effective in the treatment of patients with locally advanced or metastatic pancreatic cancer and a known deleterious BRCA mutation. - [Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors](/research/clinical-trials/cls-20115555) Rochester, MN The purpose of this study is to determine the maximum dose of LDE225 and BKM120 that can be safely given together to patients and/or the dose that will be used in future studies. This study will also learn more about how the combination of these two investigational drugs may work for patients with certain cancers (specifically metastatic breast cancer, advanced pancreatic adenocarcinoma, metastatic colorectal cancer and glioblastoma multiforme). - [Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting](/research/clinical-trials/cls-20143576) Rochester, MN Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma - [A Study of Cancer](/research/clinical-trials/cls-20510697) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the safety and effectiveness of Selpercatinib, compared to a standard treatment, in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib. - [A Study of ONO-7475 in Patients With Acute Leukemias](/research/clinical-trials/cls-20523807) Jacksonville, FL The purpose of this study is to assess the safety and tolerability of ONO-7475 monotherapy in patients with relapsed or refractory acute myeloid leukemia or relapsed or refractory myelodysplastic syndromes, and to assess the safety, tolerability, and preliminary effectiveness of the combination of ONO-7475 and venetoclax in patients with relapsed or refractory acute myeloid leukemia. - [A Study to Evaluate the Safety and Effectiveness of AB928-Based Treatment Combinations to Treat Patients with Metastatic Colorectal Cancer](/research/clinical-trials/cls-20515342) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the clinical activity, safety and tolerability of etruma-based treatment combinations. - [A Study of Effect of Different Biochemical Markers including Leptin and Spexin in Children Before and After Having Hypothalamus Surgery](/research/clinical-trials/cls-20304191) Rochester, MN The purpose of this study is to learn more about the changes in levels of Spexin, leptin and other biomarkers such as adiponectin and resting energy expenditure before and after hypothalamic surgery. - [A Dose Escalation Study of Amivantamab in Participants with Advanced Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20443510) Rochester, MN The purpose of this study is to evaluate the safety and pharmacokinetics, establish a recommended phase 2 dose (RP2D) regimen, and to assess the preliminary effectiveness of JNJ-61186372 in participants with advanced non-small cell lung cancer (NSCLC). - [Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL](/research/clinical-trials/cls-20116084) Rochester, MN The goal of this study is to evaluate a new approach to immunotherapy in NHL by combining two antibodies, veltuzumab and epratuzumab. For treatment, epratuzumab has also been attached to a radioactive isotope called 90yttrium (90Y-epratuzumab). Veltuzumab and 90Y-epratuzumab attack different areas on lymphoma cells. Because of this, treatment with the combination may provide more effective treatment in NHL than either veltuzumab or 90Y-epratuzumab given alone. - [Randomized Trial Scottsdale/Phoenix, This research is looking at two conditions, Essential Thrombocythemia (ET) and Polycythemia Vera (PV). ET causes people to produce too many blood cells called platelets and PV causes too many platelets and red blood cells to be made. Platelets are particles which circulate in the blood stream and normally prevent bleeding and bruising. Having too many platelets in the blood increases the risk of developing blood clots, which can result in life threatening events like heart attacks and strokes. When the number of red blood cells is increased in PV this will slow the speed of blood flow in the ... - [A Study to Evaluate the Safety and Effectiveness of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients](/research/clinical-trials/cls-20467298) Jacksonville, FL; Rochester, MN The purpose of this single-dose escalation study is to evaluate the safety and effectiveness of CAR2 Anti-CD38 A2 CAR-T Cells in patients with Relapsed or Refractory Multiple Myeloma. - [A Study to Determine the Effects of Activity by Ambulation in Hospital Premises versus Strict Protective Isolation on Quality of Life in Severely Neutropenic Cancer Patients during Hospitalization](/research/clinical-trials/cls-20423512) Jacksonville, FL The purpose of this study is to determine if allowing patients to ambulate in the hallways outside of their hospital room by relaxing the policy of strict protective isolation in neutropenic patients improves the quality of life, and if this increases the risk of infection among these patients during hospitalization. - [Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20145349) Jacksonville, FL The primary objective of the study is to determine the safety and tolerability of I-131-CLR1404, with and without concurrent weekly dexamethasone, in patients with relapsed or refractory multiple myeloma who have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor. - [A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20470535) Rochester, MN The purpose of this study is to evaluate the safety, clinical pharmacology and clinical activity of TNB-383B, a T-cell engaging bispecific antibody, in subjects with relapsed or refractory MM who have received at least 3 prior lines of therapy. The study consists of 2 portions, a monotherapy dose escalation (Arm A) and a monotherapy dose expansion (Arm B). Arm A will evaluate the safety, tolerability, PK and PD profiles of escalating doses of single-agent TNB-383B ranging from 25 micrograms to 40 milligrams per dose, administered once every 3 weeks (Q3W), in approximately 24 subjects. Once the maximum tolerated dose (MTD) or ... - [Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL)](/research/clinical-trials/cls-20115766) Rochester, MN The purpose of this study is to determine how well SNS01-T is tolerated by relapsed or refractory multiple myeloma, B cell lymphoma or plasma cell leukemia patients when given by intravenous infusion at various doses. - [A Study of APG-2575 Alone or in Combination with Other Therapeutic Agents to Treat Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)](/research/clinical-trials/cls-20488673) Jacksonville, FL The purpose of this study is to assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D) of APG-2575. - [A Study to Evaluate Dexamethasone Compared With Prednisone During Induction Therapy to Treat Patients with Newly-diagnosed, High Risk Acute Lymphoblastic Leukemia](/research/clinical-trials/cls-20491273) No Locations AALL0232 is a COG group-wide phase III study designed for NCI high risk patients with acute lymphoblastic leukemia (ALL) from 1-30 years of age. Although event free survival and overall survival continue to increase for children with high risk ALL, CNS disease has become an increasing cause of treatment failure. There is evidence that both dexamethasone and high dose methotrexate prevent CNS relapse. To specifically address the relative increase in CNS events this study will test safety and efficacy of these two therapeutic interventions. The study utilizes a 2 x 2 factorial design with an augmented intensity BFM backbone. Patients ... - [A Study of WVT078 in Patients With Multiple Myeloma](/research/clinical-trials/cls-20513442) Rochester, MN The purpose of this study is to establish a safe and tolerated dose of single agent WVT078 in patients with relapsed and/or refractory Multiple Myeloma (MM). - [A Phase 1 Dose-Escalation and Expansion Study of BGB-16673 in With B-Cell Malignancies](/research/clinical-trials/cls-20535895) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This study consists of two parts to explore BGB-16673 recommended dosing: a part 1 monotherapy dose finding and a part 2 (cohort expansion in two cohorts). - [P1101 in Treating Patients With Myelofibrosis](/research/clinical-trials/cls-20147442) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the effectiveness of P1101 (polyethyleneglycol [PEG]-proline-interferon alpha-2b) in treating patients with myelofibrosis. PEG-proline-interferon alpha-2b is a substance that can improve the body's natural response and may slow the growth of myelofibrosis. - [A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma](/research/clinical-trials/cls-20145312) Scottsdale/Phoenix, AZ This is a multi-center, open label, single arm phase II study evaluating BGJ398 anti-tumor activity in advanced or metastatic cholangiocarcinoma patients with FGFR genetic alterations. - [Once-daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.](/research/clinical-trials/cls-20198652) Scottsdale/Phoenix, AZ; Jacksonville, FL The goal of this clinical study is to determine the safety and efficacy of VT-464, a lyase-selective inhibitor of CYP17 and an androgen receptor antagonist, in patients with castration-resistant prostate cancer (CRPC) who have been previously treated with enzalutamide or abiraterone. - [Study of MN This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study \"Master Protocol (BAML-16-001-M1).\" The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negative sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. - [CC-220-MM-001: A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma](/research/clinical-trials/cls-20312817) Scottsdale/Phoenix, AZ This is a multicenter, multicountry, open-label, Phase 1b/2a dose-escalation study to determine the maximum tolerated dose of CC-220 when administered as monotherapy and in combination with dexamethasone. The study will consist of an escalating dose-escalation portion (Part 1) as well as an expansion of each cohort (ie, Cohort C: Monotherapy (MonoT) and Cohort D: Combination treatment with 2 drugs (DoubleT) at the recommended Phase 2 dose (RP2D) to further evaluate safety and estimate preliminary efficacy (Part 2). - [A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic and SMARCB1-Null Tumors](/research/clinical-trials/cls-20540916) Jacksonville, FL; Rochester, MN The objectives of Phase 1 and Phase 2 of this study are to characterize the safety and tolerability of CFT8634 in subjects with locally advanced or metastatic SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors. Phase 1 only: To determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for CFT8634 in subjects with locally advanced or metastatic SMARCB1-perturbed cancers. Phase 2 only: To assess preliminary antitumor activity by overall response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 in subjects with locally advanced or metastatic synovial sarcoma (Cohort 1) or SMARCB1-null tumors (Cohort 2). in Advanced Solid Tumors](/research/clinical-trials/cls-20271290) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to find out more about the side effects of rovalpituzumab tesirine (SC16LD6.5) and what doses of rovalpituzumab tesirine (SC16LD6.5) are safe for people with specific delta-like protein 3-expressing cancers. - [Phase 1/2 Study of MRTX1719 Solid With MTAP Deletion](/research/clinical-trials/cls-20542686) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to to characterize the safety, tolerability, and pharmacokinetics of MRTX1719 in patients with advanced solid malignancies with MTAP (methylthioadenosine phosphorylase) deletion. - [Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer](/research/clinical-trials/cls-20154275) Rochester, MN This randomized phase II trial studies how well iodine I-131works with or without selumetinib in treating patients with thyroid cancer that has returned or has spread from where it started to other places in the body. Many thyroid cancers absorb iodine. Because of this, doctors often give radioactive iodine (iodine I-131) alone to treat thyroid cancer as part of standard practice. It is thought that the more thyroid tumors are able to absorb radioactive iodine, the more likely it is that the radioactive iodine will cause those tumors to shrink. Selumetinib may help radioactive iodine work better in patients whose ... - [A Study of Circulating Tumor DNA as a Biomarker of a Complete Response of Disease for Advanced Gastroesophageal Adenocarcinoma](/research/clinical-trials/cls-20313731) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate circulating tumor DNA as a potential biomarker for pre-surgery treatment response in patients who have esophageal cancer. - [Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients](/research/clinical-trials/cls-20385839) Rochester, MN The study is a multicenter, open label Phase I/II trial. 1. Establish the MTD of fractionated doses of Lintuzumab-Ac225 in combination with low dose cytosine arabinoside (Low Dose Ara-C, LDAC) (Phase 1 portion) 2. Determine the response rate (CR + CRp + CRi) to fractionated doses of Lintuzumab-Ac225 alone (Phase 2 portion) - [A Study of BBI503 in Asymptomatic Recurrent Ovarian Cancer Patients With CA-125 Elevation](/research/clinical-trials/cls-20143409) Rochester, MN This is an open label, single-arm, phase II study. The study population is adult patients with asymptomatic recurrent ovarian cancer who have an elevation in their CA-125 level. - [Sym021 in Combination with Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients with Advanced Biliary Tract Carcinomas ](/research/clinical-trials/cls-20508594) Rochester, MN The purpose of this study is to evaluate the preliminary effectiveness of the 3 combinations (Sym021+Sym022 and Sym021+Sym023 and Sym023+Irinotecan) in Biliary Tract Cancer by assessing ORRs per Investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. This study will also evaluate the safety and tolerability profile of the 3 combinations (Sym021+Sym022 and Sym021+Sym023 and Sym023+Irinotecan). - [Study of Molecular Circulatory Biomarkers in Hormone Sensitive and Castration Recurrent Prostate Cancer](/research/clinical-trials/cls-20314046) Rochester, MN The purpose of this study is to collect blood and urine samples from men already diagnosed with advanced prostate cancer. The blood and urine specimens obtained from you and other participants during this research will be processed to look for proteins, protein products and genetic markers of cancer and its treatments that may have been shed in blood and urine specimens you volunteer to donate. These markers can potentially guide us to give specific treatments to the patients in future and also to develop \"precision medicine\". This way we increase the chance for the drugs to be effective and limit ... - [Validation of a Blood Assay for the Detection of BRAF Mutation Status in Patients with Metastatic Melanoma](/research/clinical-trials/cls-20323754) Rochester, MN The purpose of this study is to validate an internally developed assay for the detection of BRAF V600E mutations in cfDNA from the peripheral blood of patients with melanoma. - [A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Basal Cell Nevus Syndrome](/research/clinical-trials/cls-20467341) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the effectiveness and safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult participants with Basal Cell Nevus Syndrome (BCNS; Gorlin Syndrome). - [A for Leukemia and Lymphoma](/research/clinical-trials/cls-20112303) Scottsdale/Phoenix, AZ; Jacksonville, FL This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic Cancer Patients: A Qualitative Study](/research/clinical-trials/cls-20438553) Rochester, MN The purpose of this study is to characterize, using the patients' own words, the experience of loneliness (or lack of privacy) that may be felt on inpatient units. - [A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer](/research/clinical-trials/cls-20536109) Rochester, MN The primary objectives for this study are to compare each investigational arm versus standard of care (SOC) for superiority in overall survival in 1st and/or 2nd line metastatic pancreatic cancer patients, and to determine which, if any, patients benefit from each investigational arm. - [A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors](/research/clinical-trials/cls-20540004) Rochester, MN The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-783. LOXO-783 may be used to treat breast cancer and other solid tumors that have a change in a particular gene (known as the PIK3CA gene). Participation could last up to 36 months (3 years) and possibly longer if the disease does not get worse. - [Long-term Follow Up of Patients Previously Enrolled in MC1137 (BEAUTY)](/research/clinical-trials/cls-20540090) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to extend the follow up on the BEAUTY study (MC1137) cohort and collect additional blood samples to evaluate for minimal residual disease and tissue at the time of any breast cancer recurrence. - [Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery](/research/clinical-trials/cls-20521080) Rochester, MN The objective of this study is to determine intensity of I-123 uptake in follicular thyroid lesions before surgery and correlate with final pathology findings. - [A study of how current treatments impact the course of relapsed myeloma and the effect of the treatments on the quality-of-life measurements.](/research/clinical-trials/cls-20530810) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The primary goal of this study is to determine the impact of standard of care therapies for TCR MM, in a real-world setting, on patient-reported symptoms, functioning, and QoL, measured prospectively using questionnaires. The secondary goal is to asses clinical endopoints associated with standard of care therapies for TCR MM, in a real-world setting during 12 months of observation. - [Detection of Mutant Circulating Tumor (CT)Dna in Uveal Melanoma With of a Droplet Digital Pcr (Ddpcr) Assay](/research/clinical-trials/cls-20540812) Rochester, MN The purpose of this study is to design, develop and assess the performance characteristics of a ddPCR assay for the detection of mutations associated with uveal melanoma. The performance characteristics of the ddPCR assay for the detection of ctDNA mutation in uveal melanoma patients will be assessed by comparing the mutation results obtained for the ddPCR assay on blood to those obtained on paired paraffin embedded tumors. - [A Study to Evaluate the Safety and Effectiveness of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy](/research/clinical-trials/cls-20449886) Rochester, MN The purpose of this 2 cohort study is to evaluate the effectiveness of tipifarnib in HRAS mutant HNSCC (AIM-HN). The first cohort will assess the objective response rate (ORR) of tipifarnib in subjects with HNSCC with HRAS mutations. The second study cohort, SEQ-HN, is an observational sub-study and includes 2 types of patients: (1) the historical record of first line therapy in subjects with HRAS mutant HNSCC participating in Cohort 1 in whom first line outcome data are available and (2) matched control HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first ... - [CC-4047 in Treating Patients With Myelofibrosis](/research/clinical-trials/cls-20493130) Rochester, MN RATIONALE: Biological therapies, such as CC-4047, may stimulate the immune system in different ways and stop cancer cells from growing. CC-4047 may also stop the growth of cancer cells by blocking blood flow to the cancer. PURPOSE: This trial is studying the side effects and best dose of CC-4047 and to see how well it works in treating patients with myelofibrosis. - [A Study to Evaluate the Effectiveness and Safety of Rivaroxaban as Prophylaxis Treatment for Venous Thromboembolism (VTE) in Ambulatory Cancer Patients](/research/clinical-trials/cls-20271970) Rochester, MN The purpose of this study is to demonstrate that rivaroxaban is superior to placebo for reducing the risk of lower extremity proximal deep vein thromboembolism (VTE)-related death in ambulatory adult patients with various cancer types receiving systemic cancer therapy who are at high risk of developing a VTE. - [Study of CPI-0610 in Myelofibrosis (MF)](/research/clinical-trials/cls-20521137) Jacksonville, FL This study aims to determine the efficacy of CPI-0610 + ruxolitinib compared with placebo + ruxolitinibin patients with naive myelofibrosis (MF). - [Treatment of Milademetan Trabectedin in Patient With Dedifferentiated Liposarcoma (MANTRA)](/research/clinical-trials/cls-20526240) Jacksonville, FL The purpose of this study is to evaluate the safety and effectiveness of milademetan compared to trabectedin in patients with unresectable (i.e., where resection is deemed to cause unacceptable morbidity or mortality) or metastatic DD liposarcoma that progressed on 1 or more prior systemic therapies, including at least 1 anthracycline-based therapy. - [Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas](/research/clinical-trials/cls-20534709) Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the safety and tolerability of SP-2577 (seclidemstat) as a single agent and in combination with topotecan and cyclophosphamide (TC) in patients with relapsed or refractory Ewing sarcoma and select sarcomas. - [A Study to Follow Durability of Patient Responses from Studies UT001 and TC-BC-12](/research/clinical-trials/cls-20529232) Rochester, MN The purposes of this study are to determine the durability of response in patients with low grade upper tract urothelial carcinoma (LG-UTUC) treated with JELMYTO in Study UT001 who completed the study with a durable response, and the durability of response in patients with low grade non-muscle invasive bladder cancer (LG-NMIBC) treated with UGN-102 in Study TC-BC-12 who completed the study with a durable response. - [A Study to Evaluate ION251 to Treat Patients with Relapsed/Refractory Multiple Myleoma](/research/clinical-trials/cls-20505899) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma. - [A Study of Momelotinib Symptomatic and Anemic Myelofibrosis Patients](/research/clinical-trials/cls-20488754) Scottsdale/Phoenix, AZ The purpose of this study is to compare the effectiveness and safety of Momelotinib (MMB) to Danazol (DAN) in treating and reducing disease related symptoms, the need for blood transfusions, and splenomegaly, in adults with primary Myelofibrosis (MF), post-polycythemia vera MF or post-essential thrombocythemia MF. MOMENTUM is a randomized, double-blind, active control Phase 3 trial intended to confirm the differentiated clinical benefits of the investigational drug momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic subjects who have previously received an approved Janus kinase inhibitor (JAKi) therapy for myelofibrosis (MF). The purpose of this clinical study is to c The study ... - [A Phase 1 Study Evaluating CPI-0610 in Patients With Previously Treated Multiple Myeloma](/research/clinical-trials/cls-20116721) Scottsdale/Phoenix, AZ Open-label, sequential dose escalation and expansion study of CPI-0610 in patients with previously treated multiple myeloma. CPI-0610 is a small molecule inhibitor of bromodomain and extra-terminal (BET) proteins. - [Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies](/research/clinical-trials/cls-20401445) Jacksonville, FL The purpose of this study is to determine the safety and tolerability of weekly intravenous (IV) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) after the first dose, and then to determine the MTD after second and subsequent infusions. - [A Study to Evaluate LOXO-305 Vs. Approved BTK Inhibitor Approved Drugs to Treat Patients with Mantle Cell Lymphoma](/research/clinical-trials/cls-20517038) Jacksonville, FL; Rochester, MN The purpose of this study is to compare progression-free survival (PFS) of LOXO-305 as monotherapy (Arm A) to investigator choice of covalent BTK inhibitor monotherapy (Arm B) in patients with previously treated mantle cell lymphoma (MCL). - [A Study to Assess Safety and Effectiveness of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia](/research/clinical-trials/cls-20456367) Rochester, MN The purpose of this dose-escalation study is to evaluate the safety, tolerability, pharmacokinetics (PK) and effectiveness of venetoclax, in combination with gilteritinib, in subjects with relapsed or refractory (R/R) acute myeloid leukemia (AML) who have failed to respond to, and/or have relapsed or progressed after at least 1 prior therapy. - [A Study to Evaluate Lymphoma Epidemiology](/research/clinical-trials/cls-20519838) Albert Lea, WI; Mankato, MN; Rochester, MN The purpose of this study is to build a large and diverse observational cohort to support broad and cutting-edge research focused on non-Hodgkin lymphoma (NHL) prognosis and survivorship. - [A Study to Evaluate the Development of Patient Derived Xenografts in Patients With Breast Cancer](/research/clinical-trials/cls-20507997) Rochester, MN Collection of tissue and blood from patients with residual disease after neoadjuvant systemic therapy for breast cancer. We hope to use these samples to find out why some patients still have cancer after they have completed neoadjuvant anticancer therapy. - [A Study to Evaluate the Effectiveness and Safety of Pemigatinib in Previously-treated, Locally Advanced/Metastatic or Surgically Unresectable Solid or Translocations (FIGHT-207)](/research/clinical-trials/cls-20473263) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to evaluate the effectiveness and safety of pemigatinib in participants with previously-treated, locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations. - [The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study](/research/clinical-trials/cls-20540751) Rochester, MN The purpose of this study is to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. - [A Study to Assess the Safety and Dose Escalation of Pegtomarginase (PT01) for Subjects with Advanced Malignancies](/research/clinical-trials/cls-20477453) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this first-in-human (FIH) study to evaluate the safety, tolerability, pharmacokinetics pharmacodynamics (PD), and preliminary activity of intravenously in subjects with advanced malignancies. - [VG161 in the Treatment of Patients With Hepatocellular or Intrahepatic Cholangiocarcinoma](/research/clinical-trials/cls-20540752) Scottsdale/Phoenix, AZ; The primary objectie of Safety Run-In Cohort (Cohort 1) is to evaluate the safety and tolerability of multiple intratumoral injections (IT) of VG161 at the recommendated Phase 2 Dose (RP2D) in patients with HCC and ICC who have either disease progression or intolerable toxicity after the standard treatments. The primary objective of HCC Cohort (Cohort 2) is to evaluate the efficacy of multiple IT injections of VG161 in patients with hepatocellular carcinoma (HCC). The primary objective of ICC Cohort (Cohort 3) is to evaluate the efficacy of multiple IT injections of VG161 in patients with intrahepatic cholangiocarcinoma. - [A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the effectiveness, safety, and pharmacokinetics of mosunetuzumab subcutaneous (SC) formulation in Myeloma](/research/clinical-trials/cls-20542168) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine the maximum tolerated dose (MTD) and schedule and/or a recommended Phase 2 dose (RP2D) and schedule of KTX-1001 for patients with relapsed and refractory multiple myeloma. - [Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients](/research/clinical-trials/cls-20531007) Rochester, MN; Mankato, MN The purpose of this study is to conduct a confirmatory phase III double-blind randomized clinical trial to evaluate the ability of olanzapine to decrease nausea in patients with advanced-cancer associated nausea/vomiting. - [Apixaban or Dalteparin in Reducing Blood in With Related Thromboembolism](/research/clinical-trials/cls-20166042) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL This randomized phase III trial studies the side effects of and compares apixaban and dalteparin in reducing blood clots in patients with cancer-related venous thromboembolism. Venous thromboembolism is a condition in which a blood clot forms in a vein and then breaks off and moves through the bloodstream. Patients with cancer are at increased risk for venous thromboembolism. Apixaban and dalteparin are drugs used to prevent blood clots from forming or to treat blood clots that have formed. It is not yet known whether apixaban or dalteparin is more effective in reducing blood clots in patients with cancer related venous ... - [Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy](/research/clinical-trials/cls-20478652) Jacksonville, FL The purpose of this study is to evaluate the effectiveness of Perampanel on seizure frequency in adult patients with brain-tumor with and without seizures associated with glioma. - [A Study to Evaluate the Effectiveness and Safety of P276-00 for Mantle Cell Lymphoma that has Returned and/or is Resistant to Treatment](/research/clinical-trials/cls-20315394) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to determine whether P276-00 is safe and effective for the treatment of Mantle Cell Lymphoma that has returned or is not responding to at least one previous line of treatment. - [A Study Using Momelotinib in Transfusion-Dependent This study will evaluate the transfusion independence response rate in transfusion-dependent adults with myelofibrosis following treatment with momelotinib. - [A Study to Investigate the Safety and Tolerability of REGN1979 in Patients With CD20+ B-Cell Malignancies](/research/clinical-trials/cls-20152420) Rochester, MN This is an open-label, multi-center, dose escalation study of REGN1979 administered as an IV (intravenous) infusion. This phase 1 study will investigate the safety and tolerability of REGN1979 in patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) - [A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)](/research/clinical-trials/cls-20401452) Rochester, MN The purpose of this research study is to compare the effects and safety of the study drug, MOR00208, given with bendamustine (BEN) to another treatment combination, rituximab (RTX) in combination with BEN to find out which combination is better for treating DLBCL. MOR00208 is an investigational drug. RTX and BEN are both approved in many countries for the treatment of lymphomas. The combination of both is considered and recommended by some medical authorities in some other countries as an option to treat DLBCL. - [Study of bb2121 in Multiple Myeloma](/research/clinical-trials/cls-20209641) Rochester, CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM). - [GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC](/research/clinical-trials/cls-20525794) Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to evaluate whether CAN-2409 + prodrug added to standard of care immune checkpoint inhibitor (ICI) therapy will be safe and improve the outcome for Non-small Cell Lung Cancer (NSCLC) patients that have stable disease or readiographic progression after at least 18 weeks of ICI therapy or that have refractory disease after at least 9 weeks of ICI therapy. - [Engineering Gut Microbiome to Target Breast Cancer](/research/clinical-trials/cls-20359614) Jacksonville, FL The purpose of this study is to find out if using probiotics will help the body's immune system react to breast cancer. New studies showed that diverse species of bacteria inside the bowel might help improve immune system, particularly the ability of immune system to recognize cancer. This study will investigate how probiotics will affect the subjects' immune system on breast cancer. - [Long Term Outcomes in Pancreas Cancer Patients](/research/clinical-trials/cls-20541356) Rochester, MN The purpose of this study is to access long-term quality of life, complications, and implications of treatments on patients who are long-term survivors of pancreas cancer and were treated at Mayo Clinic. - [CAncer Survivor CArdiomyopathy DEtection (CASCADE) Pilot Study](/research/clinical-trials/cls-20525147) Rochester, MN The purpose of this study is to improve the cardiovascular care of adult cancer survivors by contributing much-needed evidence regarding optimal surveillance and treatment recommendations. This application's objective is to obtain the data necessary to plan an adequately powered randomized clinical trial (RCT) across a nation-wide network that will define prospectively the clinical and economic efficacy of a screening program that uses AI-ECG and/or NT-pro-BNP in an at-risk adult cancer survivor population. - [A Study Using Bioimpedance Spectroscopy versus Tape Measurement in Catching and Intervening in the Early Onset of Lymphedema](/research/clinical-trials/cls-20491220) Jacksonville, FL The purpose of this study is to compare the use of Bioimpedance Spectroscopy versus tape measurements for follow-up arm measurements after regional treatment for breast cancer. Catching the smallest increases in fluid buildup and intervening early may result in a decrease in the rate of progressions to chronic lymphedema. - [A Study of the Bacteria Found in Cancerous and Non-cancerous Breast Tissue](/research/clinical-trials/cls-20151750) Rochester, MN The purpose of this study is to see if having different kinds of bacteria genes in breast tissue may be connected to the risk of getting breast cancer. - [CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung (DELFI-L201)](/research/clinical-trials/cls-20535565) Rochester, MN The purpose of this study is to determine the sensitivity and specificity of a blood test (DLCST) for the detection of lung cancer in a screening setting using the reference of Chest CT screening and a histologic diagnosis of lung cancer. - [Identifying responders to MUC1 vaccine](/research/clinical-trials/cls-20491213) No Locations A preventative MUC1 vaccine being tested in a clinical trial MAY13-01-01 in individuals with a history of advanced adenomas and an increased risk for colon cancer, gives 2 different outcomes. About half of vaccinated individuals make a strong anti-MUC1 IgG (vaccine responders) and the other half do not (vaccine non-responders). We have been analyzing differential gene expression in pre-vaccination PBMCs from these two groups to identify a gene expression signature that can predict response. We are now proposing to confirm and extend these studies by doing gene expression analysis at the single cell level rather than total PBMC. ... - [A Study to Evaluate Visually Inspired Patient Education Material on Willingness to Pursue Radiation Therapy](/research/clinical-trials/cls-20510475) Scottsdale/Phoenix, AZ The purpose of this study is to measure how patient anxiety changes using a validated patient reported outcome measure, to measure radiotherapy completion rates in the American Indian/Alaska Native (AI/AN) community, and to measure patient perception of information received using a validated patient reported outcome measure. - [MDM2 Inhibitor AMG-232 and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma](/research/clinical-trials/cls-20441973) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this phase Ib trial studies the side effects of MDM2 inhibitor AMG-232 and radiation therapy in treating patients with soft tissue sarcoma. MDM2 inhibitor AMG-232 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving MDM2 inhibitor AMG-232 and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. - [Safety and Efficacy Study of PRI-724 Plus Gemcitabine in Subjects With Advanced or Metastatic Pancreatic Adenocarcinoma](/research/clinical-trials/cls-20112256) Rochester, MN Laboratory studies suggest that the study drug may stop cancer cells from growing by affecting an interaction between proteins in the cells referred to as cAMP-response element-binding protein and \u00df-catenin. The purpose of this research study is to determine the highest safe dose of study drug that may be used when it is given together with a chemotherapy drug to patients with cancer of the pancreas. - [Radiation Therapy With or Without Apalutamide in Treating Patients With Stage III-IV Prostate Cancer](/research/clinical-trials/cls-20434446) Albert Lea, MN The purpose of this study is to determine whether, in men with post-prostatectomy PSA recurrences, salvage radiation therapy (SRT) with enhanced anti-androgen therapy with apalutamide will improve biochemical progression-free survival (bPFS) compared to SRT alone. - [Prostate Imaging Using MRI +/- Contrast Enhancement](/research/clinical-trials/cls-20535717) Rochester, MN This prospective clinical trial (PRostate Imaging using Mri +/- contrast Enhancement (PRIME)) aims to assess whether biparametric MRI (bpMRI) is non-inferior to multiparametric mpMRI (mpMRI) in the detection of clinically significant prostate cancer. - [Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer](/research/clinical-trials/cls-20169971) Rochester, MN The focus of this study is to evaluate the efficacy, safety, and tolerability of veliparib in women with previously untreated, Stage III or IV, high-grade serous, epithelial ovarian, fallopian tube, or primary peritoneal cancer. - [Topical Cryotherapy in Reducing Pain in Patients With Chemotherapy Induced Peripheral Neuropathy or Paclitaxel Induced Acute Pain Syndrome](/research/clinical-trials/cls-20198328) Rochester, MN; Jacksonville, FL This randomized pilot clinical trial studies topical cryotherapy (a procedure in which an extremely cold liquid is used to freeze and destroy abnormal tissue) in reducing pain in patients with chemotherapy induced peripheral neuropathy or paclitaxel induced acute pain syndrome. Peripheral neuropathy is a nerve problem that causes pain, numbness, tingling, swelling, or muscle weakness in different parts of the body. Paclitaxel produces a disabling syndrome of acute aches and pains. Topical cryotherapy may help relieve pain from peripheral neuropathy or acute pain syndrome caused by chemotherapy. - [Bicalutamide and Raloxifene Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery](/research/clinical-trials/cls-20319884) Scottsdale/Phoenix, AZ This phase II pilot trial studies how well bicalutamide and raloxifene hydrochloride work in treating patients with prostate cancer undergoing surgery. Antihormone therapy, such as bicalutamide and raloxifene hydrochloride, may lessen the amount of androgens made by the body. - [Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)](/research/clinical-trials/cls-20493006) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea. - [A Study of Unesbulin Combined with Dacarbazine to Treat Advanced Leiomyosarcoma (LMS)](/research/clinical-trials/cls-20467889) Jacksonville, FL The primary purpose of this study is to determine the maximum tolerated dose (MTD) and overall safety profile of PTC596 in combination with dacarbazine for the treatment of advanced Locally Recurrent, Unresectable or Metastatic Relapsed/Refractory Leiomyosarcoma (LMS). - [A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis](/research/clinical-trials/cls-20493137) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of trhis study is to evaluate CPI-0610 in patients who have both received JAK inhibitors, such as ruxolitinib (Arms 1 and 2), and in patients who have never been treated with a JAK inhibitor (Arm 3). Patients who participate in Arm 1 will be treated with CPI-0610 alone (monotherapy arm), patients who participate in Arm 2 will be treated with CPI-0610 in combination with ruxolitinib (combination arm), and patients who have never been treated with a JAK inhibitor who participate in Arm 3, will also be treated with CPI-0610 and ruxolitinib, a JAK inhibitor (JAKi na\u00efve arm). - [Carboplatin and Gemcitabine Hydrochloride With or Without VX-970 in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer](/research/clinical-trials/cls-20272698) Rochester, MN; Scottsdale/Phoenix, AZ This randomized phase II trial studies the side effects and how well carboplatin and gemcitabine hydrochloride with or without ATR kinase inhibitor VX-970 work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent) and has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as carboplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. ATR kinase inhibitor VX-970 may stop the growth of tumor cells by blocking ... - [Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)](/research/clinical-trials/cls-20144048) Scottsdale/Phoenix, AZ; Rochester, MN This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes. - [Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma](/research/clinical-trials/cls-20151620) No Locations This randomized pilot clinical trial is studying the side effects and how well giving temozolomide and cixutumumab together with combination chemotherapy works in treating patients with metastatic rhabdomyosarcoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving temozolomide and cixutumumab together with ... - [A Study to Evaluate Pevonedistat, Azacitidine (or Decitabine), Venetoclax to Treat Acute Myelogenous Leukemia (AML) Patients](/research/clinical-trials/cls-20488750) Rochester, MN The purpose of this study is to determine a recommended phase 2 dose (RP2D) of pevonedistat, azacitidine (or decitabine), and venetoclax to treat Acute Myelogenous Leukemia. - [A Study to Evaluate Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma](/research/clinical-trials/cls-20508006) Rochester, MN The purpose of this study is to compare the effectiveness of Carboplatin-Paclitaxel with INCMGA00012 vs. Carboplatin-Paclitaxel with placebo in participants with inoperable, locally-advanced or metastatic Squamous Cell Anal Carcinoma (SCAC) not previously treated with systemic chemotherapy. - [A Study Evaluating Tolerability and Efficacy of Navitoclax in Combination With Ruxolitinib in Subjects With Myelofibrosis](/research/clinical-trials/cls-20423882) Jacksonville, FL This is a Phase 2, single-arm, open-label, multicenter study evaluating efficacy, safety and tolerability of navitoclax added to ruxolitinib in participants with myelofibrosis. - [A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer](/research/clinical-trials/cls-20477931) Jacksonville, FL The purpose of this study is to establish the recommended phase 2 dose (RP2D) of niraparib combination therapies of Part 1 and to evaluate the antitumor activity and safety of niraparib combination therapies of Part 2. - [Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma](/research/clinical-trials/cls-20115982) Rochester, MN This is a phase 2, multicenter, open-label study in patients with Newly Diagnosed Multiple Myeloma (NDMM) who have not received prior systemic treatment for multiple myeloma (MM) and who are ineligible for high-dose therapy (HDT)-stem cell transplantation (SCT) due to age (ie, 65 years) or comorbid disease(s) or with Relapsed and/or Refractory Multiple Myeloma (RRMM)). - [A Study to Compare Conventional Heart Echo Measurements with Newer 2 and 3 Dimensional Measurements of Mechanical Heart Strain after Trastuzumab Infusion](/research/clinical-trials/cls-20257221) Rochester, MN The purpose of this study is to compare conventional assessment of systolic ventricular function on a 2D heart echo with an assessment of more immediate changes in heart mechanics using 2D and 3D measurements of deformation and strain in patients undergoing infusion of Trastuzumab for breast cancer. - [Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide Scottsdale/Phoenix, AZ; Jacksonville, FL; tests how well pertuzumab, trastuzumab, hyaluronidase-zzxf and enzalutamide works in treating patients with castration-resistant prostate cancer that has spread from where it first started to other places in the body (metastatic). Pertuzumab and trastuzumab are monoclonal antibodies and forms of targeted therapy that attach to a receptor protein called human epidermal growth factor receptor-2 (HER2). HER2 is found on some cancer cells. When pertuzumab or trastuzumab attach to HER2, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an ... - [A Study to Identify Late-Occurring Complications in Childhood Cancer Survivors](/research/clinical-trials/cls-20472113) Rochester, MN The purpose of this trial is to identify cancer survivors who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer. A patient's genes may affect the risk of developing complications, such as congestive heart failure, heart attack, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications. - [A Study to Evaluate Accelerated Resolution Therapy in Cancer and Palliative Care](/research/clinical-trials/cls-20520846) Jacksonville, FL The following research questions will guide this study: 1) Is ART feasible and acceptable for use with distressed patients and/or family caregivers in oncology and palliative care clinical settings? 2) What is the mean dose of ART provided to distressed patients and/or family caregivers? 3) What are the patient and family stressors that result in a recommendation for ART? 4) Does ART reduce symptoms of psychological trauma, anxiety and depression, when used with distressed patients and family caregivers in oncology and palliative care clinical settings? 5) Does ART improve resilience when used with distressed ... - [Master Protocol to Assess the Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors](/research/clinical-trials/cls-20531302) Jacksonville, FL The purpose of this trial is to evaluate the safety and effectiveness of first time in human engineered T-cell therapies, in participants with advanced tumors. - [Effectiveness of Nurse-based Care Coordination on Readmissions among Primary Care Patients: a Stepped Wedge Cluster Randomized Trial](/research/clinical-trials/cls-20474789) Rochester, MN The purpose of this study is to evaluate nurse-based care coordination compared to usual care on 30-day risk-adjusted readmission rates among high risk patients. - [Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer](/research/clinical-trials/cls-20145182) Rochester, MN The purpose of this study is to determine whether TH-302 in combination with pemetrexed is safe and effective in the treatment of non-squamous non-small cell lung cancer. - [A Study to Evaluate Treatment of Established Chemotherapy-induced Neuropathy with Fingolimod](/research/clinical-trials/cls-20458951) Rochester, MN; Mankato, MN The purpose of this study is to determine if the use of Fingolimod can reduce neuropathy caused by chemotherapy. - [A Study to Reduce Disparities in High-Risk Black Men (BM) With Advanced Prostate Cancer Using Patient-Centered Home Care](/research/clinical-trials/cls-20536300) Jacksonville, FL The purpose of this study is to evaluate a highly innovative project evaluating the feasibility of patient-centered home care (PCHC) as a new model of cancer care to reduce disparities and improve health related qualtiy of life (HRQoL) and patient reported-outcomes (PROs) in Black patients with advanced prostate cancer (CaP). - [A Safety to Evaluate the Safety and Effectiveness of Pressurized Intraperitoneal Aerosolized Chemotherapy in Ovarian, Uterine, Colorectal, and Gastric Cancer Patients](/research/clinical-trials/cls-20517716) Jacksonville, FL The purpose of this study is to evaluate the safety of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in 2 groups of patients with peritoneal carcinomatosis (PC), either due to primary ovarian, uterine, or gastric carcinoma (Arm 1) or to primary colorectal carcinoma (Arm 2), based on treatment-related adverse events reported by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. - [A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Sunitinib in Patients with Gastrointestinal Stromal Tumour After Progression with Imatinib](/research/clinical-trials/cls-20115543) Jacksonville, FL; Rochester, MN The objective is to compare the efficacy and safety of masitinib at 12 mg/kg/day to sunitinib at 50 mg/day - [Sarcoma Study of Utilization: Research and Clinical Evaluation](/research/clinical-trials/cls-20112289) Jacksonville, FL; Rochester, MN This study is being done to see if MORAb-004 increases the effectiveness of the chemotherapies gemcitabine and docetaxel in people with metastatic Soft Tissue Sarcoma. - [A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma](/research/clinical-trials/cls-20202194) Jacksonville, FL The main purpose of this study is to evaluate the safety and efficacy of two anti-cancer drugs (gemcitabine and docetaxel) with and without the study drug known as olaratumab in participants with advanced soft tissue sarcoma (STS) or STS that has spread to another part(s) of the body. - [A Study to Evaluate Pevonedistat and Venetoclax Plus Azacitidine in Adults with Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy](/research/clinical-trials/cls-20508597) Jacksonville, FL The purpose of this study is to determine whether the combination of pevonedistat + venetoclax + azacitidine improves event-free survival (EFS) compared with venetoclax + azacitidine in patients with newly diagnosed acute myeloid leukemia (AML) who are unfit for intensive chemotherapy. - [PF-07284892 in Participants With Advanced Solid Tumors](/research/clinical-trials/cls-20538910) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to determine the maximum tolerated dose and/or recommended dose for further study of PF-07284892 as a single agent and in combination with lorlatinib, encorafenib and cetuximab, or binimetinib and evaluate the pharmacokinetics, safety, and preliminary clinical activity of single agent and each combination therapy. - [A Study to See if Memantine Protects the Brain During Radiation Therapy Treatment for a Brain Tumor](/research/clinical-trials/cls-20533344) Rochester, MN This phase III trial compares memantine to usual treatment in treating patients with brain tumors that are newly diagnosed or has come back (recurrent). Memantine may block receptors (parts of nerve cells) in the brain known to contribute to a decline in cognitive function. Giving memantine may make a difference in cognitive function (attention, memory, or other thought processes) in children and adolescents receiving brain radiation therapy to treat a primary brain tumor. - [Testicular Tissue Cryopreservation in Children](/research/clinical-trials/cls-20264708) Rochester, MN This protocol is being designed to offer testicular tissue cryopreservation to male pediatric patients (0-17 years of age) with fertility threatening medical diagnoses or facing surgery, chemotherapy or radiation therapy that may cause loss of reproductive potential. - [Tumor Heterogeneity of the Tumor Microenvironment in Malignant Pleural Mesothelioma (MPM)](/research/clinical-trials/cls-20389240) Rochester, MN The purpose of this study is to: - Evaluate MPM tumor heterogeneity by determining the agreement of histology, molecular abnormalities, neo-antigen expression and immunological biomarkers between three tumor samples from MPM patients. - Compare the information from tumor samples to pleural fluid, peripheral blood and density based radiomics analysis. - [Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)](/research/clinical-trials/cls-20111742) Rochester, MN The purpose of this study is to determine the safety and effectiveness of pracinostat when combined with azacitadine for patients who are 65 years of age or older and have Acute Myelogenous Leukemia (AML) - [IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma](/research/clinical-trials/cls-20111942) Rochester, MN This is a phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of IXAZOMIB versus placebo when added to lenalidomide and dexamethasone (LenDex) in patients with Newly Diagnosed Multiple Myeloma (NDMM) who are not eligible for stem cell transplant. - [Azacitidine With or Without Lenalidomide or Vorinostat in Patients phase II/III trial studies how well giving azacitidine works with or without lenalidomide or vorinostat in treating patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or stopping them from dividing. Lenalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether azacitidine is more effective with ... - [Testing the Addition of Ixazomib to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial](/research/clinical-trials/cls-20519108) Rochester, MN This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplantation. Lenalidomide may help shrink or slow the growth of multiple myeloma. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplantation. - [Everolimus and Lenalidomide in Treating Patients With Relapsed or Lymphoma](/research/clinical-trials/cls-20492232) Rochester, MN; Scottsdale/Phoenix, AZ RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving everolimus together with lenalidomide may be an effective treatment for lymphoma. PURPOSE: This phase I/II trial is studying the side effects and best dose of giving everolimus and lenalidomide together and to see how well they work in treating patients with relapsed or refractory non-Hodgkin or Hodgkin lymphoma. - [Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer](/research/clinical-trials/cls-20151020) Jacksonville, FL; Rochester, MN This pilot, phase II trial studies how well everolimus and letrozole work in treating patients with hormone receptor positive ovarian, fallopian tube, or primary peritoneal cavity cancer that has come back. Everolimus and letrozole may stop the growth of tumor cells by blocking some the enzymes needed for cell growth. - [Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma](/research/clinical-trials/cls-20132074) Rochester, MN This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma. Monoclonal antibody-drug conjugates, such as brentuximab vedotin, can block cancer growth in different ways by targeting certain cells. Crizotinib and methotrexate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is ... - [Oxaliplatin, Leucovorin Calcium, and Fluorouracil with or without Celecoxib in Treating Patients with Stage III Colon Cancer Previously Treated with Surgery](/research/clinical-trials/cls-20116791) Jacksonville, FL; Rochester, MN PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery. RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving ... - [PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies](/research/clinical-trials/cls-20314310) Jacksonville, FL Primary Objectives 1. To determine the safety and tolerability profile of weekly IV dosing of XmAb14045 2. To identify the first dose MTD/RD 3. At first dose MTD/RD, to then identify the second (and subsequent) infusion MTD/RD - [Three-Dimensional Ultrasound in the Determination of Tumor Volume and Myometrial Invasion in Endometrial Cancer](/research/clinical-trials/cls-20306519) Rochester, MN The purpose of this study is to evaluate sensitivity and specificity of 3D ultrasound in the assessment of tumor diameter and myometrial invasion in endometrial cancer in a pre-operative setting. This research is aiming to avoid the performance of sentinel node biopsy in patients at low risk of lymphatic spread. - [The Role of Cytomegalovirus and Inflammation on Patient Symptoms and Outcomes in Ovarian Cancer](/research/clinical-trials/cls-20532365) Albert Lea, MN; Mankato, MN The purpose of this study is to determine whether a common virus, cytomegalovirus (CMV), may increase fatigue and other symptoms following treatment for ovarian cancer. - [Cancer Distress Management Program for Liver and Biliary Cancer within a SPORE](/research/clinical-trials/cls-20540640) Rochester, MN The aim of this study is to develop a feasible, acceptable, and sustainable comprehensive cancer distress management program that is tailored to the unique needs of liver and biliary cancer patient survivors. - [Phase 2 Nab\u00ae-Paclitaxel (Abraxane\u00ae) Plus Gemcitabine in Subjects with Locally Advanced Pancreatic Cancer (LAPC)](/research/clinical-trials/cls-20146804) Scottsdale/Phoenix, AZ This clinical study is in subjects who are 18 years old or older with locally advanced pancreatic cancer who have not received prior treatment for their pancreatic cancer. The study treats all subjects with nab-Paclitaxel plus gemcitabine for approximately 6 months of treatment. Subjects who complete the treatment will choose, with their treating physicians, what additional treatment should be given: more nab-Paclitaxel plus gemcitabine, Chemoradiation therapy, or surgery to treat the locally advanced pancreatic cancer. - [A Study of Cediranib and Olaparib Combined, Compared to Either Drug Alone, or to a Standard Chemotherapy in Treating Patients who have a Return of Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer](/research/clinical-trials/cls-20236704) La Crosse, WI; Rochester, MN; Mankato, MN The purpose of this study is to see how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has returned after receiving chemotherapy with drugs that contain platinum (platinum-resistant) or continued to grow while being treated with platinum-based chemotherapy drugs (platinum-refractory). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping ... - [A Study to Evaluate AVB-S6-500 with Paclitaxel vs Paclitaxel in Patients with Platinum-resistant Recurrent Ovarian Cancer](/research/clinical-trials/cls-20524072) Rochester, MN The purpose of this study is to evaluate AVB-S6-500 in combination with paclitaxel (Pac) in patients with platinum resistant recurrent ovarian cancer to compare the effectiveness and of AVB-S6-500 in combination with Pac versus placebo plus Pac. - [A Study to Compare Docetaxel/Prednisone to Docetaxel/Prednisone Combined with OGX-011 in Men with Prostate Cancer](/research/clinical-trials/cls-20315396) Rochester, MN The purpose of this study is to confirm that adding custirsen to standard first-line docetaxel and prednisone treatment can slow tumor progression in men who have prostate cancer, and enhance survival outcomes compared to standard first-line docetaxel and prednisone treatment alone. - [A Study of Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)](/research/clinical-trials/cls-20469676) La Crosse, WI The purpose of this study is to evaluate the investigational drug PledOx in the prevention of chronic chemotherapy induced peripheral neuropathy (CIPN) induced by the drug oxaliplatin. - [Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.](/research/clinical-trials/cls-20111712) Rochester, MN Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy. - [Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer](/research/clinical-trials/cls-20449550) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This randomized phase III trial was originally designed to compare three different combination chemotherapy regimens to see how well they work. As of September 1, 2004, the study was expanded to a total of 6 arms (the original 3 arms (A, B, C) and 3 additional arms which were the same as the first 3 but with cetuximab) in treating patients who have undergone surgery for stage III colon cancer. Drugs used in chemotherapy, such as irinotecan hydrochloride, fluorouracil, leucovorin calcium, and oxaliplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal ... - [A Study of Catequentinib, MN; Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety and effectiveness of AL3818 (catequentibub, anlotinib) hydrochloride in the treatment of metastatic or soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial All participants with ASPS will receive open-label AL3818. In participants with LMS or SS, AL3818 will be compared to IV dacarbazine. Two-thirds of the participants will receive AL3818, one-third of the participants will receive IV dacarbazine. - [A Study to Evaluate Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers](/research/clinical-trials/cls-20461649) Eau Claire, WI; Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN; La Crosse, WI The purpose of this study is to evaluate how well gemcitabine hydrochloride and cisplatin given with or without nab-paclitaxel work in treating patients with newly diagnosed biliary tract cancers that have spread to other places in the body. Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not known if giving gemcitabine hydrochloride and cisplatin with or without nab-paclitaxel may work better at treating biliary tract cancers. - [S1406 A Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib Colorectal Cancer](/research/clinical-trials/cls-20155236) Rochester, MN This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with or without vemurafenib works in treating patients with colorectal cancer that has spread to nearby tissue or lymph nodes, that has spread to other places in the body, or cannot be removed by surgery. Irinotecan hydrochloride and vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab, may block the ability of tumor cells to grow and spread. It is not yet known whether irinotecan hydrochloride and cetuximab are more effective with or without ... - [Glutathione in Preventing Peripheral Neuropathy Caused by Paclitaxel and Carboplatin in Patients With Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer](/research/clinical-trials/cls-20341679) Rochester, MN This randomized phase III trial is studying glutathione to see how well it works in preventing peripheral neuropathy caused by paclitaxel and carboplatin in patients with ovarian cancer, fallopian tube cancer, and/or primary peritoneal cancer. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Chemoprotective drugs, such as glutathione, may help prevent peripheral neuropathy caused by paclitaxel and carboplatin. It is not yet known whether glutathione is more effective than a placebo in preventing peripheral neuropathy. - [A Study to Evaluate Nasal Vestibulitis Symptoms Undergoing Antineoplastic Mankato, MN; Albert Lea, MN; Austin, MN The purpose of this study is to evaluate treatment-emergent nasal vestibulitis symptoms in patients undergoing systemic antineoplastic therapy. - [Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer](/research/clinical-trials/cls-20400614) Rochester, MN This randomized pilot clinical trial studies the side effects and best dose of naloxegol and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer. Naloxegol may relieve some of the side effects of opioid pain medication and fight off future growth in the cancer. - [Azacitidine and Sonidegib in Treating Patients With Myeloid Malignancies](/research/clinical-trials/cls-20111752) Scottsdale/Phoenix, AZ; Rochester, MN This phase I/IB trial studies the side effects, best dose, and efficacy of azacitidine and erismodegib in treating patients with myeloid malignancies. The hedgehog (Hh) signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation may be associated with mutations in the Hh-ligand cell surface receptor Smo. Erismodegib binds to the Hh cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and the inhibition of cancer cells. Azacitidine may stop the growth of cancer cells by blocking some of the enzymes needed ... - [Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20112254) Rochester, MN This phase II trial studies how well lenalidomide and dexamethasone work in treating patients with relapsed or refractory multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with dexamethasone may kill more cancer cells. - [Multinational Clinical Study Comparing Isatuximab, Pomalidomide, and Dexamethasone to Pomalidomide AZ; MN Primary Objective: demonstrate of isatuximab in combination with pomalidomide and low-dose dexamethasone in the prolongation of Progression Free Survival (PFS) as compared to pomalidomide and low-dose dexamethasone in patients with refractory or relapsed and refractory multiple myeloma (MM). Secondary Objectives: - To evaluate the Overall Response Rate (ORR) as per International Myeloma Working Group (IMWG) criteria in each arm. - To compare the Overall Survival (OS) between the two arms. - To evaluate the Time To Progression (TTP) in each arm. - To evaluate the Progression Free Survival (PFS) in high risk cytogenetic population in each arm. ... - [Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma](/research/clinical-trials/cls-20147198) Rochester, MN To evaluate the efficacy rituximab, and prednisone (placebo-R-CHOP) chemotherapy in patients who have previously untreated ABC type DLBCL. - [Obinutuzumab With or Without PI3K-delta Inhibitor TGR-1202, Lenalidomide, or Combination Chemotherapy in Treating Patients Relapsed or Refractory Grade I-IIIa Follicular Lymphoma](/research/clinical-trials/cls-20382560) Rochester, MN This randomized phase II trial well obinutuzumab with or without PI3K-delta inhibitor TGR-1202, lenalidomide, or combination chemotherapy work in treating patients with grade I-IIIa follicular lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. PI3K-delta inhibitor TGR-1202 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer ... - [Study of ASTX727 vs versus IV decitabine. Adult subjects who are candidates to receive IV decitabine will be randomized 1:1 to receive the ASTX727 tablet Daily\u00d75 in Cycle 1 followed by IV decitabine 20 mg/m^2 Daily\u00d75 in Cycle 2, or the converse order. After completion of PK studies during the first 2 treatment cycles, subjects will continue to receive treatment with ASTX727 from Cycle 3 onward (in 28-day cycles) until disease progression, unacceptable toxicity, or the subject discontinues treatment or withdraws from the study. - [A Study to Assess Anxiety Associated with Outpatient Visits in Pediatric Oncology Patients](/research/clinical-trials/cls-20317355) Rochester, MN The purpose of this study is to assess baseline anxiety experienced by children and their parents/guardians associated with outpatient visits in pediatric oncology. Assess coping mechanisms used by children and their parents/guardians to alleviate the anxiety associated with outpatient visits in pediatric oncology. - [A Study of Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients with Previously Treated Multiple Myeloma or Plasma Cell Leukemia](/research/clinical-trials/cls-20151856) Rochester, MN This phase II trial studies how well pomalidomide, ixazomib citrate, and dexamethasone work in treating patients with previously treated multiple myeloma or plasma cell leukemia. Biological therapies, such as pomalidomide, and dexamethasone, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pomalidomide, ixazomib citrate, and dexamethasone together may be more effective in treating multiple myeloma. - [A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Relapsed and/or Refractory Multiple Myeloma](/research/clinical-trials/cls-20451081) Jacksonville, FL; Rochester, MN The purpose of this phase 3, randomized, double-blind, multicenter study is to compare Oral Ixazomib (MLN9708) Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in adult patients with relapsed and/or refractory multiple myeloma. - [Phase 1b Acute 1b, open-label, non-randomized, multicenter study to evaluate the safety of orally administered ABT-199 combined with decitabine or azacitidine and the preliminary efficacy of one of these combinations. In addition, there is a DDI sub-study only at a single site, to assess the pharmacokinetics and safety of ABT-199 in combination with posaconazole. - [A Study to Evaluate AuTophagy Activation for Cardiomyopathy Due to Anthracycline tReatment](/research/clinical-trials/cls-20474395) Rochester, MN The purpose of this study is to evaluate the additional benefit of pravastatin and spironolactone when given in combination with carvedilol and lisinopril versus carvedilol and lisinopril alone. - [AUTO1 in Relapsed or Refractory B-ALL](/research/clinical-trials/cls-20513569) Rochester, MN The purpose of this study is to evaluate the safety and effectiveness of AUTO1 (t-cells) in adult patients (r/r B-ALL). - Efficacy and Parsaclisib and Ruxolitinib in Participants With Myelofibrosis](/research/clinical-trials/cls-20519534) Scottsdale/Phoenix, AZ The purpose of this study is to compare the effectiveness of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis. - [A Study to Evaluate Brigatinib Before Brain Irradiation](/research/clinical-trials/cls-20515341) Rochester, MN The purpose of this study is to evaluate brigatinib alone for patients with brain metastases from anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC), who have either not been treated previously with a tyrosine kinase inhibitor (TKI) targeting ALK or who have had prior exposure to crizotinib. - [A Study to Assess the Effectiveness of Osimertinib Plus Savolitinib in Patients with Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Osimertinib Treatment (SAVANNAH Study) Following Prior Osimertinib](/research/clinical-trials/cls-20482125) Rochester, MN The purpose of this study (the SAVANNAH study) is tol investigate the effectiveness of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic Non Small Cell Lung Cancer (NSCLC) who have progressed following treatment with osimertinib. - [A Study to Compare Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors](/research/clinical-trials/cls-20509320) Rochester, MN The purpose of this study is to compare a mobile health and social media physical activity intervention versus wearing a physical activity tracker among adolescent and young adult childhood cancer survivors. Regular physical activity helps maintain healthy weight, energy levels, and health. Adolescents and young adults who complete treatment for cancer are often less active. They may gain weight and have more health problems compared to people the same age who have not had treatment for cancer. Comparing the 2 programs will help researchers learn how to increase physical activity levels over time and also how changes in physical activity levels ... - [A Study to Evaluate EAA181 to Treat Newly-diagnosed Multiple Myeloma](/research/clinical-trials/cls-20510275) La Crosse, WI; Rochester, MN The primary purpose of this study is to determine if bortezomib, daratumumab, lenalidomide and dexamethasone (Btz-DRd) consolidation followed by daratumumab (DR) maintenance standard induction therapy with daratumumab, lenalidomide and dexamethasone (DRd) results in superior overall survival compared to DRd consolidation followed by DR maintenance, in MRD positive patients. - [An Extension Study to Evaluate Subjects Who Have Benefited from Previous Treatment with Niraparib](/research/clinical-trials/cls-20520637) Jacksonville, FL The purpose of this study is to provide continued access to niraparib and further characterize the long-term safety of niraparib treatment. - [Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy With High-Grade Upper Tract Urothelial Carcinoma](/research/clinical-trials/cls-20113754) Scottsdale/Phoenix, AZ The purpose of this study is to see if getting chemotherapy with Gemcitabine and Cisplatin for four 21 day cycles for a total of 12 weeks can help shrink the tumor before undergoing surgery for kidney cancer. - [Short-course Radiation Therapy for Hepatocellular Carcinoma](/research/clinical-trials/cls-20507056) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to determine the safety and effectiveness of 5 fraction stereotactic pencil beam scanning proton radiotherapy for the treatment of hepatocellular carcinoma (HCC). Scottsdale/Phoenix, AZ This is a study to evaluate the safety of MRX34 in patients with primary liver cancer or those with liver metastasis from other cancers. The drug is given intravenously, twice per week for three weeks in a row and then one week off. Additionally patients with hematologic malignancies will be evaluated on a treatment schedule of five days in a row with two weeks off. - [A Study of Standard Systemic Therapy with or without Definitive Treatment in Treating Participants with Metastatic Prostate Cancer](/research/clinical-trials/cls-20462229) La Crosse, WI; Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaouate how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the body. - [A Study of INCMGA00012 in Squamous Carcinoma of Following Platinum-Based Chemotherapy](/research/clinical-trials/cls-20467529) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to assess the effectiveness of INCMGA00012 in participants with locally advanced or metastatic squamous carcinoma of the anal canal (SCAC) who have progressed after platinum-based chemotherapy. - [Treatment of Soft AZ; an open-label, randomized, controlled, two-arm multi-center study of the efficacy of L19TNF treatment in combination with doxorubicin versus doxorubicin alone in metastatic or unresectable soft-tissue sarcoma patients. In the study, 122 patients will be randomized in a 1:1 ratio to receive doxorubicin treatment (Arm 1) or L19TNF treatment in combination with doxorubicin (Arm 2). The primary objective of the trial is to evaluate if L19TNF in combination with doxorubicin (Arm 2) given for unresectable or metastatic soft tissue sarcoma improves efficacy measured as progression free survival, as compared to doxorubicin alone (Arm 1). Anti-cancer activity will ... - [A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib to To Treat Newly-diagnosed AML with or without FLT3 Mutations](/research/clinical-trials/cls-20536645) Rochester, MN The purpose of this study is to compare standard chemotherapy to therapy with CPX-351 and/or gilteritinib for patients with newly diagnosed acute myeloid leukemia with or without FLT3 mutations. - [A Study Using Docetaxel with or without MLN1117 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20271971) Rochester, MN The purpose of this study is to determine the recommended phase 2 dose of MLN1117 when administered in combination with docetaxel in patients with non-small cell lung cancer and to evaluate the effectiveness, safety, and tolerability of MLN1117 when given alone and in combination with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer. - [DNA Damage Using hERY-MNT Technology can Predict Chemotherapy Induced Toxicity in Women with Ovarian Cancer](/research/clinical-trials/cls-20304190) Rochester, MN The purpose of this study is to understand changes that take place in the blood of patients with ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. This portion of the study is to understand the changes that occur in your blood during and after treatment with carboplatin and paclitaxel chemotherapy in women with ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. - [A Study to Evaluate Bleomycin, Carboplatin, Etoposide, or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors](/research/clinical-trials/cls-20461210) Rochester, MN The purpose of this study is to evaluate how well bleomycin, carboplatin, etoposide, or cisplatin work in treating pediatric and adult patients with germ cell tumors. Active surveillance may help doctors to monitor subjects with low risk germ cell tumors after their tumor is removed. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. - [A Study of Paclitaxel with or without Cixutumumab as Second-Line Therapy for Treating Patients with Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer](/research/clinical-trials/cls-20314930) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to assess how well paclitaxel, with or without cixutumumab, works for treating patients who have esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cixutumumab may kill cancer cells by blocking the action of a protein needed for cancer cell growth. Giving paclitaxel with or without cixutumumab may kill more tumor cells. - [A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy](/research/clinical-trials/cls-20111906) Jacksonville, FL The purpose of this study is to determine if lenalidomide (Revlimid\u00ae) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the duration of your response. This study will compare the effects (good and bad) of lenalidomide with the dummy drug. - [A Study to Evaluate 9-ING-41 As a Single Agent or in Combination with Ruxolitinib in Myelofibrosis Patients](/research/clinical-trials/cls-20491072) Rochester, MN The purpose of this study is to evaluate the effectiveness of 9-ING-41, either by itself or in combination with Ruxolitinib, in patients with advanced myelofibrosis. 9-ING-41 has anti-cancer clinical activity while not causing myelosuppression, and has both pre-clinical anti-fibrotic activity and activity against myelofibrosis. 9-ING-41 may reduce the dose of Ruxolitinib needed for optimal therapeutic response and/or reverse myelosuppression so than an adequate dose of Ruxolitinib can be tolerated for an adequate duration to confer an optimal therapeutic outcome. - [Lenalidomide or Observation in Treating Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma](/research/clinical-trials/cls-20116799) Rochester, MN This phase II/III trial studies how well lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk smoldering multiple myeloma. Biological therapies such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient. - [A Study of the Safety and Effectiveness of Using Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia](/research/clinical-trials/cls-20169973) Jacksonville, FL The purpose of the study is to explore the safety and efficacy of CLT-008 as an extra supportive care measure during induction chemotherapy for patients with acute myeloid leukemia (AML). - [A Study of Tretinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia](/research/clinical-trials/cls-20199623) No Locations The purpose of this study is to assess the effectiveness and long term side effects of using combined tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia. Standard treatment for acute promyelocytic leukemia involves high doses of a common class of chemotherapy drugs called anthracyclines, which are known to cause long-term side effects, especially to the heart. Tretinoin may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Arsenic trioxide may stop the growth of cancer cells by either killing the cells, by stopping them from dividing, or by ... - [A Study Using Clofarabine and Cytarabine in Treating Children with Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia](/research/clinical-trials/cls-20152031) No Locations Drugs used in chemotherapy, such as clofarabine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. The purpose of this trial is studying the side effects and best dose of clofarabine when given together with cytarabine and to see how well they work in treating young patients with refractory or relapsed acute myeloid leukemia or acute lymphoblastic leukemia. (Phase I closed to enrollment as of 09/16/09) - [A Study of Performing Surgery for Resectable Malignant Pleural Mesothelioma After Radiation Therapy](/research/clinical-trials/cls-20164779) Rochester, MN The purpose of this study is to assess the possibility, safety, and therapeutic effect of administering a short, quick course of high-dose radiation treatment focused on half of the chest, followed by surgery to remove that portion of the lungs, in patients with malignant pleural mesothelioma. - [Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma](/research/clinical-trials/cls-20132076) Rochester, MN This phase II trial studies how well combination chemotherapy works in treating younger patients with newly diagnosed, non-metastatic desmoplastic medulloblastoma. Drugs used in chemotherapy, such as vincristine sulfate, cyclophosphamide, methotrexate, etoposide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. - [Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Non-Hodgkin Lymphoma](/research/clinical-trials/cls-20308916) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This phase II trial studies how well combination chemotherapy and pralatrexate works in treating patients with non-Hodgkin lymphoma (NHL). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing - [Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia](/research/clinical-trials/cls-20148824) No Locations This phase III trial is studying combination chemotherapy to see how well it works in treating young patients with newly diagnosed acute promyelocytic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more cancer cells. - [Study of Palbociclib Combined with Chemotherapy In Pediatric Patients with Recurrent/Refractory Solid Tumors](/research/clinical-trials/cls-20535976) Rochester, MN The purpose of the open-label, multicenternon-randomized Phase 1 portion of the study will evaluate the safety, pharmacokinetics, pharmacodynamic, and antitumor activity of palbociclib in combination with chemotherapy consisting of either IRN and TMZ or TOPO and CTX in children, adolescent and young adult patients with recurrent/refractory solid tumor for whom no standard therapy is available. The open-label, randomized Phase 2 portion of the study will evaluate palbociclib in combination with IRN and TMZ versus IRN and TMZ alone in children, adolescent, and young adult patients with recurrent/refractory EWS for whom no standard therapy is available. - [Brightline-1: A Study to Compare Bi 907828 With Doxorubicin In People With a Type of Cancer Called Dedifferentiated Liposarcoma](/research/clinical-trials/cls-20541566) Jacksonville, FL; Rochester, MN The purpose of this study is to compare a medicine called BI 907828 with doxorubicin in people with liposarcoma. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. Doxorubicin is a medicine already used to treat cancer including liposarcoma. During the study, participants get either BI 907828 or doxorubicin. Every 3 weeks, participants take BI 907828 as tablets or doxorubicin as an infusion into a vein. Participants can switch to BI 907828 treatment if they did not benefit from doxorubicin treatment. Participants can continue treatment in the study as long as they benefit from it and ... - [Temozolomide and Irinotecan Hydrochloride with or without Bevacizumab in Treating Young Patients with Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors](/research/clinical-trials/cls-20118803) Rochester, MN This randomized phase II trial studies how well giving temozolomide and irinotecan hydrochloride together with or without bevacizumab works in treating young patients with recurrent or refractory medulloblastoma or central nervous system (CNS) primitive neuroectodermal tumors. Drugs used in chemotherapy, such as temozolomide and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells ... - [Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Monoclonal Antibody Ch14.18 in Treating Younger Patients with Refractory or Relapsed Neuroblastoma](/research/clinical-trials/cls-20151632) No Locations This randomized phase II trial studies how well irinotecan hydrochloride and temozolomide with temsirolimus or dinutuximab work in treating younger patients with neuroblastoma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as irinotecan hydrochloride and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as dinutuximab, may find tumor cells and help kill them ... - [Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery](/research/clinical-trials/cls-20411780) Rochester, MN This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. - [Effect of TTFields (150 kHz) in Non-small Cell Lung Cancer Radiosurgery (METIS)](/research/clinical-trials/cls-20312019) Jacksonville, FL The study is a prospective, randomized controlled phase III trial, to test the efficacy, safety and neurocognitive outcomes of advanced NSCLC patients, following stereotactic radiosurgery (SRS) for 1-10 brain metastases, treated with NovoTTF-100M compared to supportive treatment alone. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays. - [Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies](/research/clinical-trials/cls-20119663) Rochester, MN This clinical trial is studying long-term follow-up in patients who are or have participated in Children's Oncology Group studies. Developing a way to track patients enrolled in Children's Oncology Group studies will help doctors gather long-term follow-up information and may help the study of cancer in the future. - [Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin](/research/clinical-trials/cls-20515423) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue pathology confirmed non-muscule invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease, with either carcinoma in situ with or without Ta/T1 disease. - [Quality of Life Intervention for Patients Receiving Radiation Therapy for Advanced Cancer Treatment and Their Caregivers](/research/clinical-trials/cls-20492432) Rochester, MN; Jacksonville, FL This study will use video technology in conjunction with in-person participation. This is a pilot project, where all enrolled participants will receive the multidisciplinary intervention. Participants (patients and caregivers) from Mayo Clinic Rochester will attend an in-person group session, and participants (patients and caregivers) from Mayo Clinic Florida or Northfield Mayo Clinic Radiation Oncology Center will participate through the use of video conferencing. The goals are to examine feasibility (percent of eligible patients and caregivers who enroll), attrition, and adherence (attend at least four of the six sessions), to determine any differences between the two formats, and to examine potential ... - [A Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and Combined with Chemotherapy or Tislelizumab to Treat Patients with Metastatic Solid Tumors](/research/clinical-trials/cls-20508583) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to establish the safety and tolerability, and to determine the recommended Phase 2 dose (RP2D) for LYT-200. - [A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens](/research/clinical-trials/cls-20148995) Rochester, MN This is a Phase 2, open-label, single arm study to evaluate the safety and efficacy of niraparib in ovarian cancer patients who have received three or four previous chemotherapy regimens. Niraparib is an orally active PARP inhibitor. Niraparib will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by Eastern Cooperative Oncology Group performance status (ECOG). Safety and tolerability will be assessed by clinical review of adverse events (AEs), physical examinations, electrocardiograms (ECGs), RECIST tumor assessments and safety laboratory values. - [A Study to Investigate the Presence of Malignant Cells in Seminal Fluid During Radical Prostatectomy](/research/clinical-trials/cls-20478845) Rochester, MN The purpose of this study is to investigate whether malignant prostate cancer cells can be identified in seminal fluid expressed during the course of robotic radical prostatectomy, as such cells may be a currently unrecognized source of local recurrence after surgery. - [Mayo Clinic Cancer Genomics Service Line Biorepository](/research/clinical-trials/cls-20454961) Eau Claire, WI; Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The goal of the study is to create a database of clinical information and a repository of biological specimens for genetic, molecular and microbiological research to better understand hereditary cancer and help develop new therapies and preventive strategies. - [Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer](/research/clinical-trials/cls-20306804) Scottsdale/Phoenix, AZ The objective of this trial is to evaluate the safety and tolerability of BI 695502 in combination with leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) and as maintenance therapy (when applicable). As well as to evaluate the following efficacy parameters: Progression-free survival (PFS), objective response rate (proportion of patients with complete response [CR] plus partial response [PR]), overall survival (OS), duration of response (DOR), time to progression (TTP). - [A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer](/research/clinical-trials/cls-20145304) Rochester, MN This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gBRCAmut or a tumor with high-grade serous histology and who have responded to their most recent chemotherapy containing a platinum agent. Niraparib is an orally active PARP inhibitor. Niraparib or placebo (in a 2:1 ratio) will be administered once daily continuously during a 28-day cycle. Health-related quality of life will be measured by the Functional Assessment of Cancer Therapy - Ovarian Symptom Index (FOSI), European Quality of Life scale, 5-Dimensions (EQ-5D), and a neuropathy questionnaire. Safety and ... - [A Study Comparing X-396 (Ensartinib) to Crizotinib in with ALK Positive Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20302554) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the effectiveness and safety of X-396 (ensartinib) versus crizotinib in patients who have ALK-positive non-small cell lung cancer that have received up to 1 prior chemotherapy regimen and no prior ALK inhibitor. - [A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusions Rochester, MN This pivotal, open-label, single-arm study will evaluate the anti-cancer activity of ARQ 087 by Objective Response Rate (ORR) by central radiology review as per RECIST v1.1 in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) whose tumors harbor FGFR2 gene fusions (by FISH performed by the central laboratory) and who received at least one prior regimen of systemic therapy. Subjects will be dosed orally once per day at 300 mg of ARQ 087 capsules. - [Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma](/research/clinical-trials/cls-20538365) Rochester, MN The purpose of this study is to determine if open surgical resection is superior to thoracoscopic resection for thoracic in patients with resectable oligometastatic pulmonary osteosarcoma. Furthermore, to determine if open surgical resection is superior to thoracoscopy for event free survival (EFS), for overall survival (OS), and if thoracoscopy is superior to open surgical resection for postoperative pain interference in patients with resectable oligometastatic pulmonary osteosarcoma. - [Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression](/research/clinical-trials/cls-20526989) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The main objective of this study is to compare effectiveness of bemarituzumab combined with oxaliplatin and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS). - [A Study to Evaluate Gemcitabine in Patients Undergoing Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma](/research/clinical-trials/cls-20502628) Rochester, MN; Jacksonville, FL The primary purpose of this study is to assess the effectiveness of a single intraoperative intravesical instillation of gemcitabine at time of radical nephroureterectomy (RNU) to prevent intravesical recurrence of urothelial carcinoma (UC) at 1 year in patients with clinically localized upper tract urothelial carcinoma (UTUC). - [A Trial AZ; Rochester, MN The purpose of this study is to compare the effectiveness and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm B) in patients with CLL/SLL who have been previously treated with at least one prior line of therapy. Participation could last up to five years. - [A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade Glioma](/research/clinical-trials/cls-20522813) Rochester, MN The primary objectives of this study are to determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of selumetinib + vinblastine for children with progressive or recurrent LGGs, and to determine if selumetinib + vinblastine will lead to improved event-free survival (EFS) outcome compared with selumetinib alone for children with progressive or recurrent LGGs. - [A Study of DCC-2618 vs. Sunitinib in Advanced GIST Patients after Treatment with Imatinib](/research/clinical-trials/cls-20453743) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to compare the effectiveness of DCC-2618 to sunitinib in GIST patients who progressed on or were intolerant to first-line anticancer treatment with imatinib. Approximately 358 patients will be randomized in a 1:1 ratio to DCC-2618 150 mg once daily (QD) (continuous dosing for 6 week cycles) or sunitinib 50 mg QD (6 week cycles, 4 weeks on, 2 weeks off). - [A Study to Evaluate Family Member Exposure to Antineoplastic Drugs in the Home Setting](/research/clinical-trials/cls-20454963) Eau Claire, WI The purpose of this study is to quantify active antineoplastic drug metabolites in the urine samples, oral fluids, and skin of patients receiving intravenous chemotherapy on days 1 through 7 post infusion, to quantify active antineoplastic drug metabolites in the urine samples of family member/caregiver of patient receiving chemotherapy on days 1 through 7 post infusion, and to identify the instructions received by patient/family members to avoid exposure to contaminated bodily fluids from patients' receiving intravenous antineoplastic drugs and whether the instructions were followed. - [Oxaliplatin, Leucovorin Calcium, and Fluorouracil with or without Celecoxib in Treating Patients with Stage III Colon Cancer Previously Treated with Surgery](/research/clinical-trials/cls-20146503) Eau Claire, WI PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery. RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving oxaliplatin, leucovorin ... - [A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Patients Treated Metastatic Colorectal Cancer](/research/clinical-trials/cls-20366147) Scottsdale/Phoenix, AZ; multi-center, prospective, open-label, randomized phase 3 trial of the cancer stem cell pathway inhibitor napabucasin plus standard bi-weekly FOLFIRI versus standard bi-weekly with previously treated metastatic colorectal cancer (CRC). - [A Study in Subjects with Malignant Pleural Mesothelioma to Assess ADI-PEG 20 with Pemetrexed and Cisplatin](/research/clinical-trials/cls-20366133) Scottsdale/Phoenix, AZ; Rochester, (pegylated arginine deiminase), an arginine degrading enzyme versus placebo in patients with malignant pleural mesothelioma with low argininosuccinate synthetase 1 expression. Malignant pleural mesothelioma have been found to require arginine, an amino acid. Thus the hypothesis is that by restricting arginine with ADI-PEG 20, the malignant pleural mesothelioma cells will starve and die. - [A Study Evaluating Effectiveness and Safety of FFX Versus Combination of CPI-613 with mFFX in Patients with Metastatic Adenocarcinoma of the Pancreas](/research/clinical-trials/cls-20461637) Jacksonville, FL The purpose of this study is to evaluate the effectiveness and safety of Folfirinox (FFX) versus CPI-613 + Modified Folfirinox (mFFX) in patients with metastatic adenocarcinoma of the pancreas. - [A Study Evaluating MM-310 in Patients With Solid Tumors](/research/clinical-trials/cls-20317860) Rochester, MN MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid tumors. In the first part of the study, MM-310 will be assessed as a monotherapy until a maximum tolerated dose (MTD) is established. After an MTD of MM-310 as a monotherapy is established, an expansion cohort and MM-310 in combination with other therapies will be assessed. - [Temsirolimus and Bevacizumab in Treating Patients with Advanced Endometrial, Ovarian, Liver, Carcinoid, Islet Cell Cancer](/research/clinical-trials/cls-20116754) Rochester, MN; Jacksonville, FL; Scottsdale/Phoenix, AZ This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of cancer by blocking blood flow to the tumor. Giving temsirolimus together with bevacizumab may ... - [Study of AG-270 in Participants With Solid or Lymphoma With MTAP Loss](/research/clinical-trials/cls-20533354) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to determine the maximum tolerated dose (MTD) of AG-270 and characterize its dose-limiting toxicities (DLTs) when given daily by mouth to subjects with advanced solid tumors or lymphoma with homozygous deletion of methylthioadenosine phosphorylase (MTAP). - [A Study to Evaluate Docetaxel With or Without Bintrafusp Alfa to Treat Patients with Advanced Non-small Cell Lung Cancer](/research/clinical-trials/cls-20486395) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to compare the progression-free survival (PFS) of docetaxel in combination with bintrafusp alfa vs. docetaxel alone. - [A Study to Evaluate Effectiveness and Safety of MBG453 in Combination with Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia-2 (CMML-2)](/research/clinical-trials/cls-20507819) Jacksonville, FL The purpose of this study is to evaluate the safety and effectiveness of MBG453, or placebo added to azacitidine, in adult subjects with intermediate, high or very high risk myelodysplastic syndrome (MDS) as per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) who have an indication for treatment with azacitidine in first-line setting and are not eligible for intensive chemotherapy or hematopoietic stem cell transplantation (HSCT) according to medical judgment by the investigator. - [(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib Jacksonville, FL; Rochester, MN The purpose of this study is to compare CGT9486 in combination with sunitinib to treat gastrointestinal stromal tumors. - [A Study of NOX66 Plus Doxorubicin in Anthracycline-na\u00efve, Adult Patients With Soft Tissue Sarcoma](/research/clinical-trials/cls-20532367) Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate NOX66 given rectally, in cohorts of patients with metastatic soft tissue sarcoma (STS) who have not been exposed to anthracycline therapy, using a fixed dose-escalation schema every 21 days to establish the maximum tolerated dose (MTD) of the combination of NOX66 and doxorubicin. - [A Study to Evaluate the Effectiveness and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma](/research/clinical-trials/cls-20457162) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the effectiveness and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with or cholangiocarcinoma with FGFR2 rearrangement. - Cyclophosphamide in Combination with Bevacizumab or Temsirolimus in Treating Patients with Recurrent or Refractory Rhabdomyosarcoma](/research/clinical-trials/cls-20118805) No Locations This randomized phase II trial studies how well vinorelbine tartrate and cyclophosphamide work in combination with bevacizumab or temsirolimus in treating patients with recurrent or refractory rhabdomyosarcoma. Drugs used in chemotherapy, such as vinorelbine tartrate and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop ... - [An Efficacy Study Comparing Oral Ixazomib/Dexamethasone and Oral Pomalidomide/Dexamethasone in Relapsed and/or Refractory Multiple Myeloma](/research/clinical-trials/cls-20402161) Rochester, MN The purpose of this study is to compare the effect of ixazomib+dexamethasone (ixa+dex) versus pomalidomide+dexamethasone (pom+dex) on progression-free survival with relapsed and/or refractory multiple myeloma (RRMM) who have received at least 2 prior lines of therapy, including lenalidomide and a proteasome inhibitor, and are refractory to proteasome inhibitors. - [Dinaciclib, Bortezomib, and Dexamethasone in Patients Relapsed Multiple Myeloma](/research/clinical-trials/cls-20115476) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when given together with dexamethasone in treating patients with relapsed multiple myeloma. Dinaciclib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dinaciclib and bortezomib together with dexamethasone may kill more cancer cells. - [Combination Therapy of Acalabrutinib, Venetoclax and Durvalumab to Treat Richter Transformation](/research/clinical-trials/cls-20529098) Rochester, MN The purpose of this study is to determine if the drug combination of acalabrutinib, durvalumab, and venetoclax will work to treat Richter's transformation, and what doses of these drugs are safe for people to take. We also want to learn about the side effects of this combination. All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma. Durvalumab is FDA approved for treatment in lung cancers including non-small cell lung cancer and small cell lung cancer. Venetoclax is FDA approved for the treatment of CLL and SLL. ... - [A Study of Using Bortezomib and Combination Chemotherapy in Treating Children with Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma](/research/clinical-trials/cls-20152029) Rochester, MN This pilot, phase II trial studies the side effects of giving bortezomib together with combination chemotherapy and to see how well it works in treating young patients with relapsed acute lymphoblastic leukemia or lymphoblastic lymphoma. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib together with combination chemotherapy may kill more cancer cells. - [Lenalidomide and Dexamethasone With or Without Anakinra in Treating Patients With Early Stage Multiple Myeloma](/research/clinical-trials/cls-20147452) Rochester, MN This partially randomized phase I/II trial studies the side effects and best dose of anakinra when given together with lenalidomide and dexamethasone in treating patients with early stage multiple myeloma. Biological therapies, such as lenalidomide and anakinra, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether lenalidomide and dexamethasone are more effective with ... - is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated subjects with locally advanced unresectable or metastatic pancreatic adenocarcinoma. - [Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy](/research/clinical-trials/cls-20110798) Rochester, MN This pilot clinical trial studies the safety and immunogenicity of vaccine therapy in treating patients with stage IIIC-IV ovarian epithelial, fallopian tube, or primary peritoneal cavity cancer following surgery and chemotherapy. Vaccines made from a person's peptide treated white blood cells may help the body build an effective immune response to kill tumor cells. - [Tele-Medicine in an Advanced Prostate Cancer Clinic](/research/clinical-trials/cls-20488027) Rochester, MN The purpose of this study is to describe the use of tele-medicine during the COVID-19 pandemic in our advance prostate cancer practice and evaluate patient satisfaction. - [Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma](/research/clinical-trials/cls-20198483) Jacksonville, FL The primary objective of this study is to determine the maximum tolerated dose of R-(-)-gossypol acetic acid (AT-101) that can be combined with lenalidomide and dexamethasone in patients with relapsed symptomatic multiple myeloma (MM). (Phase I) II, and to determine the overall response rate (partial response or better) of AT-101 when used in combination with lenalidomide and dexamethasone in patients with relapsed symptomatic MM. (Phase II) - [A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma](/research/clinical-trials/cls-20433620) No Locations The purpose of this study is to tailor treatment for medulloblastoma based on molecular distinctions between tumors in order to improve cure rates for molecularly aggressive medulloblastoma, while reducing treatment-related morbidities in survivors of less aggressive medulloblastoma. It is possible that subjects in this study will benefit from a reduction in treatment complications, more effective therapy, and higher rates of survival. - [A Trial of TTI-621 in Combination With Doxorubicin in Patients With Leiomyosarcoma](/research/clinical-trials/cls-20529099) Jacksonville, FL The purpose of this study to evaluate TTI-621 combined with Doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma. - [A Study to Evaluate Genetic Testing in Guiding Treatment for Patients with Brain Metastases](/research/clinical-trials/cls-20477123) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evauate how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such as abemaciclib, GDC-0084, and entrectinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation. - [hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse](/research/clinical-trials/cls-20271975) Rochester, MN; Scottsdale/Phoenix, AZ This is a Phase I, open label study to evaluate the safety, tolerability, and immunogenicity of INO-1400 alone or in combination with INO-9012, delivered by electroporation in subjects with high-risk solid tumor cancer with no evidence of disease after surgery and standard therapy. Subjects will be enrolled into one of six treatment arms. Subjects will be assessed according to standard of care. Restaging and imaging studies will be performed to assess disease relapse per NCCN guidelines. RECIST will be used to validate the findings in cases of relapse. - [3D Surface Scanning](/research/clinical-trials/cls-20507933) Scottsdale/Phoenix, AZ The purpose of this study is to examine the potential for using a 3D scan of a patient's treatment surface as a surrogate for a conventional CT simulation in electron radiation therapy. - [Evaluating Patient Reported Outcomes in Radiation Therapy, The PRO-RT Study](/research/clinical-trials/cls-20527782) Rochester, MN The purpose of this study is to address the gaps in data completeness regarding treatment toxicities, patient reported outcomes, and biometric information. Hugo device enabled patient specific data aggregation, will increase the completeness and accuracy of the Outcomes Registry and improve patient engagement with the care teams, post radiation, by acquiring linked outside EHR information facilitating improved collection of patient reported outcome surveys, and biometric data via a wearable device. With a rise in health care costs, there is an urgent need to evaluate patient outcomes and the value of care levering real patient, big data from the ... - [Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer](/research/clinical-trials/cls-20477936) Rochester, MN The purpose of this study is to look at the safety and immune response to a vaccine used in patients previously treated for HER2 (human epidermal growth factor receptor 2) positive breast cancer. - [A Study to Analyze Supine Breast MRI](/research/clinical-trials/cls-20460922) Rochester, MN The purpose of this study is to characterize the changes occurring in breast tumor-associated properties/ dimensions between the prone and supine imaging positions and to develop a dataset of supine-positioned MRIs that can be translated into an operative setting for real-time visualization. - [A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With Folate Receptor-Alpha Expression](/research/clinical-trials/cls-20490425) Rochester, MN; Jacksonville, FL; Scottsdale/Phoenix, AZ The purpose of this study is to compare the effectiveness and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FR. Patients will be, in the opinion of the Investigator, appropriate for single-agent therapy for their next line of therapy. - [Collection of Specimens and Clinical Data for Patients with Recurrent or Metastatic Breast Cancer or Male Breast Cancer](/research/clinical-trials/cls-20309083) Rochester, MN The purpose of this study is to collect blood samples and fresh tissue from biopsies of metastatic lesions from Mayo Clinic patients with metastatic breast cancer. The biospecimens will be used for analysis of genetic alterations in germline and tumor DNA and for tracking of response to therapy using blood-based liquid biopsy approaches. - [A Study to Assess Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients with Prostate Cancer](/research/clinical-trials/cls-20467502) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to assess how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametric MRI may be useful for evaluating the type of cancer in finding aggressive disease. - [Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer](/research/clinical-trials/cls-20235802) Rochester, MN This phase II trial studies how well olaparib and cediranib maleate work in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back (recurrent). Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. - [Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Mankato, or cediranib maleate and olaparib to see how well they work compared with standard platinum-based chemotherapy in treating patients with platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer that has come back. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Cediranib maleate may stop the growth of ovarian, fallopian tube, or primary peritoneal cancer by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine hydrochloride, Patients With Urothelial Cancer](/research/clinical-trials/cls-20168930) Rochester, MN The main purpose of this study is to evaluate the safety and effectiveness of the study drug ramucirumab in combination with docetaxel in patients with urothelial cancer who failed prior platinum-based therapy. - [Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer](/research/clinical-trials/cls-20507133) Jacksonville, FL This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer. Drugs used in chemotherapy, such as carboplatin, cisplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Olaparib and cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib, cediranib maleate, and standard chemotherapy may work better in treating patients with small cell lung cancer. - [Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer](/research/clinical-trials/cls-20145302) Rochester, MN This randomized phase II trial studies how well metformin hydrochloride and combination chemotherapy works in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer. Drugs used in chemotherapy, such as carboplatin, paclitaxel and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin hydrochloride may help carboplatin, paclitaxel and docetaxel work better by making tumor cells more sensitive to the drugs. Studying samples of blood and tissue in the laboratory from patients receiving metformin hydrochloride may help doctors ... - [A Study to Evaluate Trifluridine/Tipiracil in Combination with Irinotecan to Treat Biliary Tract Cancers](/research/clinical-trials/cls-20476255) Rochester, MN The purpose of this study is assess the effectiveness of trifluridine/tipiracil plus irinotecan in treating advanced, refractory biliary tract cancers (BTCs). - [Comparison of Mitoxantrone-Based Salvage Therapies (MEC vs Relapsed or Refractory Acute Myeloid Leukemia](/research/clinical-trials/cls-20506882) Scottsdale/Phoenix, AZ The purpose of this study is to determine potential differences between the 2 therapeutic regimens. - [ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary or Ovarian High-Grade Serous Carcinoma, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to test an experimental combination of two drugs, ABT-888 and Cyclophosphamide (CP), which we hope may eventually lead to promising new therapies for cancer. - [Study to Evaluate the Efficacy and Safety of Lutathera in Patients with Grade 2 and Grade 3 Advanced GEP-NET](/research/clinical-trials/cls-20490906) Rochester, MN The purpose of this study is to determine if Lutathera in combination with long-acting octreotide prolongs PFS in GEP-NET patients with high proliferation rate tumors (G2 and G3), when given as a first line treatment compared to treatment with high dose (60 mg) long-acting octreotide. Somatostatin analog (SSA) naive patients are eligible, as well as patients previously treated with SSAs in the absence of progression. - [A Study to Evaluate Ramucirumab Plus Trifluridine/Tipiracil to Treat Patients with Previously-treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma](/research/clinical-trials/cls-20513942) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to compare, in a non-inferiority fashion, the progression-free survival (PFS) in patients with metastatic gastric/Gastroesophageal vs. and ramucirumab. - [Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors](/research/clinical-trials/cls-20146638) No Locations This phase I trial studies the side effects and the best dose of wild-type reovirus (viral therapy) when given with sargramostim in treating younger patients with high grade brain tumors that have come back or that have not responded to standard therapy. A virus, called wild-type reovirus, which has been changed in a certain way, may be able to kill tumor cells without damaging normal cells. Sargramostim may increase the production of blood cells and may promote the tumor cell killing effects of wild-type reovirus. Giving wild-type reovirus together with sargramostim may kill more tumor cells. - [Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma](/research/clinical-trials/cls-20476258) Rochester, MN The purpose of this study is to estimate the event-free survival (EFS) distribution for newly-diagnosed patients with anaplastic ganglioglioma (aGG) treated with radiation therapy followed by a maintenance combination of dabrafenib and trametinib and to compare this EFS to contemporary historical controls. - [Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma](/research/clinical-trials/cls-20523644) Jacksonville, FL; Rochester, MN The purpose of the ALLO-605-201 study is to assess the safety, effectiveness, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion Tumors](/research/clinical-trials/cls-20425083) Scottsdale/Phoenix, AZ; Rochester, MN The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors. The main purpose of the safety lead-in (dose-finding) part of the study is to determine the safety and tolerability of anetumab ravtansine in combination with cisplatin and in combination with gemcitabine, and to determine the MTD of anetumab ravtansine in combination with cisplatin for mesothelin expressing advanced cholangiocarcinoma and in combination with gemcitabine for mesothelin expressing advanced adenocarcinoma of the pancreas. Patients will receive anetumab ravtansine every three weeks in ... - [A Phase 1b/2 Study of Onvansertib (PCM-075) in and Bevacizumab for Second-Line Treatment of Metastatic Mutation](/research/clinical-trials/cls-20469679) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine the safety and effectiveness of Onvansertib, in combination with FOLFIRI + Avastin, as second-line treatment in adult patients who have metastatic colorectal cancer with a Kras mutation. Participants must have histologically confirmed metastatic and unresectable disease, and previously failed treatment or be intolerant to fluoropyrimidine and oxaliplatin with or without bevacizumab. - [Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma](/research/clinical-trials/cls-20112249) Rochester, MN This open-label, randomized, 2-arm, multicenter, phase 3 study has the primary objective of comparing the modified progression-free survival (mPFS) (doxorubicin [Adriamycin],bleomycin, vinblastine, and dacarbazine) for the frontline treatment of advanced classical Hodgkin lymphoma(HL) - [Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia](/research/clinical-trials/cls-20151614) No Locations This phase II trial is studying the side effects and best dose of bortezomib and to see how well it works when given together with combination chemotherapy in treating younger patients with recurrent, refractory, or secondary acute myeloid leukemia (AML). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as idarubicin, cytarabine, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with bortezomib ... - [Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer](/research/clinical-trials/cls-20178858) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This phase II trial studies how well ribociclib and letrozole work in treating patients with estrogen receptor (ER) positive ovarian, fallopian tube, primary peritoneal, or endometrial cancer that has returned (come back) after a period of improvement. Ribociclib may stop the growth of tumor cells by blocking some enzymes needed for cell growth. Cancer cells that are estrogen receptor positive may need estrogen to grow. Letrozole lowers the amount of estrogen made by the body and this may stop the growth of tumor cells that need estrogen to grow. Giving ribociclib together with letrozole may be an effective treatment in ... - [A Study to Evaluate Ribociclib Plus Letrozole to Treat Cancer of the Ovary, Fallopian Tube or Peritoneum](/research/clinical-trials/cls-20474559) Rochester, MN The purpose of this study is to evaluate the response to treatment with Ribociclib and Letrozole in patients with low-grade serous cancer of the ovary, fallopian tube or peritoneum. - [Accelerated vs Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours](/research/clinical-trials/cls-20491469) Rochester, MN The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours. - [Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers](/research/clinical-trials/cls-20147215) Rochester, MN This randomized phase III trial studies how well early palliative care integrated with standard care works compared with standard care alone in improving the quality of life of patients and their family caregivers. Palliative care focuses on improving the quality of life for patients with advanced diseases and their family members by providing support for relief of physical symptoms, emotional and psychological support, and counseling. Patients who receive palliative care along with their regular care at an earlier time in their disease may experience fewer emotional and physical issues from their cancer. This may also improve the quality of life ... - [Transbronchial Biopsy Assisted by Robot Guidance in the Evaluation of Tumors of the Lung](/research/clinical-trials/cls-20508550) Scottsdale/Phoenix, AZ The primary objective of this trial is to determine safety of the robotic bronchoscopy procedures performed in routine clinical practice at multiple centers. Secondary objectives include overall safety assessment as well as description of diagnostic accuracy of the robotassisted bronchoscopy procedure. - [A Study to Determine the Effect of Distance Reiki on Patient Reported Quality of Life (PRQoL) and Immunity Among Multiple Myeloma Patients](/research/clinical-trials/cls-20509071) Rochester, MN This study aims to demonstrate acceptability and feasibility of the use of Distance Reiki therapy versus sham Reiki therapy among multiple myeloma patients.It also aims to determine if there is a minimal clinically meaningful improvement in various QOL domains (Physical, Social, Emotional), overall QOL with use of Patient-Reported Outcomes Measurement Information System (PROMIS-29) and Single Item Linear Analogue Scale (LASA) after Distance Reik. Lastly, it aims to analyze the effect of Distance Reiki on expansion of the immune repertoire by comparing immune repertoires at baseline and at the end of the study by using Mass spectrometry by CyTOF\u00ae and multiplex ... - [Serum Bovine Immunoglobulin Protein Isolate in Improving Quality of Life and Post-Operative Recovery in Patients With Gynecological Cancer After Undergoing Surgery](/research/clinical-trials/cls-20112310) Rochester, MN This randomized pilot phase II trial studies how well serum bovine immunoglobulin protein isolate works in improving quality of life and post-operative recovery in patients with gynecological cancer after undergoing surgery. Serum bovine immunoglobulin supplementation may improve the quality of life of patients with gynecological cancer. - [Auranofin and Sirolimus in Treating Participants With Ovarian Cancer](/research/clinical-trials/cls-20410688) Rochester, MN This phase II trial studies how well auranofin and sirolimus work in treating participants with ovarian cancer. Immunosuppressive therapy, such as auranofin and sirolimus, is used to decrease the body?s immune response and may increase blood cell count. - [A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer](/research/clinical-trials/cls-20111719) Scottsdale/Phoenix, AZ; Rochester, MN This is an open label, multi-center, Phase Ib dose escalation study of BBI608 administered in combination with either FOLFOX6 with and without bevacizumab, or CAPOX, or FOLFIRI with and without bevacizumab, or regorafenib. A study cycle will consist of daily and continuous oral administration of BBI608 for four weeks (28 days) in combination with FOLFOX6 with and without bevacizumab, or CAPOX or FOLFIRI with and without bevacizumab, or regorafenib. - [A Study of the Diagnostic Performance of the Nonlinear Elasticity Parameter Mapping Method with Suspicious Breast Masses](/research/clinical-trials/cls-20195844) Rochester, MN The purpose of this study is to determine the diagnostic performance of the nonlinear elasticity parameter mapping method by associating its results with pathology in a population of patients with suspicious breast masses. - [A Phase 1b, Multicenter, Randomized, Blinded, Placebo-controlled Study to Evaluate Subjects with Familial Adenomatous Polyposis](/research/clinical-trials/cls-20469366) Scottsdale/Phoenix, AZ; Jacksonville, FL This is a proof-of-concept study to evaluate the preliminary clinical activity of guselkumab in subjects with Familial Adenomatous Polyposis. The study is designed to determine if guselkumab has clinical activity in the colorectum and duodenum, by reducing the number of polyps over a period of 24 weeks. - [GPS Compared With BAT in AML CR2/CR2p](/research/clinical-trials/cls-20492951) Jacksonville, FL This is an open-label, multicenter, randomized, parallel groups study of GPS vs. best available treatment (BAT) in patients with AML in second complete remission (CR2) or in second complete remission with incomplete platelet recovery (CRp2). All patients will have their historical bone marrow samples stained for WT1 via IHC by central pathology review. The primary goal of the study will be to demonstrate an advantage for GPS in overall survival in these patient populations. The study will enroll approximately 116 patients and will be conducted at up to 50 investigational sites. Patients will be randomized 1:1 to GPS or BAT stratified by whether they are in CR2 or ... - [Trial of Multi-epitope HER2-expressing DCIS](/research/clinical-trials/cls-20439962) Jacksonville, FL; Rochester, MN The purpose of this study is to determine the safety, effcicacy and tolerability of H2NVAC in patients with HER2-expressing DCIS in order to prevent future invasive breast cancer among patients who are diagnosed with DCIS. - [Pharmacogenomic Testing in Patients with Hand-Foot Skin Reaction on Tyrosine Kinase Inhibitors](/research/clinical-trials/cls-20398313) Scottsdale/Phoenix, AZ The purpose of this research study is to: - Find out whether there are any DNA (genetic) changes and mutations that put you at risk of developing this skin reaction and use that information to predict the side effect on patients with similar results in the future. - Help us better manage the hand-foot skin reaction if it develops by recommending the appropriate treatment - [Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease](/research/clinical-trials/cls-20533935) Rochester, MN; La Crosse, WI The purpose of this study is to determine what kind of chemotherapy to recommend to patients based on the presence or absence of circulating tumor DNA (ctDNA) after surgery for colon cancer. - [Safety and Efficacy Study of PRI-724 in Subjects With Advanced Solid Tumors](/research/clinical-trials/cls-20112349) Scottsdale/Phoenix, AZ; Rochester, MN PRI-724 is a new investigational drug being studied to treat subjects with cancer who have advanced solid tumors. PRI-724 is thought to work by blocking the Wnt signaling pathway that cancer cells need to grow and spread(metastasize). Phase Ia: Patient cohorts with solid tumor malignancies will be treated with escalating doses (per cohort) of PRI-724 in order to identify the MTD of this single-agent regimen. PRI-724 dosing is to start at 40 mg/m2/day, CIV infusion over 24 hours \u00d7 7 days. Phase Ib: This phase is to begin upon identification of the MTD in Phase 1a. Patient cohorts with CRC will be ... - [Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer](/research/clinical-trials/cls-20154281) Scottsdale/Phoenix, AZ The study seeks to assess the efficacy of veliparib (ABT-888) in combination with carboplatin and etoposide in participants with extensive disease small cell lung cancer (ED SCLC). ED SCLC is defined herein as any SCLC except a disease confined to the hemithorax of origin, with or without the involvement of regional lymph nodes, including ipsilateral and contralateral mediastinal, Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1](/research/clinical-trials/cls-20521961) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to assess whether there is superiority of overall survival (OS) when enzastaurin rather than placebo is added to the regimen of temozolomide with radiation therapy followed by temozolomide for the treatment of patients with newly diagnosed glioblastoma in Denovo Genomic Marker 1 (DGM1) biomarker-positive patients. - [A Study to Evaluate Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, Uterine Leiomyosarcoma](/research/clinical-trials/cls-20467893) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate olaparib and temozolomide in treating patients with uterine leiomyosarcoma (LMS) that has spread to other places of the body or cannot be removed by surgery. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving olaparib and temozolomide may work better than giving either drug alone in treating patients with ... - [Sunitinib Malate with or without Gemcitabine Hydrochloride in Treating Patients with Advanced Kidney Cancer that Cannot be Removed by Surgery](/research/clinical-trials/cls-20116793) Rochester, MN RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth or tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving sunitinib malate and gemcitabine hydrochloride together is more effective than sunitinib malate alone in treating patients with kidney cancer. PURPOSE: This randomized phase II clinical trial is studying giving sunitinib malate together with or ... - [Phase II Study Regimen Pancreatic Cancer Patients](/research/clinical-trials/cls-20397704) Scottsdale/Phoenix, AZ; Rochester, MN study of nab-paclitaxel, gemcitabine and cisplatin (NGC triple regimen) as preoperative therapy in potentially resectable pancreatic cancer patients. DISEASE STATE - Potentially operable or borderline resectable pancreatic adenocarcinoma as assessed by standard CT criteria and histologically confirmed. - Staging by pancreatic protocol, helical abdominal computed tomography (with contrast) or MRI (with contrast) required (endoscopic ultrasound is not required). - No evidence of metastatic disease. Lymphadenopathy (defined as nodes measuring >1 cm in short axis) outside the surgical basin (i.e., para-aortic, peri-caval, celiac axis, or distant nodes) is considered M1 (unless nodes are biopsied and ... - [Study to Compare the Safety and Effectiveness of Treatment Combinations in Patients with Recurrent Ovarian Cancer](/research/clinical-trials/cls-20449729) Rochester, MN The primary purpose of this study is to evaluate the effectiveness of the niraparib combinations defined in each cohort-specific supplement, as assessed by confirmed objective response rate (ORR), in patients with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal cancer. - [Phase 3 Study of Vimseltinib for Tenosynovial Giant Cell Tumor](/research/clinical-trials/cls-20533786) Rochester, MN This is a multicenter study which aims to evaluate the effectiveness of an investigational drug called vimseltinib for the treatment of tenosynovial giant cell tumor (TGCT) in cases where surgical removal of the tumor is not an option. The study consists of two parts. In Part 1, eligible study participants will be assigned to receive either vimseltinib or matching placebo for 24 weeks. A number of assessments will be carried out during the course of the study, including physical examinations, blood tests, imaging studies, electrocardiograms, and questionnaires. MRI scans will be used to evaluate the response of the tumors to the ... - [The OLYMPUS Study - Optimized DeLivery Primary UTUC Study](/research/clinical-trials/cls-20391188) Scottsdale/Phoenix, AZ; Jacksonville, FL The study is investigating the ability of UroGen's MitoGel procedure to treat urothelial carcinoma tumors from the upper urinary tract. If this treatment will prove to be effective this will lead to the development of a new treatment approach for patients suffering from Low Grade Upper Urinary Urothelial Carcinoma (UTUC). - [A Study of the Gut Microbiome in Chemotherapy Treatment](/research/clinical-trials/cls-20467532) Rochester, MN The purpose of this study is to investigate the impact of microbiome on the effectiveness and toxicity of anti-cancer therapy and to develop microbiome- based markers to personalize cancer treatment. - [Ginseng as an Intervention to Decrease Cancer-Related Fatigue in Post-Treatment Cancer Survivors](/research/clinical-trials/cls-20396725) Scottsdale/Phoenix, AZ The purpose of this study is to find out if ginseng decreases fatigue in people who were treated for cancer. - [Virtual Dignity Therapy for Palliative Care Patients with Advanced Cancer](/research/clinical-trials/cls-20521065) Rochester, MN The purpose of this study is to determine if it is feasible to recruit for and deliver the Virtual Dignity Therapy intervention to palliative care patients with advanced cancer and whether the intervention is beneficial in terms of improvement in distress, patient dignity, and quality of life. - [NRG-GY012 \"A Randomized Phase II Study Comparing Single-Agent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women with Recurrent or Persistent Endometrial Cancer\"](/research/clinical-trials/cls-20442275) Eau Claire, WI; Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this randomized phase II trial study is to determine how well olaparib, cediranib maleate, and Week 1 inhibitor AZD1775 work in treating patients with endometrial cancer that has come back, does not respond to treatment, or has spread to other places in the body. Olaparib, cediranib maleate, and Wee1 inhibitor AZD1775 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. - [A Study to Analyze Onvansertib Treatment in Jacksonville, FL; Rochester, study aims to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil metastatic pancreatic ductal adenocarcinoma (PDAC). - [A Study of the Safety and Effectiveness of INC280 Alone and in Combination with Erlotinib, When Compared to Chemotherapy in Advanced or Metastatic Non-Small Cell Lung Cancer Patients with EGFR Mutation and Amplified cMET](/research/clinical-trials/cls-20271973) Rochester, MN The purpose of this study is to determine the maximum tolerated dose, the next recommended study dose, and the anti-tumor activity and safety of INC280 alone and in combination with erlotinib, when compared to standard platinum with pemetrexed chemotheapy in adult patients who have EGFR mutated and cMET amplified advanced/metastatic non-small cell lung cancer,and have acquired resistance to prior EGFR tyrosine kinase inhibitors. - [Ruxolitinib in Combination with Pemetrexed/Cisplatin Non Small Cell Lung Cancer](/research/clinical-trials/cls-20145323) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent. - [Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS](/research/clinical-trials/cls-20111697) Rochester, a hypomethylating agent (HMA) to treat MDS. In this study, patients with intermediate- or high-risk MDS will receive treatment with mocetinostat and azacitidine to evaluate the safety of the study treatment. Safety assessments will include echocardiograms, electrocardiograms and routine safety laboratory studies (hematology and serum chemistry). In addition, clinical response to treatment will be monitored using bone marrow aspirates or biopsies, and other routine methods. - [Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes](/research/clinical-trials/cls-20115547) Rochester, MN This is a Phase II therapeutic trial combining Decitabine days 1-5 with oral Vorinostat twice daily days 6-15 followed by a single infusion of CD3-/CD19- enriched donor natural killer (NK) cells on day 17 and a short course of Interleukin-2 (IL-2) to facilitate NK cell survival and expansion. Two courses of treatment will be given separated by 6-8 weeks. The intent is to administer all treatment in the outpatient setting. - [WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome](/research/clinical-trials/cls-20193934) Scottsdale/Phoenix, AZ This trial well WEE1 inhibitor AZD1775 with or without cytarabine works in treating patients with acute myeloid leukemia or myelodysplastic syndrome that has spread to other places in the body and usually cannot be cured or controlled with treatment. WEE1 inhibitor AZD1775 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is ... - [Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Rochester, MN This randomized phase II trial studies how well lenalidomide improves immune response to pneumococcal 13-valent conjugate vaccine in patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or monoclonal B cell lymphocytosis. Biological therapies, such as lenalidomide, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Lenalidomide may also improve the effectiveness of pneumococcal 13-valent conjugate vaccine that is used to prevent infection. - [An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy](/research/clinical-trials/cls-20319150) Rochester, MN The primary objective of study Part A is to assess the safety of talacotuzumab (formerly CSL362) monotherapy and confirm the recommended Phase 2 dose (RP2D) in participants with acute myeloid leukemia (AML) for whom experimental therapy is appropriate. The primary objective of study Part B are to assess complete response (CR) rate and overall survival (OS) in participants with AML who are not eligible for intense induction chemotherapy and who are randomly assigned to receive decitabine plus talacotuzumab at the RP2D or decitabine alone. - [A Study to Evaluate Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer](/research/clinical-trials/cls-20463723) La Crosse, WI; Eau Claire, WI; Rochester, MN The purpose of this study is to evaluate how well dexamethasone works in reducing everolimus-induced oral stomatitis in patients with cancer. Dexamethasone may help to reduce the everolimus-induced oral stomatitis so as to improve quality of life in cancer patients. - [A Study to Evaluate A Resilient Living Program for Patients with Advancer Cancer and Their Caregivers](/research/clinical-trials/cls-20480310) Rochester, MN The primary purpose of this study is to determine feasibility as measured by consent of at least 25% of eligible patients and their caregivers (defined as those who met with the study coordinator), adherence (75% of the enrolled participants will complete at least 3 of the 4 Resilient Living sessions), and acceptability (measured by ) of the delivery of the Resilient Living intervention to patients with advanced cancer and their caregivers. - [A Study to Assess AC220 Given in Combination with Induction and Consolidation Therapy for Newly Diagnosed Acute Myeloid Leukemia (AML)](/research/clinical-trials/cls-20340075) Jacksonville, FL The purpose of this study is to define the maximum tolerated dose of AC220 when combined with induction and consolidation therapy and as maintenance therapy following induction and consolidation. - [Learning from Patients How They Were Educated on Chemotherapy Side Effects](/research/clinical-trials/cls-20493096) Rochester, MN To learn in patients' own words how they were educated on chemotherapy side effects, what aspects of that education were most helpful, and what aspects could be done better (and why). - [A Study to Evaluate The Effect of Diet and Exercise on Biomarkers Associated with Obesity and Breast Cancer in Overweight Women with Early Stage Breast Cancer](/research/clinical-trials/cls-20460306) Rochester, MN The primary purpose of this study is to investigate the relationship between a technology-assisted diet and exercise program which is easily implemented in an outpatient setting and the levels of biomarkers that have been associated with breast cancer recurrence risk in overweight women with stage 0, I, or II breast cancer. - [Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors](/research/clinical-trials/cls-20531933) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors. - [MC1733, Phase I Trial of Intratumoral Administration of a Measles Virus Derivative Expressing the Helicobacter pylori Neutrophil-activating Protein (NAP) (MV-s-NAP) in Patients with Metastatic Breast Cancer](/research/clinical-trials/cls-20502718) Rochester, MN To determine the maximally tolerated dose (MTD) of intratumoral administration of an Edmonston strain measeles virus genetically engineered to express NAP (MV-s-NAP) in patients with metastatic breast cancer; to determine the safety and toxicity of on-time and serial administration of MV-s-NAP in patients with metastic breast cancer. - [Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin](/research/clinical-trials/cls-20523996) Scottsdale/Phoenix, AZ This phase I trial investigates the side effects and best dose of peposertib when given together with radiation therapy in treating patients with head and neck cancer that has spread to other places in the body (advanced) who cannot take cisplatin. Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. This trial aims to see whether adding peposertib to radiation therapy is safe and works well in treating patients with head and neck cancer. - [Cisplatin and Gemcitabine Hydrochloride With or Without ATR This randomized phase II trial studies how well cisplatin and gemcitabine hydrochloride with or without ATR kinase inhibitor VX-970 works in treating patients with urothelial cancer that has spread to other places in the body. Drugs used in chemotherapy, such as cisplatin and gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. ATR kinase inhibitor VX-970 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if cisplatin ... - [A Study of Adding AMG 479 to First Line Chemotherapy in Patients with Optimally Debulked Epithelial Ovarian Cancer](/research/clinical-trials/cls-20314152) Rochester, MN The purpose of this study is to determine the value of adding AMG 479 (a fully human monoclonal antibody against IGF-1R) to paclitaxel and carboplatin (first line chemotherapy) for the treatment of patients who have ovarian epithelial cancer that has been surgically removed to less than 1 cm thick. - [A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma](/research/clinical-trials/cls-20522382) Rochester, MN This study aims to demonstrate that the efficacy of treatment with selumetinib as measured by event-free survival (EFS) is non-inferior compared treatment with carboplatin/vincristine in previously-untreated low-grade (LGG) not or systemic neurofibromatosis type 1 (NF1). - [A No Locations The purpose of this study is to evaluate the safety, effectiveness and drug/body interactions of the combination of MM-151, nal-IRI, 5-FU, and leucovorin for the treatment (genetic mutations), metastatic, colorectal cancer. - [A Study Comparing Combination Chemotherapy to Gemcitabine Hydrochloride and Nab-Paclitaxel Given Before Surgery for Treating Patients who have Pancreatic Cancer that can be Removed by Surgery](/research/clinical-trials/cls-20318089) Rochester, MN The purpose of this study is to assess the best 2-year overall survival when comparing fluorouracil, irinotecan hydrochloride, and oxaliplatin (combination chemotherapy) to gemcitabine hydrochloride and nab-paclitaxel, given before surgery for treating patients who have pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as fluorouracil, irinotecan hydrochloride, oxaliplatin, gemcitabine hydrochloride, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether combination chemotherapy ... - [Study of Nanoliposomal Irinotecan Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to assess the safety, tolerability and preliminary efficacy of nal-IRI in combination with 5-FU/LV and oxaliplatin in patients not previously treated for metastatic pancreatic adenocarcinoma to select a regimen for further development. - [Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib purpose of these phase I/II trial studies is to analyze the side effects and best dose of liposomal irinotecan and rucaparib when given together with fluorouracil and leucovorin calcium, and to see how well they work in treating patients with pancreatic, colorectal, gastroesophageal, or biliary cancer that has spread to other places in the body. Drugs used in chemotherapy, such as liposomal irinotecan, fluorouracil, leucovorin calcium, and rucaparib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. - [Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma](/research/clinical-trials/cls-20539575) Rochester, MN The purpose of this study is to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma. Additionally, to find out how well patients with low risk rhabdomyosarcoma (LR-RMS) respond to standard chemotherapy when patients with VLR-RMS and patients who have rhabdomyosarcoma with DNA mutations get separate treatment. Finally, this study examines the effect of therapy intensification in patients who have RMS cancer with DNA mutations to see if their outcomes ... - [Study of Magrolimab Combination Therapy to Treat Breast Cancer](/research/clinical-trials/cls-20527577) Scottsdale/Phoenix, AZ; FL; Rochester, MN The primary purpose of the Safety-Run-in Cohort 1 of this study is to evaluate the safety, tolerability, and recommended Phase 2 dose of magrolimab in combination with nab-paclitaxel or paclitaxel. In Phase 2 Cohort 1, the study will compare the efficacy of magrolimab in combination with nab-paclitaxel or paclitaxel versus nab-paclitaxel or paclitaxel alone as determined by progression-free survival (PFS) by investigator assessment The primary purpose of the Safety-Run-in Cohort 2 of this study is to evaluate the safety, tolerability, and recommended Phase 2 dose of magrolimab in combination with sacituzumab govitecan. In Cohort 2 (Safety Run-in Cohort 2 and Phase 2 Cohort 2) the study will evaluate the efficacy of magrolimab in combination ... - [Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer](/research/clinical-trials/cls-20425293) Rochester, MN This research study is evaluating ways to provide palliative care to patients who have recently been diagnosed with lung cancer and their families. - [Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma](/research/clinical-trials/cls-20387441) Rochester, MN This randomized phase III trial studies how well combination chemotherapy (vincristine sulfate, dactinomycin, cyclophosphamide alternated with vincristine sulfate and irinotecan hydrochloride) works compared to combination chemotherapy plus temsirolimus in treating patients with rhabdomyosarcoma (cancer that forms in the soft tissues, such as muscle), and has an intermediate chance of coming back after treatment (intermediate risk). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combination chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some ... - [A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma](/research/clinical-trials/cls-20475985) Rochester, MN The pupose of this study is to evaluate whether or not selumetinib works just as well as the standard treatment with carboplatine/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by ... - [Experiences of Acupuncture among Breast Cancer Survivors](/research/clinical-trials/cls-20438478) Rochester, MN The purpose of this study is to determine the feasibility and perceived effectiveness of acupuncture for breast cancer-related symptoms. - [A Study to Compare Somatostatin Analogues with Perioperative Antibiotics versus Prolonged Antibiotics](/research/clinical-trials/cls-20467501) Rochester, MN The purpose of this study is to to determine the individual treatment effect of somatostatin and whether duration of antibiotic therapy coupled with octreotide provides improved outcomes after pancreaticoduodenectomy. - [A Study to Evaluate APR-246 & Azacitidine for Treatment TP53 Mutant Myelodysplastic Syndromes (MDS)](/research/clinical-trials/cls-20475816) Jacksonville, FL; Rochester, MN This study is designed to investigate whether a new experimental treatment known as APR 246 will be an effective and safe treatment option for patients with MDS. - [Lenalidomide and Low-Dose Dexamethasone in Patients with Previously Multiple Myeloma and Kidney Dysfunction](/research/clinical-trials/cls-20115760) Scottsdale/Phoenix, AZ; Rochester, MN Patients with previously treated multiple myeloma and kidney dysfunction will be treated with lenalidomide and low-dose dexamethasone. Phase I will study the side effects and best dose of lenalidomide when given together with low-dose dexamethasone therapy. After the maximum safe and tolerated dose is found in Phase I, the study will proceed to Phase II. Phase II will study how well the the treatment works in patients with previously treated (relapsed or refractory) multiple myeloma and kidney dysfunction. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used ... - [Lenalidomide and AT-101 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia](/research/clinical-trials/cls-20112298) Jacksonville, FL This phase I/II trial studies the side effects and best dose of lenalidomide when given together with R-(-)-gossypol acetic acid and to see how well they work in treating patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL). Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as R-(-)-gossypol acetic acid, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. - [A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)](/research/clinical-trials/cls-20316363) Jacksonville, FL Phase I Dose Escalation: Primary objective is to determine the MTD and the recommended dose for Phase I Extension. Secondary objective is to investigate the safety, pharmacokinetics and efficacy of BI 836858 in combination with decitabine Phase I Extension: Primary objective is to collect additional data on safety, pharmacokinetics and efficacy and to define the Recommended Phase II Dose (RP2D) of BI 836858 in combination with decitabine. Phase II: Primary objective is to investigate efficacy, safety and pharmacokinetics of BI 836858 in combination with decitabine compared to decitabine monotherapy. - [A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects a 1, open-label, study of TGR-1202, a PI3K delta inhibitor, administered of in Treating Patients With Epithelioid Hemangioendothelioma That Is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery](/research/clinical-trials/cls-20457505) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate how well trametinib works in treating patients with epithelioid hemangioendothelioma that has spread to other places in the body, nearby tissue or lymph nodes, or cannot be removed by surgery. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. - [A Study Comparing Temozolomide and Selumetinib for Treating Patients with Metastatic Melanoma of the Eye](/research/clinical-trials/cls-20314931) Rochester, MN The purpose of this study is to compare the effectiveness of temozolomide to selumetinib for the treatment of patients who have melanoma of the eye that has spread to other places in the body. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective than selumetinib in treating melanoma of the eye. - [Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma](/research/clinical-trials/cls-20115823) Rochester, MN This phase II trial studies how well giving ruxolitinib phosphate (oral JAK inhibitor INCB18424) works in treating patients with relapsed or refractory diffuse large B-cell or peripheral T-cell non-hodgkin lymphoma and are ineligible to stem cell transplant or have recurrent disease after stem cell transplant. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. - [Study of Cisplatin-Induced Peripheral Neuropathy in Patients with Germ Cell Tumor](/research/clinical-trials/cls-20195848) Rochester, MN The purpose of this study is to investigate the incidence, characteristics of, and changes in chronic neuropathy symptoms related to cisplatin and evaluate the natural history of platinum induced peripheral neuropathy during active treatment and the first 12 months post chemotherapy. - [Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma](/research/clinical-trials/cls-20145363) Rochester, MN This randomized phase II trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body. Monoclonal antibodies, such as ganitumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective ... - [A Study of Carboplatin, Cabazitaxel and Abiraterone in Volume Metastatic Castration Sensitive Prostate Cancer (CASCARA)](/research/clinical-trials/cls-20516352) Scottsdale/Phoenix, AZ The primary objective of this study is to determine the proportion of patients who have no PSA or radiographic progression as determined by RECIST 1.1 or PCWG3 criteria 1 year, with 6 cycles of carboplatin and cabazitazel followed by continued abiraterone. - [Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma](/research/clinical-trials/cls-20143793) Rochester, MN This randomized phase III trial compares how well combination chemotherapy works when given with or without bortezomib in treating patients with newly diagnosed T-cell acute lymphoblastic leukemia or stage II-IV T-cell lymphoblastic lymphoma. may help reduce the number of leukemia or lymphoma cells by blocking some of the enzymes needed for cell growth. It may also help chemotherapy work better by making cancer cells more sensitive to the drugs. It is not yet known if giving standard chemotherapy with or without bortezomib is more effective in treating T-cell acute lymphoblastic leukemia Cancer](/research/clinical-trials/cls-20438460) Rochester, MN The purpose of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best supportive/best standard of care versus patients treated with best supportive/best standard of care alone. - [A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20447066) Rochester, MN; Jacksonville, FL The purpose of this study is to evaluate the safety and effectiveness of venetoclax plus dexamethasone (VenDex) compared with pomalidomide plus dexamethasone t(11;14)-positive Relapsed or Refractory Multiple Myeloma. - [Combination Chemotherapy in Treating Patients with Non-Metastatic Extracranial Ewing Sarcoma](/research/clinical-trials/cls-20118801) Rochester, MN This randomized phase III trial studies combination chemotherapy to see how well it works compared to combination chemotherapy with topotecan hydrochloride in treating patients with non-metastatic extracranial Ewing sarcoma. Drugs used in chemotherapy, such sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, etoposide, and topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known whether combination chemotherapy is more effective with topotecan hydrochloride in treating Ewing sarcoma. - [A Study to Assess the Safety and Tolerability of ADI-PEG 20 Combined with Pemetrexed and Cisplatinin in Subjects with Tumors Requiring Arginine](/research/clinical-trials/cls-20260173) Rochester, MN The purpose of this study is to assess the safety and tolerability of ADI-PEG 20 combined with pemetrexed and cisplatin in patients with tumors requiring arginine such as advanced malignant pleural mesothelioma, advanced peritoneal mesothelioma (for dose escalation cohort only), non squamous non-small cell lung cancer (stage IIIB/IV), metastatic uveal melanoma, liver cell cancer or recurrent - [Incidence of Chemotherapy and Targeted Therapy-Related Nasal Vestibulitis](/research/clinical-trials/cls-20326294) Rochester, MN The purpose of this study is to determine the percentage of patients receiving cancer-directed therapy at the Gonda 10 chemotherapy unit who have had or are currently experiencing symptoms of nasal vestibulitis. - [Study of RP-6306 Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The primary purpose of this study is to assess the safety and tolerability of RP-6306 in combination gemcitabine, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-6306 in combination with gemcitabine, identify a recommended phase 2 dose (RP2D) and preferred schedule, examine preliminary pharmacokinetics (PK) and assess anti-tumor activity. - [Envafolimab ](/research/clinical-trials/cls-20510700) Jacksonville, FL; Rochester, MN The purpose of this study is determine objective response rate (ORR) by RECIST 1.1 by blinded independent central review (BICR) of envafolimab (cohort A), and of envafolimab combined with ipilimumab at 1 mg/kg (cohort B), in separate cohorts of patients with locally advanced, unresectable or metastatic UPS/MFS that has progressed following one or two lines of chemotherapy, without a formal statistical comparison between the two cohorts. - [Grief Among Older Adult Family Caregivers](/research/clinical-trials/cls-20533134) Jacksonville, FL The purpose of this study is to evaluate the trajectory of loss and grief over 12 months, the risk factors associated with high levels of pre-loss grief, and the preliminary effectiveness of ART for treatment of high levels of pre-loss grief among family caregivers (FCG) of persons nearing the end of life. - [A Study to Evaluate Trabectedin with Olaparib in Advanced Unresectable or Metastatic Sarcoma](/research/clinical-trials/cls-20513444) Rochester, MN The purpose of this study is to evaluate how well trabectedin and olaparib work in treating patients with sarcoma that cannot be removed by surgery or has spread to other places in the body. Drugs used in chemotherapy, such as trabectedin, work in different ways to stop the growth of tumor cells, either by killing cells, stopping them from dividing or stopping them from spreading. Olaparib may stop the growth of tumor cells by blocking pathways responsible for repairing damaged cells. Giving trabectedin and olaparib may shrink or stop the tumor from growing. - [Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers](/research/clinical-trials/cls-20148448) Scottsdale/Phoenix, AZ The goal of this clinical research study is to learn if adding abraxane (nab-paclitaxel) to gemcitabine and cisplatin can help to control metastatic or unresectable biliary cancer. The safety of this drug combination will also be studied. - [A Study to Evaluate Cryotherapy to Prevent Taxane-induced Sensory Neuropathy of the Hands and Feet](/research/clinical-trials/cls-20478971) Jacksonville, FL The purpose of this study is to evaluate the effectiveness and tolerability of cryotherapy (cold therapy) in the form of Elasto Gel\u00ae frozen mittens and foot wraps to determine whether or not they can prevent or ameliorate taxane-induced sensory peripheral neuropathy. The hypothesis of our pilot study is that patients receiving cryotherapy during infusion of taxane therapy will have lower incidence of peripheral neuropathy, better physical function, and higher quality of life as compared to patients previously reported in literature. - [Phase I Study of LB-100 With Docetaxel in Solid Tumors](/research/clinical-trials/cls-20111961) Rochester, MN The purpose of this study is to test the safety of an investigational drug called LB 100 for Injection for treatment of solid tumors, when given with or without docetaxel. LB-100 is a small molecule that in laboratory and animal studies has shown activity when used by itself or together with drugs approved to treat some types of cancer (chemotherapeutic agents). Docetaxel is a drug that has been approved for the treatment of some types of cancer; one of the trade names for docetaxel is Taxotere\u00ae. The study is in 2 parts. Part 1: Patients will receive injections of LB-100. ... - [Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies](/research/clinical-trials/cls-20145343) Scottsdale/Phoenix, AZ 2-stage crossover study consisting of 2 phases: Stage I - Pharmacokinetics (Bioequivalence), with an Extension Stage II - Pharmacokinetics (Food Effect) with an Extension This study will enroll approximately 60 subjects in stage I and 60 subjects in stage II with hematologic or solid tumor malignancies, excluding gastrointestinal tumors and tumors that have originated or metastasized to the liver for which no standard treatment exists or have progressed or recurred following prior therapy. Subjects must not be eligible for therapy of higher curative potential where an alternative treatment has been shown to ... - [A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma](/research/clinical-trials/cls-20193937) Jacksonville, FL The main purpose of this study is to evaluate the efficacy of the combination of doxorubicin plus the study drug known as olaratumab versus doxorubicin plus placebo in participants with advanced or metastatic soft tissue sarcoma. - [A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Metastatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment](/research/clinical-trials/cls-20503767) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to look at the effectiveness and safety of Irinotecan liposome injection in combination with other approved drugs used for cancer therapy, namely 5 fluorouracil/leucovorin (5FU/LV) plus oxaliplatin compared to nab-paclitaxel + gemcitabine treatment in improving the overall survival of patients not previously treated for metastatic pancreatic cancer. - [PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy](/research/clinical-trials/cls-20539378) Eau Claire, WI; Rochester, MN The purpose of this study the efectiveness of PEA (N-palmitoylethanolamide) at two different doses relative to placebo responses, as a treatment for chemotherapy-induced neuropathy (CIPN). Also, to assess the safety of PEA at the two study doses, and to evaluate changes in patient-reported symptoms and quality of life from baseline to the end of 8 weeks. - [Cyclophosphamide, Ixazomib, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma](/research/clinical-trials/cls-20112352) Scottsdale/Phoenix, AZ; Rochester, MN This phase I/II trial studies the side effects and the best dose of cyclophosphamide when given together with ixazomib and dexamethasone in treating patients with previously untreated symptomatic multiple myeloma. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide together with ixazomib and dexamethasone may be an effective treatment for multiple myeloma. - [Pevonedistat Plus Azacitidine Versus Single-Agent Myelogenous Leukemia (AML)](/research/clinical-trials/cls-20438443) Jacksonville, FL The purpose of this study is to determine whether the combination of pevonedistat and azacitidine improves overall response rate (ORR) by Cycle 6 and whether the combination of pevonedistat and azacitidine improves event-free survival (EFS) when compared with single-agent azacitidine. - [Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome](/research/clinical-trials/cls-20492216) Rochester, MN This phase III trial studies response-based chemotherapy in treating newly diagnosed acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Response-based chemotherapy separates patients into different risk groups and treats them according to how they respond to the first course of treatment (Induction I). Response-based treatment may be effective in treating acute myeloid leukemia or myelodysplastic syndrome in younger patients with Down syndrome while reducing the ... - [A Study to Evaluate IMGN632 with Venetoclax and/or Azacitidine to Treat Patients with CD123-Positive Acute Myeloid Leukemia](/research/clinical-trials/cls-20517713) Rochester, MN The purpose of this study is is to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN632 when administered in combination with azacitidine and/or venetoclax in patients with relapsed and frontline CD123-positive AML, and antileukemia activity of IMGN632 when administered as monotherapy in patients with MRD+ AML after frontline treatment. - [A Study of Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy](/research/clinical-trials/cls-20460923) Rochester, MN The purpose of this study is to evaluate how well daunorubicin and cytarabine, with or without uproleselan, works in treating older adult patients with acute myeloid leukemia receiving intensive induction chemotherapy. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Uproleselan may prevent cancer from returning or getting worse. Giving daunorubicin and cytarabine with uproleselan may work better in treating patients with acute myeloid leukemia compared to daunorubicin and cytarabine alone. - [Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL)](/research/clinical-trials/cls-20467364) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate whether a reduction in the dose of consolidation radiation therapy (RT) in patients who achieve a negative post-chemotherapy PET-CT scan following 3 to 6 cycles of chemoimmunotherapy, will be associated with a low risk of in-field failure. - [Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis](/research/clinical-trials/cls-20111726) Scottsdale/Phoenix, AZ; Jacksonville, FL This study is to determine the efficacy of momelotinib (MMB) versus ruxolitinib in participants post-essential thrombocythemia myelofibrosis (post-PV/ET received treatment with a Janus kinase inhibitor (JAK inhibitor). Participants will be randomized to receive either MMB or ruxolitinib for 24 weeks during a double-blind treatment phase, after which they will be eligible to receive open-label MMB for up to an additional 168 weeks. After discontinuation of study medication, assessments will continue for 12 additional weeks, after which participants will be contacted for survival follow-up approximately every 6 months ... - [A Study to Evaluate Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy MN; Mankato, MN; Eau Claire, WI The purpose of this study is to determine the best dose of duloxetine and how well it works in preventing pain, tingling, and numbness (peripheral neuropathy) caused by treatment with oxaliplatin in patients with stage II-III colorectal cancer. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. Giving duloxetine in patients undergoing treatment with oxaliplatin for colorectal cancer may help prevent peripheral neuropathy. - [Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients with Myelofibrosis](/research/clinical-trials/cls-20115519) Scottsdale/Phoenix, AZ This phase II pilot trial studies how well ruxolitinib phosphate and danazol work in treating anemia in patients with myelofibrosis. Ruxolitinib phosphate and danazol may cause the body to make more red blood cells. They are used to treat anemia in patients with myelofibrosis. - [A Study to Evaluate the Effectiveness and Safety of Panzyga in Patients with Chronic Lymphocytic Leukemia](/research/clinical-trials/cls-20488337) Rochester, MN The purpose of this study is to demonstrate the benefit of Panzyga administration compared with placebo as primary infection prophylaxis in Chronic Lymphocytic Leukemia (CLL) patients with secondary immunodeficiency (SID) undergoing CLL antineoplastic therapy. - [A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors](/research/clinical-trials/cls-20542252) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to investigate the antitumor activity of navicixizumab monotherapy or in combination with paclitaxel or irinotecan in patients with advanced solid tumors including: - Cohort A: Colorectal cancer (CRC); - Cohort cancer; - Cohort C: Triple-negative breast cancer (TNBC); - Cohort D: Platinum-resistant/refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer (ovarian cancer). - [A Study to Investigate the da Vinci SP\u00ae Surgical System in Colorectal Procedures for Benign and Malignant Disease](/research/clinical-trials/cls-20507457) Jacksonville, FL; Rochester, MN The purpose of this study is to confirm the safety and performance of the da Vinci SP Surgical System, Instruments and Accessories in a complex colorectal procedure such as low anterior resections. - [Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced G12C Mutation](/research/clinical-trials/cls-20520141) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to compare the effectiveness of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation. - [CODY: A Study Evaluating The Safety And Efficacy Of QTORIN 3.9% Sirolimus Topical Gel For The Prevention Of In Patients With Gorlin Syndrome](/research/clinical-trials/cls-20529097) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to compare the number of new biopsy confirmed Basal Cell Carcionomas (BCCs) that develop on the face over a 6-month period between the treatment arms, active and placebo. - [A Study to Evaluate DS-8201a Combined with Olaparib in HER2-Expressing Cancers with Expansion in Endometrial Cancer Patients Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Endometrial Cancer](/research/clinical-trials/cls-20519837) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the safety and tolerability of the combination of DS-8201a in combination with olaparib, and to determine the recommended phase 2 dose (RP2D) 1.1.2 To evaluate the safety and tolerability of this combination in a dose expansion cohort in patients with uterine serous carcinoma. - [A Study to Evaluate Ascorbic Acid and Chemotherapy to Treat Patients with Relapsed / Refractory Lymphoma and Patients with Clonal Cytopenia of Undetermined La Crosse, WI; Eau Claire, WI; Mankato, MN The purpose of this study is to examine how well ascorbic acid and combination chemotherapy work in treating patients with lymphoma that has come back or does not respond to therapy. Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may work better at treating lymphoma. In the Clonal Cytopenia of Undetermined Significance (CCUS) Cohort D, we want to find out if ascorbic acid will ... - [Gemini Study to Evaluate the Integration of Cancer Genetic Testing into a Cancer Clinical Practice at Mayo Clinic at Arizona](/research/clinical-trials/cls-20482100) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to determine the prevalence of genetic mutations in cancer patients from various ethnic populations seeking care at Mayo Clinic Arizona cancer clinics. - [A Study to Evaluate User Feedback Using Affirm\u00ae Contrast Biopsy](/research/clinical-trials/cls-20510372) Scottsdale/Phoenix, AZ The purpose of this study is to collect user and subject feedback on the design, use and operation of Affirm\u00ae Contrast Biopsy. - [A Study to Evaluate Immune Response Changes to Ovarian Cancer During Chemotherapy](/research/clinical-trials/cls-20506868) Rochester, MN The study will determine whether the type and number of immune cells (white blood cells) in ovarian cancer tumors after initial chemotherapy impacts ovarian cancer patient outcomes. - [A Study to Evaluate User Feedback Using Affirm\u00ae Contrast Biopsy](/research/clinical-trials/cls-20510372) Scottsdale/Phoenix, AZ The purpose of this study is to collect user and subject feedback on the design, use and operation of Affirm\u00ae Contrast Biopsy. - [A Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy](/research/clinical-trials/cls-20323755) Jacksonville, FL This study is a double-blind, randomized, placebo-controlled (2:1 niraparib:placebo) study in patients with Stage III or IV ovarian cancer. Patients must have completed front-line platinum based regimen with a physician-assessed response of Complete Response (CR) or Partial Response (PR). Additionally, patients must have a normal or >90% decrease in cancer antigen 125 (CA-125) following front-line platinum treatment. The study will assess the efficacy of niraparib as maintenance treatment, as measured by PFS. - [Fat Emulsion in Preventing Hypersensitivity Reactions in Patients With Cancer Receiving Carboplatin or Oxaliplatin](/research/clinical-trials/cls-20311357) Rochester, MN This randomized pilot trial studies how well fat emulsion works in preventing hypersensitivity reactions in patients with cancer receiving carboplatin or oxaliplatin. Giving lipids before chemotherapy may prevent some drug reactions from carboplatin or oxaliplatin. - [Study of Safety and Efficacy of Iberdomide (CC-220) CC-99282 With AZ; Rochester, MN; Jacksonville, FL The primary objective of Part 1 of this study is to define the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of CC-220 in combination with rituximab, cyclophosphamide, in (R-CHOP-21) and CC99282 in combination with R-CHOP-21 in subjects with previously untreated, high risk (International Prognostic Index [IPI] 3 to 5), a-BCL. The primary objective of Part 2 of this study is to further evaluate the safety and tolerability associated with CC-220 and CC-99282 at the RP2D in combination with R-CHOP-21 in subjects with previously untreated, high-risk (IPI 3 to 5), a-BCL. - [A Study to Evaluate the Safety, Tolerance and Anti-tumor Activity of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Non-Hodgkin Lymphoma](/research/clinical-trials/cls-20507610) Rochester, MN The primary purpose of this study is to determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed refractory multiple myeloma (RRMM) and refractory non-Hodgkin lymphoma (RR-NHL), the Phase 2 dose (RP2D). - [A Study Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma](/research/clinical-trials/cls-20524069) Rochester, MN The purpose of this study is to determine how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as olaparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping ... - [Phase 3 Study to Treat Patients with Soft Tissue Sarcomas](/research/clinical-trials/cls-20145297) Jacksonville, FL; Rochester, MN The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas. - [A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20520966) Rochester, MN The purpose of this study is to compare the effectiveness and safety of combining amivantamab and lazertinib (Arm A) versus single-agent osimertinib (Arm B) as first-line treatment in participants with EGFR-mutated locally advanced or metastatic NSCLC not amenable to curative therapy. Combining amivantamab and lazertinib may lead to improved treatment outcomes through synergistic anti-EGFR activity, prevention of EGFR- or MET-based resistance to a third-generation EGFR TKI, and potential recruitment of Fc-bearing immune cells in the anti-tumor response. The contribution of amivantamab to the activity of the combination will be assessed by comparing the efficacy observed in the amivantamab and lazertinib combination arm (Arm A) with that in ... - [Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia](/research/clinical-trials/cls-20506032) Rochester, MN The purpose of this study is to test any good and bad effects of adding the drug Blinatumomab to different doses of standard combination of chemotherapy drugs. - [MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment](/research/clinical-trials/cls-20203534) Scottsdale/Phoenix, AZ This is a Phase I study to understand the biodistribution of MM-398 and to determine the feasibility of using Ferumoxytol as a tumor imaging agent. - [Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery](/research/clinical-trials/cls-20306795) Rochester, MN This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Drugs used in chemotherapy, such as temozolomide, capecitabine, cisplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Certain types of neuroendocrine carcinomas may respond better to treatments other than the current ... - [Study to Analyze Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy](/research/clinical-trials/cls-20441566) La Crosse, WI; Eau Claire, WI; Rochester, MN This randomized phase III trial studies how well olanzapine, with or without fosaprepitant, work in preventing chemotherapy induced nausea and vomiting in cancer patients receiving chemotherapy that causes vomiting. Olanzapine and fosaprepitant dimeglumine may help control nausea and vomiting in patients during chemotherapy. Olanzapine is usually given in combination with other drugs, including fosaprepitant dimeglumine. It is not yet known if olanzapine when given with other drugs, is still effective without using fosaprepitant dimeglumine for controlling nausea and vomiting. - [A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy](/research/clinical-trials/cls-20524595) Rochester, MN This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 in combination with the HMA azacitidine and the Bcl-2 inhibitor venetoclax. The primary purpose of Part 1 (Safety Run-in) is to rule out excessive toxicity of MBG453, when administered in combination with azacitidine and venetoclax. The primary purpose of the combined Part 1 and Part 2 (Safety run-in and Expansion Part) is to evaluate efficacy of MBG453, when administered in combination with azacitidine and venetoclax in adult patients with newly diagnosed AML, who are not suitable for treatment ... - [A Study to Analyze NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma](/research/clinical-trials/cls-20516465) Rochester, MN; Jacksonville, FL The objectives of this study are to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of NMS-03305293 in combination with temozolomide (TMZ) in patients with diffuse gliomas at first relapse (Phase I), and to determine the antitumor effectiveness of the combination of NMS-03305293 and TMZ in patients with isocitrate dehydrogenase (IDH) wild type glioblastoma at first relapse as measured by the 6-month Progression Free Survival (PFS) rate (Phase II). - [Cardiotoxic Effects of Chemotherapy in Patients with Sarcomas](/research/clinical-trials/cls-20306997) Rochester, MN The purpose of this study is to determine if two-dimensional speckle tracking echocardiography (2D-STE) derived-strain can detect early myocardial dysfunction and thus predict cardiotoxicity in sarcoma subjects undergoing anthracycline therapy and to compare three dimensional speckle tracking echocardiography (3D-STE) to 2D-STE in the same group of patients. - [SGI-110 in Patients with Myelodysplastic Syndromes 1-2 dose escalation randomized study in patients with intermediate or high risk myelodysplastic syndromes (MDS) or acute myelogenous leukemia (AML). The Dose Escalation Segment will evaluate the biological activity, preliminary safety and efficacy of SGI-110 with two dosing schedules in MDS and AML patients while the Dose Expansion Segment will further evaluate safety and efficacy at the biological effective dose (BED) or maximum tolerated dose (MTD) as defined in the Dose Escalation Segment. - [A Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia](/research/clinical-trials/cls-20115999) Rochester, MN This Phase 3 study assesses two drug regimens as the initial treatment of patients who are at least 70 years of age and have newly diagnosed acute myeloid leukemia (AML) for whom the doctor does not recommend the use of standard intensive treatment or the patient has decided not to receive standard intensive treatment after being fully informed about its benefits and risks by his/her doctor. The two drug regimens are sapacitabine administered in alternating cycles with decitabine, or decitabine alone. The purpose of the study is to learn which drug regimen is more likely to keep AML in check ... - [Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients Relapsed Multiple Myeloma](/research/clinical-trials/cls-20164773) Jacksonville, FL; Rochester, MN Does idasanutlin in combination with ixazomib and dexamethasone contribute to better outcomes for patients with multiple myeloma who have been previously treated for their disease? - for Myelodysplastic Syndrome Refractory to Hypomethylating Agents](/research/clinical-trials/cls-20115819) Scottsdale/Phoenix, AZ The purpose of this study is to determine the proportion of confirmed responses (complete response, partial response), and hematologic improvement as defined by revised IWG criteria during the 12 months of treatment. - [Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS](/research/clinical-trials/cls-20314741) Jacksonville, FL This is a phase 1/2 study to evaluate the combination of vadastuximab talirine (SGN-CD33A; 33A) and azacitidine in subjects with previously untreated International Prognostic Scoring System (IPSS) Intermediate-2 or high risk myelodysplastic syndrome (MDS). - [A Study to Evaluate Induction Chemotherapy ABVD Followed by Brentuximab Vedotin Consolidation in Previously-untreated, Non-bulky Stage I or II Hodgkin Lymphoma](/research/clinical-trials/cls-20116519) Rochester, MN The standard chemotherapy for Hodgkin lymphoma is called ABVD which is a combination of 4 chemotherapy drugs (doxorubicin, bleomycin, vinblastine, and dacarbazine). The number of cycles of ABVD chemotherapy Hodgkin lymphoma patients receive is about 4-6 cycles. In addition to the ABVD chemotherapy, patients with Hodgkin lymphoma will routinely receive radiation therapy. The use of chemotherapy and radiation may cause long term treatment related side effects such as heart problems and other cancers. Researchers are trying to find if combining ABVD chemotherapy with new drugs and reducing the number of ABVD chemotherapy cycles given is just as effective as the ... - [A Study to Evaluate the Combination of Selinexor with Pomalidomide and Dexamethasone +/- Carfilzomib to Treat Patients with Refractory Multiple Myeloma](/research/clinical-trials/cls-20510368) Rochester, MN The purpose of this study is to evaluate selinexor combined with carfilzomib, pomalidomide and dexamethasone or pomalidomide and dexamethasone for of relapsed refractory multiple myeloma. - [Brentuximab Vedotin and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Hodgkin Lymphoma](/research/clinical-trials/cls-20154279) Rochester, MN This randomized phase III trial studies brentuximab vedotin and combination chemotherapy to see how well they work compared to combination chemotherapy alone in treating younger patients with newly diagnosed Hodgkin lymphoma. Combinations of biological substances in brentuximab vedotin may be able to carry cancer-killing substances directly to Hodgkin lymphoma cells. Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate, vincristine sulfate, etoposide, prednisone, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if combination ... - [A Study to Compare Three Chemotherapy Regimens for the Treatment of Patients with Newly- diagnosed Mantle Cell Lymphoma](/research/clinical-trials/cls-20475515) Rochester, MN; Jacksonville, FL The purpose of this study is to compare three chemotherapy regimens consisting of bendamustine, rituximab, high dose cytarabine, and acalabrutinib, and to determine how well they work in treating patients with newly-diagnosed mantle cell lymphoma. Drugs used in chemotherapy, such as bendamustine and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Acalabrutinib may stop the growth of cancer cells by blocking some of the ... - [Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma](/research/clinical-trials/cls-20395982) Rochester, MN This phase I/II trial studies the side effects and best dose of venetoclax when given together with ixazomib citrate and dexamethasone and to see how well they work in treating patients with multiple myeloma that has come back. Venetoclax and ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with ixazomib citrate and ... - [Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)](/research/clinical-trials/cls-20111793) Rochester, MN The primary objective of this study is to determine the Maximum Tolerated Dose (MTD) for belinostat when combined with CHOP regimen and establish the recommended belinostat dose for the Phase 3 study. - [Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1](/research/clinical-trials/cls-20111785) Rochester, MN; Scottsdale/Phoenix, AZ This is a Phase 1 multi-center study to evaluate the clinical safety and immune response of ID-LV305 when injected intradermally in patients with advanced cancer. ID-LV305 is a novel immunotherapy agent designed to target dendritic cells and stimulate the body's immune system to fight the spread and growth of cancer for patients whose tumors express the NY-ESO-1 protein. Patients with melanoma, sarcoma, ovarian cancer, or non-small cell lung cancer that express NY-ESO-1 may be considered for the trial. Selected sites will be evaluating ID-LV305 with pembrolizumab for patients with melanoma who have inadequately responded to anti-PD-1 therapy. - [Duvelisib and Nivolumab for the MN This phase I trial identifies the best dose, possible benefits, and/or side effects of duvelisib in combination with nivolumab in treating patients with stage IIB-IVB mycosis fungoides and Sezary syndrome. Duvelisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving duvelisib in combination with nivolumab may work better than giving each of these drugs individually, or treating with the usual approach in ... - [A Dose-Finding Study of Folotyn\u00ae (Pralatrexate With Peripheral T-Cell Lymphoma (PTCL)](/research/clinical-trials/cls-20210072) Rochester, MN The purpose of this study is to evaluate the Maximum Tolerated Dose (MTD) of pralatrexate in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with diagnosed peripheral T-cell lymphoma (PTCL). - [Study of CX-4945 in Combination for Treatment of Cholangiocarcinoma](/research/clinical-trials/cls-20117040) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This study considers the safety and tolerability of increasing doses of CX-4945 in combination with gemcitabine plus cisplatin to determine the maximum tolerated dose (MTD), followed by a randomized study that compares antitumor activity in cholangiocarcinoma patients receiving the standard of care gemcitabine plus cisplatin versus CX-4945 at the combination MTD with gemcitabine plus cisplatin. - [A Study Assessing Compliance with Mercaptopurine Treatment in Children with Acute Lymphoblastic Leukemia in First Remission](/research/clinical-trials/cls-20152037) Rochester, MN This randomized phase III trial studies compliance to a mercaptopurine treatment intervention compared to standard of care in younger patients with acute lymphoblastic leukemia in remission. Assessing ways to help patients who have acute lymphoblastic leukemia to take their medications as prescribed may help them in taking their medications more consistently and may improve treatment outcomes. - [A Study to Compare Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian or Primary Peritoneal Cancer](/research/clinical-trials/cls-20470742) Albert Lea, MN; Rochester, MN The purpose of this study is to evaluate how well letrozole, with or without paclitaxel and carboplatin, works in treating patients with stage II-IV low-grade serous carcinoma of the ovary or peritoneum. Letrozole an enzyme inhibitor that lowers the amount of estrogen made by the body which in turn may stop the growth of tumor cells that need estrogen to grow. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is ... - [A Study to Evaluate Pembrolizumab with Standard Therapy to Treat Newly-diagnosed Glioblastoma](/research/clinical-trials/cls-20366126) Rochester, MN; Scottsdale/Phoenix, AZ This phase II trial studies the side effects and how well pembrolizumab works in combination with standard therapy in treating patients with glioblastoma. Drugs used in the chemotherapy, such as pembrolizumab and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving pembrolizumab and standard therapy comprising of temozolomide and radiation therapy may kill tumor cells. - [A Study Investigating Integrated Genomics and Patient-derived Cancer Models](/research/clinical-trials/cls-20532499) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The aim of this project is to characterize a landscape of DNA alterations and proteomic changes in both biopsies and resected tumors of patients which have been diagnosed with aggressive/metastatic disease to identify molecular targets for which therapeutic drugs may exist. - [A Study to Evaluate Reiki Therapy as an Intervention in Hematology/Oncology Cancer Patients Hospitalized in an Inpatient Setting](/research/clinical-trials/cls-20461419) Rochester, MN The primary purpose of this study is to evaluate the feasibility of offering and providing Reiki Therapy in hospitalized hematology/oncology cancer patients. - [A Study of Biomarkers to Therapy-related Cardiotoxicity](/research/clinical-trials/cls-20461657) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The primary purpose of this study is to collect Biospecimens from patients who developed chemotherapy related cardiac toxicity (CRCT) and patients who are at a high risk for developing CRCT identified prior to the onset of therapy. - [A Study to Evaluate Contouring Organs at Risk for Treatment Planning](/research/clinical-trials/cls-20511050) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine: if the artificial intelligence (AI)-generated results are less arduous than manual tracing by radiation oncologist, and the non-inferiority of the quality of AI vs. manual tracing. These aims will be evaluated in a clinical environment to investigate the impact of an AI algorithm on the clinical workflow. Radiotherapy treatment planning requires precise calculations of radiation exposure, not only for the target volumes (tissue containing malignancy), but of nearby organs-at-risk (OARs), in which the exposure needs to be minimized. Manual segmentation of these organs is a time-consuming task with high interobserver variability. Producing these segmentations ... - [Deep Learning-based Automated Segmentation of Organs at Risk in Treat Head and Neck Radiotherapy](/research/clinical-trials/cls-20523033) Rochester, MN The purpose of this study is to validate the ability of GHMCA to produce expert-level contouring on retrospective Mayo data with a considerable time savings benefit. - [SC16LD6.5 in Recurrent Small Cell Lung Cancer](/research/clinical-trials/cls-20143567) Rochester, MN The purpose of this study is to assess the safety and tolerability of SC16LD6.5 at different dose levels in patients with small cell lung cancer whose cancer has progressed or recurred following standard chemotherapy. Once a safe and tolerable dose is determined, the anti-cancer activity of SC16LD6.5 will be assessed by measuring the extent of tumor shrinkage. SC16LD6.5 is an antibody-drug conjugate (ADC). The antibody (SC16) targets a protein that appears to be expressed on the surface of most small cell lung cancers that have been assessed using an immunohistochemical assay. The drug, D6.5, is a very potent form of ... - [Durvalumab+/- Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (Caspian)](/research/clinical-trials/cls-20387118) Scottsdale/Phoenix, AZ This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab \u00b1 tremelimumab with platinum based chemotherapy (EP) followed by \u00b1 tremelimumab maintenance therapy versus EP alone as first-line treatment in patients with extensive-stage small-cell lung cancer. - [A Study to Evaluate Artificial Intelligence-driven Assistance for Treatment Planning in Radiation Oncology](/research/clinical-trials/cls-20505055) Rochester, MN The purpose of this study is to evaluate whether the innovations under development for an AI-augmented service platform software are desirable for customers, viable for stakeholders, and feasible to build and deliver, a multi-disciplinary design team will conduct human-centered design research. The results of this research will help the team design, develop, build, and improve current and future products and services. - [A Study to Explore MRI to Stage Bladder Cancer](/research/clinical-trials/cls-20502003) Jacksonville, FL The purposes of this study are to assess image quality of a multiparametric MRI protocol for local staging imaging among patients with bladder cancer, and to assess accuracy of MR imaging in determining muscle invasion. - [A Study to Evaluate the Effectiveness and Safety of UGN-101 in Patients with Recurrent Upper Urinary Tract Urothelial Carcinoma](/research/clinical-trials/cls-20477444) Jacksonville, FL The purpose of this study is to evaluate the effectiveness and safety of UGN-101 administered to the upper urinary tract (UUT) in patients who were treated in Trial TC-UT-03, found to be a complete response (CR) at the Primary Disease Evaluation (PDE) 1 Visit, and are subsequently found to have a documented recurrence of low grade (LG) upper tract urothelial carcinoma (UTUC) at follow up (FU). - [A Study of ALX148 With Azacitidine for Higher Risk Myelodysplastic Syndrome](/research/clinical-trials/cls-20529999) Rochester, MN The purpose of this study is to evaluate ALX148 in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS). - [Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer](/research/clinical-trials/cls-20143944) Rochester, MN This randomized phase II/III trial studies how well paclitaxel, carboplatin, and metformin hydrochloride works and compares it to paclitaxel, carboplatin, and placebo in treating patients with endometrial cancer that is stage III, IV, or has come back. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Metformin hydrochloride may help paclitaxel and carboplatin work better by making cancer cells more sensitive to the drugs. It is not yet known whether paclitaxel and carboplatin ... - [Olaparib in Treating Patients With Metastatic Biliary Cancer With Aberrant DNA Repair Gene Mutations](/research/clinical-trials/cls-20493194) Scottsdale/Phoenix, AZ; Rochester, MN This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. - [Bendamustine Hydrochloride and Rituximab with or without Bortezomib Followed by Rituximab with or without Lenalidomide in Treating Patients with High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma](/research/clinical-trials/cls-20116801) Rochester, MN RATIONALE: Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and ... - [Birinapant With 5-azacitidine in MDS Subjects Who Are Refractory to 5-azacitidine Therapy](/research/clinical-trials/cls-20111949) Scottsdale/Phoenix, AZ; Jacksonville, FL This is a dose escalation followed by dose expansion study of TL32711 in combination with 5-Azacitidine in subjects with Myelodysplastic syndrome who are na\u00efve, have relapsed or have failed prior 5-azacitidine therapy. Pre-clinical and mechanistic studies support that 5-Azacitidine may modulate pathways that enable birinapant-mediated anti-tumor activity. - [Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia](/research/clinical-trials/cls-20151610) Rochester, MN This phase III trial is studying the side effects and how well giving dasatinib together with combination chemotherapy works in treating young patients with newly diagnosed acute lymphoblastic leukemia (ALL). Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dasatinib together with combination chemotherapy may kill more cancer cells. - [Exploring the Role of B-cell Activating Factor Receptor (BAFFR)-based Chimeric Receptor T-cell and Autoimmune Rheumatologic Disorders](/research/clinical-trials/cls-20513089) Jacksonville, FL The purposes of this study are to explore the therapeutic efficacy of BAFFR-CAR T cells in BAFFR-expressing B-cell hematologic malignancies leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-cell ALL) using primary tumor and/or patient derived xenograft models, and to explore the therapeutic efficacy of BAFFR-CAR T cells in autoimmune rheumatologic diseases including systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models. - [A Study to Evaluate Tadalafil and Lenalidomide with or without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma](/research/clinical-trials/cls-20146634) Jacksonville, FL This research is being done to find out if altering the immune system by giving Prevnar vaccine, Tadalafil, and activated marrow infiltrating lymphocytes (MILs) can improve outcomes for multiple myeloma patients who receive a standard autologous stem cell transplant. - [Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations](/research/clinical-trials/cls-20152035) Rochester, MN This randomized phase III trial studies how well combination chemotherapy works in treating young patients with newly diagnosed B acute lymphoblastic leukemia that is likely to come back or spread, and in patients with Philadelphia chromosome (Ph)-like tyrosine kinase inhibitor (TKI) sensitive mutations. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) and giving the drugs in different doses and in different combinations may kill more cancer cells. - [A Study Investigating the Safety, Tolerability, Pharmacokinetics, and Effectiveness of Mosunetuzumab (BTCT4465A) in Combination With or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma](/research/clinical-trials/cls-20462227) Rochester, MN The purpose of this study is to evaluate the safety, pharmacokinetics, and preliminary effectiveness of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHP) plus (R/R) B-cell non-Hodgkin lymphoma (NHL), and in previously large B-cell lymphoma (DLBCL). - [Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary](/research/clinical-trials/cls-20542553) Rochester, MN RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well carboplatin given together with paclitaxel and everolimus works in treating patients with previously untreated cancer of unknown primary. - [Low-Dose or High-Dose Lenalidomide in Treating Children with Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma](/research/clinical-trials/cls-20152039) Rochester, MN This randomized phase II trial studies how well low-dose lenalidomide works compared with high-dose lenalidomide in treating children with juvenile pilocytic astrocytomas or optic nerve pathway gliomas that have come back (recurrent), have not responded to treatment (refractory), or are growing, spreading, or getting worse (progressive). Lenalidomide may stop the growth of tumor cells by blocking blood flow to the tumor. It is not yet known whether low-dose lenalidomide is more or less effective than high-dose lenalidomide in treating patients with juvenile pilocytic astrocytomas or optic nerve pathway gliomas. - [Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme](/research/clinical-trials/cls-20146670) Rochester, MN; Scottsdale/Phoenix, trial studies how well temozolomide and veliparib work and compare them to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective with or without veliparib in treating glioblastoma multiforme. - [AKT Inhibitor MK2206, Combined with Bendamustine Hydrochloride, and Rituximab for Treating Patients who have Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma](/research/clinical-trials/cls-20340074) No Locations The purpose of this study is is to assess the side effects and best dose of akt inhibitor MK2206 when given together with bendamustine hydrochloride and rituximab, and to see how well they work in treating patients with treatment resistant chronic lymphocytic leukemia or small lymphocytic lymphoma. Akt inhibitor MK2206 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, ... - [A Safety and Efficacy Study of Domvanalimab + Zimberelimab Combination Therapy in Participants With Advanced Upper Gastrointestinal Tract Malignancies](/research/clinical-trials/cls-20536556) Scottsdale/Phoenix, AZ; Jacksonville, FL This Phase 2, open-label, parallel, 3-cohort, multicenter study will evaluate the safety and efficacy of various combinations of the anti-T-cell immunoglobulin and ITM domain (TIGIT) monoclonal 1 monoclonal antibody zimberelimab, and multiagent chemotherapy in the first--line setting, and of various combinations of domvanalimab, zimberelimab, the cluster of differentiation 73 (CD73) inhibitor quemliclustat, and chemotherapy in the second-line (2L) or greater setting in participants with locally advanced unresectable or metastatic gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma. - [A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas](/research/clinical-trials/cls-20147211) Jacksonville, FL; Rochester, MN The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas. - [A Study of the Combination of IMCgp100 with Durvalumab and/or Tremelimumab for Patients with Advanced Cutaneous Melanoma](/research/clinical-trials/cls-20258810) No Locations The purpose of this study is to characterize the safety, tolerability, effectiveness, biological activity, and drug/body interactions of IMCgp100, alone and in combination with durvalumab (MEDI4736) and/or tremelimumab for the treatment of patients who have advanced metastatic cutaneous melanoma. - [A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer](/research/clinical-trials/cls-20325993) Jacksonville, FL; Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to determine whether Nivolumab in combination with other therapies is more effective than Nivolumab in combination with Ipilimumab in treating patients/subjects with advanced gastric cancer. - [A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)](/research/clinical-trials/cls-20429229) Rochester, MN This is a randomized, double-blinded study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in patients with resectable Stage II, IIIA, or select IIIB nonsmall cell lung cancer (NSCLC) followed by open-label adjuvant atezolizumab or best supportive care and monitoring. - [A Study to Evaluate Effectiveness and Quality of Life Outcomes of Daratumumab in Relapsed/Refractory Multiple Myeloma Patients](/research/clinical-trials/cls-20531970) Rochester, MN The primary purpose of this study is to evaluate patient-reported health-related quality of life outcomes in subjects with Relapsed/Refractory Multiple Myeloma (RRMM) treated with daratumumab-based regimens in a real life setting. - [Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors](/research/clinical-trials/cls-20512718) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the effectiveness, safety, tolerability, PK, and pharmacodynamics of etigilimab in combination with nivolumab in subjects with locally advanced or metastatic solid tumors. - [ACP-196 in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies](/research/clinical-trials/cls-20147330) Rochester, MN; Jacksonville, FL The purpose of this study is to characterize the safety profile of acalabrutinib and pembrolizumab in subjects with hematologic malignancies. - [An Expanded Access Study of Iniparib Combined with Gemcitabine and Carboplatin for the Treatment of Breast Cancer](/research/clinical-trials/cls-20314154) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to offer pre-approval drug access of iniparib combined with gemcitabine and carboplatin, in order to provide potential clinical benefit to patients who have ER-, PR-, and HER2-negative metastatic breast cancer. - [A Study of (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Phase III, multicenter, open-label study is designed to evaluate the safety and efficacy of atezolizumab in combination with carboplatin + nab-paclitaxel compared with treatment with carboplatin + nab-paclitaxel in chemotherapy-naive participants with Stage IV non-squamous NSCLC. Participants will be randomized in a 2:1 ratio to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) or Arm B Radioimmunotherapy toTreat Recurrent or Refractory Medulloblastoma](/research/clinical-trials/cls-20525452) No Locations The purpose of this study is to assess 177Lu-DTPA-omburtamab, which is a radioactive labelling of a murine monoclonal antibody targeting B7-H3, to treat children and adolescents diagnosed with medullablastoma and with recurrent or refractory to frontline therapy. - [A Study Evaluating Pembrolizumab and Epacadostat in Treating Participants With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma](/research/clinical-trials/cls-20446035) Rochester, MN The purpose of this trial is to assess how well pembrolizumab and epacadostat work in treating participants with ovarian clear cell carcinoma that has come back, remains despite treatment, or is growing, spreading, or getting worse. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Epacadostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and epacadostat may work better in treating participants with ovarian clear cell carcinoma. - [A Phase 2/3 Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab in Subjects With Unresectable or Metastatic Melanoma](/research/clinical-trials/cls-20368635) Rochester, MN This is an adaptive clinical trial that includes a dose escalation phase followed by a randomized controlled Phase 3 trial. The purpose of the dose escalation phase is to establish the Phase 3 dose of indoximod in combination with pembrolizumab or nivolumab in subjects with unresectable or metastatic melanoma and evaluate PK. Subsequently the efficacy, safety and tolerability of indoximod plus pembrolizumab or nivolumab versus placebo plus pembrolizumab or nivolumab will be studied in subjects with unresectable or metastatic melanoma in the Phase 3 portion of the trial. - [A Study to Evaluate Firstline Pembrolizumab Alone or in Combination with Pemetrexed and Carboplatin in Induction/Maintenance or Postprogression in Treating Patients with Stage IV Non-squamous Non-small Cell Lung Cancer](/research/clinical-trials/cls-20477326) La Crosse, WI; Claire, WI; Mankato, MN; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression, is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as pemetrexed and carboplatin, work in different ways to stop the growth of ... - [Study of INO-5401 + INO-9012 in Combination Urothelial Carcinoma](/research/clinical-trials/cls-20445071) Phase I/IIA, open-label, multi-center trial is to evaluate the safety, immunogenicity and preliminary clinical efficacy of INO-5401 + INO-9012 delivered by intramuscular (IM) injection followed by electroporation (EP), in combination with atezolizumab in participants with locally advanced unresectable or metastatic/recurrent Urothelial Carcinoma (UCa). The trial population is divided into two cohorts: Cohort A: Participants with locally advanced unresectable or metastatic/recurrent UCa, who have confirmed disease progression during or following treatment with anti-Programmed Death receptor-1/Programmed Death receptor Ligand-1 (anti-PD-1/PD-L1) therapy; with advanced unresectable or metastatic/recurrent UCa, who are treatment na\u00efve and ineligible for ... - [Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.](/research/clinical-trials/cls-20145057) Jacksonville, FL; Rochester, MN This open label, randomised, controlled, multi-centre phase III study will assess the efficacy and safety of single agent olaparib vs standard of care based on physician's choice of capecitabine, vinorelbine or eribulin in metastatic breast cancer patients with gBRCA 1/2 mutations. - [Study of TBio-6517, Given Intratumorally, Alone or in Combination With in Solid Tumors](/research/clinical-trials/cls-20490405) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to determine the recommended Phase 2 dose (RP2D) of TBio-6517 when administered by direct injection into tumor(s) alone and when combined with pembrolizumab in patients with solid tumors (RIVAL-01). - [Study of Oraxol and Pembrolizumab in Subjects Solid Tumors](/research/clinical-trials/cls-20441567) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine dose escalation of paclitaxel administered as Oraxol in combination with Pembrolizumab, and dose expansion to assess the ORR per Response Evaluation Criteria in subjects with advanced Solid Tumors, Urothelial Carcinoma, Gastric cancer, Gastro-esophageal cancer, and Non-small cell lung - [Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients With Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer](/research/clinical-trials/cls-20541358) Rochester, MN The purpose of this study is to evaluate how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative breast cancer that is stage IV or is not able to be removed by surgery (unresectable) and has come back (recurrent). - [A Study of Cell, Serum, and Bone Marrow Bank for Patients receiving Chimeric Antigen Receptor T Cell Therapy for the Treatment of Cancer](/research/clinical-trials/cls-20306567) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to store blood, serum and bone marrow so that they can be used for laboratory studies that may contribute to finding the exact function of the CART cells or T-cell engager therapy such as bispecific and trispecific antibodies and the factors that may determine disease progression and treatment response. - [A Study of Gemcitabine-Cisplatin Chemotherapy plus Necitumumab in the First-Line Treatment of Patients with Lung Cancer](/research/clinical-trials/cls-20314525) Scottsdale/Phoenix, AZ The purpose of this study is to assess the safety and effectiveness of combined gemcitabine and cisplatin chemotherapy plus necitumumab for the treatment of patients who have late stage lung cancer. - [A Study of the Use of Cold Caps to Prevent Hair Loss in Chemotherapy Patients](/research/clinical-trials/cls-20509329) Rochester, MN The purpose of this study is to learn, in patients' own words, what cancer patients who are using a cold cap to prevent hair loss are experiencing. - [Effects of a Hospitality Initiative on Referral Patterns for Native American Cancer Patients in Maricopa County](/research/clinical-trials/cls-20530949) Scottsdale/Phoenix, AZ The purpose of this study is to interview patients and providers at Phoenix Indian Medical Center and Mayo Clinic Arizona to identify perceptions, experiences, and perceived factors influencing referrals and enrollment on clinical trials in the Department of Radiation Oncology at Mayo Clinic Arizona. The overall goal of this line of research is to enhance the hospitality, cultural responsiveness, and efficiency with which a leading cancer center can collaborate with a neighboring treatment hub for an important, underserved population within that cancer center's catchment area. American Indian and Alaska Native people experience higher rates of cancer ... - [Breast MR](/research/clinical-trials/cls-20533404) Rochester, MN The purpose of this study is to examine the capability of contrast enhanced breast PCD-CT in staging breast cancer within the breasts and regional nodes of human subjects. Developing and using a PCD-CT imaging technique and postprocessing algorithms, dedicated for breast cancer detection. - [Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults](/research/clinical-trials/cls-20528100) Rochester, MN This phase III trial compares the effect of usual treatment of chemotherapy and steroids and a tyrosine kinase inhibitor (TKI) to the a Bi-specific T-Cell Engager ('BiTE') that may interfere with the ability of cancer cells to grow and spread. The information gained from this study may help researchers determine if combination therapy with steroids, TKIs, and blinatumomab work better than the standard of care. - [A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk Rhabdomyosarcoma](/research/clinical-trials/cls-20522275) Rochester, MN This phase III trial compares the effect of vinorelbine with vincristine, dactinomycin, and cyclophosphamide (VAC) VAC followed by vinorelbine and cyclophosphamide for the treatment of high risk rhabdomyosarcoma. Chemotherapy drugs, such as vinorelbine, vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving vinorelbine and VAC may kill more tumor cells. Adding maintenance therapy (vinorelbine and cyclophosphamide) after VAC therapy, with or without vinorelbine, may help get rid of the cancer and/or ... - [Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors](/research/clinical-trials/cls-20147208) Scottsdale/Phoenix, AZ The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486. - [Panitumumab, Regorafenib, or TAS-102, in Jacksonville, FL The purpose of this study is to evaluate how well retreatment with panitumumab works compared to standard of care regorafenib or trifluridine and tipiracil hydrochloride (TAS-102) in treating patients with colorectal cancer that is: negative for RAS wild-type colorectal cancer and has spread to other places in the body, and/or cannot be removed by surgery, and is negative for resistance mutations in blood. Treatment with panitumumab may interfere with the ability of tumor cells to grow and spread. Some tumors need growth factors to keep growing. Growth factor antagonists, such as regorafenib, may interfere with the growth factor and stop the ... - [A Study of BBI608 Combined with Standard Chemotherapies in Adult Patients who have Pancreatic Cancer](/research/clinical-trials/cls-20238170) Scottsdale/Phoenix, AZ The purpose of this study is to assess the safety, tolerability, and best study dose of BBI608 when administered in combination with Gemcitabine and nab-Paclitaxel, mFOLFIRINOX, FOLFIRI, or with in who have pancreatic adenocarcinoma that has spread. - [CBT-1\u00ae in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin](/research/clinical-trials/cls-20425001) Jacksonville, FL This study evaluates the combination of CBT-1\u00ae and doxorubicin for the treatment of metastatic, unresectable sarcoma in patients who have progressed after treatment with 150mg/m2 or less of doxorubicin. Participants will receive CBT-1\u00ae on days 1-7 of each 21-day cycle, as well as doxorubicin on days 5 and 6. - [A Study of the Safety and Effectiveness of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unremoveable Malignant Pleural Mesothelioma](/research/clinical-trials/cls-20260175) Rochester, MN The purpose of this study is to evaluate the safety and effectiveness of amatuximab in combination with pemetrexed and cisplatin in subjects with unremovable malignant pleural mesothelioma, who have not received prior systemic therapy. - [A Study for Women who have Platinum Resistant Ovarian Cancer to Evaluate EC145 Combined with Rochester, MN purpose of this study is to compare the progression-free survival in women who have platinum-resistant ovarian cancer, who receive combination therapy with EC145 and pegylated liposomal doxorubicin (EC145+PLD) with those who receive PLD alone. - [A Study to Compare Trilaciclib versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer](/research/clinical-trials/cls-20515340) Rochester, MN This study aims to evaluate the impact of trilaciclib on myelopreservation and anti-tumor efficacy when administered prior to FOLFOXIRI/bevacizumab in patients with pMMR/MSS mCRC who have not received systemic therapy for metastatic disease. - [A Study for Subjects Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)](/research/clinical-trials/cls-20492348) Rochester, MN The purpose of this extension study is for subjects who participated in a previous Astex-sponsored clinical study of ASTX727 (including, but not limited to ASTX727-01, ASTX727-02, ASTX727-04). - [Ventricular Remodeling and Myocardial Deformation in Patients Undergoing Chemotherapy for Sarcomas](/research/clinical-trials/cls-20307515) Rochester, MN The aim of this study is to determine if there is subclinical systolic or diastolic myocardial mechanical dysfunction by 2D and 3D speckle tracking echocardiography derived strain and strain rate in this patient population at baseline, during and after chemotherapy. This could be an early marker of myocardial dysfunction in patients treated for sarcoma. - [A Study to Evaluate the Feasibility of Memantine in Reducing Cognitive Impairment in Pediatric Patients After Radiation Therapy for Central Nervous System Tumors](/research/clinical-trials/cls-20475817) Rochester, MN The purpose of this study is to evaluate the feasibility of twice daily memantine started before radiation therapy (RT) and continued one month after radiation therapy (RT), and to evaluate the feasibility of twice daily (BID) memantine started before RT and continued 3 and 6 months after RT. - [A Study of Lenalidomide Combined with a Standard Chemotherapy for Treating Patients with Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma](/research/clinical-trials/cls-20260203) Rochester, MN The purpose of this study is to assess the safety, effectiveness and strongest tolerated dose of lenalidomide when given together with a standard chemotherapy to treat patients who have newly diagnosed stage II-IV peripheral T-cell non-Hodgkin's lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and etoposide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide may stop the growth of peripheral T-cell non-Hodgkin's lymphoma by blocking the growth of new blood vessels necessary for cancer growth. Giving combination chemotherapy with ... - [Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia](/research/clinical-trials/cls-20436923) Rochester, MN This partially randomized phase III trial studies the side effects of inotuzumab ozogamicin and how well it works when given with frontline chemotherapy in treating patients with newly diagnosed B acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab ozogamicin, may block cancer growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin with chemotherapy may work better in treating young adults with B acute lymphoblastic leukemia. - [A Study of Parsaclisib in Combination With Ruxolitinib to Treat Subjects with Myelofibrosis](/research/clinical-trials/cls-20470096) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety, tolerability, and effectiveness of the combination of parsaclisib and ruxolitinib in subjects with myelofibrosis. - [Volasertib + in Patients With Acute Myeloid Leukemia (AML)](/research/clinical-trials/cls-20143772) Scottsdale/Phoenix, AZ Phase I Dose Escalation: To investigate the MTD, safety, efficacy and pharmacokinetics of volasertib in combination with decitabine in patients 65 years of age with newly diagnosed previously untreated AML, relapsed or refractory AML or high risk MDS, and considered ineligible for standard intensive therapy. Phase I MTD Extension: To collect additional data on safety, efficacy and pharmacokinetics and to confirm the Recommended Phase II Dose (RP2D), of volasertib in combination with decitabine in previously untreated patients with AML 65 years of age and considered ineligible for standard intensive therapy. Phase IIa: Efficacy of volasertib in combination with ... - [A Study to Assess the Safety and Preliminary Effectiveness of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)](/research/clinical-trials/cls-20477935) Rochester, MN The purpose of this study is to evaluate the safety and preliminary effectiveness of the human anti-CD19 antibody Tafasitamab, in addition to R-CHOP in adult patients with newly diagnosed, previously untreated Diffuse Large B-cell Lymphoma (DLBCL). - [Study of Azacitidine With With MDS or CMMoL](/research/clinical-trials/cls-20145332) Scottsdale/Phoenix, AZ; Jacksonville, FL This is a randomized double blind placebo controlled study of azacitidine with or without birinapant in subjects with higher risk Myelodysplastic syndrome, secondary MDS or myelomonocytic leukemia (CMMoL) who are na\u00efve, to azacitidine therapy. Pre-clinical and mechanistic studies support that azacitidine may modulate pathways that enable birinapant-mediated anti-tumor activity. 1-2 Study Risk Myelodysplastic Syndromes](/research/clinical-trials/cls-20475712) Jacksonville, FL; Rochester, MN The purpose of this study of various ASTX727 LD doses and schedules to assess safety, pharmacodynamics, pharmacokinetics, and hematologic response in subjects with International Prognostic Scoring System (IPSS) risk category of low-risk or Intermediate-1 Myelodysplastic Syndromes (MDS). This study will be conducted in two phases. In phase 1 subjects will be randomized into 3 cohorts in a 28-day cycles. Phase 2, 80 new subjects will be randomized in a 1:1 ratio into 2 doses/schedules. - Versus Bleomycin, for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors](/research/clinical-trials/cls-20154273) Rochester, MN The purpose of this study is to learn about the safety and effectiveness of two different drug combinations in patients who have intermediate- and poor-risk germ cell tumors (GCT). One combination of drugs, paclitaxel, ifosfamide and cisplatin (TIP), is experimental. The other combination of drugs, bleomycin, etoposide and cisplatin (BEP), is the standard of care treatment for intermediate- and poor-risk germ cell tumors. However, BEP does not cure every patient and therefore newer treatments are needed. - [Genetic Mutations and Environmental Exposure in Young Patients With Retinoblastoma and in Their Parents and Young Healthy Unrelated Volunteers](/research/clinical-trials/cls-20151616) No Locations This laboratory study is looking at genetic mutations and environmental exposure in young patients with retinoblastoma and in their parents and young healthy unrelated volunteers. Gathering information about gene mutations and environmental exposure may help doctors learn more about the causes of retinoblastoma in young patients. - [A Study of Niraparib Combined with Abiraterone Acetate and Prednisone Versus Abiraterone Prednisone to Treat Metastatic Prostate Cancer](/research/clinical-trials/cls-20511612) Scottsdale/Phoenix, AZ The objectives of this study are to determine if Niraparib, Abiraterone Acetate (AA), and Prednisone compared with AA and Prednisone in participants with deleterious germline or somatic Homologous Recombination Repair (HRR) gene-mutated mCSPC provides superior effectiveness in improving radiographic progression-free survival (rPFS), to assess the clinical benefit of niraparib, AA, and prednisone compared with AA and prednisone in participants with deleterious germline or somatic HRR gene-mutated mCSPC, to characterize the safety profile of niraparib, AA, and prednisone compared with AA and prednisone in participants with deleterious germline or somatic HRR gene-mutated mCSPC. - Refractory AML, MRD Positive AML or Higher Risk MDS](/research/clinical-trials/cls-20523796) Rochester, MN The purpose of this study is to determine the safety and best dose of PRGN-3006 T Cells to treat relapsed/refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome. - [A Study to Find the Recommended Dose for Further Research for VX-970 and Whole Brain Radiation Therapy to Treat Patients with Brain Metastases from Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20308939) Jacksonville, FL; Rochester, MN The purpose of this study is to assess the side effects and best dose of ATR kinase inhibitor VX-970 when given together with whole brain radiation therapy for the treatment of patients who have non-small cell lung cancer that has spread from the original (primary) tumor to the brain. VX-970 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving VX-970 together with radiation therapy may be a better treatment for non-small cell lung cancer. - [A Study to Evaluate Magnetic Resonance Spectroscopy Diagnosis and Follow-up of IDH-mutant Glioma](/research/clinical-trials/cls-20474098) Rochester, MN The purpose of this study is to develop an MRS-based measurement of 2-HG that is reliable, and to assess the reproducibility of the method(s) above on a cohort of patients with IDH mutant low grade gliomas. - [Spinal Cord Stimulation to Treat Chemotherapy-Induced Peripheral Neuropathy](/research/clinical-trials/cls-20530343) Rochester, MN The purpose of this study is to understand pain outcomes in patients with cancer who have Chemotherapy-Induced Peripheral Neuropathy (CIPN). - [A Study of Combination Radiation Therapy and Cisplatin with or without Triapine for Treating Patients with Newly Diagnosed Stage IB2, II, or IIIB-IVA Cervical Cancer or Stage II-IVA Vaginal Cancer](/research/clinical-trials/cls-20207995) Jacksonville, FL; Rochester, MN The purpose of this study is to see how well radiation therapy and cisplatin with triapine work in combination compared to the standard radiation therapy and cisplatin alone to treat patients with newly diagnosed stage IB2, II, or IIIB-IVA cervical cancer or stage II-IVA vaginal cancer. Radiation therapy uses high energy protons to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Triapine may stop the growth of tumor cells ... - [Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer](/research/clinical-trials/cls-20491134) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate how OSI-906 compares to Topotecan in trying to slow down the growth and/or progression of the tumors of participants with relapsed or recurrent Small Cell Lung Cancer. This study also plans to find out what effects, good or bad (side effects), OSI-906 has on participants and or Small Cell Lung Cancer. The study will also investigate if some proteins measured in the blood or tumor and some imaging features obtained from computed tomography (CT) scans can help predict whether OSI-906 or topotecan will be effective against Small Cell Lung Cancer. - [Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations](/research/clinical-trials/cls-20273193) Rochester, MN This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Diffuse Large B-Cell Lymphoma (DLBCL). - [A Study to Determine Recommended Dose, Regimen and Evaluate the Safety and Preliminary Effectiveness of CC-92480 in Combination With Standard Treatments in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)](/research/clinical-trials/cls-20477442) Rochester, MN The purpose of this study is to determine the maximum tolerated dose (MTD) / recommended phase 2 dose (RP2D), and to evaluate the safety and preliminary effectiveness of CC-92480 in combination with standard treatments. - [Phase II Study to Assess AFM13 in Patients With T-cell Lymphoma or Transformed Mycosis Fungoides](/research/clinical-trials/cls-20490429) Rochester, MN The purpose of this study is to learn about the effects of a research medicine called AFM13 and to see how well AFM13 is tolerated. - [Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies](/research/clinical-trials/cls-20531310) Jacksonville, FL The purpose of the study is to the evaluate safety, tolerability, pharmacokinetics (PK), and effectiveness of AZD0466 as monotherapy in participants with advanced haematological malignancies, and also to assess drug-drug interaction (DDI) potential between AZD0466 and the azole antifungal voriconazole. - [Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body](/research/clinical-trials/cls-20486007) Rochester, MN; Jacksonville, FL The purpose of this study is to describe, under real-world conditions, the safety and effectiveness of larotrectinib in patients with locally advanced or metastaticTRK fusion cancer for whom a decision to treat with larotrectinib has been made before enrollment. - [Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence](/research/clinical-trials/cls-20508019) Rochester, MN The main purpose of this study is to compare the effectiveness of bempegaldesleukin plus nivolumab versus nivolumab in patients with completely resected Stage IIIA/B/C/D, or Stage IV cutaneous melanoma who are at high risk for recurrence. - [A Study to Evaluate Mutanome-directed Immunotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck](/research/clinical-trials/cls-20509075) Jacksonville, FL The purpose of this study is to evaluate the safety and tolerability of multiple subcutaneous injections of a mutanome-directed active in patients with newly-diagnosed, locoregionally advanced, HPV-negative Squamous Cell Carcinoma of the Head and Neck (SCCHN) initiated at completion of primary treatment (Arm A) or at the time of recurrence (Arm B) - [A Study to Evaluate the Epidemiology of Estrogen Genotoxicity in Breast Cancer](/research/clinical-trials/cls-20506018) Rochester, MN The purpose of this study is to recruit 2000 incident cases of primary breast cancer in order to perform laboratory assays to measure frequencies of genetic polymorphisms for genes that encode enzymes involved in candidate gene pathways, including: estrogen and catecholestrogen formation, bioactivation and inactivation, cellular proliferation and apoptosis, nuclear factor kappa-beta; to compare genotype frequencies for polymorphisms of genes in breast cancer cases and controls, and to evaluate possible interactions among common polymorphisms in candidate genes. - [Phase Ib/II of TG4001 and Jacksonville, FL; Rochester, MN The study will consist of two parts. The purpose of Phase Ib is to evaluate the safety and tolerability of the combination of TG4001 plus avelumab in patients with recurrent or metastatic HPV-16 positive advanced malignancies. The purpose of Phase II part 1 is to evaluate the effectiveness of TG4001 combined to avelumab in terms of Overall Response Rate (ORR) by using RECIST 1.1 in patients with recurrent or metastatic (R/M) HPV-16 positive advanced malignancies including oropharyngeal SCCHN. The purpose of Phase II part 2 is to compare the Progression-Free Survival (PFS) of TG4001 in combination with avelumab vs avelumab alone in patients with recurrent or metastatic ... - [Prehabilitation](/research/clinical-trials/cls-20528668) Rochester, MN Physical activity plays an important role in reducing the adverse effects of cancer treatment. There are few studies using prehabilitation to improve peri-operative outcomes in patients undergoing cancer surgery. This study will pilot a program of structured activity for women undergoing neoadjuvant chemotherapy with the intent to improve their physical state prior to surgical intervention and thus improve outcomes. It has been shown that patients with advanced ovarian cancer may suffer from high levels of cancer -specific distress, depression and anxiety. It has also been proposed that psychological resilience can favorably affect psychological and treatment-related outcomes in cancer ... - [Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, Adenocarcinoma](/research/clinical-trials/cls-20391800) Scottsdale/Phoenix, AZ study was conducted to assess the safety and tolerability of (1) polyethylene glycol (PEG) PEGylated Recombinant Human Hyaluronidase (PEGPH20) in combination with cisplatin (CIS) and gemcitabine (GEM) (PEGCISGEM), and (2) PEGPH20 in combination with CIS, GEM, and atezolizumab (PEGCISGEMATEZO). - [A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)](/research/clinical-trials/cls-20462460) Scottsdale/Phoenix, AZ The purpose of this study is to assess the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of major pathological response. - [A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection](/research/clinical-trials/cls-20538059) Jacksonville, FL The purpose of this study is to compare the drug levels of nivolumab administered subcutaneously versus intravenous administration in participants with melanoma following complete resection. - [Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer](/research/clinical-trials/cls-20306566) Rochester, MN; Scottsdale/Phoenix, AZ This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy. - [A Study to Continue A Long Term Follow-Up of Patients Given Doxorubicin-Cyclophosphamide Therapy for Breast Cancer](/research/clinical-trials/cls-20318075) La Crosse, WI The purpose of this study is to continue with a long term follow-up of previously enrolled people treated with doxorubicin-cyclophosphamid followed by paclitaxel or docetaxel for axillary node-positive or high risk node-negative breast cancer. - [Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer](/research/clinical-trials/cls-20538969) La Crosse, WI The purpose of this research is to determine if previously adding a medication by the name of bevacizumab to the current standard chemotherapy of cancer-reducing medications, namely doxorubicin, cyclophosphamide and paclitaxel, reduces the risk of recurrence (called disease-free survival) compared to standard chemotherapy alone. - [A Study to Test Adding Pembrolizumab to Olaparib Alone as Therapy for Patients with Pancreatic Cancer That Has Spread with Inherited BRCA Mutations](/research/clinical-trials/cls-20522522) Eau Claire, WI; La Crosse, WI; Rochester, MN The primary purpose of this study is to evaluate the progression free survival (PFS) of advanced pancreatic cancer patients with germline BRCA1 or BRCA2 mutations treated with olaparib + pembrolizumab compared to olaparib alone as maintenance therapy. - [A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) With or Without Addition of Unresectable Biliary Tract Cancers](/research/clinical-trials/cls-20531053) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to assess the response rate (ORR) of patients with unresectable, pre-treated biliary cancers treated with the combination of atezolizumab and CDX-1127 (varlilumab) with or without cobimetinib, and to assess the progression free survival (PFS) of patients with unresectable, pre-treated biliary cancers treated with the combination of atezolizumab and CDX-1127 (varlilumab) with or without cobimetinib. - [A Study to Explore the Effects of the Measles Virus on Tumor Immunity](/research/clinical-trials/cls-20317230) Rochester, MN The purpose of this study is to explore the effects of the measles virus on tumor immunity in a laboratory-based study. - [Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients](/research/clinical-trials/cls-20358110) Rochester, MN The purpose of this study is to test the effectiveness and tolerability of the combination of Nivolumab and Ipilimumab compared to Pemetrexed and Cisplatin or Carboplatin in patients Advanced Solid Tumors](/research/clinical-trials/cls-20469368) Scottsdale/Phoenix, AZ; Rochester, MN The purpose for this study is to find out if MEDI5395 and durvalumab will work and be safe for the treatment of solid tumors. - [Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Lung Cancer](/research/clinical-trials/cls-20416405) Scottsdale/Phoenix, AZ; Jacksonville, FL This phase I/II trial studies the best dose and side effects of anetumab ravtansine when given together with atezolizumab and how well they work in treating participants with non-small cell lung cancer that has spread to other places in the body. Monoclonal antibodies, such as anetumab ravtansine and atezolizumab, may interfere with the ability of tumor cells to grow and spread. - [VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer](/research/clinical-trials/cls-20435271) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in combination with a fixed dose of avelumab in patients with advanced non-small cell lung cancer. The dose escalation portion of the study will determine the maximum tolerated dose (MTD) of VX15/2503 administered in combination with avelumab. - [A Study to Evaluate the Safety, Tolerability, and Determine the Optimal Dose for the Expansion Cohorts of VSV-IFN-NIS in Combination with Pembrolizumab in Patients with Refractory Solid Tumors](/research/clinical-trials/cls-20454964) Rochester, MN The purpose of this study is to determine the safety of VSV-IFN-NIS in combination with pembrolizumab, followed by expansion to examine effectiveness of combination therapy in patients with refractory Non-Small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC). - [A Study to Evaluate Pembrolizumab Combined with Intensive Chemotherapy to Treat Patients with Acute Myeloid Leukemia](/research/clinical-trials/cls-20514157) Jacksonville, FL The purpose of this study is to determine how well cytarabine and idarubicin or daunorubicin with or without pembrolizumab work in treating patients with newly-diagnosed acute myeloid leukemia. Drugs used in chemotherapy, such as cytarabine, idarubicin, and daunorubicin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving induction chemotherapy with pembrolizumab may work ... AZ This is a phase 1b study evaluating a combination of PEGPH20 and pembrolizumab in hyaluronan-high (HA-high) subjects with relapsed/refractory HA-high subjects with relapsed/refractory gastric adenocarcinoma. - [Role of Immunity in Efficacy of Chemotherapy Plus Trastuzumab](/research/clinical-trials/cls-20314935) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate T cell and antibody immunity in patients with HER2+ breast cancer who will receive trastuzumab with standard chemotherapy in order to address whether the immunity is associated with the patient's response to treatment. - [Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer](/research/clinical-trials/cls-20193944) Rochester, MN This partially randomized phase Ib/II trial studies the side effects and best dose of taselisib when given together with enzalutamide and to see how well they work in treating patients with androgen receptor positive triple-negative breast cancer that has spread to other places in the body. Taselisib is a PI3K inhibitor. The PI3K pathway is involved is cancer growth. Androgen may cause the growth of tumor cells. Enzalutamide may stop the growth of tumor cells by blocking the androgen receptor from working. Giving taselisib with enzalutamide may be a better treatment for patients with breast cancer. - [A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors](/research/clinical-trials/cls-20132083) Scottsdale/Phoenix, AZ This global, multicenter, open-label study will evaluate the safety and tolerability of atezolizumab in combination with other immune-modulating therapies in the treatment of selected advanced or metastatic malignancies. The atezolizumab plus ipilimumab arm (Arm A) will focus primarily on participants with advanced or metastatic non-small cell lung cancer (NSCLC). The atezolizumab plus interferon arm (Arm B), plus pegylated interferon (PEGinterferon C), and atezolizumab plus PEG-interferon Alfa-2a plus bevacizumab (Arm D) will enroll participants with advanced or metastatic renal cell carcinoma (RCC), metastatic NSCLC and melanoma. The atezolizumab plus obinutuzumab) (Arm E) will enroll participants with recurrent ... - [Study Evaluating the Antitumor Activity and Safety of Niraparib as Neoadjuvant Treatment](/research/clinical-trials/cls-20429230) Rochester, MN This is an open-label, single-arm pilot study evaluating the antitumor activity and safety of niraparib as neoadjuvant therapy in patients with HER2 negative and BRCAmut localized breast cancer (primary tumor >1 cm). - [Trial Using Keytruda as Initial Therapy in the Treatment of Advanced Mycosis Fungoides](/research/clinical-trials/cls-20438796) Jacksonville, FL The purpose of this trial is to evaluate the antitumor activity of Pembrolizumab in patients with advanced mycosis fungoides (MF) as initial systemic therapy. - [Long Term Follow-Up of Subjects Exposed to GSK3377794](/research/clinical-trials/cls-20502723) Jacksonville, FL; Rochester, MN The purpose of this long-term, followup study is to evaluate subjects who have, during the interventional study, received GSK3377794 generated by a process that utilizes lentiviral vectors. Subjects enrolled in the interventional studies who complete the interventional study or who withdraw from the interventional study will enter this LTFU study and will be followed for up to 15 years from the infusion of genetically modified T lymphocytes. Subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. - [MC200404, Safety and Immunogenicity of PolyPEPI1018 Vaccine in the Treatment of Late-stage Metastatic Colorectal Cancer](/research/clinical-trials/cls-20522054) Rochester, MN The purpose of this study is to investigate the combination of standard of care treatment of TAS-102 and the experimental peptide vaccine, PolyPEPI1018, to learn more about the side effects of combination and to collect information on how cancer responds to this combination. PolyPEPI1018 peptide vaccine is a mixture of 6 synthetic peptides and the adjuvant Montanide and is used to immunize against proteins present on the surface of tumor cells. In a high number of patients, this mixture will activate the body's immune cells, called T cells. T cells fight infections and can also kill cancer cells. Participants will receive TAS-102 and PolyPEPI1018 which ... - [A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with AZ; WI; Jacksonville, FL; La Crosse, WI The purpose of this study is to evaluate the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioblastoma that has come back (recurrent) and carries a high number of mutations. Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations may respond well to immunotherapy. Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving ipilimumab and nivolumab may lower the chance of recurrent glioblastoma ... - [Neoadjuvant Pembrolizumab](/research/clinical-trials/cls-20409727) Rochester, MN This multi-institutional, phase 2 clinical trial is studying two doses of pembrolizumab administered prior to surgery (neoadjuvant therapy) and 4 doses administered after surgery (adjuvant therapy) for stage IB, II or IIIA non-small cell lung cancer. Pembrolizumab is a type of immunotherapy that may enhance the ability of the immune system to fight off cancer. The study will investigate the effects of pembrolizumab on the immune system and how certain immune cells, called TILs (tumor infiltrating lymphocytes), respond to pembrolizumab. Previous studies suggest that pembrolizumab could alter the immune cells in a way that the the immune cells identify cancer ... - [Expanded Access Program With Nivolumab (BMS-936558) in AZ The purpose of this study is to provide treatment with Nivolumab in combination with Ipilimumab and to assess the safety and tolerability of this combination in subjects who are anti-cytotoxic T lymphocyte associated antigen (CTLA)-4 treatment-naive and have - [Therapeutic Drug Monitoring of Pembrolizumab and Nivolumab to Determine Dosages for Cancer Treatment](/research/clinical-trials/cls-20317682) Rochester, MN Drug monitoring of Pembrolizumaband Nivolumab for determining the pharmacokinetic (PK) profile of these medications and to provide information for dose adjustments to guide physicians in the future. - [Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC).](/research/clinical-trials/cls-20194579) Scottsdale/Phoenix, AZ This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination therapy and MEDI4736 monotherapy versus platinum-based SoC chemotherapy in the first-line treatment of patients with epidermal growth factor receptor (EGFR) and anaplastic lymphoma locally advanced or metastatic NSCLC - [Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer](/research/clinical-trials/cls-20202196) Rochester, MN This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement (recurrent) and/or has spread to other parts of the body (metastatic). Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. - [Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma](/research/clinical-trials/cls-20346007) Rochester, MN The trial is a single arm phase II clinical trial of Ipilimumab and Nivolumab in patients with mg/kg) and Nivolumab (3 mg/kg) will be administered day 1 of a 21-day cycle in cycles 1-4 and then nivolumab 480 mg will be administered day 1 of a 28-day cycle for cycles 5-15 or until disease recurrence. - [Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer](/research/clinical-trials/cls-20202196) Rochester, MN This phase II trial studies how well nivolumab works in treating patients with nasopharyngeal cancer that has returned after a period of improvement (recurrent) and/or has spread to other parts of the body (metastatic). Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells. - [A Study to Evaluate Preoperative Oral Microbiota-Based Investigational New Drug to Target Immune Response in Patients with Operable Stage I-III Breast Cancer](/research/clinical-trials/cls-20477441) Jacksonville, FL The primary purposes of this trial are to determine the safety and tolerability of RBX7455 given for at least 2 weeks and not more than 4 weeks prior to surgery, and to evaluate intratumoral immune system resonse, including TILs, CD4, and CD8 T cells, in operable breast cancer patients. - [Screening for High Frequency Malignant Disease](/research/clinical-trials/cls-20534182) Rochester, MN; Eau Claire, WI; La Crosse, WI The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations. - [An Investigational Immuno-therapy Study to Assess the Safety, Tolerability and Effectiveness of Anti-LAG-3 With and Without Anti-PD-1 in the Treatment of Solid Tumors](/research/clinical-trials/cls-20421996) Rochester, MN The purpose of the study is to assess the safety, tolerability and effectiveness of experimental medication BMS-986016 administered alone and in combination with nivolumab in patients with solid tumors that have spread and/or cannot be removed by surgery. The following tumor types are included in this study: Non-Small Cell Lung Cancer (NSCLC), gastric cancer, hepatocellular carcinoma, renal cell carcinoma, bladder cancer, squamous cell carcinoma of the head and neck, and melanoma, that have NOT previously been treated with immunotherapy. NSCLC and melanoma that HAVE previously been treated with immunotherapy. - [Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)](/research/clinical-trials/cls-20540869) Rochester, MN The purpose of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1). - [Melanoma Relatlimab Nivolumab](/research/clinical-trials/cls-20438451) Jacksonville, FL; Rochester, MN The purpose of this study is to determine whether Nivolumab in combination with Relatlimab is more effective than Nivolumab by itself in treating unresectable Melanoma or Melanoma that has spread - [A Study of Combination Chemotherapy for Treating Women with Stage II or Stage IIIA Breast Cancer that has Spread to the Lymph Nodes](/research/clinical-trials/cls-20314727) Eau Claire, WI The purpose of this study is to compare the effectiveness of two different combinations of chemotherapy in treating women who have stage II or stage IIIA breast cancer that has spread to the lymph nodes. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer. - [Cytotoxic Activity of Lenalidomide in Combination with the Bispecific CD30/CD16a Therapeutic Monoclonal Antibody, AFM13](/research/clinical-trials/cls-20493365) Jacksonville, FL The purpose of this study is to determine whether lenalidomide enhances the activation potential of NK cells derived from Hodgkin's lymphoma patients. The study also aims to determine if lenalidomide treated NK cells are more efficient in killing CD30+ tumor cells (cancer cell lines) in combination with an investigational agent (AFM13, CD30/CD16a mAb, Affimed Therapeutics, Germany), tumor cell and CD16a+ NK cells. - [A Study a Personalized Neoantigen Cancer Vaccine](/research/clinical-trials/cls-20467519) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to evaluate the safety, dose, immunogenicity and early clinical activity of GRT-C901 and GRT-R902, a personalized neoantigen cancer vaccine, in combination with nivolumab and ipilimumab, in patients with metastatic non-small cell and metastatic urothelial cancer. - [Dose Escalation and Expansion Study of GSK525762 in Combination With Fulvestrant in Subjects With Estrogen Receptor (ER+) Breast Cancer](/research/clinical-trials/cls-20398665) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This is a combination Phase I and Phase II study, with an aim to evaluate the combination of GSK525762 and fulvestrant in women with advanced or metastatic ER+ breast cancer, who have disease that has progressed after prior treatment with at least one line of endocrine therapy. The objectives of the study are to first identify, in open-label single-arm Phase I, a recommended Phase II dose of GSK525762 that may be combined safely with fulvestrant. Phase I will follow a modified toxicity probability interval (mTPI) design, and a sentinel group will be evaluated first for dose-limiting toxicity and further expanded ... - [Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT)](/research/clinical-trials/cls-20209639) Rochester, MN The purpose of this research study is to see if Atorvastatin(Lipitor) 40 mg by mouth daily decreases the chance of developing heart problems in women who are receiving anthracycline-based chemotherapy for breast cancer. - [Evaluation of CRS-207 With Pembrolizumab in Previously Treated MPM](/research/clinical-trials/cls-20357890) Rochester, MN The purpose of this study is to evaluate whether CRS-207 with pembrolizumab is safe and effective in adults with MPM who have failed prior anti-cancer therapy. - [Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Scottsdale/Phoenix, AZ; Rochester, MN This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with myelodysplastic syndrome after treatment with hypomethylating agents - [A Study to Evaluate the Effectiveness and Safety of bb2121 in Subjects with Relapsed and Refractory Multiple Myeloma and in Subjects with Clinical High-Risk Multiple Myeloma](/research/clinical-trials/cls-20453738) Scottsdale/Phoenix, AZ The purpose of this study is to determine the effectiveness and safety of bb2121 in subjects with relapsed and refractory MM (Cohort 1) and in subjects with HR MM having progressed within one year of initial treatment (Cohort 2). Approximately 122 subjects will be enrolled into one of two cohorts. Cohort 1 will enroll approximately 73 RRMM subjects with 3 prior anti-myeloma treatment regimens. Cohort 2 will enroll approximately 49 MM subjects with 1 prior anti-myeloma treatment regimen and HR disease defined as Stage III by the Revised International Staging System (R-ISS) and early relapse. The cohorts will start in ... - [A Study Evaluating the Effectiveness and Safety of Axicabtagene Ciloleucel in Subjects with High-Risk Large B-Cell Lymphoma](/research/clinical-trials/cls-20449462) Rochester, MN The purpose of this study is to to estimate the effectiveness of axicabtagene ciloleucel, as measured by complete response (CR) rate, in subjects with high-risk large B-cell lymphoma. - [A Study to Evaluate the Effects of Exercise on Fatigue in Thyroid Cancer Survivors](/research/clinical-trials/cls-20482101) Rochester, MN The purpose of this study is to determine whether an exercise program reduces fatigue and improves physical activity in thyroid cancer patients, and to determine the effect of a home-based program compared to a center- based program. - [Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)](/research/clinical-trials/cls-20127205) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects with triple negative metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer. - [Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma](/research/clinical-trials/cls-20312413) Rochester, MN; Scottsdale/Phoenix, AZ; Jacksonville, FL This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells. - [A Study of Targeted Agents With Atezolizumab for Patients With Recurrent or Persistent Endometrial Cancer](/research/clinical-trials/cls-20536766) Rochester, MN The purpose of this study is to evaluate the effectiveness and safety of targeted agents plus cancer immune checkpoint therapy with atezolizumab for patients with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening with homogeneous basic eligibility criteria in order to direct study subjects into biomarker-matched study cohorts consisting of testing targeted agents with atezolizumab. - [A Study Evaluating KTE-X19 in Adult Subjects With B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)](/research/clinical-trials/cls-20306561) Rochester, MN This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell in relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL). - [Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck](/research/clinical-trials/cls-20150027) Rochester, MN Primary Objective: To assess the efficacy of MEDI4736 monotherapy in terms of ORR - [An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma](/research/clinical-trials/cls-20323057) Rochester, MN The purpose of this study is to determine whether an investigational immunotherapy Nivolumab, when combined with Ipilimumab, is more effective than Nivolumab by itself, in delaying the return of cancer in patients who have had a complete surgical removal of stage IIIb/c/d or stage IV Melanoma - [Study of CG0070 Given in Combination With Pembrolizumab, in Non Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin](/research/clinical-trials/cls-20508002) Rochester, MN The primary purpose of this study is to evaluate the activity of intravesical administration of CG0070 and intravenous administration of Pembrolizumab in patients with tissue pathology-confirmed non-muscular invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin (BCG) unresponsive disease with carcinoma in situ (CIS) with or without Ta/T1 papillary disease. - [Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production](/research/clinical-trials/cls-20529510) Rochester, MN The purpose of this study is to investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for patients with Adrenocortical Carcinoma with Excess Glucocorticoid Production. - [Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes](/research/clinical-trials/cls-20154140) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy in treating women who have stage II or stage IIIA breast cancer that has spread to the lymph nodes. - [A Study of BMS-813160 in Combination with Chemotherapy or Nivolumab in Patients with Advanced Solid Tumors BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors](/research/clinical-trials/cls-20440976) Scottsdale/Phoenix, AZ; Rochester, MN This study will evaluate the safety profile, tolerability, PK, PD, and preliminary efficacy of BMS-813160 in combination with either chemotherapy or nivolumab in participants with metastatic colorectal and pancreatic cancers. of Intransit Melanoma](/research/clinical-trials/cls-20531108) Jacksonville, FL; Rochester, MN The purpose of this phase trial is to identify the best dose of STI-3031 that can be administered through the DoseConnect device in treating patients with melanoma that is visibly metastasizing (spreading to other parts of the body. This condition is referred to as \"in-transit metastases\" or \"ITM.\" Immunotherapy with STI-3031 may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. - [A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer](/research/clinical-trials/cls-20536359) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to learn about the effects of three study medicines (encorafenib, cetuximab, and pembrolizumab) given together for the treatment of colorectal cancer that is metastatic (spread to other parts of the body), has the condition of genetic hypermutability (tendency to mutation) or impaired DNA mismatch repair (MMR), has a certain type of abnormal gene called \"BRAF,\" and has not received prior treatment. All participants in this study will receive pembrolizumab at the study clinic as an intravenous (IV) infusion (given directly into a vein) at the study clinic. In addition, half of the participants will take ... - [Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)](/research/clinical-trials/cls-20111763) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to determine whether Nivolumab is effective in the treatment of DLBCL in patients that have failed or are ineligible for ASCT - [A Study of Copanlisib and Nivolumab in Treating Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma](/research/clinical-trials/cls-20455120) Rochester, MN The purpose of this study is to evaluate how well copanlisib and nivolumab work in treating participants with diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma that has come back or does not responded to the treatment. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving copanlisib and nivolumab may work better in treating participants with diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma. - [A Study to Compare Elacestrant vs. Standard of Care for the Treatment of Patients with ER+/HER2- Advanced Breast Cancer](/research/clinical-trials/cls-20467632) Rochester, MN The purpose of this study is to compare the effectiveness and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhibitor in combination with fulvestrant or an aromatase inhibitor (AI) . - [Z-Endoxifen Hydrochloride in Treating Patients or Recurrent Estrogen Receptor-Positive Breast Cancer](/research/clinical-trials/cls-20116796) Scottsdale/Phoenix, AZ; Rochester, MN This phase I trial studies the side effects and the best dose of Z-endoxifen hydrochloride in treating patients with estrogen receptor-positive (ER+) breast cancer that has spread to other places in the body (metastatic) or has come back at or near the same place as the original tumor (locally recurrent). Estrogen can cause the growth of breast cancer cells. Hormone therapy using Z-endoxifen hydrochloride may fight breast cancer by blocking the use of estrogen by tumor cells. - [Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)](/research/clinical-trials/cls-20317023) Rochester, MN The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in patients with metastatic castrate resistant prostate cancer (mCRPC). There will be three cohorts in this study with 70 participants enrolled in each cohort: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, and Cohort C will receive pembrolizumab + enzalutamide. Outcome measures will be assessed individually for each cohort. - [Genetic Analysis in Blood and Tumor Samples From Patients With Advanced or Metastatic Estrogen Receptor Positive and HER2 Negative Breast Endocrine Therapy](/research/clinical-trials/cls-20366155) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This research trial studies genetic profiles in blood and tumor samples from patients with estrogen receptor positive and HER2 negative breast cancer that has spread to other places in the body who are receiving palbociclib and endocrine therapy. Examine the genetic changes associated with the cancer and comparing the genetic material from the cancer tissue with the genetic material found in the blood may help doctors to develop customized treatment for breast cancer. - [Combination Chemotherapy and Trastuzumab in Treating Women With Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel, carboplatin, and trastuzumab in treating women who have metastatic breast cancer that overexpresses HER2. - [An Expansion Study to Evaluate Dose Escalation, Safety and Tolerability of SAR444881 in Patients with Advanced Solid Tumors](/research/clinical-trials/cls-20512980) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate the safety, tolerability, and preliminary anti-tumor activity of SAR444881 alone and in combination with pembrolizumab or with cetuximab. The study will enroll advanced cancer patients with unresectable or metastatic disease who are refractory to or are not candidates for standard approved therapy and will be comprised of two parts - an initial \"3 + 3\" dose escalation phase with (BND-22 in combination with cetuximab) followed by a dose expansion phase (part 2) - [Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Breast Cancer](/research/clinical-trials/cls-20511487) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This study will evaluate the efficacy, safety and tolerability of trastuzumab deruxtecan compared with investigator's choice chemotherapy in human epidermal growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting. - [Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck](/research/clinical-trials/cls-20314945) Rochester, MN A study in patients with metastatic or recurrent squamous cell cancer of the head and neck to evaluate the effectiveness of Nivolumab plus Ipilumumab vs. Nivolumab alone (CheckMate 714) - [A Study to Understand the Connections of Genetic Variation and Mammographic Density within the Mountain Park Health Center Mammography Study](/research/clinical-trials/cls-20310393) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to understand the causes of breast cancer, in particular the connection between genetic variations and breast density or how tissue is distributed on a mammogram. - [A Study to Evaluate Adjuvant Ado-Trastuzumab Emtansine (T-DM1) in HER2 Positive Breast Cancer](/research/clinical-trials/cls-20453422) Rochester, MN The purpose of this study is to evaluate an investigational drug as a possible treatment for breast cancer that is positive for the protein Human Epidermal Growth Factor Receptor 2, also known as HER2-positive breast cancer. The drug involved in this study is: -ado-trastuzumab emtansine (T-DM1) - [Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma](/research/clinical-trials/cls-20134468) Rochester, MN To evaluate the preliminary efficacy of the established dose of indoximod in combination with immune checkpoint inhibition as measured by the best overall response rate (ORR) (complete response (CR) + partial response (PR))across both standard of care agents administered sequentially in patients with unresectable stage III or stage IV melanoma - [Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer](/research/clinical-trials/cls-20192077) Rochester, MN This is a randomized, open-label, multi-center, 3-arm, global Phase III study to determine the efficacy and safety of MEDI4736 + tremelimumab combination or MEDI4736 monotherapy versus SoC (EXTREME regimen) in the treatment of patients with SCCHN who have not received prior systemic chemotherapy for recurrent or metastatic disease. - [An Investigational Immuno-therapy Study of Nivolumab, Compared to Placebo, in Patients With Bladder or Upper Urinary Tract Cancer, Following Surgery to Remove the Cancer](/research/clinical-trials/cls-20203303) Rochester, MN The purpose of this study is to determine the effectiveness and safety of Nivolumab compared to placebo in participants who have undergone radical surgery for invasive urothelial cancer. - [A Study of Durvalumab Plus CV301 Colorectal or Pancreatic Adenocarcinoma](/research/clinical-trials/cls-20467312) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety and clinical activity of the combination of durvalumab with CV301 in combination with maintenance chemotherapy for patients with metastatic colorectal or pancreatic cancer whose disease is stable on, or responding to 1st line therapy for metastatic disease. - [A Study to Evaluate the Effectiveness of M7824 Monotherapy in Locally Advanced or FL; Rochester, MN purpose of this study is to evaluate M7824 monotherapy in participants with advanced or metastatic biliary tract cancer (BTC) who failed or were intolerant to first-line (1L) chemotherapy. - [A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer](/research/clinical-trials/cls-20443508) Scottsdale/Phoenix, AZ The primary objective of the study is to compare the objective response rate (ORR) of high dose cemiplimab (HDREGN2810) and standard dose cemiplimab plus ipilimumab combination therapy (SDREGN2810/ipi) to the ORR of standard dose cemiplimab (SDREGN2810) in the second-line treatment of patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC), in patients whose tumors express programmed cell death ligand 1 (PD-L1) in <50% of tumor cells. - [Trial of Measles Virotherapy in Combination With Nivolumab in Patients With Metastatic Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20318097) Rochester, MN This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with nivolumab in patients with recurrent and metastatic (NSCLC). - [Veliparib with or without Carboplatin in Treating Patients with Stage III or Stage IV Breast Cancer](/research/clinical-trials/cls-20116509) Rochester, MN; Scottsdale/Phoenix, AZ; Jacksonville, FL This phase II trial is studying giving veliparib together with carboplatin to see how well they work compared to veliparib alone in treating patients with stage III or stage IV breast cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether veliparib is more effective with or without carboplatin in treating breast cancer. - [A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies](/research/clinical-trials/cls-20490402) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments. This study will evaluate the safety and effects of the treatment. - [A Study of the Combination of ACP-196 and Pembrolizumab in with Platinum-Refractory Metastatic Bladder Cancer](/research/clinical-trials/cls-20155249) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate the effect of combining ACP-196 and Pembrolizumab in subjects with platinum resistant metastatic bladder cancer. - [Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes](/research/clinical-trials/cls-20154105) La Crosse, WI RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two different regimens of combination chemotherapy in treating women who have stage II or stage IIIA breast cancer that has spread to the lymph nodes. - [Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer](/research/clinical-trials/cls-20325802) Rochester, MN In pancreatic cancer, targeting the tumor microenvironment has become a promising therapeutic strategy. Focal adhesion kinase (FAK) pathway activation is essential for promoting a fibrotic and inflammatory tumor microenvironment, and FAK inhibitors have demonstrated reasonable anti-tumor activity in the preclinical setting. Furthermore, a maximal synergetic effect was achieved when a FAK inhibitor was given in combination with a PD-1 antagonist and chemotherapy in multiple pancreas tumor animal models. This supports the concept of using FAK inhibitors to reduce stromal fibrosis during checkpoint immunotherapeutic treatment. Therefore, these robust preclinical findings will be tested in the proposed phase I trial. - [Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008)](/research/clinical-trials/cls-20538368) Jacksonville, FL; Rochester, MN Randomized, Double-Blind, Phase 3 Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants with Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) - [A Study of APR-246 and Pembrolizumab in Patients with Solid Tumor Malignancies](/research/clinical-trials/cls-20490904) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to determine the safety and preliminary effectiveness of APR-246 in combination with pembrolizumab in subjects with solid tumor malignancies. The study will include a safety lead-in portion followed by a phase 2 expansion portion in specific disease groups. - [Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)](/research/clinical-trials/cls-20425286) Rochester, MN The purpose of this study is to assess whether copanlisib in combination with standard immunochemotherapy (rituximab in combination with bendamustine [R-B] and rituximab in combination with a 4 drug combination of cyclophosphamide, doxorubicin, vincristine and prednisone/prednisolone [R-CHOP]) is effective and safe, compared with placebo in combination with standard immunochemotherapy (R-B or R-CHOP) in patients with relapsed iNHL who have received at least one, but at most three, lines of treatment, including rituximab-based immunochemotherapy and alkylating agents. - [MM-302 Plus Trastuzumab vs. of Physician's Choice Plus Scottsdale/Phoenix, AZ; Jacksonville, FL; MN This study is open label, randomized, multicenter trial of MM-302 plus trastuzumab. The trial is designed to demonstrate whether MM-302 plus trastuzumab is more effective than the chemotherapy of physician's choice (CPC) plus trastuzumab in locally advanced/metastatic HER2-positive breast cancer patients. Patients may not have been previously treated with an anthracycline in any setting. Patients must have received prior treatment with trastuzumab in any setting, have either progressed or are intolerant to ado-trastuzumab emtansine in the metastatic or locally advanced setting, have either progressed or are intolerant to pertuzumab in the metastatic or locally advanced setting or had disease ... - [Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer](/research/clinical-trials/cls-20154109) Eau Claire, WI This randomized phase III trial studies combination chemotherapy and trastuzumab to see how well they work compared to combination chemotherapy alone in treating women with breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy is more effective with or without trastuzumab in treating breast cancer. - [Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients](/research/clinical-trials/cls-20484358) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to determine the preliminary anti-tumor activity and confirm the safety of VV1 in combination with Cemiplimab. The study will concurrently enroll patients with four distinct advanced malignancies in 5 separate tumor cohorts. The four cancer types are: Non-Small Cell Lung Cancer (NSCLC) and melanoma that are progressing on checkpoint inhibitor (CPI, generally refers to anti-PD(L)1 antibodies) treatment, CPI-na\u00efve (HCC), and Patients With Mesothelin-Positive Pleural Mesothelioma](/research/clinical-trials/cls-20440738) Jacksonville, Rochester, MN The purpose of this randomized phase I/II trial is to study the side effects and how well pembrolizumab with or without anetumab ravtansine work in treating patients with mesothelin-positive pleural mesothelioma. Monoclonal antibodies, such as anetumab ravtansine and pembrolizumab, may interfere with the ability of tumor cells to grow and spread. - [A Study of the Effectiveness and Safety of Pembrolizumab (MK-3475) for Women with Advanced Recurrent Ovarian Cancer](/research/clinical-trials/cls-20260195) Rochester, MN The purpose of this study is to assess the effectiveness and safety of pembrolizumab (MK-3475) for the treatment of women with advanced ovarian cancer who have had recurring disease following front line platinum-based treatment and debulking surgery. - [Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to evaluate whether bintrafusp alfa in combination with the current standard of care (SoC) (gemcitabine plus cisplatin) improves overall survival (OS) or progression-free survival (PFS) in chemotherapy and immunotherapy-na\u00efve participants with locally advanced or metastatic BTC compared to placebo, gemcitabine and cisplatin. - [A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens](/research/clinical-trials/cls-20478019) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, a neoantigen-based therapeutic cancer vaccine, in combination with immune checkpoint blockade, in patients with advanced or metastatic non-small cell lung cancer, microsatellite stable colorectal cancer, shared neoantigen-positive tumors. - [Novel (SEQUEL)](/research/clinical-trials/cls-20507129) Rochester, MN This is a randomized study of novel SEQUEnced immunotherapy (pembrolizumab) with anti-angiogenesis and chemotherapy in advanced gastric and gastroesophageaL junction (GEJ) adenocarcinoma (SEQUEL) designed to to evaluate the best overall response rate (BORR) of combined ramucirumab (RAM) plus paclitaxel (+/- pembrolizumab) following and GEJ adenocarcinoma. - [A Study to Evaluate UV1 Vaccination and Ipilimumab in Treatment of Melanoma](/research/clinical-trials/cls-20489497) Scottsdale/Phoenix, AZ The purpose of this study is to explore the effectiveness and safety of UV1 administered with GM-CSF in combination with nivolumab and ipilimumab. UV1 is a therapeutic cancer vaccine that has been explored in prostate, lung cancer, in combination with ipilimumab in malignant melanoma and in combination with pembrolizumab in metastatic melanoma. - [A Study to Test the Addition of Nivolumab to Chemotherapy to Treat Soft Tissue Sarcoma](/research/clinical-trials/cls-20511048) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine how well paclitaxel with and without nivolumab works in treating patients with soft tissue sarcoma that have not received taxane drugs, and how well nivolumab and cabozantinib work in treating taxane pretreated patients with soft tissue sarcoma. Nivolumab works through the body's immune system to help the immune system act against tumor cells. Chemotherapy drugs, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cabozantinib may stop the growth of tumor ... - [A Study of Grapiprant and Pembrolizumab in Advanced or Progressive MSS Colorectal Cancer](/research/clinical-trials/cls-20447145) Scottsdale/Phoenix, AZ This study will be conducted in adult participants diagnosed with any form of an advanced or progressive MSS CRC for which 1st and 2nd line standard therapy (at least one of which contained fluorouracil) is no longer effective or is intolerable. The purpose of this study is to assess safety and tolerability of grapiprant in combination with pembrolizumab, to determine the recommended phase 2 dose (RP2D) with pembrolizumab, and to evaluate and characterize the PK of grapiprant alone and in combination with pembrolizumab. Disease response, pharmacodynamics, and response biomarkers will also be assessed. - [A Study to Evaluate Lasofoxifene versus Fulvestrant in Advanced or Metastatic ER+/HER2 Breast ESR1 Mutation](/research/clinical-trials/cls-20467508) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the activity of lasofoxifene relative to fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic ER+/HER2 breast cancer with an acquired ESR1 mutation and who have disease progression on an aromatase inhibitor (AI) in combination with a cyclin dependent kinase (CDK) 4/6 inhibitor. The primary objective is to evaluate the progression free survival (PFS) of 5 mg lasofoxifene relative to fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2) breast cancer with an ESR1 mutation. - [Study of Pembrolizumab With Ipilimumab or Placebo in Participants with Untreated Metastatic Non-small Cell Lung Cancer](/research/clinical-trials/cls-20441687) Scottsdale/Phoenix, AZ The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo. - [A Study to Evaluate Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients with Chronic Myeloid Leukemia and Persistently- Detectable Minimal Residual Disease](/research/clinical-trials/cls-20463655) Eau Claire, WI; Rochester, MN The purpose of this study is to evaluate how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid ... - [Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK-3475) Refractory Refractory Multiple Myeloma (rrMM) (MK-3475-183/KEYNOTE-183)](/research/clinical-trials/cls-20204589) Jacksonville, FL The purpose of this study is to compare the efficacy of pomalidomide and low dose dexamethasone with pembrolizumab (MK-3475) to that of pomalidomide and low dose dexamethasone without pembrolizumab in terms of Progression-Free Survival (PFS) in participants with refractory or relapsed and refractory multiple myeloma (rrMM) who have undergone at least 2 lines of prior treatment. - [A Study to Evaluate the Safety and Effectiveness of Lisocatagene Maraleucel in Patients](/research/clinical-trials/cls-20507055) Jacksonville, FL; Rochester, MN The purpose of this study is to assess the safety of nonconforming lisocabtagene maraleucel in patients, and to assess the effectiveness of nonconforming lisocabtagene maraleucel in patients. - [Avelumab In An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Refractory Diffuse Large B-cell Lymphoma (R/R multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL). - [\"Prescribing\" Exercise to Cancer Patients at High-Risk for Falls](/research/clinical-trials/cls-20474788) Rochester, MN Falls are common and catastrophic in cancer patients. Cancer patients are vulnerable to falls due to muscle loss. In prescribing exercise in a data driven manner to cancer patients, our hypothesis is this \"prescription\" for exercise will eventually be demonstrated to reduce the occurrence of injurious falls. - [T-DM1 vs Paclitaxel/Trastuzumab for Breast](/research/clinical-trials/cls-20152324) Rochester, MN This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug to learn whether the drug works in treating a specific cancer. \"Investigational\" means that the drug is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if the drug is effective for treating different types of cancer. It also means that the FDA has not approved this drug for use patients undergoing adjuvant treatment for HER2+ breast cancer. Trastuzumab emtansine Scottsdale/Phoenix, AZ The purpose of this study is to determine whether a supervised exercise-training program, initiated prior to chemotherapy induction (pre-conditioning) and continued throughout chemotherapy treatment, can preserve short- and long-term cardiovascular performance, skeletal muscle function, cognitive ability and quality of life better than current standard or care recommendations for exercise during chemotherapy. - [Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery](/research/clinical-trials/cls-20145280) Rochester, MN This phase I trial studies the side effects and best dose of alisertib when given together with fulvestrant in treating patients with hormone positive breast cancer that has spread to other parts of the body or is locally advanced and cannot be removed by surgery. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen and progesterone are type of hormones made by the body and they can cause the growth of breast cancer cells. Hormone therapy using fulvestrant may fight breast cancer by lowering the amount of estrogen or progesterone ... - [Genetic Risk Estimation and Improving Health Disparities in Breast Cancer Screening of Racial Minorities](/research/clinical-trials/cls-20540914) Jacksonville, FL The aim of this study is to use the combine clinical risk assessment models that are already used in routine clinical practice with information derived from polygenic risk score (PRS) testing in women of racial minorities to see if this can improve adherence to recommended breast cancer screening and prevention strategies. - [A Study to Reduce Cardiomyopathy in Breast Cancer Patients Being Treated With Trastuzumab](/research/clinical-trials/cls-20438531) Rochester, MN The purpose of this study is to evaluate different strategies of cardiovascular therapy with carvedilol aiming to reduce the incidence of heart function declines and heart failure in at-risk breast cancer patients while on trastuzumab therapy. - [Study Treating Patients with Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine how well nivolumab with or without varlilumab works in treating patients with aggressive B-cell lymphomas that have come back or do not respond to treatment. Monoclonal antibodies, such as varlilumab and nivolumab, may work by stimulating the immune system to attack cancer tumor cells. - [A Study to Evaluate the Addition of Immunotherapy into Adjuvant Therapy for Non-small Cell Lung Cancer](/research/clinical-trials/cls-20511385) Rochester, MN This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by ... - [A Study to Evaluate MRI-guided Cryoablation for Focal Native Intermediate Grade Prostate Cancer](/research/clinical-trials/cls-20509686) Rochester, MN The purpose of this study is to investigate MR-guided cryoablation of biopsy proven Gleason 7 prostate cancers using the Galil MR-compatible cryoablation system to monitor the technqiue and prospectively collect the data. The system is already FDA (510k) approved for soft tissue ablation and has been utilized successfully at Mayo previously. - [Comparison of Combination Chemotherapy Regimens in Treating Older Women Who Have Undergone Surgery for Breast Cancer](/research/clinical-trials/cls-20416017) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways after surgery may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective in treating older women with breast cancer. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to see how well they work in treating older women who have undergone surgery for breast cancer. - [A Study to Compare CMP-001 Combined with Nivolumab to Nivolumab Alone in Advanced Melanoma Subjects](/research/clinical-trials/cls-20517036) Scottsdale/Phoenix, AZ The purpose of this two-phase to compare CMP-001 intratumoral (IT) and nivolumab intravenous (IV) compared to administered to participants with unresectable or metastatic melanoma. The primary objective of Phase 2 is to determine confirmed objective response rate (ORR) for treatment with first-line CMP-001 in combination with nivolumab versus nivolumab monotherapy in subjects with unresectable or metastatic melanoma. The primary objective of Phase 3 is to evaluate progression-free survival (PFS) for subjects receiving first-line CMP-001 in the Sofusa\u00ae DEVICE in Patients with Metastatic Melanoma](/research/clinical-trials/cls-20516863) Rochester, MN The primary objective of the overall study is to determine the maximum tolerated dose (MTD) of ipilimumab that can be administered through the DoseConnect device, followed 30 minutes later by nivolumab IV on Day 1 of a 21-day cycle in patients with metastatic melanoma. - [Evaluation of Outcomes in Metastatic Gastric and Esophageal Carcinoma in Relation to Immunotherapy](/research/clinical-trials/cls-20405570) Rochester, MN The purpose of this study is: - To assess the efficacy of treatment with checkpoint inhibitors (Pembrolizumab or Nivolumab) in metastatic gastric and esophageal carcinoma through retrospective chart review. - To explore if response to checkpoint inhibitors is dependent on biomarkers on tumor tissue. - [Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combo In Cervical or HPV+ Head & Neck Cancer](/research/clinical-trials/cls-20323756) Jacksonville, FL Part A: (ADXS11-001 + MEDI4736 Combination Therapy) will determine the safety and tolerability of the combination and to identify a RP2D. Part B: Phase 2 design which will randomize subjects 1:1 to either MEDI4736 alone or MEDI4736+ADXS11-001 in subjects who have failed at least 1 prior systemic treatment for their recurrent/persistent or metastatic cervical cancer. - [Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)](/research/clinical-trials/cls-20116098) Scottsdale/Phoenix, AZ; Rochester, MN This study will be done in 6 parts. In Part A the dose of intravenous (IV) pembrolizumab (MK-3475) will be escalated to find the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for participants with a histologically or cytologically confirmed diagnosis of any type of carcinoma or melanoma (MEL). Part B of the study will explore the safety, tolerability, and efficacy of the drug in participants with advanced or metastatic MEL and compare every 2 week to every 3 week dosing. Part C of the study will explore the safety, tolerability, and efficacy of the drug in participants ... - [Efineptakin alfa (NT-I7) Plus Pembrolizumab for the Treatment of Recurrent Glioblastoma](/research/clinical-trials/cls-20534587) Rochester, MN The purpose of this study is to determine the response rate to the combination of pembrolizumab and NT-I7 in patients with recurrent glioblastoma. - [A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer](/research/clinical-trials/cls-20147196) Scottsdale/Phoenix, AZ The purpose the study is to measure the effect of nivolumab (BMS-936558) in reducing tumor size in subjects with metastatic or unresectable bladder cancer. - [Study of the NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung](/research/clinical-trials/cls-20446034) Rochester, MN Patients with medically inoperable primary soft tissue lesion of the lung will have transbronchial microwave ablation performed via transbronchial approach by an interventional pulmonologist or thoracic surgeon using CT imaging. Prior to the ablation procedure, the treating physician will use endobronchial ultrasound to confirm staging. Patients will be followed for one year following the ablation procedure for efficacy and safety. - [A Study to Evaluate T-DM1 With or Without Abemaciclib in Women and Men with HER2-positive Advanced or Metastatic Breast Cancer](/research/clinical-trials/cls-20510642) Jacksonville, FL; Rochester, MN The primary objective of this study is to compare progression-free survival (PFS) in patients with advanced HER2-positive breast cancer treated with T-DM1 and abemaciclib vs. T-DM1 monotherapy. - [Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy Treating Women With HER2-Negative Breast Cancer](/research/clinical-trials/cls-20474100) Rochester, MN RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating women with non-metastatic breast cancer. - [Study to Evaluate CCS1477 in Haematological Malignancies](/research/clinical-trials/cls-20533340) Scottsdale/Phoenix, AZ The purpose of this study is primarily designed to evaluate the safety and tolerability of CCS1477 in patients with relapsed or B or CCS1477 is a potent, and orally bioavailable inhibitor the bromodomain of p300 and CBP, critical transcriptional co-activators of genes that drive cell proliferation and survival. The compound causes G1 cell cycle arrest and is anti-proliferative across a broad range of haematological cell models, representative of AML, MM and lymphomas. This is also accompanied by an increase in myeloid differentiation in ... - [Combination Chemotherapy in Treating Women With Breast Cancer](/research/clinical-trials/cls-20154132) No Locations RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective for breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens in treating women with breast cancer who have undergone surgery to remove the tumor. - [Study to Evaluate Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple Myeloma](/research/clinical-trials/cls-20529025) Jacksonville, FL; Rochester, MN; Scottsdale/Phoenix, AZ The primary goal of this study is to determine response rates (>=PR) of prospectively treated MM patients with one cycle of therapy containing a combination of an immunomodulator and dexamethasone. - [Phase 2 Study of Ipilimumab in Children and Adolescents (12 to < 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma](/research/clinical-trials/cls-20112265) Rochester, MN The purpose of the study is to comply with the Pediatric Investigation Plan requirements of Ipilimumab - [Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer](/research/clinical-trials/cls-20523999) Rochester, MN This phase II trial compares the effect of oxybutynin versus placebo for reducing hot flashes in men receiving androgen deprivation (hormone) therapy for the treatment of prostate cancer . Androgen deprivation therapy decreases testosterone and other androgens through medications or surgical removal of the testicles. Relative to placebo, low- or high-dose oxybutynin may reduce hot flashes in men receiving androgen deprivation therapy. - [Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer](/research/clinical-trials/cls-20440743) No Locations The purpose of this study is to determine how well atezolizumab with or without cobimetinib works in treating patients with bile duct cancer that has spread to other places in the body and cannot be removed by surgery or gallbladder cancer. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab with cobimetinib may work better at treating patients with bile duct and gallbladder cancer. - [A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia](/research/clinical-trials/cls-20260194) Rochester, MN This open-label, multicenter, global study is designed to determine the recommended phase 2 dose, safety, efficacy, and pharmacokinetics/pharmacodynamics of durvalumab in subjects with certain lymphoma subtypes or CLL. Globally, 265 subjects may be enrolled into 4 treatment arms, including durvalumab monotherapy; durvalumab bendamustine. The study will have 3 parts: dose finding, dose confirmation, and dose expansion. Subjects receiving monotherapy may receive combination therapy or involved-field radiation to a single nodal site at time of progressive disease. - [A Study of Pembrolizumab Alone as Therapy for Cancer](/research/clinical-trials/cls-20166037) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to examine the effectiveness and safety of pembrolizumab as first line or above treatment in patients with metastatic triple-negative breast cancer. - [A Study to Evaluate TVB-2640 and Trastuzumab Plus Paclitaxel or Endocrine Therapy for Treating Patients with HER2 Positive Advanced Breast Cancer](/research/clinical-trials/cls-20366138) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This phase studies how well FASN inhibitor TVB-2640 and trastuzumab plus either paclitaxel or endocrine therapy with an aromatase inhibitor work in treating patients with HER2 positive breast cancer that has spread to other places in the body. FASN inhibitor TVB-2640 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and trastuzumab, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Endcocrine therapy helps reduce ... - [Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer](/research/clinical-trials/cls-20467516) Rochester, MN The purpose of this study is to evaluate how well pembrolizumab works in treating participants with ovarian cancer that has come back after previous treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. - [A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus Herceptin (t rastuzumab) as adjuvant therapy in patients with operable HER2-positive primary breast cancer. After surgery, patients will be randomized to receive either pertuzumab or placebo intravenously (iv) every 3 weeks for one year, in addition to 6-8 cycles of chemotherapy and 1 year of Herceptin (trastuzumab) iv every 3 wee ks. Anticipated time on study treatment is 52 weeks. This study will be carried out in collaboration with the Breast International Group (BIG). - [A Study to Evaluate Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in patients with advanced cancer](/research/clinical-trials/cls-20490571) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The primary purposes of this study are to is to assess safety and tolerability of IV administration of TVH vaccine alone and in combination with HER2 antibodies in patients with advanced cancer. - [A Study Risk Large B-Cell Lymphoma](/research/clinical-trials/cls-20493009) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The primary purpose of this study in the dose-finding phase is to establish the maximum tolerated dose (MTD) of parsaclisib in combination with R-CHOP in newly-diagnosed DLBCL. The primary purpose of the study in the dose-expansion phase is to assess the compete metabolic response rate by PEWT (PETW CR) of combining parsaclisib and R-CHOP in patients with newly-diagnosed DLBCL. - [A Study to Evaluate the Use of Nivolumab and Pomalidomide Combination for Relapsed/Refractory Primary Central Nervous System Lymphoma and Primary Vitreoretinal Lymphoma](/research/clinical-trials/cls-20450254) Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the side effects and best dose of pomalidomide when given together with dexamethasone in treating patients with primary central nervous system lymphoma that has come back (relapsed) or does not respond to treatment (refractory) or intraocular lymphoma that is newly diagnosed, relapsed or refractory. Pomalidomide may stimulate the immune system to kill cancer cells. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Giving pomalidomide together with dexamethasone ... - [A Phase I Study MSB2311 in Advanced Solid Tumors](/research/clinical-trials/cls-20435274) Scottsdale/Phoenix, AZ; Jacksonville, FL This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors. - [A Study of Women undergoing Mammogram Screening at Mountain Park Clinic](/research/clinical-trials/cls-20314837) Scottsdale/Phoenix, AZ; Rochester, MN The goal of this research is to identify risk profiles of women (with particular emphasis on Hispanic women) for breast cancer based on family history, breast density and other factors known to impact risk such as age, weight, age at menarche, age at birth of first child, etc. - [A Phase 1/2 Study to Evaluate MEDI4736](/research/clinical-trials/cls-20146794) Jacksonville, FL This is a multicenter, open-label, first-time-in-human study with a standard 3+3 dose-escalation phase in subjects with advanced solid tumors followed by an expansion phase in patients with advanced solid tumors. An exploration cohort has been added to determine the safety using Q4W dosing. - [A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Subjects With Select Advanced Malignancies](/research/clinical-trials/cls-20146797) Rochester, MN To evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination with Durvalumab versus Nivolumab Monotherapy in Subjects with Select Advanced Malignancies. - [Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors](/research/clinical-trials/cls-20391630) Jacksonville, FL This is an open-label, two-part, multiple study to evaluate the safety and tolerability of DS-8201a in patients with advanced solid malignant tumors. - [A Registry for the Collection and Maintenance of Biological Specimens for Breast Cancer Research](/research/clinical-trials/cls-20307740) Rochester, MN The purpose of this registry is to collect and maintain samples of breast tissue from women and men undergoing surgery for a breast related concern at Mayo Clinic Rochester, to create a biospecimen resource for the study of benign and cancerous breast conditions. - [A Study to Evaluate Durvalumab plus Topotecan or Lurbinectedin in Patients with Small Cell Lung Cancer](/research/clinical-trials/cls-20507178) Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to evaluate whether the combination of durvalumab plus lurbinectedin can increase 6 month progression-free survival, in patients with extensive stage small cell lung cancer who have progressed after treatment with an initial combination of chemotherapy and immunotherapy. - [A Study to Evaluate Cemiplimab Survivorship Epidemiology](/research/clinical-trials/cls-20477446) Jacksonville, FL The primary purpose of this study is to identify potential determinants of disease progression, Quality of Life (QOL), and other health-related outcomes for patients with Cutaneous squamous cell carcinoma (CSCC) undergoing treatment with cemiplimab. In addition, the study will aim to assess patient experience, including QOL and functional status, to identify and describe long-term effects of treatment of patients with CSCC, to collect and describe serious adverse event (SAE) and immune-related adverse event (irAE) data on study participants, to describe patients who receive cemiplimab as treatment for CSCC in a real-world setting, to describe real-world use patterns of cemiplimab for CSCC, to assess the long-term ... - [A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma](/research/clinical-trials/cls-20521962) Rochester, MN The purpose of this study is to define the recommended dose, safety, tolerability, immunogenicity, and preliminary effectiveness of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent Non-Hodgkin's Lymphoma (NHL). - [A Study to Evaluate the Safety and Effectiveness of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer](/research/clinical-trials/cls-20509929) Jacksonville, FL; Rochester, MN The purpose of this study is to assess the effectiveness of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after Aromatase Inhibitor (AI) therapy. - [A Study of Tamoxifen Citrate for Treating Patients with Metastatic or Recurrent Breast Cancer](/research/clinical-trials/cls-20314522) Rochester, MN The purpose of this studyis to assess how well tamoxifen citrate works in patients with metastatic or recurrent breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight cancer by blocking the use of estrogen by tumor cells. - [A Study Using Avelumab in Non-Small Cell Lung Cancer that has Progressed](/research/clinical-trials/cls-20166039) Scottsdale/Phoenix, AZ The purpose of this study is to demonstrate avelumab's overall survival superiority versus docetaxel in patients with programmed death ligand 1 (PD-L1) positive non-small cell lung cancer (NSCLC) after the failure of a platinum-based doublet. - [Acetylsalicylic Acid in Preventing Disease Recurrence in Patients With Barrett's Esophagus After Successful Elimination by Radiofrequency Ablation](/research/clinical-trials/cls-20492214) Rochester, MN This randomized phase II trial studies the safety of and how well acetylsalicylic acid (Aspirin) works in preventing Barrett's esophagus from returning after it has been successfully eliminated by radiofrequency ablation. Studying samples of tissue from patients with Barrett's esophagus for the levels of a specific protein that is linked to developing Barrett's esophagus may help doctors learn whether acetylsalicylic acid can prevent it from returning after it has been successfully treated. - [Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients With Stage I-III HER2 Positive Breast Cancer](/research/clinical-trials/cls-20478015) Jacksonville, FL This phase II trial studies how well rifaximin works for the treatment of gastrointestinal toxicities related to pertuzumab-based therapy in patients with stage I-III HER2 positive breast cancer. Rifaximin may reduce the incidence and severity of pertuzumab induced gastrointestinal toxicities without interrupting or delaying the chemotherapy schedule. - [A Study to Test the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer](/research/clinical-trials/cls-20468973) Rochester, MN The purpose of this study is to determine how well the combination of pembrolizumab, paclitaxel and carboplatin works compared with paclitaxel and carboplatin alone in treating patients with endometrial cancer that is stage III or IV, or has come back (recurrent). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Paclitaxel and carboplatin are chemotherapy drugs used as part of the usual treatment approach for this type of cancer. This study aims to assess if adding immunotherapy to these drugs ... - [Natural History Evaluation Among Female Breast Cancer Survivors with Endocrine Therapy-Induced Alopecia](/research/clinical-trials/cls-20537621) Rochester, MN; Albert Lea, MN; Mankato, MN The purpose of this study is to learn about potential side effects facing people who are undergoing treatments for their cancer, specifically, hair loss. While this is not a well-documented side effect of hormone-blocking medications (such as tamoxifen, letrozole, anastrozole, or exemestane), we have preliminary evidence that it is a problem for some patients getting this treatment. This study will include some patients receiving the hormone therapy and some patients who are not, so we can better understand whether patients getting the hormonal therapy have more hair loss than patients who are not getting such. - [Pembrolizumab With Chemotherapy and With/Without MK-4830 for Treating Participants With Ovarian Cancer](/research/clinical-trials/cls-20540184) Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate whether the reduction from baseline in circulating tumor DNA at Cycle 3 (ctDNA) is larger in participants receiving MK-4830 + pembrolizumab in combination with standard of care (SOC) therapy than in those receiving pembrolizumab + Standard of Care (SOC) therapy. - [Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer](/research/clinical-trials/cls-20438464) Scottsdale/Phoenix, AZ; Rochester, MN This randomized phase clinical trial studies how well nivolumab after combined modality therapy works in treating patients with high risk stage II-IIIB anal cancer. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. - [Intrapleural Measles Virus Therapy in Patients with Malignant Pleural Mesothelioma](/research/clinical-trials/cls-20116771) Rochester, MN This phase I clinical trial investigates the side effects and the best dose of local (intrapleural measles virus therapy in treating patients with malignant pleural mesothelioma (MPM). The investigators anticipate that the intrapleural of the vaccine strain measles virus will enable the virus to specifically infect and kill cancer cells and spare, without damaging normal cells. Furthermore, the investigators expect the measles virus to trigger an anti-tumor immune response which will result in additional destruction of the tumor by immune cells. - [Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma](/research/clinical-trials/cls-20207302) Rochester, MN This phase II trial studies how well nivolumab and brentuximab vedotin work in treating older patients with untreated Hodgkin lymphoma. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells. Biological therapies, such as brentuximab vedotin, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Nivolumab and brentuximab vedotin may work better in treating older patients with untreated Hodgkin lymphoma. - [A Study of Atezolizumab Alone or Combined with Immunomodulatory Drug and/or Daratumumab in Multiple Myeloma Patients](/research/clinical-trials/cls-20150035) Jacksonville, FL This multicenter, open-label, Phase I study will evaluate the safety, efficacy, and pharmacokinetics of atezolizumab alone or in combination with daratumumab and/or various immunomodulatory agents in participants with MM who have relapsed or who have undergone autologous stem cell transplantation (ASCT). The planned duration of this study is approximately 36 months. Cycle length will be 21 days in Cohorts A to C and 28 days in Cohorts D to F. - [S1211, Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma](/research/clinical-trials/cls-20145163) Jacksonville, FL; Rochester, MN RATIONALE: Lenalidomide and bortezomib may stop the growth of multiple myeloma by blocking blood flow to the tumor. Also, bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as elotuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as lenalidomide and dexamethasone also work in different ways to kill tumor cells or stop them from growing. Giving elotuzumab together ... - [A Study of Brentuximab Vedotin Combined Nivolumab for Relapsed or Refractory Hodgkin Lymphoma](/research/clinical-trials/cls-20194586) Rochester, MN The purpose of this study is to assess the safety profile and antitumor activity of brentuximab vedotin administered in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma (HL) - [Study of Cabozantinib Combined With Atezolizumab Vs. Second Novel Hormonal Therapy in Subjects with Metastatic Castration-Resistant Prostate Cancer](/research/clinical-trials/cls-20521244) Rochester, MN The purpose of this study is to evaluate the safety and effectiveness of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with one, and only one, NHT for their prostate cancer disease. - [A Study of Sonidegib and Pembrolizumab in Advanced Solid Tumors](/research/clinical-trials/cls-20467295) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine the maximum tolerated dose (MTD) of sonidegib in combination with pembrolizumab in participants with advanced solid tumors as part of the dose escalation phase, and to estimate the response rate of sonidegib in combination with pembrolizumab in participants with NSCLC or pancreas cancer as part of the expansion cohort based on RECIST criteria. - [Radiation Therapy With or Without Chemotherapy in Treating Patients With High-Risk Malignant Salivary Gland Tumors That Have Been Removed By Surgery](/research/clinical-trials/cls-20398312) Rochester, MN RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with chemotherapy or alone after surgery in treating salivary gland tumors. PURPOSE: This randomized phase II/III trial is studying radiation therapy with or without chemotherapy to see how well it works in treating patients with high-risk malignant salivary gland tumors that have been removed by surgery. - [A Study to Evaluate MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation](/research/clinical-trials/cls-20491075) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to characterize the safety and tolerability of MRTX849 in patients having advanced solid tumor mutation. Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone](/research/clinical-trials/cls-20261803) Rochester, MN This randomized lenalidomide, dexamethasone and zoledronic acid with zoledronic acid alone to see how well they work when given after radiation therapy in treating patients with solitary plasmacytoma of bone. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may help the immune system kill abnormal blood cells or cancer cells. Dexamethasone is a drug used in chemotherapy that may cause tumor cells to die. Zoledronic acid may prevent bone fractures and reduce bone pain, and may also improve survival. Standard treatment for ... - [Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion](/research/clinical-trials/cls-20146656) Jacksonville, FL The primary objective of this study is to evaluate overall response rate (ORR) following treatment with idelalisib plus rituximab in participants with previously untreated chronic lymphocytic leukemia (CLL) with 17p deletion. An increased rate of deaths and serious adverse events (SAEs) among participants with front-line CLL and early-line indolent non-Hodgkin lymphoma (iNHL) treated with idelalisib in combination with standard therapies was observed by the independent data monitoring committee (DMC) during regular review of 3 Gilead Phase 3 studies. Gilead reviewed the unblinded data and terminated those studies in agreement with the DMC recommendation and in consultation with the US Food ... - [A Study of SAR442085 in Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20473851) Rochester, MN The purpose of this study is to determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B. - [A Study to Evaluate CB-839 With Radiation Therapy and Temozolomide in Treating Participants With Diffuse Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the side effects and best dose of CB-839 hydrochloride (CB-839) in combination with radiation therapy and temozolomide in treating participants with IDH-mutated diffuse or anaplastic astrocytoma. CB-839 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or stopping them from spreading. Giving CB-839 with ... - [LGX818 and MEK162 in AZ The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safety and tolerability of the novel triple combinations. - [A Study of Shared Decision Making in the Cardiovascular Care of Cancer Patients Seen in the Cardio-oncology Clinic](/research/clinical-trials/cls-20362900) Rochester, MN The purpose of this study is to explore, through surveys of providers and patients, the frequency and nature of shared decision making aspects in the cardiovascular care of cancer patients seen in the cardio-oncology clinic referred by an oncology provider. - [A Study Using Chemotherapy Followed by Radiation Therapy in Treating Younger Patients with Newly Diagnosed Localized Central Nervous System Germ Cell Tumors](/research/clinical-trials/cls-20152249) Rochester, MN Drugs used as chemotherapy, such as carboplatin, etoposide, and ifosfamide work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x rays to kill tumor cells. Giving chemotherapy with radiation therapy may kill more tumor cells. This phase II trial studies how well chemotherapy and radiation therapy work in treating younger patients with newly diagnosed central nervous system germ cell tumors. - [Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Ependymoma](/research/clinical-trials/cls-20119667) Rochester, MN This randomized phase III trial is studying maintenance chemotherapy to see how well it works compared to observation following induction chemotherapy and radiation therapy in treating young patients with newly diagnosed ependymoma. Drugs used in chemotherapy, such as vincristine sulfate, carboplatin, cyclophosphamide, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to ... - [Novel Combinations of CC-122, CC-223, Diffuse Large B-cell Lymphoma](/research/clinical-trials/cls-20115978) Rochester, MN First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL) - [A Study of TAK-981 in Rochester, MN The purpose of this study is to determine the safety and tolerability of TAK-981 in combination with rituximab in participants with r/r CD20+ NHL in Phase 1b, and to evaluate the effectiveness of TAK-981 in combination with rituximab in r/r CD20+ NHL in Phase 2. - [A Study of Using Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant](/research/clinical-trials/cls-20152041) Rochester, MN This randomized phase III trial studies how well caspofungin acetate works compared to fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant. Caspofungin acetate, fluconazole, and voriconazole may be effective in preventing fungal infections in patients following donor stem cell transplant. It is not yet known whether caspofungin acetate is more effective than fluconazole or voriconazole in preventing fungal infections in patients following donor stem cell transplant. - [Comparison of Hepatic Intraarterial vs. Rochester, MN tumor radiotracer hepatic intraarterial (I.A.) by PET/CT. - [Defining Meaningful Within-Patient Change in Symptoms of Advanced Cancer Patients](/research/clinical-trials/cls-20542639) Rochester, MN The purpose of this study is to define meaningful change in symptoms and physical function for advanced cancer patients receiving treatment. - [Predicting Immunotherapy Response in Metastatic Kidney Cancer](/research/clinical-trials/cls-20525150) Rochester, MN Immunotherapy has revolutionized the therapeutic landscape for patients with metastatic RCC and response rates are higher than previously observed with tyrosine kinase inhibitors. Despite this, there is a growing need for molecular markers that can help identify patients who will benefit from immunotherapy, especially in the landscape of multiple available regimens, potential toxicities and financial burden. In this study, we propose to use blood biopsies to study tumor-derived extracellular vesicles (tdEVs) to assess disease burden, monitor response to therapy, and to predict earlier disease progression. In addition to tdEVs, these samples will also be analyzed for other biomarkers ... - [Atezolizumab Immunotherapy Phase II with unresectable stage IIIB NSCLC (AJCC 7th Edition) eligible for chemoradiotherapy with curative intent. - [A Study of to the PK, subjects with - [Comparison of Operation to Monitoring With/Without Endocrine Therapy For Low Risk DCIS](/research/clinical-trials/cls-20425277) Jacksonville, FL; Rochester, MN; Scottsdale/Phoenix, AZ This study looks at the risks and benefits of active surveillance (AS) compared to guideline concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AS approach does not yield inferior cancer or quality of life outcomes compared to GCC. - [Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck](/research/clinical-trials/cls-20150029) Rochester, MN The purpose of this study is to determine the efficacy and safety of investigational medical products (MEDI4736 monotherapy, tremelimumab monotherapy, and MEDI4736 + tremelimumab combination therapy) in the treatment of patients with recurrent or metastatic carcinoma of the head and neck who have progressed during or after treatment with a platinum containing regimen for recurrent/metastatic disease. - [Nivolumab With or Without Ipilimumab in AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine how well nivolumab, with or without ipilimumab, works in treating patients with anal canal cancer that has not responded to previous treatment (refractory) and has spread to other places in the body (metastatic). - [A Study to Evaluate the Effectiveness and Safety of Pembrolizumab Combined with Bacillus Calmette-Guerin in High-Risk Non-Muscle Invasive Bladder Cancer](/research/clinical-trials/cls-20492003) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction or that is na\u00efve to BCG treatment. - [A Trial of Tumor Necrosis Factor Alpha and Interleukin-2 Coding Oncolytic Adenovirus (TILT-123) Combined with Pembrolizumab to Treat Refractory Ovarian Cancer](/research/clinical-trials/cls-20531999) Rochester, MN The purpose of this study is to evaluate the safety [including dose-limiting toxicities (DLTs)] of the combination therapy of TILT-123 and pembrolizumab in patients with platinum resistant or refractory ovarian cancer. - [A Study of IMO-2125 in Combination With Ipilimumab Versus Anti-PD-1 Refractory Melanoma (ILLUMINATE-301)](/research/clinical-trials/cls-20456809) Scottsdale/Phoenix, AZ The purpose of this study is to compare ipilimumab with and without IMO-2125 in advanced melanoma patients. - [Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)](/research/clinical-trials/cls-20116806) Rochester, MN This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003 in combination with standard treatment versus subjects treated with standard treatment alone. - [Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)](/research/clinical-trials/cls-20116808) Scottsdale/Phoenix, AZ This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003 in combination with standard treatment versus subjects treated with standard treatment alone. - [A Study to Evaluate the Safety and Effectiveness of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma Patients](/research/clinical-trials/cls-20457506) Rochester, MN; Jacksonville, FL The purpose of this 2-part study is to evaluate the safety and effectiveness of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design for up to 17 cycles. Participants who receive placebo or who stop treatment after receiving 17 cycles of pembrolizumab in Part 1, do not experience disease recurrence within 6 months of completing pembrolizumab in Part 1, and do not stop treatment with pembrolizumab for disease recurrence or intolerability, may be eligible to receive up to 35 additional cycles of ... - [Diet in Altering Disease Progression in Patients with Prostate Cancer on Active Surveillance](/research/clinical-trials/cls-20115508) Rochester, MN RATIONALE: Eating a diet high in vegetables may slow down disease progression in patients with prostate cancer. PURPOSE: This randomized clinical trial is studying how well diet works in altering disease progression in patients with prostate cancer on active surveillance. - [Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair](/research/clinical-trials/cls-20379679) Albert Lea, MN; Eau Claire, WI; Mankato, Rochester, MN; La Crosse, WI This randomized phase III trial studies combination chemotherapy and atezolizumab to see how well it works compared with combination chemotherapy alone in treating patients with stage III colon cancer and deficient deoxyribonucleic acid (DNA) mismatch repair. Drugs used in combination chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy with atezolizumab may work better ... - [A Study of Pembrolizumab (MK-3475) in Participants With or Gastric or Gastroesophageal Junction Adenocarcinoma](/research/clinical-trials/cls-20146811) Scottsdale/Phoenix, AZ; Rochester, MN This is a study of pembrolizumab for advanced gastric or gastroesophageal junction adenocarcinoma; pembrolizumab will be given as monotherapy to participants who have had previous treatment or who are treatment-na\u00efve; pembrolizumab will also be evaluated as combination therapy with cisplatin and 5-Fluorouracil (5-FU) in treatment-na\u00efve participants. The primary study hypothesis is that pembrolizumab will provide a clinically meaningful overall response rate. - [A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer](/research/clinical-trials/cls-20502122) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be randomized 1:1 to receive one of the following and CE Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) or atezolizumab plus placebo (Arm B). - [A Study of the Safety and Effectiveness of Atezolizumab Combined with Etoposide, and Carboplatin for Patients with Untreated Extensive-Stage Small Cell MN This randomized, Phase I/III, multicenter, double-blinded, placebo-controlled study is designed to evaluate the safety and efficacy of atezolizumab (anti-programmed death ligand 1 [anti-PD-L1]) in combination with carboplatin plus (+) etoposide compared with treatment with placebo + carboplatin + etoposide in treatment-naive participants with extensive-stage small cell lung cancer (ES-SCLC). Participants will be randomized in a 1:1 ratio to receive either atezolizumab + carboplatin + etoposide or placebo + carboplatin + etoposide on 21 day-cycles for 4 cycles in the induction phase followed by maintenance with atezolizumab or placebo until disease progression (PD) as assessed by the investigator using Response Evaluation ... - [A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)](/research/clinical-trials/cls-20271979) Rochester, MN This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma - [Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer](/research/clinical-trials/cls-20531575) Jacksonville, FL The purpose of this study is to compare the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery ... - [A Study to Evaluate Oral Tamoxifen vs. TamGel vs. Control in Women with Atypical Hyperplasia or Lobular Carcinoma In Situ](/research/clinical-trials/cls-20520844) Rochester, MN The purpose of this study is to analyze breast tissue changes after a short course of Tamoxifen (Tam). - [A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495)](/research/clinical-trials/cls-20453733) Jacksonville, FL; Rochester, MN The purpose of this study is to investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with MK-4280 or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either MK-4280 or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with ... - [Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)](/research/clinical-trials/cls-20134470) Rochester, MN The purpose of this study is to evaluate the effectiveness and safety of Nivolumab in previously treated (cohorts, A, B & C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma subjects. - [A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard MN AALL1731 is a group-wide risk-stratified trial with newly diagnosed B-ALL and localized B-lymphoblastic lymphoma (B-LLy) that will test if the addition of blinatumomab to standard chemotherapy in patients with NCI SR B-ALL at highest risk for relapse will improve disease-free survival (DFS). Risk stratification will be determined by traditional prognosticators (tumor genetics, extent of extramedullary involvement, early response to therapy as determined by flow cytometry) combined with the new DNA-based MRD detection technology of high throughput sequencing (HTS) of the immunoglobulin heavy chain (IgH). - [A Study to Evaluate RP1 Monotherapy and Combined with Nivolumab](/research/clinical-trials/cls-20517717) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate the dose escalation and expansion of RP1 alone and combined with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary effectiveness. - [A Study to Measure the Proteins Expressed in tissue Samples from Women who have been Treated with New Endocrine Therapy for Invasive Lobular Breast Cancer](/research/clinical-trials/cls-20239997) Rochester, MN The purpose of this study is to compare the effectiveness of fulvestrant to anastrozole or tamoxifen in treating invasive lobular breast cancer, by measuring the level of the biomarker Ki67 found in tumor tissue before and then after treatment. - [Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, Jacksonville, FL; Rochester, MN The purpose of this study is to compare the effect of adding cabozantinib to avelumab versus avelumab alone in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and avelumab together may further shrink the cancer or prevent it from returning/progressing. - [CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20522389) Rochester, MN The purpose of this study is to increase N2 nodal clearance (N2NC) to 50% or greater for combined platinum doublet chemotherapy with durvalumab induction therapy from historical rate of 30% for platinum doublet chemotherapy alone in patients with potentially resectable stage IIIA/B (N2) NSCLC. - [Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)](/research/clinical-trials/cls-20260187) Rochester, MN This is a Phase 1b, open-label, multi-center study comprising a lead-in phase and an expansion phase. The lead-in phase is a multiple-dose, randomized, parallel-arm, pharmacokinetic and pharmacodynamic study of avelumab as a single agent in adult patients with cHL. Patients enrolled in the lead-in phase of this study are required to have relapsed following a prior autologous or allogeneic HSCT, or to be ineligible for HSCT. Based on the preliminary TO, safety, and efficacy results from the lead-in phase, the expansion phase will evaluate the anti-tumor activity and safety of single-agent avelumab utilizing an intra-patient dose escalation paradigm based on ... - [Predicting Immunotherapy Response in Metastatic Kidney Cancer](/research/clinical-trials/cls-20525150) Rochester, MN Immunotherapy has revolutionized the therapeutic landscape for patients with metastatic RCC and response rates are higher than previously observed with tyrosine kinase inhibitors. Despite this, there is a growing need for molecular markers that can help identify patients who will benefit from immunotherapy, especially in the landscape of multiple available regimens, potential toxicities and financial burden. In this study, we propose to use blood biopsies to study tumor-derived extracellular vesicles (tdEVs) to assess disease burden, monitor response to therapy, and to predict earlier disease progression. In addition to tdEVs, these samples will also be analyzed for other biomarkers ... - [Atezolizumab Immunotherapy Phase II with unresectable stage IIIB NSCLC (AJCC 7th Edition) eligible for chemoradiotherapy with curative intent. - [A Study of to the PK, subjects with - [Comparison of Operation to Monitoring With/Without Endocrine Therapy For Low Risk DCIS](/research/clinical-trials/cls-20425277) Jacksonville, FL; Rochester, MN; Scottsdale/Phoenix, AZ This study looks at the risks and benefits of active surveillance (AS) compared to guideline concordant care (GCC) in the setting of a pragmatic prospective randomized trial for low risk DCIS. Our overarching hypothesis is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an AS approach does not yield inferior cancer or quality of life outcomes compared to GCC. - [Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer](/research/clinical-trials/cls-20519861) Eau Claire, WI; La Crosse, WI The purpose of this study is to estimate the adverse event profile of MK-3475 (pembrolizumab) over the first six months of treatment, in non-small cell lung cancer patients who are 70 years of age or older and who are treated with MK-3475 (pembrolizumab) +/- chemotherapy in a first-line setting. - [Bemarituzumab and Nivolumab Versus Nivolumab Alone](/research/clinical-trials/cls-20527084) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The primary objective of this study is to evaluate the safety and tolerability of bemarituzumab plus mFOLFOX6 and nivolumab to treat previously-untreated advanced gastric and gastroesophageal junction cancer. - [A Study to Evaluate HKI-272 and Capecitabine for HER2-Positive Breast Cancer and Brain Metastases](/research/clinical-trials/cls-20111795) Rochester, MN The purpose of this research study is to determine how well neratinib works in treating breast cancer that has spread to the brain. Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). In this research study, the investigators are looking to see how well neratinib works to decrease the size of or stabilize breast cancer that has spread to the brain. The investigators are also looking at how previous treatments have affected your ... - [A Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) as Monotherapy or in Combination With Avastin (Bevacizumab) Compared to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma [IMmotion150]](/research/clinical-trials/cls-20111708) No Locations This multicenter, randomized, open-label study will evaluate the efficacy and safety of atezolizumab as monotherapy or in combination with Avastin (bevacizumab) versus sunitinib in patients with previously untreated locally advanced or metastatic renal cell carcinoma. Patients in Arm A will receive atezolizumab 1200 mg IV every 3 weeks (6-week cycles) plus Avastin 15 mg/kg IV until disease progression. Patients in Arm B will receive atezolizumab alone (until disease progression), and patients in Arm C will receive sunitinib 50 mg orally daily for 4 weeks followed by 2 weeks rest until disease progression. Following disease progression, patients in Arms B and ... - [A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal Cancer](/research/clinical-trials/cls-20368025) Rochester, study in subjects with MSS relapsed/refractory colorectal cancer. The primary objective of Part 1 is to evaluate the safety and tolerability of escalating doses of eFT508 in combination with a fixed dose of avelumab to determine the maximum tolerated dose (MTD) of eFT508 and to select a recommended dose for Part 2. The primary objective of Part 2 is to evaluate antitumor activity of eFT508 at the recommended dose in combination with avelumab or eFT508 monotherapy. Parts 1 and 2 will also evaluate pharmacokinetics (PK) and pharmacodynamics. - [A Study to Analyze The Impact of Pharmacist Consultation in Patients Beginning Intravenous Cancer Treatment](/research/clinical-trials/cls-20461288) La Crosse, WI The purpose of this study is to assess the impact of pharmacist consultation in patients receiving first dose, first cycle intravenous cancer treatment on patient understanding of the cancer treatment, adverse drug events, and adherence. Additionally, this study will report the frequency of healthcare utilization for side effect management. - [Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer](/research/clinical-trials/cls-20535714) Jacksonville, FL The purpose of this study is to study to collect tissue samples from patients with early stage hormone receptor-positive HER2-negative breast cancer. - [Study of RP-3500 With Rochester, MN; Scottsdale/Phoenix, AZ; Jacksonville, FL The primary purpose of this study is to assess the safety and tolerability of Niraparib or Olaparib in combination with RP-3500, in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD) of RP-3500 in combination with Niraparib or Olaparib, examine pharmacokinetics (PK) and assess anti-tumor activity. - [A Study To Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC](/research/clinical-trials/cls-20484363) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the effect of canakinumab or pembrolizumab as monotherapy or combined as neo-adjuvant treatment for subjects with early stage non-small cell lung cancer. - [Pembrolizumab Plus Epacadostat Alone or With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-02/ECHO-306)](/research/clinical-trials/cls-20423881) Rochester, MN The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus epacadostat alone or with platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy plus placebo as first-line therapy in participants with metastatic non-small cell lung cancer (NSCLC). - [Effectiveness and Safety of Pembrolizumab for Participants with Resectable Stage IIB or IIIA Non-small Cell Lung Cancer](/research/clinical-trials/cls-20441969) Jacksonville, FL; Rochester, MN This trial will evaluate the safety and effectiveness of pembrolizumab (MK-3475) in combination with platinum doublet neoadjuvant chemotherapy (NAC) before surgery [neoadjuvant phase], followed by pembrolizumab alone after surgery [adjuvant participants with resectable stage IIB lung cancer (NSCLC). Trial of Vigil in Ewing's Sarcoma](/research/clinical-trials/cls-20454815) Jacksonville, FL The purpose of this study is to determine the overall survival of patients treated with Vigil versus gemcitabine/docetaxel. - [Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases](/research/clinical-trials/cls-20323761) Rochester, MN; Eau Claire, WI; La Crosse, WI This randomized phase II trial studies how well cisplatin works with or without veliparib in treating patients with triple-negative breast cancer and/or BRCA mutation-associated breast cancer that has come back or has or has not spread to the brain. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known if cisplatin is more ... - [Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast La Crosse, WI; treatment patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy - [A Study to Evaluate the Immune Response to Anti-HER2 Therapies](/research/clinical-trials/cls-20492289) Jacksonville, FL The purpose of this study is to determine the correlation between HER2 specific T-cell response in HER2-positive breast cancer patients with stage I-IV who receive anti-HER2 therapies, such as trastuzumab, pertuzumab, lapatinib, or neratinib and clinical responses. - [A Study to Evaluate At Home Administration of Pertuzumab Combined with Trastuzumab to Treat Patients with HER2-Positive Breast Cancer During COVID-19 Pandemic](/research/clinical-trials/cls-20514660) Jacksonville, FL; Rochester, MN The purpose of this study is to assess the safety of PH FDC SC when administered at home by an HHNP. Patients will be assessed for safety by regular evaluation of AEs, vital signs, routine clinical laboratory tests (hematology, blood chemistry), LVEF assessments, and by physical examinations. - [A Study to Evaluate LY3484356 Alone or Combined with Anticancer Therapies to Treat Patients with Breast or Endometrial Cancer](/research/clinical-trials/cls-20511490) Jacksonville, FL; Rochester, MN The purpose of this study is to identify the recommended Phase 2 dose (RP2D) of LY3484356 administered as monotherapy and in combination with other anticancer therapies in patients with locally advanced or metastatic ER+ breast cancer or ER+ recurrent, persistent, endometrioid cancer (EEC). - [Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer](/research/clinical-trials/cls-20387111) Rochester, MN; Scottsdale/Phoenix, AZ This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body or cannot be removed by surgery or ovarian, fallopian tube, primary peritoneal, or triple-negative breast cancer that has come back. Olaparib and onalespib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. - [Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer](/research/clinical-trials/cls-20513512) Rochester, MN This is a single-arm, two-stage, phase II trial to assess the efficacy of futibatinib plus pembrolizumab in advanced hepatocellular carcinoma for patients with FGF19 expression. Patients will receive futibatinib 20mg daily Days 1-21 and will receive pembrolizumab 200mg Day 1 of each 21 day cycle per current clinical standard of care. Patient will receive treatment until disease progression or unacceptable toxicities. Patients will undergo restaging scans every 3 cycles. Subjects will be monitored for adverse events from the beginning of the study drug to 28 days after the last dose. We will collect blood samples for determination of cell ... - [Study of Pembrolizumab Combined with Cutaneous T-cell Lymphoma](/research/clinical-trials/cls-20459374) Rochester, MN The purpose of this research study is to determine the maximum tolerated dose and safety of three drug combinations. Each combination is assigned to a different treatment Arm. - [A Study of FT 2102 in Participants with Advanced Solid Tumors and Gliomas with an IDH1 Mutation](/research/clinical-trials/cls-20475815) Jacksonville, FL The purpose of this is to evaluate the safety, effectivess, pharmacokinetics, and pharmacodynamics of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas. The study is divided into two parts: single agent FT-2102 followed by combination therapy. Part 1: A single agent, open-label study in up to five cohorts (glioma, hepatobiliary tumors, chondrosarcoma, intrahepatic cholangiocarcinoma, and other IDH1 mutant solid tumors) that will include a Phase 1 dose confirmation followed by a Phase 2 investigation of clinical activity in up to 4 cohorts. During the dose confirmation, additional doses or ... - [(Z)-Endoxifen for the Treatment of Premenopausal Women Breast Cancer](/research/clinical-trials/cls-20542688) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to identify a (Z)-endoxifen dose that achieves (Z)-endoxifen steady-state plasma concentrations (Css) between 500-1000 ng/mL. Dosing will begin with the (Z)-endoxifen 40 mg/day dose and may additionally explore either a lower (20 mg/day) or higher (80 mg/day) dose level based on (Z)-endoxifen Css as well as toxicity. - [A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)](/research/clinical-trials/cls-20271979) Rochester, MN This is a phase 3 randomized trial evaluating the anti-tumor activity and safety of avelumab in combination with axitinib and of sunitinib monotherapy, administered as first-line treatment, in patients with advanced renal cell carcinoma - [Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer](/research/clinical-trials/cls-20531575) Jacksonville, FL The purpose of this study is to compare the effect of adding durvalumab to chemotherapy versus chemotherapy alone before surgery in treating patients with upper urinary tract cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as methotrexate, vinblastine, doxorubicin, cisplatin, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Durvalumab in combination with chemotherapy before surgery ... - [A Study to Evaluate Oral Tamoxifen vs. TamGel vs. Control in Women with Atypical Hyperplasia or Lobular Carcinoma In Situ](/research/clinical-trials/cls-20520844) Rochester, MN The purpose of this study is to analyze breast tissue changes after a short course of Tamoxifen (Tam). - [A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495)](/research/clinical-trials/cls-20453733) Jacksonville, FL; Rochester, MN The purpose of this study is to investigate the utility of biomarker-based triage for study participants with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy. Study participants within groups defined by a biomarker-based classifier (gene expression profile [GEP] and tumor mutational burden [TMB]) will be randomized to receive pembrolizumab in combination with MK-4280 or lenvatinib. The primary hypotheses are as follows: In participants receiving pembrolizumab in combination with either MK-4280 or lenvatinib, the Objective Response Rate (ORR) will be 1) greater than 5% among participants with low GEP and low TMB, 2) greater than 20% among participants with ... - [Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)](/research/clinical-trials/cls-20134470) Rochester, MN The purpose of this study is to evaluate the effectiveness and safety of Nivolumab in previously treated (cohorts, A, B & C) or newly diagnosed (cohort D) classical Hodgkin Lymphoma subjects. - [A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard MN AALL1731 is a group-wide risk-stratified trial with newly diagnosed B-ALL and localized B-lymphoblastic lymphoma (B-LLy) that will test if the addition of blinatumomab to standard chemotherapy in patients with NCI SR B-ALL at highest risk for relapse will improve disease-free survival (DFS). Risk stratification will be determined by traditional prognosticators (tumor genetics, extent of extramedullary involvement, early response to therapy as determined by flow cytometry) combined with the new DNA-based MRD detection technology of high throughput sequencing (HTS) of the immunoglobulin heavy chain (IgH). - [A Study to Measure the Proteins Expressed in tissue Samples from Women who have been Treated with New Endocrine Therapy for Invasive Lobular Breast Cancer](/research/clinical-trials/cls-20239997) Rochester, MN The purpose of this study is to compare the effectiveness of fulvestrant to anastrozole or tamoxifen in treating invasive lobular breast cancer, by measuring the level of the biomarker Ki67 found in tumor tissue before and then after treatment. - [A Study to Evaluate RP1 Monotherapy and Combined with Nivolumab](/research/clinical-trials/cls-20517717) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate the dose escalation and expansion of RP1 alone and combined with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary effectiveness. - [Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, Jacksonville, FL; Rochester, MN The purpose of this study is to compare the effect of adding cabozantinib to avelumab versus avelumab alone in treating patients with urothelial cancer that has spread to other places in the body (metastatic). Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib and avelumab together may further shrink the cancer or prevent it from returning/progressing. - [CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20522389) Rochester, MN The purpose of this study is to increase N2 nodal clearance (N2NC) to 50% or greater for combined platinum doublet chemotherapy with durvalumab induction therapy from historical rate of 30% for platinum doublet chemotherapy alone in patients with potentially resectable stage IIIA/B (N2) NSCLC. - [Avelumab In Patients With Previously Treated Advanced Stage Classical Hodgkin's Lymphoma (JAVELIN HODGKINS)](/research/clinical-trials/cls-20260187) Rochester, MN This is a Phase 1b, open-label, multi-center study comprising a lead-in phase and an expansion phase. The lead-in phase is a multiple-dose, randomized, parallel-arm, pharmacokinetic and pharmacodynamic study of avelumab as a single agent in adult patients with cHL. Patients enrolled in the lead-in phase of this study are required to have relapsed following a prior autologous or allogeneic HSCT, or to be ineligible for HSCT. Based on the preliminary TO, safety, and efficacy results from the lead-in phase, the expansion phase will evaluate the anti-tumor activity and safety of single-agent avelumab utilizing an intra-patient dose escalation paradigm based on ... - [A Study to Analyze CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma](/research/clinical-trials/cls-20515795) Scottsdale/Phoenix, AZ The purpose of this study is to determine confirmed objective response with CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma. It also aims to evaluate the safety and tolerability of CMP-001 administered by intratumoral (IT) injection in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma and to evaluate the effectiveness of CMP-001 in combination with nivolumab in subjects with refractory unresectable or metastatic melanoma. - [A Study of Mogamulizumab Combined with Nivolumab in Patients who have Locally Advanced or Metastatic Solid Tumors](/research/clinical-trials/cls-20363247) Jacksonville, FL The purpose of this study is to characterize the safety and tolerability of combined treatment with mogamulizumab and nivolumab, and also determine the maximum tolerated dose and the recommended fixed dose for the treatment of patients who have locally advanced or metastatic solid tumors. - [Niraparib + TSR042 In BRCA Mutated Breast Cancer](/research/clinical-trials/cls-20527528) Rochester, MN The purpose of this study is to evaluate pre-operative therapy that is specifically targeted for breast cancer in individuals with BRCA mutations. The drugs are Niraparib (Zejula) and Dostarlimab. - [Spatial and Molecular Architecture of Tumor Environments Responsive to IO (immuno-oncology) Therapy](/research/clinical-trials/cls-20358111) Rochester, MN The purpose of this study is to gain stepwise understanding of the fundamental biology governing human antitumor immunity, by systematic study of the tumor-immune interface at the level of the TME, taking advantage of the heterogeneity of different interacting tumor and immune cell subsets. - [A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer](/research/clinical-trials/cls-20439037) Scottsdale/Phoenix, AZ The purpose of this study is to determine whether an investigational immuno-therapy, cabiralizumab in combination with nivolumab, with or without chemotherapy, is effective for the treatment of advanced pancreatic cancer. - [A Study to Evaluate Estrogen Receptor (ER) Reactivation Therapy for Breast Cancer](/research/clinical-trials/cls-20474321) Rochester, MN The purpose of this study is to evaluate whether or not treatment with alternating 17B-estradiol / anti-estrogen therapies on a defined 8-week / 16-week schedule will more effectively prevent cancer growth than continuous treatment with either type of therapy in patients with metastatic anti-estrogen-resistant ER+ breast cancer. - [Chemotherapy With for Peritoneal Mesothelioma](/research/clinical-trials/cls-20524001) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this trial is to compare the usual treatment alone to using immunotherapy (atezolizumab) plus the usual treatment in treating patients with peritoneal mesothelioma. The usual treatment consists of surgery or chemotherapy. Chemotherapy drugs, such as carboplatin and pemetrexed, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the ... - [A Study to Better Understand How to Predict and Manage Patients Who are at High Risk for Developing Rheumatic Immune-related Adverse Events While Receiving Treatment for Melanoma](/research/clinical-trials/cls-20409728) Rochester, MN The purpose of this study is to: - Understanding how to better predict and manage patients at high risk for rheumatic irAEs and tailor therapy without diminishing cancer treatment efficacy and, - Further inform our understanding on the pathogenesis of classic rheumatologic diseases. - Establish a repository of biological samples from patients with irAE and corresponding rheumatologic - [A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with locally advanced unresectable or metastatic G/GEJ cancer (hereafter referred to as gastric cancer). Two cohorts will be enrolled in parallel in this study: the second-line (2L) Cohort will consist of patients with gastric cancer who have progressed after receiving a platinum-containing or fluoropyrimide-containing chemotherapy regimen in the first-line setting, and the first-line (1L) Cohort will consist of patients with gastric cancer who have not received prior chemotherapy in this setting. In each cohort, eligible ... - [A Study to Evaluate Chemotherapy-Induced Nausea in Breast Cancer Patients](/research/clinical-trials/cls-20509328) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of the study is to alleviate the occurrence of chemotherapy-induced nausea (CIN) and to improve chemotherapy treatment outcomes. Recent research has shown that changes in the functions performed by the gut microbiome can cause the occurrence of chemotherapy-induced symptoms that include chemotherapy-induced nausea. - [A Study to Evaluate Exemestane in Post-Menopausal Women with Non-Small Cell Lung Cancer (NSCLC)](/research/clinical-trials/cls-20480295) Albert Lea, MN; Mankato, MN This study is being conducted to see if adding Exemestane to the immune checkpoint blockade can slow disease progression in post-menopausal women with non-small cell lung cancer. - [A Study of MPDL3280A (Anti-PD-L1 Antibody) Combined with Carboplatin and Paclitaxel , and with or without Bevacizumab, for Patients who have Stage IV Non-Squamous Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20318079) Jacksonville, FL The purpose of this study is to evaluate the safety and effectiveness of a treatment of Atezolizumab (MPDL3280A) combined with carboplatin, paclitaxel, and with or without bevacizumab, versus carboplatin, paclitaxel and bevacizumab in patients with stage IV non-squamous non-small cell lung cancer who have never had chemo therapy. - [A Global Study to Assess the Effects of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer](/research/clinical-trials/cls-20164354) Scottsdale/Phoenix, AZ This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth factor - Prevention of Paclitaxel-Associated Neuropathy with Fingolimod](/research/clinical-trials/cls-20459309) Rochester, MN The purpose of this study is to determine if the use of Gilenya\u00ae can reduce neuropathy caused by paclitaxel. - [A Study Assessing the Effectiveness and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced Triple Negative Breast Cancer](/research/clinical-trials/cls-20493090) Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss without PIK3CA mutation (Study Parts B1 and B2) - [Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20526756) Rochester, MN The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treatment options - [A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)](/research/clinical-trials/cls-20463509) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This is an open-label, nonrandomized, Phase 1/2 study in subjects with advanced or metastatic solid tumors. Phase 1 is an assessment to evaluate the safety and tolerability of epacadostat when given in combination with pembrolizumab and chemotherapy. Once the recommended doses have been confirmed, subjects with advanced or metastatic CRC, PDAC, NSCLC (squamous or nonsquamous), UC, SCCHN or any advanced or metastatic solid tumor who progressed on previous therapy with a PD-1 or PD-L1 inhibitor will be enrolled in Phase 2. - [Combination Vaccine Immunotherapy (DRibbles) for Patients with Definitively-treated Stage III Non-small Cell Lung Cancer](/research/clinical-trials/cls-20151340) Scottsdale/Phoenix, AZ This study will test an investigational vaccine, called DRibbles, for the treatment of non-small cell lung cancer (NSCLC). We hypothesize that vaccination with the DRibble vaccine will cause an immune response against proteins contained in the DRibble vaccine and the protein antigens targeted by this strong immune response will include common antigens shared by both the vaccine and the patient's tumor. - [A Study to Evaluate a New Anti-Cancer Vaccine for Patients with Non-Small Cell Lung Cancer, Given After Tumor Removal by Surgery](/research/clinical-trials/cls-20311337) Rochester, MN The purpose of this clinical study is to assess the safety and effectiveness of the immunotherapeutic product GSK 2302032A when given to Non-Small Cell Lung Cancer (NSCLC) patients, after tumor removal by surgery. - [A Study to Evaluate Immunotherapy for Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20510162) Scottsdale/Phoenix, AZ The primary objectives of this study are to evaluate safety/tolerability and immunogenicity of IMU-201 as monotherapy and in combination with an immune checkpoint inhibitor (ICI) or an ICI and chemotherapy in participants with advanced NSCLC tumors that are positive for PD-L1, and to identify the Optimal Biological Dose (OBD) of IMU-201 as monotherapy and in combination with an ICI, or an ICI and chemotherapy, in participants with advanced NSCLC tumors that are positive for PD-L1. - [Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20143411) Jacksonville, FL The purpose of this study is to assess the effects of administration of daratumumab when combined with VELCADE (bortezomib) and dexamethasone compared with bortezomib and dexamethasone alone, for participants with relapsed or refractory multiple myeloma. - [Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma](/research/clinical-trials/cls-20111799) Rochester, MN This phase I trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin in treating patients with Hodgkin lymphoma that has returned after a period of improvement or has not responded to previous treatment. Monoclonal antibodies, such as ipilimumab and nivolumab, may interfere with the ability of cancer cells to grow and spread. Brentuximab vedotin is a combining monoclonal antibody with an anticancer drug that binds to a protein on the surface of lymphoma cells called cluster of differentiation (CD)30 and may kill the cells. Giving ipilimumab or nivolumab or both with ... - [A Study to Evaluate Immunotherapy and Ovarian Function Among Pre-menopausal Melanoma Survivors](/research/clinical-trials/cls-20516788) Rochester, MN The purposes of this study are to analyze the ovarian function of female premenopausal melanoma survivors who have undergone immunotherapy, and compare with data from age-matched controls, prospectively investigate ovarian function in premenopausal women with melanoma undergoing immunotherapy, and to identify the impact of ovarian function change on the frequency and function of CD8+ T cells during immunotherapy. - [The BEACON Study (Breast Cancer Outcomes With NKTR-102)](/research/clinical-trials/cls-20153364) Jacksonville, FL; Rochester, MN The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens. The primary study objective is to compare overall survival of patients who receive NKTR-102 given once every 21 days to patients who receive treatment of Physician's Choice selected from a list of seven single-agent intravenous therapies. - [SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab](/research/clinical-trials/cls-20502365) Rochester, MN The primary objective of this study is to determine the safety profile of SX-682 alone and in combination with pembrolizumab in subjects with metastatic melanoma, including the maximum dose that can be administered until adverse effects prevent further dose increases (i.e., the MTD or recommended phase 2 dose), and the dose-limiting toxicity (DLT). The secondary objectives are to evaluate the efficacy of SX-682 in combination with pembrolizumab on the basis of the objective response rate, the duration of response, and the rate of progression, and to characterize the single-dose and multidose pharmacokinetic (PK) profile of SX-682. Ovarian Carcinoma](/research/clinical-trials/cls-20470626) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the safety and tolerability, as well as some activity parameters, of TG4050 in patients with ovarian, fallopian or peritoneal serous carcinoma. - [Phase II Trial of Sargramostim and Nivolumab for Metastatic Melanoma to the Lung](/research/clinical-trials/cls-20542311) Rochester, MN This phase II trial is looking to see if sargramostim given with a nebulizer, in combination with standard immune checkpoint inhibitor therapy with nivolumab can help control melanoma that has metastasized to the lungs. - [A Study of Microvasculature Imaging of Breast Masses](/research/clinical-trials/cls-20308035) Rochester, MN The overall goal is to investigate the value of ultrasound imaging of small vasculature as a new biomarker for cancer characterization and early treatment evaluation. - [Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer](/research/clinical-trials/cls-20111746) Rochester, MN This randomized phase II trial studies radiation therapy and cisplatin with or without surgery in treating patients with stage III-IV oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with radiation therapy may kill more tumor cells. It is not yet known whether radiation therapy and cisplatin are more effective with or without surgery in treating patients with oropharyngeal cancer. - [A Study of MCLA-128 in Patients with Solid Tumors Harboring an NRG1 Fusion](/research/clinical-trials/cls-20471592) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to assess the safety, tolerability, movement (pharmcokinetics, \"PK\"), biological response (pharmacodynamics, \"PD\"), ability of the drug to provoke an immune response (immunogenicity) and anti-tumor activity of MCLA-128 in patients with solid tumors harboring an NRG1 fusion. - [An Early Access Program (EAP) for Avapritinib in Patients with Locally Advanced FL The purpose of this expanded access program is to provide access to avapritinib until such time that avapritinib becomes available through other mechanisms or the Sponsor chooses to discontinue the program. - [A Study to Evaluate Abemaciclib to Treat Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration](/research/clinical-trials/cls-20502977) Jacksonville, FL The purpose of this study is to evaluate the 12-week progression free survival (PFS) rate in treated subjects, based on historical sarcoma trial outcomes (PFS at 12 weeks 20% will be considered a negative outcome, and 12- week PFS rate of 40% or more will be considered positive). - [A Study to Evaluate Binimetinib in Combination with Encorafenib in Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate the side effects and how well the combination of binimetinib and encorafenib work in treating patients with pancreatic cancer with a somatic BRAF V600E mutation. Binimetinib and encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and encorafenib may work better compared to the usual treatment in treating patients with pancreatic cancer and a somatic BRAF V600E mutation. - [High-Dose Radiation Therapy Versus Standard Care in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery](/research/clinical-trials/cls-20111744) Rochester, MN; La Crosse, WI This randomized phase II trial studies how well standard systemic chemotherapy followed by intensified radiochemotherapy or standard radiochemotherapy preceded by intensified systemic chemotherapy works compared to standard systemic chemotherapy followed by standard radiochemotherapy in treating patients with pancreatic cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride or FOLFIRINOX, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as capecitabine, may make tumor cells more sensitive to radiation therapy. Giving ... - [Patient Self-sampling of HPV to Screen for Cervical Cancer](/research/clinical-trials/cls-20539802) Rochester, MN The purpose of this study is to validate a patient self-sampling vaginal collection kit and laboratory testing for the detection of HPV (human papillomavirus) infection. Its secondary aim is to assess the patient perspective on acceptability and feasibility of a self-sampling approach to cervical cancer screening through a survey of study enrollees. - [A Study Comparing BGB-3111 and Ibrutinib (WM)](/research/clinical-trials/cls-20391798) Scottsdale/Phoenix, AZ; Rochester, MN This study is to evaluate the safety, efficacy and clinical benefit of BGB-3111 vs ibrutinib in subjects with MYD88 Mutation Waldenstr\u00f6m's Macroglobulinemia. - [A Study to Evaluate Larotrectinib to Treat Patients with Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia](/research/clinical-trials/cls-20472685) Rochester, MN The purpose of this study is to evaluate the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. - [Characterizing Heart Changes Related to Chemo-Radiotherapy](/research/clinical-trials/cls-20469675) Scottsdale/Phoenix, AZ The purpose of this study is to determine the 12-month cardiac event rate after radiation or chemo-radiation for the treatment of lung or esophageal cancer. - [Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery](/research/clinical-trials/cls-20336945) Rochester, MN This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IV squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known if radiation therapy is more effective with or without cisplatin in treating patients with squamous cell ... - [A Study of Microvasculature Imaging of Breast Masses](/research/clinical-trials/cls-20308035) Rochester, MN The overall goal is to investigate the value of ultrasound imaging of small vasculature as a new biomarker for cancer characterization and early treatment evaluation. - [Radiation Therapy and Cisplatin With or Without Surgery in Treating Patients With Stage III-IV Oropharyngeal Cancer](/research/clinical-trials/cls-20111746) Rochester, MN This randomized phase II trial studies radiation therapy and cisplatin with or without surgery in treating patients with stage III-IV oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy with radiation therapy may kill more tumor cells. It is not yet known whether radiation therapy and cisplatin are more effective with or without surgery in treating patients with oropharyngeal cancer. - [A Study of MCLA-128 in Patients with Solid Tumors Harboring an NRG1 Fusion](/research/clinical-trials/cls-20471592) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to assess the safety, tolerability, movement (pharmcokinetics, \"PK\"), biological response (pharmacodynamics, \"PD\"), ability of the drug to provoke an immune response (immunogenicity) and anti-tumor activity of MCLA-128 in patients with solid tumors harboring an NRG1 fusion. - [An Early Access Program (EAP) for Avapritinib in Patients with Locally Advanced FL The purpose of this expanded access program is to provide access to avapritinib until such time that avapritinib becomes available through other mechanisms or the Sponsor chooses to discontinue the program. - [A Study to Evaluate Binimetinib in Combination with Encorafenib in Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate the side effects and how well the combination of binimetinib and encorafenib work in treating patients with pancreatic cancer with a somatic BRAF V600E mutation. Binimetinib and encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving binimetinib and encorafenib may work better compared to the usual treatment in treating patients with pancreatic cancer and a somatic BRAF V600E mutation. - [High-Dose Radiation Therapy Versus Standard Care in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery](/research/clinical-trials/cls-20111744) Rochester, MN; La Crosse, WI This randomized phase II trial studies how well standard systemic chemotherapy followed by intensified radiochemotherapy or standard radiochemotherapy preceded by intensified systemic chemotherapy works compared to standard systemic chemotherapy followed by standard radiochemotherapy in treating patients with pancreatic cancer that cannot be removed by surgery. Drugs used in chemotherapy, such as gemcitabine hydrochloride or FOLFIRINOX, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as capecitabine, may make tumor cells more sensitive to radiation therapy. Giving ... - [A Study to Evaluate Abemaciclib to Treat Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration](/research/clinical-trials/cls-20502977) Jacksonville, FL The purpose of this study is to evaluate the 12-week progression free survival (PFS) rate in treated subjects, based on historical sarcoma trial outcomes (PFS at 12 weeks 20% will be considered a negative outcome, and 12- week PFS rate of 40% or more will be considered positive). - [Patient Self-sampling of HPV to Screen for Cervical Cancer](/research/clinical-trials/cls-20539802) Rochester, MN The purpose of this study is to validate a patient self-sampling vaginal collection kit and laboratory testing for the detection of HPV (human papillomavirus) infection. Its secondary aim is to assess the patient perspective on acceptability and feasibility of a self-sampling approach to cervical cancer screening through a survey of study enrollees. - [A Study Comparing BGB-3111 and Ibrutinib (WM)](/research/clinical-trials/cls-20391798) Scottsdale/Phoenix, AZ; Rochester, MN This study is to evaluate the safety, efficacy and clinical benefit of BGB-3111 vs ibrutinib in subjects with MYD88 Mutation Waldenstr\u00f6m's Macroglobulinemia. - [A Study to Evaluate Larotrectinib to Treat Patients with Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia](/research/clinical-trials/cls-20472685) Rochester, MN The purpose of this study is to evaluate the side effects and how well larotrectinib works in treating patients with previously untreated TRK fusion solid tumors and TRK fusion acute leukemia that has come back. Larotrectinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. - [Characterizing Heart Changes Related to Chemo-Radiotherapy](/research/clinical-trials/cls-20469675) Scottsdale/Phoenix, AZ The purpose of this study is to determine the 12-month cardiac event rate after radiation or chemo-radiation for the treatment of lung or esophageal cancer. - [NL-201 in Patients With Relapsed or Refractory Cancer](/research/clinical-trials/cls-20522599) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to understand the safety of NL-201 when given intravenously as monotherapy in patients with advanced cancer to evaluate tolerability and to identify a recommended dose and schedule for further testing. - [A Study to Test Nivolumab with Usual Chemotherapy Treatment or Usual Chemotherapy Treatment Alone to Treat Recurrent or Metastatic Nasopharyngeal Cancer](/research/clinical-trials/cls-20509172) Jacksonville, FL The purpose of this study is to compare the effect of adding nivolumab to the usual chemotherapy (cisplatin or carboplatin with gemcitabine) versus the usual chemotherapy alone in treating patients with nasopharyngeal cancer that has come back (recurrent) or spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, carboplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by ... - [Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients](/research/clinical-trials/cls-20464383) Rochester, MN This study will test whether immune functions in individual cancer patients can be characterized in a quantitative manner using new technologies that analyze nucleic acids from peripheral blood cells and whether those quantitations can be used to predict the response outcomes of patients being treated with Pembrolizumab. - [A Study to Assess Dendritic Cell Immunotherapy Plus Standard-of-Care to Treat Advanced Renal Cell Carcinoma](/research/clinical-trials/cls-20520964) Rochester, MN The purpose of this study is to evaluate CMN-001 in a randomized trial between standard-of-care (SOC) (first line ipilimumab+nivolumab followed by second line lenvatinib+everolimus) with or without CMN-001. - [A Study to Evaluate Gemcitabine and MK-3475 (Pembrolizumab) with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer](/research/clinical-trials/cls-20488812) Scottsdale/Phoenix, AZ The purpose of this study is to assess the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Drugs used in chemotherapy, such as gemcitabine, work in different ways by stopping the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the patient's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding pembrolizumab to gemcitabine ... - [Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer](/research/clinical-trials/cls-20453011) Rochester, MN RATIONALE: Giving calcium together with magnesium may stop or delay the development of peripheral neuropathy in patients with cancer who are receiving treatment with ixabepilone. It is not yet known whether calcium and magnesium are more effective than a placebo in preventing peripheral neuropathy caused by ixabepilone. PURPOSE: This randomized phase III trial is studying calcium given together with magnesium to see how well it works compared with a placebo in preventing peripheral neuropathy caused by ixabepilone in patients with breast cancer. - [A Study of Pembrolizumab Alone or Combined with CC-486 for Patients with Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer](/research/clinical-trials/cls-20316365) Rochester, MN The purpose of the study is to determine the best dose of CC-486 (oral azacitidine) combined with pembrolizumab for the treatment of platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer. - [A Study of ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer](/research/clinical-trials/cls-20308205) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to assess the effectiveness, safety, biological activity, and drug/body interactions of ACP-196 alone and combined with Pembrolizumab for the treatment of patients who have advanced or metastatic pancreatic cancer. - [A Study to Evaluate Pemetrexed Jacksonville, FL; Rochester, MN The purpose of this study is to determine the response rate of the combination of Pemetrexed and Pembrolizumab in patients with recurrent With or Without Goserelin Acetate Treating Patients With Stage II-III Breast Cancer](/research/clinical-trials/cls-20112344) Scottsdale/Phoenix, AZ; Rochester, MN This phase II studies how well Akt inhibitor MK-2206 (MK-2206) and anastrozole with or without goserelin acetate works in treating patients with stage II-III breast cancer. MK-2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole and goserelin acetate may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving MK-2206, anastrozole, and goserelin acetate together may kill more cancer cells. - [A Study to Evaluate DS-1062a Combined with Pembrolizumab in Advanced or Metastatic Non-Small Cell Lung Cancer Without Genomic Alterations ](/research/clinical-trials/cls-20503525) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This study will assess safety and treatment activity of DS-1062a in combination with pembrolizumab in participants with advanced or metastatic NSCLC without actionable genomic alterations who have had previously treated with platinum-based therapy with or without prior immunotherapy. - [A Study to Evaluate PDS0101 and Pembrolizumab Combination to Treat Subjects with HPV16 + Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma](/research/clinical-trials/cls-20505329) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the effectiveness and safety of PDS0101 administered in combination with Pembrolizumab in the first line treatment of adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). - [A Phase 2 Study of Anti-PD-L1 Antibody Atezolizumab in Alveolar Soft Part Sarcoma](/research/clinical-trials/cls-20366152) Rochester, MN Sometimes the cancer advanced alveolar soft part sarcoma (ASPS) cannot be helped with surgery or other treatment. The drug atezolizumab unblocks the immune system. This allows immune cells to recognize and attack tumor cells. The drug could shrink cancer but could also have side effects. Researchers want to study if the drug will shrink a tumor in people with advanced ASPS. Objective: To test good and bad effects of the drug atezolizumab. Eligibility: People at least 6 years old with ASPS that cannot be cured with surgery Design: Participants will be screened with heart and pregnancy tests. Some may ... - [M6620 First in Human Study](/research/clinical-trials/cls-20306556) Scottsdale/Phoenix, AZ; and Pharmacokinetics (PK) of M6620 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors - [A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab](/research/clinical-trials/cls-20425957) Scottsdale/Phoenix, AZ; Jacksonville, FL; multi-center, dose-escalation of PT-112 in combination with the anti-PD-L1 antibody, avelumab, in selected advanced solid tumors. The study is to be conducted in two parts: the Dose Escalation Phase of PT-112 within the combination and the Dose Confirmation Phase. The Dose Escalation Phase will determine the Maximum Tolerated Dose (MTD) and recommended Phase 2 dose (RP2D) of PT-112 in the combination as avelumab will be administered at a flat dose of 800 mg. The trial will evaluate the PK (pharmacokinetic) effects of PT-112 and the safety and tolerability of the combination as ... - [A Study to Evaluate Pembrolizumab, Ixazomib Citrate, and Dexamethasone to Treat Participants with Relapsed Multiple Myeloma](/research/clinical-trials/cls-20425426) Rochester, MN This phase II trial studies how well pembrolizumab works when given together with ixazomib citrate and dexamethasone in treating participants with multiple myeloma that has come back. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Ixazomib citrate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab together ... - [A Study to Determine Molecular Mechanisms in Breast Implant Associated-Anaplastic Large Cell Lymphoma](/research/clinical-trials/cls-20461647) Jacksonville, FL The purpose of this study is to utilize the systematic application of transcriptome-wide microarray to measure differential gene expression in banked breast implant associated-anaplastic large cell lymphoma (BIA-ALCL) tumor specimens and healthy control - [Doxorubicin Hydrochloride, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab With Stage I-II Hodgkin Lymphoma](/research/clinical-trials/cls-20410691) Rochester, MN This phase II trial evaluates how well AVD (doxorubicin hydrochloride, vinblastine, dacarbazine) in combination with brentuximab vedotin and nivolumab work in treating patients with stage I-II Hodgkin lymphoma. Drugs used in the chemotherapy, such as doxorubicin hydrochloride, vinblastine, dacarbazine, and brentuximab vedotin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, and/or by stopping them from spreading. Targeted agent, such as nivolumab, may interfere with the ability of cancer cells to grow and spread by enhancing the immune system. Giving doxorubicin hydrochloride, vinblastine, dacarbazine, Neuropathy ](/research/clinical-trials/cls-20467375) Rochester, MN The purpose of this study is to collect clinical and biomarker data from patients receiving neurotoxic chemotherapy who are at risk for developing Chemotherapy-induced Peripheral Neuropathy (CIPN). - [Study of Pembrolizumab Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (MK-3475-177/KEYNOTE-177)](/research/clinical-trials/cls-20203472) Scottsdale/Phoenix, AZ; Rochester, MN; MN study, participants with MSI-H or dMMR advanced colorectal carcinoma will be randomly assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for the treatment of advanced colorectal carcinoma. The primary study hypothesis is that pembrolizumab will prolong progression-free survival (PFS) or overall survival (OS) compared to current SOC chemotherapy. - [I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer](/research/clinical-trials/cls-20116766) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to further advance the ability to practice personalized medicine by learning which new drug agents are most effective with which types of breast cancer tumors and by learning more about which early indicators of response (tumor analysis prior to surgery via magnetic resonance imaging (MRI) images along with tissue and blood samples) are predictors of treatment success. - [Genetics of Chemotherapy-Related Amenorrhea in Breast Cancer Survivors](/research/clinical-trials/cls-20306910) Rochester, MN The purpose of this study is to assess genetic predictors of chemotherapy-related amenorrhea in breast cancer survivors of both European and non-European ancestry. - [Phase 1 Study of Oral TP-1454](/research/clinical-trials/cls-20509127) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to establish the safety of oral TP-1454 administered once daily in patients with advanced metastatic or progressive solid tumors as monotherapy and in patients who are eligible for standard of care treatment with ipilimumab and nivolumab as combination therapy, and to establish the dose of TP-1454 recommended to be used alone and in combination with ipilimumab and nivolumab in future studies for selected advanced solid tumors. - [A Study of Nivolumab in Relapsed/Refractory Primary Central Primary Testicular Lymphoma (PTL)](/research/clinical-trials/cls-20308387) Rochester, MN The purpose of this study is to determine whether Nivolumab is effective in the treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Relapsed/Refractory Primary Testicular Lymphoma (PTL) - [Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma](/research/clinical-trials/cls-20199984) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and to assess the safety and tolerability of this combination therapy. - [A Study Evaluating the Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma](/research/clinical-trials/cls-20409731) Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to determine if axicabtagene ciloleucel is superior to standard of care (SOC) as measured by event-free survival (EFS), as determined by blinded central review. - [A Study to Evaluate Pembrolizumab for Surgically Treated Adjuvant Merkel Cell Carcinoma](/research/clinical-trials/cls-20449889) Eau Claire, WI; Rochester, MN The purpose of this study is to determine how well pembrolizumab works compared to standard of care observation in treating patients with stage I-III Merkel cell cancer that has been completely removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. - [Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer](/research/clinical-trials/cls-20480286) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This phase II trial studies how well anastrozole and letrozole after surgery work in treating patients with stage I-III breast cancer. Drugs, such as anastrozole and letrozole may stop the growth of tumor cells by decreasing the amount of estrogen made by the body. Giving anastrozole and letrozole after surgery may prevent breast cancer from coming back (recurrence). - [A Study to Evaluate the Efficacy of a Hybrid Imaging and Measurement Tool for Breast Cancer Detection and Monitoring](/research/clinical-trials/cls-20320671) Rochester, MN The purpose of this research is to optimize and evaluate the efficacy of a hybrid imaging and quantitative viscoelasticity measurement tool for breast cancer detection and monitoring. - [First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b](/research/clinical-trials/cls-20530076) Jacksonville, FL; Rochester, MN The primary objective of this study is to determine the confirmed investigator-assessed objective response rate of XMT-1536 (upifitamab rilsodotin) in patients with higher (NaPi2b) expressing platinum-resistant high-grade serous ovarian cancer (HGSOC), including cancers of ovarian, fallopian tube or primary peritoneal origin) Note: Mayo Clinic is only participating in the Phase 2 - Cohort 3 (UPLIFT) portion of the study. Mayo Clinic will not be participating in the QTC sub-study. - [MElanoma Research Lymph node prediction Implementation National_001 (MERLIN_001)](/research/clinical-trials/cls-20517575) Rochester, MN This study aims to create a registry for primary melanoma gene-signature to predict sentinel node (SN) status and determine its prognostic value for more accurate staging of SN-negative melanoma patients. - [A Study of ](/research/clinical-trials/cls-20479117) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate dose escalation and expansion of MT-5111 (a recombinant fusion protein) in subjects with HER2-positive solid tumors. - [A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors](/research/clinical-trials/cls-20533785) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the safety, tolerability, and preliminary effectiveness of ZB131 in patients with solid tumors where prevalence of CSP expression is high. - [Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia](/research/clinical-trials/cls-20111992) No Locations This phase II trial studies how well ibrutinib works in treating patients with relapsed hairy cell leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. - [Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy](/research/clinical-trials/cls-20170202) Jacksonville, FL This phase II trial studies the side effects and how well ibrutinib works in treating patients with chronic lymphocytic leukemia who responded to initial treatment used to reduce a cancer (front-line therapy) but have residual disease. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. - [A Trial to Evaluate the Safety of GEN1046 in Patients with Malignant Solid Tumors](/research/clinical-trials/cls-20490430) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this trial is to evaluate the safety of GEN1046 in patients with malignant solid tumors. - [A Study to Evaluate a Standard-dose and High- dose Regimen of Encorafenib + Binimetinib in Patients with BRAFV600-mutant Melanoma Brain Metastasis](/research/clinical-trials/cls-20474785) Rochester, MN The purpose of this study is to assess the safety, effectiveness and pharmacokinetic (PK) of 2 dosing regimens of encorafenib + patients with BRAFV600-mutant melanoma with brain metastasis. - [A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment](/research/clinical-trials/cls-20534942) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding to treatment or has not responded to treatment (relapsed/refractory multiple myeloma). This study will also look at the safety and effectiveness of different doses of elranatamab, as well as different intervals between doses. Participants in the study will receive elranatamab as an injection under the skin at the study clinic. After the initial step-up doses, participants will start receiving one dose every ... - [Comparing the Investigational Imaging System with Sonography](/research/clinical-trials/cls-20316541) Rochester, MN The short-term goal of the proposed research is to develop a new method for viscoelasticity imaging of breast that can work with any type of wave, and not restricted to plane shear waves. The long-term goal of this project is to develop an ultrasound-based breast imaging technique to improve the diagnostic specificity in breast cancer. - [Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC](/research/clinical-trials/cls-20536334) Rochester, MN The main purpose of the study is to evaluate safety and effectiveness of taletrectinib (also known as AB-106 or DS-6051b) monotherapy in the treatment of advanced NSCLC. - [Specialized Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery](/research/clinical-trials/cls-20112247) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to test the safety of radiation therapy given at increased doses in a shorter period of time in order to find out what effects, good and/or bad, it has on the patient and the lung cancer. The standard way of giving the radiation therapy is to give it once daily for 6 to 7 weeks. The study is currently testing if a higher amount of radiation therapy per treatment can be given as well as shorten the total number of treatments to 4 or 5 weeks. The goal is that a higher dose of ... - [A Study of LY2875358 in Non Small Cell Lung Cancer (NSCLC) Participants](/research/clinical-trials/cls-20111933) Scottsdale/Phoenix, AZ; Rochester, MN The primary purpose of this study is to evaluate the efficacy of the study drug known as LY2875358, administered alone or in combination with a second drug named Erlotinib, in participants affected by a defined type of lung cancer (MET biomarker diagnostic positive Non-Small-Cell Lung Cancer) that experienced a disease progression during the most recent treatment with Erlotinib. - [Phase IIb Study of Dasatinib Versus Imatinib in Patients With CML-CP Who Have Not Achieved an Early Optimal Response to Imatinib](/research/clinical-trials/cls-20115571) Rochester, MN The study purpose is to test the hypothesis that patients with Chronic phase-Chronic Myeloid Leukemia (CP-CML) with BCR-ABL transcript level > 10% International Standard (IS) after 3 months of treatment with first line Imatinib 400mg will achieve a greater rate of major molecular response (MMR) by early switching to Dasatinib therapy 100mg once daily (QD) compared with continued treatment with Imatinib at any dose. - [A Study to Evaluate the Safety and Effectiveness of JBH492 in Patients with Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma](/research/clinical-trials/cls-20486464) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary effectiveness of agent. - [A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma](/research/clinical-trials/cls-20314177) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety/tolerability and efficacy of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) - [A Study Desorption Electrospray Ionization Mass Spectrometry for Intraoperative Molecular Diagnosis of Brain Cancer](/research/clinical-trials/cls-20478654) Jacksonville, FL The purpose of this study is to explore the translational abilities of desorption electrospray ionization mass spectrometry (DESI-MS) as intraoperative diagnostic tool to identify cancerous versus noncancerous tissue and estimate the percentage of tumor infiltration in tissue biopsies, by monitoring depletion of N-acetylaspartate (NAA) and aberrations of the phospholipid signature of neurological tissue; and to identify the presence of IDH mutations by monitoring the 2-hydroxyglutarate (2HG) and, therefore, differentiate between IDH-mutant and wild-type gliomas. (BMT CTN 1301)](/research/clinical-trials/cls-20207286) Rochester, MN The study is designed as a three arm randomized Phase III, multicenter trial comparing two calcineurin inhibitor hematologic malignancies undergoing myeloablative conditioning hematopoietic stem cell transplantation. - [TheraSphere With and Without Durvalumab and Tremelimumab for HCC](/research/clinical-trials/cls-20533342) Jacksonville, FL The objective of the ROWAN clinical study is to assess the the durability of local tumor control in Hepatocellular Carcinoma (HCC) patients who receive TheraSphere followed by durvalumab and tremelimumab, compared to those who receive TheraSphere treatment alone. - [Breast Cancer: Can We Predict Pathological Complete Response following Neoadjuvant Treatment?](/research/clinical-trials/cls-20308371) Scottsdale/Phoenix, AZ This project will investigate whether ctDNA analysis in newly diagnosed stage I, II, III breast cancer patients treated with neoadjuvant systemic therapy can predict pathological Complete Response (pCR). - [Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer](/research/clinical-trials/cls-20405974) Rochester, MN This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC). The Following drugs will be use in combination with Ruxolinitinib. - Paclitaxel (also called Taxol) - Doxorubicin also called Adriamycin - Cyclophosphamide, also called Cytoxan - [Pregnancy Outcome and Safety of Interrupting Therapy for Women With Endocrine Responsive Breast Cancer](/research/clinical-trials/cls-20310178) Rochester, MN The best available evidence suggests that pregnancy after breast cancer does not increase a woman's risk of developing a recurrence from her breast cancer. In particular, the most recent data suggest that this is the case also in women with a hormone receptor-positive breast cancer. There is also no indication of increased risk for delivery complications or for the newborn. The aim of the study is to investigate if temporary interruption of endocrine therapy, with the goal to permit pregnancy, is associated with a higher risk of breast cancer recurrence.The study aims also to evaluate different specific indicators related to ... - [Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery](/research/clinical-trials/cls-20450323) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN RATIONALE: chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with trastuzumab and lapatinib after surgery may kill ... - [A Safety Study of SGN-LIV1A in Breast Cancer Patients](/research/clinical-trials/cls-20111716) Rochester, MN This study will examine the safety and tolerability of SGN-LIV1A in patients with metastatic breast cancer. SGN-LIV1A will be given every 3 weeks alone or in combination with trastuzumab. - [A Study to Evaluate the Use of Organoids to Advance Precision Medicine in Bladder Cancer](/research/clinical-trials/cls-20505058) Rochester, MN The purpose of this study is to develop patient-derived organoid cultures of urothelial carcinoma from non-invasively obtained urine samples and to characterize the histological, molecular and functional features of patient-derived organoids. - [A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma](/research/clinical-trials/cls-20502163) Jacksonville, FL The purpose of this study is to test the safety and effectives of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma (SS) in children and young adults. This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond. - [Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck](/research/clinical-trials/cls-20474101) Rochester, MN This randomized phase II/III trial studies how well radiation therapy works when given together with cisplatin compared to docetaxel or cetuximab and docetaxel after surgery in treating patients with stage III-IV squamous cell head and neck cancer. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab, can ... - [Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations](/research/clinical-trials/cls-20460379) Rochester, MN The purpose of this study is to evaluate how well veliparib, radiation therapy, and temozolomide work in treating participants with newly diagnosed malignant glioma without H3 K27M or BRAFV600E mutations. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib, radiation therapy, and temozolomide ... - [A Study to Evaluate CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma](/research/clinical-trials/cls-20457165) Rochester, MN The purpose of this study is to determine the best dose of CB-839 HCl when given together with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back or does not respond to previous treatment. CB-839 HCl and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CB-839 HCl, carfilzomib, and dexamethasone may work ... - [A Study of Donor Stem Cell Transplant in Treating Young Patients With Acute Myeloid Leukemia, or Refractory or Relapsed Acute Myelogenous Leukemia](/research/clinical-trials/cls-20151149) Rochester, MN RATIONALE: Giving chemotherapy before a donor stem cell transplant using stem cells that closely match the patient's stem cells, helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving antithymocyte globulin before transplant and cyclosporine, tacrolimus, and methotrexate before and after transplant may stop this from happening. PURPOSE: Natural Killer (NK) ... an international, multi-center, open-label, randomized, Phase III study in patients with metastatic TNBC refractory or relapsing after at least 2 prior chemotherapies (including a taxane) for their metastatic disease. Patients meeting eligibility will be randomized 1:1 to receive either sacituzumab govitecan or treatment of physician choice (TPC), which needs to be selected prior to randomization from one of the 4 allowed regimens. Randomization will be stratified by number of prior chemotherapies for advanced disease (2-3 vs > 3) and geographical location (North America vs Europe). Patients will be treated until progression, unacceptable toxicity, study withdrawal, or death, whichever ... - [Semen Analysis in Chemotherapy](/research/clinical-trials/cls-20315028) Rochester, MN The purpose of this study is to correlate the impact of chemotherapy on semen analysis and the disease-free survival of patients undergoing gonadotoxic treatment for leukemia or lymphoma. - [informCLL: A Disease Registry for Patients With Chronic Lymphocytic Leukemia](/research/clinical-trials/cls-20438471) Jacksonville, FL The purpose of the InformCLL Registry is to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL /SLL therapies/regimens. This study also evaluates association of treatment patterns with patient characteristics, healthcare resource utilization and patient reported Health related Quality of Life (HRQoL). - [A Study to Evaluate the Safety, Tolerability, of WSD0922-FU](/research/clinical-trials/cls-20473609) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of WSD0922-FU in subjects with recurrent glioblastoma, cancer (NSCLC). - [Specialty Compared to Oncology Delivered Palliative Care for Treating Acute Myeloid Leukemia](/research/clinical-trials/cls-20532387) Rochester, MN The purpose of this study is to evaluate whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML). - [Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors](/research/clinical-trials/cls-20535467) Rochester, MN The purpose of this study is to evaluate the safety and effectiveness of using Exablate Model 4000 Type-2.0/2.1 in adults with Glioblastoma brain tumors to increase temporarily the permeability of the blood brain barrier, allowing increased passage of circulating free DNA (cfDNA) for sampling and analysis. - [A Study Assessing the Effectiveness and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women who have Advanced Breast Cancer which Progressed on or after Aromatase Inhibitor Treatment](/research/clinical-trials/cls-20243717) Scottsdale/Phoenix, AZ The purpose of this study is to determine whether treatment with alpelisib plus fulvestrant will lengthen progression-free survival compared to fulvestrant and a placebo in men and postmenopausal women who have hormone receptor positive (HR+), HER2-negative advanced breast cancer. - [Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 Fusions](/research/clinical-trials/cls-20145283) Scottsdale/Phoenix, AZ; Rochester, MN This pilot phase II trial studies how well ponatinib hydrochloride works in treating patients with biliary cancer that has spread to other places in the body and that have alterations (fusions) in a gene known as fibroblast growth factor receptor 2 (FGFR2). Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. - [(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive](/research/clinical-trials/cls-20116725) Rochester, MN The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with FMS-like tyrosine kinase 3 - Internal Tandem Duplication (FLT3-ITD) positive AML who are refractory to or have relapsed within 6 months, after first-line AML therapy. - [Elevate CLL R/R: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Subjects With High Chronic Lymphocytic Leukemia](/research/clinical-trials/cls-20189127) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN to evaluate PFS endpoint for acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia. - [A Study of Three-dimensional (3-D) Tissue Models in Patients with Serous Endometrial Cancer Planning to Undergo Surgery](/research/clinical-trials/cls-20359615) Rochester, MN The purpose of this research study is to learn more about serous endometrial cancer by creating three-dimensional (3-D) tissue models in the laboratory setting. The tissue models will provide scientists with a reliable, sensitive method to test biomarkers and cellular responses to treatment for endometrial cancer. - [Pembrolizumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Merkel Cell Cancer](/research/clinical-trials/cls-20426682) Rochester, MN This randomized phase II trial studies how well pembrolizumab with or without stereotactic body radiation therapy works in treating patients with merkel cell cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving pembrolizumab with stereotactic body radiation therapy may work better in treating patients with merkel cell cancer. - [Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma](/research/clinical-trials/cls-20151080) No Locations This phase III trial is studying how well giving combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed Hodgkin lymphoma. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high energy x-rays to kill cancer cells. Giving combination chemotherapy together with radiation therapy may kill more cancer cells. - [A Study to Evaluate the Surgical Removal of Residual Brain Tumors Prior to Recurrence](/research/clinical-trials/cls-20509903) Rochester, MN The purpose of this study is to evaluate the safety and feasibility of surgical resection for pre-recurrent brain tumors. Eligible patients with surgically accessible latent tumors desiring surgical resection will be enrolled to prospectively track short- and long-term outcomes. Safety will be evaluated by quantifying rates of surgical morbidity as compared to patients undergoing RT after surgery, or no surgery for similar latent disease. Variables evaluated will include postoperative complications including death within 30 days, wound infection, length of hospital stay, and readmission rates. - [A Study to Determine the Best Individualized Cancer Therapy Using Circulating Tumor DNA (ctDNA) in Patients with GI, CNS, and Thoracic Cancers.](/research/clinical-trials/cls-20438430) Jacksonville, FL This study proposes to develop and maintain a biorepository of blood samples collected from patients receiving definitive chemoradiotherapy for locally advanced rectal cancer, locally advanced pancreatic cancer, non-small cell lung cancer, or cervical cancer. The ultimate goal of this biorepository will be to provide the resource to initiate an exploration of ctDNA as a potential liquid biopsy for GI and Thoracic malignancy detection and surveillance. - [Expanded Access Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer](/research/clinical-trials/cls-20336194) Rochester, MN The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program. - [Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma](/research/clinical-trials/cls-20530183) Jacksonville, FL The purpose of this study is to evaluate abemaciclib versus placebo to treat Advanced Dedifferentiated Liposarcoma. Patients with progression of disease will cross over to open label abemaciclib. - [Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20145353) Scottsdale/Phoenix, AZ This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving selinexor, carfilzomib, and dexamethasone may be a better treatment for ... - [A Study of HFB200301 in Adult Patients With Advanced Solid Tumors](/research/clinical-trials/cls-20532537) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to test the safety and tolerability of HFB200301 in patients with advanced cancers. There are two parts in this study. During the escalation part, groups of participants will receive increasing doses until a safe and tolerable dose of HFB200301 is determined. During the expansion part, participants will take the dose of study drug that was determined from the escalation part of the study and will be assigned to a group based on the type of cancer the participants have. - [Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma](/research/clinical-trials/cls-20403517) Rochester, MN This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as ... - [A Comparison Study to Cross-validate the Linear Analogue Self-Assessment (LASA), Patient-Reported Outcomes Measurement Information System (PROMIS), and Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Assessing Cancer Patient Well-being](/research/clinical-trials/cls-20314844) Rochester, MN This study is being done to compare questions from a large set of questions called the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), the Patient-reported Outcomes Measurement Information System (PROMIS) and the Linear Analogue Self-Assessment (LASA). These are questions which ask patients about their symptoms. This study will look at properties of these questions and will provide information about how these questions can be improved for future clinical trials. The study items have been developed under a contract from the National Cancer Institute (NCI). - [Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer](/research/clinical-trials/cls-20143929) Rochester, MN This research is being done to determine if early changes on a type of imaging procedure called PET (Positron Emission Tomography) can predict which patients are most likely to respond to the combination of trastuzumab and pertuzumab when given prior to surgery. - [Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Cancer Undergoing Surgery](/research/clinical-trials/cls-20144027) Scottsdale/Phoenix, AZ; Rochester, MN This randomized phase III trial has several primary objectives. One primary objective is to compare the efficacy of 3 different endocrine therapies, the estrogen receptor down regulator fulvestrant and the aromatase inhibitor anastrozole, either alone or in combination, in reducing cancer growth before surgery (neoadjuvant) in postmenopausal women with clinical stage II-III estrogen receptor positive and HER2 negative breast cancer. Another primary objective is to evaluate whether patients who achieved a modified PEPI (Preoperative Endocrine Prognostic Index) score of 0, defined by tumor size <5 cm,=\"\" n0,=\"\">5><2.7% (by central testing), at surgery post post 6 months of neoadjuvant endocrine therapy ... > - [Perfusion MRI for Therapy Response Assessment in Brain Cancer](/research/clinical-trials/cls-20525379) Scottsdale/Phoenix, AZ The purpose of this study is to improve patient care by optimizing and measuring magnetic resonance imaging methods for the early detection of brain cancer response to therapy. - [A Study to Establish a Platform for Managing Pancreatic Adenocarcinoma Using Patient-derived Tumoroids](/research/clinical-trials/cls-20510163) Jacksonville, FL The purposes of this study are to determine the optimal patient-derived tumoroid (PDT) model, to determine the feasibility of establishing patient-derived tumoroids (PDT) as a platform for a personalized approach for response prediction and guide optimal neoadjuvant and/or adjuvant approach, to determine drug sensitivity, predict the response to chemotherapy agents and radiation therapy, and validate this response in treated patients, and to establish PDT as a platform for a personalized approach to guide multimodality treatment. - [A Study to Evaluate Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment for Stage I-IIIA Malignant Pleural Mesothelioma](/research/clinical-trials/cls-20507811) Rochester, MN The purpose of this study is to determine how well the addition of targeted radiation therapy to surgery and the usual chemotherapy treatment works for the treatment of stage I-IIIA malignant pleural mesothelioma. Targeted radiation therapy such as intensity-modulated radiation therapy or pencil beam scanning uses high energy rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving targeted radiation therapy in addition to surgery ... - [Pemigatinib to Treat Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to assess how well Pemigatinib works in treating patients with colorectal cancer with mutations (alterations) in a FGFR gene and that has spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Pemigatinib may stop the growth of tumor cells by blocking FGFR, which is needed for cell growth. - [Neratinib +/- in Cancer](/research/clinical-trials/cls-20111679) Rochester, MN This phase II study will test cancer to see if it has a HER2 mutation and, if so, see how HER2 mutated cancer responds to treatment with neratinib. - [Veliparib and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer](/research/clinical-trials/cls-20366139) Jacksonville, FL; Rochester, MN This randomized phase II trial studies how well veliparib works with combination chemotherapy and radiation therapy in treating patients with rectal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced). Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as modified (m)FOLFOX6 regimen, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells ... - [First In Human (FIH) Study of REGN5459 in Patients With Relapsed or Refractory Multiple Myeloma (MM)](/research/clinical-trials/cls-20485748) Rochester, MN The purpose of this study is to assess the safety, tolerability, and dose-limiting toxicities (DLTs) and to determine a recommended phase 2 dose regimen (RP2DR) (defined as either a maximum tolerated dose regimen [MTDR] or biologically effective dose regimen [BEDR]) of REGN5459 as monotherapy in patients with relapsed or refractory multiple myeloma (MM) who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit. - [Radiation Therapy, Paclitaxel, and Carboplatin with or without Trastuzumab in Treating Patients with Esophageal Cancer](/research/clinical-trials/cls-20115992) Scottsdale/Phoenix, AZ; Rochester, MN This randomized phase III trial studies how well radiation therapy, paclitaxel, and carboplatin with or without trastuzumab work in treating patients with esophageal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to ... - [A Study Using Targeted Inhibitors to Treat Specific Tumor Mutations in Patients with Meningiomas](/research/clinical-trials/cls-20169983) Jacksonville, FL; Rochester, MN This phase II trial studies how well vismodegib and focal adhesion kinase (FAK) inhibitor GSK2256098 work in treating patients with meningiomas that may have gotten bigger or grew back after treatment. Vismodegib and FAK inhibitor GSK2256098 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. - [A Study of the Safety and Effectiveness of Combined Toca 511 and Toca FC for Patients Having Removal Surgery for Recurring Glioblastoma or Anaaplastic Astrocytoma](/research/clinical-trials/cls-20359595) Jacksonville, FL The purpose of this study is to assess the safety and effectiveness of combined Toca 511 and Toca FC, versus a standard of care single agent chemotherapy, for patients who are having surgery to remove a first or second recurrence of glioblastoma or anaplastic astrocytoma. - [A Study to Evaluate Ablation in Patients with A Soft-Tissue Liver Lesion](/research/clinical-trials/cls-20506122) Rochester, MN The purpose of this study is to evaluate the use of the NEUWAVE MicroWave Ablation System with AC (Ablation Confirmation) software in patients undergoing ablation of a soft tissue liver lesion. - [Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With II-III Cancer Undergoing Surgery](/research/clinical-trials/cls-20144027) Scottsdale/Phoenix, AZ; Rochester, MN This randomized phase III trial has several primary objectives. One primary objective is to compare the efficacy of 3 different endocrine therapies, the estrogen receptor down regulator fulvestrant and the aromatase inhibitor anastrozole, either alone or in combination, in reducing cancer growth before surgery (neoadjuvant) in postmenopausal women with clinical stage II-III estrogen receptor positive and HER2 negative breast cancer. Another primary objective is to evaluate whether patients who achieved a modified PEPI (Preoperative Endocrine Prognostic Index) score of 0, defined by tumor size <5 cm,=\"\" n0,=\"\">5><2.7% (by central testing), at surgery post post 6 months of neoadjuvant endocrine therapy ... > - [Impact of Neoadjuvant Chemotherapy on the Peripheral Blood Immune Phenotype in Operable Breast Cancer, the ENHANCE Study](/research/clinical-trials/cls-20513567) Rochester, MN The purposes of this study are to evaluate whether pre-NAC peripheral blood immune phenotypes (defined by mass cytometry) are associated with pathologic complete response (pCR) after neoadjuvant chemotherapy in patients with operable breast cancer, and to evaluate whether the baseline peripheral blood immune phenotype differs between patients with breast cancer and age-matched healthy controls. - [A Study to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors](/research/clinical-trials/cls-20505631) Rochester, MN; Jacksonville, FL To evaluate the effectiveness of NY-ESO-1-Specific (c259) T Cells, alone or in combination with other anti-cancer agents, in HLA-A*02:01, HLA-A*02:05 and/or HLA-A*02:06 participants with NY-ESO-1- and/or LAGE-1a positive solid tumors. - [Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma](/research/clinical-trials/cls-20536147) Rochester, MN The purpose of this study is to evaluate the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as CC-486, cyclophosphamide, doxorubicin, vincristine, etoposide and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help find out if this approach is better or ... - [Testing Nivolumab and Ipilimumab With Short-Course Radiation in Advanced Rectal Cancer](/research/clinical-trials/cls-20526189) Rochester, MN The purpose of this trial is to investigate the effect of nivolumab and ipilimumab when given together with short-course radiation therapy in treating patients with rectal cancer that has spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving nivolumab, ipilimumab, and radiation therapy may kill more cancer cells. - [Study Comparing Thin Dressings to Prevent Skin Inflammation in Breast Cancer Patients](/research/clinical-trials/cls-20304707) Rochester, MN We are doing this research study to compare radiation dermatitis severity in exposed skin protected by a thin film dressing versus skin that is not protected during radiation treatment. We will also be comparing two types of film; a perforated thin film dressing versus the standard thin film. - [De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)](/research/clinical-trials/cls-20534808) Scottsdale/Phoenix, AZ; Jacksonville, FL; Albert Lea, MN; La Crosse, WI; Mankato, MN The purpose of this study is to evaluate whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy. - [Inotuzumab Ozogamicin in Treating Younger Patients With Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia](/research/clinical-trials/cls-20416407) Rochester, MN This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with CD22 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. Immunotoxins, such as inotuzumab ozogamicin, are antibodies linked to a toxic substance and may help find cancer cells that express CD22 and kill them without harming normal cells. - [Safety and Efficacy of ALLO-715 and ALLO-647 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)](/research/clinical-trials/cls-20484366) Rochester, MN The purpose of this research study is to find out if the experimental treatment, ALLO-715 in combination with ALLO-647, is safe and effective in treating multiple myeloma. - [Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors](/research/clinical-trials/cls-20432226) Scottsdale/Phoenix, AZ; Jacksonville, Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), and non-small-cell lung cancer (NSCLC). The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established. In the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment ... - [Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects](/research/clinical-trials/cls-20398314) is a biomarker preselected, randomized, open-label, multicenter, phase II study in men with metastatic castration resistant prostate cancer (mCRPC). Patients with tumors that have ATM, BRCA1 and/or BRCA2 mutations/deletions/loss of heterozygosity will be randomized in a 1:1:1 fashion to each arm. Patients with mutations in noncanonical DNA repair to Arm IV with single agent olaparib. - [A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer](/research/clinical-trials/cls-20146630) Scottsdale/Phoenix, AZ; Jacksonville, FL This is a 3 arm Phase 3 study to evaluate the safety and efficacy of the addition of veliparib plus carboplatin versus the addition of carboplatin to standard neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy in subjects with early stage TNBC. - [A Study to Test the Addition of berzosertib to Usual Radiation Treatment for Chemotherapy-Resistant Breast Cancer](/research/clinical-trials/cls-20491855) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to determine the recommended Phase 2 dose twice weekly of berzosertib administered concurrently with conventionally fractionated radiation therapy to the breast/chest wall and regional nodes. - [A Study to Evaluate Radiation Therapy, Plasma Exchange, and Immunotherapy in Melanoma](/research/clinical-trials/cls-20507746) Rochester, MN The purpose of this study is to determine the kinetics of sPD-L1 removal and regeneration by plasma exchange in patients with melanoma. - [Measuring Cell Free DNA During the Course of Treatment for Esophageal Cancer as a Marker of Response and Recurrence](/research/clinical-trials/cls-20308709) Rochester, MN To prospectively collect blood and tumor tissue from esophageal cancer patients to identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence. To prospectively collect blood and tumor tissue from esophageal cancer patients to identify specific esophageal cancer mutations that can be measured in the blood (cell free DNA) during the course of treatment as a marker of response and recurrence. - [Optimizing Pancreatic Cancer Management Using Next Generation Imaging and Liquid Biopsy](/research/clinical-trials/cls-20511291) Rochester, MN The purpose of this study is to examine the relationship of ctDNA status and FDG PET/MRI findings with other clinicopathologic variables and standard staging examinations. We will develop a multivariable model combining ctDNA and FDG PET/MRI biomarkers to predict treatment response and survival. In addition, we will define the quantitative thresholds for early chemotherapy switch in patients who do not respond to first-line chemotherapy. - [A Study to Evaluate the Safety of HANAROSTENT\u00ae Biliary Flap Lasso Stent System Use to Treat Cancer Patients with Biliary Obstruction](/research/clinical-trials/cls-20531159) Rochester, MN The purpose of this study is to demonstrate clinical performance and safety of the fully covered (FC) HANAROSTENT\u00ae Biliary Flap Lasso Stent System with anti-migration flaps for the palliative treatment of malignant biliary obstruction. - [Phase II Trial of Irinotecan, Cetuximab, and Colorectal Cancer](/research/clinical-trials/cls-20145310) Rochester, MN The purpose of this research study is to see if cancer will respond better to a combination of irinotecan and cetuximab with or without bevacizumab - [A Study to Understand Symptoms from Olaparib](/research/clinical-trials/cls-20467396) Rochester, MN The purpose of this study is to gather real-world, patient-reported experiences of ovarian cancer patients who have been prescribed olaparib; this experience will be captured in patients' own words with qualitative research methodology. - [Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers](/research/clinical-trials/cls-20490431) Rochester, MN This phase II trial studies how well ramucirumab and paclitaxel or the FOLFIRI regimen (leucovorin calcium, fluorouracil, and irinotecan hydrochloride) work in treating patients with small bowel cancers that have spread extensively to other anatomic sites (advanced) or are no longer responding to treatment (refractory). Ramucirumab is a monoclonal antibody that attaches to and inhibits a molecule called VEGFR-2. This may restrain new blood vessel formation therefore reducing nutrient supply to tumor which may interfere with tumor cell growth and expansion. Drugs used in chemotherapy, such as paclitaxel, leucovorin calcium, fluorouracil, and irinotecan hydrochloride work in different ways to stop ... - [Nab-Paclitaxel and Bevacizumab in Treating Patients With Cancers](/research/clinical-trials/cls-20116521) Rochester, MN; Scottsdale/Phoenix, AZ; Jacksonville, FL This phase I trial studies the side effects and best dose of paclitaxel albumin-stabilized nanoparticle formulation and bevacizumab in treating patients with stage IV melanoma, gynecological cancers, or other malignancies that cannot be removed by surgery. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing ... - [Study Comparing CB-839 with Cabozantinib vs. Cabozantinib in Patients with Metastatic Renal Cell Carcinoma](/research/clinical-trials/cls-20442900) Scottsdale/Phoenix, AZ This study is a randomized Phase 2 evaluation of CB-839 in combination with cabozantinib versus placebo with cabozantinib in patients with advanced or metastatic Renal Cell Carcinoma. - [Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1](/research/clinical-trials/cls-20463114) Rochester, MN The purpose of this study is to enroll approximately 235 treatment-na\u00efve subjects with high-risk Diffuse Large B-Cell Lymphoma (DLBCL). Subjects will be randomized 1:1 to R-CHOP plus enzastaurin or R CHOP (plus placebo during induction). All subjects will receive up to 6 cycles (3 weeks per cycle) of treatment. PET/ CT will be used to assess radiographic response at the end of treatment. Each subject's treatment assignment will be unblinded after initial phase of treatment. Subjects randomized to the enzastaurin arm who have a response will be offered maintenance treatment of the study drug for up to 2 additional years. - [De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA](/research/clinical-trials/cls-20536699) Scottsdale/Phoenix, AZ; Rochester, MN The primary goal of this study is to prospectively incorporate ctHPVDNA in combination with clinical and pathologic factors to appropriately select patients for treatment intensity. - [A Study to Evaluate the Combination of Margetuximab, Retifanlimab, MGD013, and Chemotherapy Phase Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the treatment of patients with HER2-positive Gastric cancer (GC) or Gastroesophageal Junction (GEJ) cancer to determine the effectiveness of margetuximab combined with INCMGA00012 (also known as MGA012) (Cohort A) and margetuximab combined with INCMGA00012 or MGD013 and chemotherapy compared to trastuzumab combined with chemotherapy (Cohort B). - [A Study of Caring Hand Massage for Cancer Patients Undergoing Chemotherapy in an Outpatient Setting](/research/clinical-trials/cls-20266940) Rochester, MN The purpose of this study is to evaluate the feasibility and outcomes of hand massage therapy in cancer patients undergoing chemotherapy, and to measure its influence on their symptoms. - [A Study to Evaluate Regional Radiotherapy in Biomarker Low-Risk Node Positive Breast Cancer](/research/clinical-trials/cls-20475822) Jacksonville, FL The purpose of this study is to compare the effects on low-risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back. - [A Study to Evaluate AFP\u00b3\u00b3\u00b2T in Advanced HCC](/research/clinical-trials/cls-20438537) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to test the safety of genetically changed T cells that target alpha-fetoprotein (AFP) and find out what effects, if any, they have in subjects with liver cancer. - [Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas](/research/clinical-trials/cls-20515237) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to assess the combination of INCMGA00012 with radiation therapy (RT) and bevacizumab with or without epacadostat in the treatment of recurrent glioblastoma (GBM). Regimen A of this study has been completed and Mayo Clinic will only be participating in the Regimen B portion. - [A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens](/research/clinical-trials/cls-20441685) Jacksonville, FL The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) regimens in participants with MM as measured by overall response rate (ORR) or very good partial response (VGPR) or better rate. - [A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma](/research/clinical-trials/cls-20318103) Rochester, MN This Phase 2, two-arm, open-label study is designed to evaluate the safety, clinical activity, predictive biomarkers and pharmacokinetics/ pharmacodynamics of durvalumab in combination with R-CHOP (Arm A) or R2-CHOP (Arm B), followed by durvalumab consolidation therapy in previously untreated subjects with high-risk DLBCL. Patients with non-ABC subtype (determined by gene expression profiling) will be allocated to Arm A while patients with ABC (activated B-cell type) subtype will be allocated to Arm B. Approximately 120 patients may be enrolled and assigned into the appropriate treatment arms dependent upon their cell of origin status. Induction treatment with R-CHOP (\u00b1 Lenalidomide) will last of TJ011133 Relapsed/ and Lymphoma](/research/clinical-trials/cls-20471589) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma. - [A Safety and Effectiveness Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity](/research/clinical-trials/cls-20477443) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety and effectiveness of defibrotide for the prevention of CAR-T-associated neurotoxicity in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) receiving Yescarta\u00ae. - [A Study Evaluating the Safety and Effectiveness of UCART Targeting CS1 in Patients with Relapsed/Refractory Multiple Myeloma (MELANI-01)](/research/clinical-trials/cls-20490435) Rochester, MN The purpose of this study is to evaluate the safety and clinical activity of one infusion of UCARTCS1A (t-cells) and to determine the Maximum Tolerated Dose (MTD). - [A Study to Compare the Effectiveness and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Myeloma (RRMM)](/research/clinical-trials/cls-20467300) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to compare the effectiveness and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM). - [A Study to Evaluate the Safety and Effectiveness of Idecabtagene Vicleucel to Treat Multiple Myeloma](/research/clinical-trials/cls-20511486) Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the safety and effectiveness of nonconforming idecabtagene vicleucel (ide-cel) in subjects with multiple myeloma per approved prescribing information. - [Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple Myeloma](/research/clinical-trials/cls-20390470) Jacksonville, FL This is a Phase Ib, open-label, multicenter, global study designed to assess the safety and tolerability of RO6870810 as monotherapy and in combination with daratumumab in participants with relapsed/refractory multiple myeloma. Each treatment cycle will be 21 days in length. There are two parts to this study. A dose-escalation phase (Part I) will be used to evaluate the safety and tolerability and dose limiting toxicities, and to establish the maximum tolerated dose/optimum biological dose of RO6870810 when given as monotherapy or in combination with daratumumab. A dose-expansion phase (Part II) will further characterize the safety, tolerability and activity of RO6870810 ... - [Long-Term Follow-up Protocol Cells](/research/clinical-trials/cls-20420017) Rochester, MN; Scottsdale/Phoenix, AZ; Jacksonville, FL This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult subjects exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Subjects who received at least one GM T cell infusion, will be asked to roll-over to this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol. - [A Study of Tucatinib or Placebo With FL; Rochester, MN The purpose of this study is to determine if tucatinib works better than placebo when given with other drugs to treat participants with HER2-positive breast cancer. A placebo is a pill that looks the same as tucatinib but has no medicine in it. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body ... - [Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer](/research/clinical-trials/cls-20536240) Rochester, MN The purpose of this trial is to test whether atezolizumab in combination with a multi-kinase inhibitor (cabozantinib or lenvatinib) compared to multi-kinase inhibitor alone in treating patients with liver cancer that cannot be removed by surgery (unresectable), has spread to has spread to nearby tissue or lymph nodes (locally advanced), or has spread to other places in the body (metastatic), for which the patient has received treatment in the past (previously treated). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ... - [Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory AZ; MN This phase trial studies how well pembrolizumab alone or with idelalisib or ibrutinib works in treating patients with chronic lymphocytic leukemia or other low-grade B-cell non-Hodgkin lymphomas that have returned after a period of improvement or have not responded to treatment. Monoclonal antibodies can block cancer growth in different ways. Pembrolizumab may block cancer growth by blocking a cell that protects the cancer from the immune system and allowing the immune system to attack the cancer. Idelalisib and ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab alone ... - [A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer](/research/clinical-trials/cls-20524004) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the objective response rate (ORR) by RECIST 1.1 in subjects with TPS 1 percent. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays. - [survey with parents of children who had proton treatment for brain tumors](/research/clinical-trials/cls-20509315) Rochester, MN The overall goal of this project is to survey parents of children who have undergone proton radiation for brain tumors and collect key information that will improve the feasibility of our proposed intervention. The survey will include questions on experience with proton treatment and opinion regarding a proposed early intervention. - [A Study of Breast Imaging with F-18 Fluoroestradiol in Patients with Newly Diagnosed ER+ Breast Cancer](/research/clinical-trials/cls-20362903) No Locations The purpose of this study is to obtain additional high resolution images of your breast cancer using a Positron Emission Mammography (PEM) system. This system only allows us to image the breast, but provides higher quality and better resolution than those images we obtain with the PET/CT scanner. - [Regorafenib in Metastatic Colorectal Cancer](/research/clinical-trials/cls-20150039) Rochester, MN The purpose of the study is to measure high grade (3-5) toxicity of regorafenib and to monitor the impact of treatment with regorafenib on the quality of life in older adults with metastatic colorectal cancer. - [A Study to Evaluate Tazemetostat Combined Lenalidomide Plus Rituximab Subjects With Relapsed/Refractory Follicular Lymphoma](/research/clinical-trials/cls-20505327) Rochester, MN; Jacksonville, FL The purpose of this study is to evaluate the effectiveness and safety of tazemetostat in combination with R2 in subjects with Relapsed/Refractory Follicular Lymphoma (R/R FL), who have completed at least 1 prior systemic chemotherapy, immunotherapy, or chemoimmunotherapy. - [A Study of Breast Imaging with F-18 Fluoroestradiol in Patients with Newly Diagnosed ER+ Breast Cancer](/research/clinical-trials/cls-20362903) No Locations The purpose of this study is to obtain additional high resolution images of your breast cancer using a Positron Emission Mammography (PEM) system. This system only allows us to image the breast, but provides higher quality and better resolution than those images we obtain with the PET/CT scanner. - [Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer](/research/clinical-trials/cls-20163661) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This randomized trial studies oxaliplatin, leucovorin calcium, fluorouracil, and bevacizumab to see how well they work compared to oxaliplatin, leucovorin calcium, and fluorouracil in treating patients who have undergone surgery for stage II colon cancer. Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving combination ... - [A Study Using Chemotherapy to Treat Patients with Myelodysplastic Syndrome Before Donor Stem Cell Transplant](/research/clinical-trials/cls-20156877) Scottsdale/Phoenix, AZ The purpose of this study is to see the effect of a chemotherapy treatment for patients with myelodysplastic syndrome before donor stem cell transplant. Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells, and may prevent the myelodysplastic syndrome from coming back after the transplant. - [A Randomized Study of Olaparib or Placebo in Patients With Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial](/research/clinical-trials/cls-20523170) Rochester, MN The purpose of this study is to evaluate how well the addition of olaparib following completion of surgery and chemotherapy works in treating patients with pancreatic cancer that has been surgically removed (resected) and has a pathogenic mutation in BRCA1, BRCA2, or PALB2. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. - [A Study to Evaluate Biomarker/ALK Inhibitor Combinations in Treating Patients With Stage IV ALK Positive Non-squamous Non-small Cell Lung Cancer (The NCI-NRG ALK Protocol)](/research/clinical-trials/cls-20491460) Rochester, MN The purpose of this study is to determine whether a combination of biomarker/ALK inhibitors or chemotherapy may work better in treating patients with ALK positive non-squamous non-small cell lung cancer. This National Cancer Institute (NCI)-NRG ALK Protocol phase II trial studies how well a combination of different biomarker/ALK inhibitors work in treating patients with stage IV ALK positive non-squamous non-small cell lung cancer. Lorlatinib, ceritinib, alectinib, brigatinib, ensartinib, and crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pemetrexed, cisplatin, and carboplatin, work in different ... 2, Multicenter, Randomized, Open-label Study of MEDI-551 in with Refractory Diffuse Large B-Cell Lymphoma (DLBCL)](/research/clinical-trials/cls-20115540) Rochester, MN The overall purpose of the study is to determine if MEDI-551, when used in combination with salvage chemotherapy, Ifosfamide-carboplatin-etoposide (ICE) or Dexamethasone-cytarabine (DHAP) in patients with relapsed or refractory DLBCL who are eligible for Autologous Stem Cell Transplant (ASCT), has superior efficacy compared to rituximab in the same population. - [A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Leukemia or Small Lymphocytic Lymphoma](/research/clinical-trials/cls-20112259) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to examine the safety and efficacy of Ibrutinib administered in combination with bendamustine and rituximab in patients with relapsed or refractory chronic leukemia or small Randomized Trial Comparing GA101 Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma](/research/clinical-trials/cls-20118027) Rochester, MN Patients with previously untreated low tumor burden indolent Non-Hodgkin's Lymphoma (NHL) will receive either rituximab or GA101 weekly for 4 weeks followed by re-staging to determine response. Rituximab, an anti-CD20 chimeric antibody, was approved by the United States Food and Drug Administration in 1998 for the treatment of patients with relapsed low-grade B-cell lymphomas. Clinically, four weekly doses of rituximab have proven to be well tolerated and effective in previously untreated as well as relapsed patients with low-grade lymphoma. GA101 is an anti-CD20 humanized and glyco-engineered been have increased antibody-dependent cellular cytotoxicity ... - [A Study to Optimize Patient in Laryngeal Vascular Composite Allograft Transplantation](/research/clinical-trials/cls-20513441) Scottsdale/Phoenix, AZ In-depth qualitative interviews will be performed to explore beliefs of laryngotracheal transplant candidates, their caregivers, and clinicians about their perceptions and experience of the laryngotracheal transplantation process. In addition, we will explore the quality of life of patients with a laryngectomy. - [Tucatinib, Trastuzumab, Ramucirumab, and Scottsdale/Phoenix, AZ This is an international, multicenter study in subjects with locally-advanced unresectable or metastatic HER2+ GEC who have received prior treatment with a HER2-directed antibody, and have received 1 prior line of therapy in the advanced disease setting. - [Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer](/research/clinical-trials/cls-20533345) Rochester, MN The purpose of this study is to evaluate a new treatment using a potent Poly polymerase (PARP) inhibitor known as Niraparib. Niraparib will be combined with trastuzumab, a HER2-targeted agent, to evaluate the safety and tolerability in patients with metastatic HER2 positive breast cancer. It is anticipated that the combination of drugs will improve survival and have few side effects. The human epidermal growth factor receptor 2 (HER2) regulates cell growth and survival. Approximately 15-20% of all breast cancers are HER2-positive, which are an aggressive and fast-growing subtype of breast cancer. - [A Study of DKN-01 in Combination with Tislelizumab \u00b1 Chemotherapy in Patients with Gastric or Gastroesophageal Cancer](/research/clinical-trials/cls-20486724) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to characterize the safety and tolerability of DKN-01 in combination with tislelizumab \u00b1 CAPOX (capecitabine + oxaliplatin) patients or metastatic G/GEJ adenocarcinoma. - [Study of Tumor-treating Fields to Treat Metastases from Breast Carcinoma Involving the Spine](/research/clinical-trials/cls-20540776) Jacksonville, FL The purpose of this study is to evaluate the safety and feasibility of the spinal array in treatment of patients with leptomeningeal metastases within the spine The median survival of patients with LM with treatment is generally less than 5 months. There are four FDA-approved drugs for intra-CSF use in LM, but all have shown limited activity with no clear increase in survival outcome with treatment. Intra-CSF treatment is also invasive, involving either surgical placement of an intraventricular reservoir, or treatment (intrathecal) via repetitive lumbar punctures, and there is risk of adverse events including vomiting, headache, arachnoiditis and ... - [A Study to Evaluate Treatment of Papillary Thyroid Carcinoma with Radiofrequency Ablation](/research/clinical-trials/cls-20486574) Rochester, MN The purpose of this study is to evaluate the efficiency of Radiofrequency ablation (RFA) therapy to treat papillary thyroid carcinoma. - Study of Participants Previously with Ciltacabtagene Autoleucel](/research/clinical-trials/cls-20530074) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to collect data on delayed adverse events after administration of cilta-cel in a previous clinical study, and to characterize and understand the long-term safety profile of cilta-cel. - [Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery](/research/clinical-trials/cls-20388741) Jacksonville, FL The purpose of this study is to evaluate the timing of AVB-620 administration relative to surgery on the fluorescence and accuracy of the AVB-620 imaging data to distinguish between malignant and nonmalignant tissues in women undergoing surgery with primary, nonrecurrent and nonmetastatic breast cancer. - [A Study to Examine Axillary Reverse Mapping in Preventing Lymphedema in Patients With Breast Cancer Undergoing Axillary Lymph Node Dissection](/research/clinical-trials/cls-20477445) Jacksonville, FL The purpose of this study is to examine how well axillary reverse mapping works in preventing lymphedema in patients with breast cancer undergoing axillary lymph node dissection. Axillary reverse mapping may help to preserve the lymph node drainage system around the breast so as to prevent lymphedema after surgery. - [An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 in EGFR Expressing Solid Tumors](/research/clinical-trials/cls-20511113) Rochester, MN Open-label study using ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy in patients with recurrent or metastatic head and neck and squamous cell cancer or advanced or metastatic cutaneous squamous cell carcinoma. - [Defining the Immunologic Profile of Sentinel Lymph Nodes and Identifying the Mechanisms Responsible for Immunosuppression](/research/clinical-trials/cls-20314731) Rochester, MN; Jacksonville, FL The purpose of this study is to look at the effects cancer and melanoma have on the immune cells found in lymph nodes. - [Cabozantinib and Nivolumab in Treating Patients With Advanced, Recurrent or Metastatic Endometrial Cancer](/research/clinical-trials/cls-20440737) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to determine how well cabozantinib and nivolumab work in treating patients with endometrial cancer that has come back or spread to other places in the body. - [A Study to Evaluate Tazemetostat and Pembrolizumab to Carcinoma](/research/clinical-trials/cls-20504066) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The primary purpose of this study is to conduct a safety lead-in phase that identifies the safe recommended phase II dose for combination tazemetostat and MK-3475 (pembrolizumab) in patients with advanced urothelial carcinoma. - [A Study to Evaluate the Safety of Lasofoxifene in Combination with Abemaciclib in Advanced or Metastatic ER+/HER2 Breast Cancer with ESR1 Mutation](/research/clinical-trials/cls-20490433) Jacksonville, FL; Rochester, MN The purpse of this study is to evaluate the safety and tolerability of the lasofoxifene and abemaciclib combination for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2 breast cancer who have disease progression on first and/or 2nd lines of hormonal treatment for metastatic disease and have an ESR1 mutation. - [Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative](/research/clinical-trials/cls-20533787) Scottsdale/Phoenix, AZ; Jacksonville, FL; La Crosse, WI; Rochester, MN The purpose of this phase II/III trial is to compare the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) vs. usual treatment alone in treating patients with non-small cell lung cancer that has spread to nearby tissue or lymph nodes (advanced) or has spread to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Stereotactic body radiation therapy (SBRT) is a type of radiation therapy that uses high energy x-rays to kill tumor cells and shrink tumors. This method uses special equipment to position a patient and precisely ... - [Study of Lenzilumab and Axicabtagene Ciloleucel in Relapsed or Refractory Large B-cell Lymphoma](/research/clinical-trials/cls-20491417) Rochester, MN The purpose of this study is to see if giving lenzilumab prior to axicabtagene ciloleucel will reduce the neurologic side effects of axicabtagene ciloleucel when used to treat lymphoma. - [A Phase 1b/2 Safety and Tolerability of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies](/research/clinical-trials/cls-20131239) Scottsdale/Phoenix, AZ The main purpose of this study is to determine the best dose of MEDI6469 that is safe and tolerable when given as monotherapy and in combination with tremelimumab, MEDI4736, or rituximab in subjects with either advanced solid tumors or diffuse large B-cell lymphoma (DLBCL). Tremelimumab and MEDI4736 will be tested with MEDI6469 in a set of subjects with advanced solid tumors while rituximab will be tested with MEDI6469 in subjects with DLBCL. MEDI6469 will be tested as monotherapy in subjects with advanced solid tumors. - [FT516 in Subjects With Advanced Hematologic Malignancies](/research/clinical-trials/cls-20484523) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate appropriate dosage of FT516 as monotherapy in acute myeloid leukemia (AML), and in combination with CD20 directed monoclonal antibodies, in B-cell lymphoma. The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-sepcific cohorts. - [Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab Intravenous (Dara-IV)](/research/clinical-trials/cls-20484361) Rochester, MN The purpose of this study is to compare the effectiveness (rate of very good partial response [VGPR] or better as best response as defined by the International Myeloma Working Group [IMWG] criteria) of daratumumab subcutaneous (Dara-SC) in combination with carfilzomib and dexamethasone (Kd) with the efficacy of Kd in participants with relapsed refractory multiple myeloma who were previously exposed to daratumumab intravenous (Dara-IV) to evaluate daratumumab retreatment. - [Phase II Study Evaluating Combination Chemotherapy + Radiotherapy (RT) with Avelumab in Muscle Invasive Bladder Cancer](/research/clinical-trials/cls-20434750) No Locations The purpose of this study is to evaluate the complete response rate of concurrent chemotherapy radiation treatment combined with avelumab for patients with muscle invasive bladder cancer. - [TRPC6 to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure (Prospective Study)](/research/clinical-trials/cls-20536765) Jacksonville, FL The purpose of this study is to characterize TRPC6 risk variants for doxorubicin-related cardiotoxicity in prospectively collected samples from breast cancer patients. Breast cancer patients are more than three times at risk for developing congestive heart failure (CHF), compared with patients who did not have cancer. The increased risk of HF is observed as early as one year from diagnosis of cancer and overall, 7% of patients develop CHF (median follow-up 8.5 years) - [A Study to Assess a Multicenter Cancer Biospecimen Collection](/research/clinical-trials/cls-20529234) Rochester, MN This is a retrospective specimen acquisition study of pre-treatment head and neck squamous cell carcinoma tumor biopsy samples. The sponsor-provided protocol allows for multiple different tumor types. However, Mayo Clinic, Rochester will only enroll head and neck squamous cell carcinoma. - [Obtain Fresh Glioblastoma Tissue to Analyze Cell Count and Viability in Developing IGV-001](/research/clinical-trials/cls-20534514) Jacksonville, FL The purpose of this study is to utilize fresh tumor tissue to aid the development of future therapies for brain cancer. - [A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma](/research/clinical-trials/cls-20489498) Rochester, MN; Jacksonville, FL The primary purposes of this study are to identify experimental therapies that improve OS for GBM patients in the Screening stage (Stage 1), determining if predefined patient subtypes or associated biomarkers uniquely benefit from the treatment and to confirm identified effective experimental therapies and associated biomarker signatures in an expansion stage (Stage 2) designed to support a new drug application. - [A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients](/research/clinical-trials/cls-20143555) Rochester, MN The purpose of the study is to compare the efficacy and safety of nivolumab administered alone versus bevacizumab in patients diagnosed with recurrent glioblastoma (a type of brain cancer, also known as GBM), and to evaluate the safety and tolerability of nivolumab administered alone or in combination with ipilimumab in patients with different lines of GBM therapy. - [Pilot Study of PROS Monitoring](/research/clinical-trials/cls-20536232) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine the ability to capture PROs during patients' radiation and during 3 months after. Additionally, the study plans to conduct a retrospective chart review of prospectively accrued patients and ask subjects to complete a questionnaire. - [Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery](/research/clinical-trials/cls-20199974) Rochester, MN; Scottsdale/Phoenix, AZ This phase Ib/II trial studies the side effects and best way to give pembrolizumab with combination chemotherapy and radiation therapy before surgery and to see how well it works in treating adult patients with gastroesophageal junction or gastric cardia cancer that has spread from where it started to nearby tissue and can be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping ... - [Efficacy and Safety of Treatment With Alpelisib Plus Endocrine Therapy in Patients With HR+, HER2-negative aBC, With PIK3CA Mutations, Whose Disease Has Progressed on or After CDK 4/6 Treatment With an Aromatase Inhibitor (AI) or Fulvestrant](/research/clinical-trials/cls-20450020) Scottsdale/Phoenix, AZ Efficacy and safety of treatment with alpelisib plus endocrine therapy in patients with HR+, HER2-negative aBC, with PIK3CA mutations, whose disease has progressed on or after CDK 4/6 treatment with an aromatase inhibitor (AI) or [Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study](/research/clinical-trials/cls-20529594) Jacksonville, FL The purpose of this study ia to determine the safety and tolerability of personalized neoantigen peptide administered in combination with pembrolizumab to patients with advanced solid tumors. Patients' tumors will be sequenced during a pre-registration component or will have had successful sequencing pre-study. A personalized neoantigen peptide vaccine containing up to 20 unique peptides will be manufactured for each qualifying patient based on the results. - [Belantamab, Lenalidomide, and Daratumumab for Newly-diagnosed Multiple Myeloma](/research/clinical-trials/cls-20511649) Rochester, MN The purpose of the phase 1 portion of this research study is to find out more about the side effects of belantamab and what doses of belantamab are safe for people when combined with lenalidomide and daratumumab, and to find the right dose for the phase 2 portion of the trial. This trial is exploring the use of a new drug called belantamab to be used in combination with daratumumab and lenalidomide and not using the same doses of dexamethasone as has been done with previous combinations. Belantamab is an anti-B-cell maturation antigen (BCMA) antibody-drug conjugate. This ... - [A Study to Evaluate the Safety and Effectiveness of ALLO-501A CAR T Cell Therapy in Adults with Relapsed/ Refractory Large B Cell Lymphoma](/research/clinical-trials/cls-20510895) Scottsdale/Phoenix, AZ The primary purpose of this study is to assess the safety and effectiveness of ALLO-501A to treat patients with relapsed/refractory large B cell lymphoma (LBCL) to determine the maximum tolerated dose (MTD). Immunotherapy Treatment Antigen-Directed for EBV the efficacy of autologous EBV-specific T-cells for the treatment of patients extranodal NK/T-cell lymphoma Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer](/research/clinical-trials/cls-20366156) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate how well multi-epitope folate receptor alpha peptide vaccine, sargramostim, and cyclophosphamide work in treating patients with triple negative breast cancer. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving multi-epitope folate receptor alpha peptide vaccine, sargramostim, and cyclophosphamide may work better ... - [Mindfulness-Based Intervention in Breast Cancer Patients Undergoing Chemotherapy](/research/clinical-trials/cls-20139085) Rochester, MN There is evidence that mindfulness-based interventions (MBIs) such as meditation, mindfulness-based stress reduction (MBSR) and yoga might improve Quality of Life (QOL) and reduce stress in breast cancer survivors. These interventions are becoming increasingly popular in cancer survivors. However, little is known about the feasibility and effect of MBIs administered during the interval of time of chemotherapy, on QOL and stress. The investigators are planning a MBI intervention study developed specifically for breast cancer survivors receiving chemotherapy (usually 4-5 months) at the investigators institution, for at least 8 sessions combined with at least 8 weeks of home-practice, in 25 women ... - [Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Relapsed/Refractory Large B-cell Lymphoma](/research/clinical-trials/cls-20453739) Rochester, MN The purpose of this study is to evaluate the safety of axicabtagene ciloleucel in combination with utomilumab and to identify the most appropriate dose and timing of utomilumab to carry forward from Phase 1 into Phase 2, and to evaluate the effectiveness of axicabtagene ciloleucel and utomilumab in participants with refractory large B-cell lymphoma in Phase 2. - [A Study to Provide Access to CTL019 Out of Specification Managed Access Program (MAP) for ALL or DLBCL Patients](/research/clinical-trials/cls-20453747) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release. - [A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer](/research/clinical-trials/cls-20484365) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate and prednisone (AA-P) compared to AA-P plus placebo. - [Open-label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety of CAR-BCMA T-cells (CT053) in Patients](/research/clinical-trials/cls-20472611) Scottsdale/Phoenix, AZ; Rochester, purpose of this study is to evaluate Chimeric Antigen Receptor T Cells targeting BCMA in patients with myeloma. - [A Study to Compare Intravesical Therapy and Surgery to Treat Bladder Cancer](/research/clinical-trials/cls-20516955) Scottsdale/Phoenix, AZ The purpose of CISTO is to conduct a large prospective study that directly compares the impact of medical management versus bladder removal in recurrent high-grade NMIBC patients with BCG (Bacillus Calmette-Guerin) failure on clinical outcomes and patient and caregiver experience using standardized patient-reported outcomes (PROs). Bladder cancer is the most common urinary tract cancer and the 5th most common cancer in the US. Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinicians. The Comparison of Intravesical Therapy and Surgery ... - [Efficacy of PET/MRI in Detecting Metastatic Disease in Endometrial Cancer](/research/clinical-trials/cls-20205550) Rochester, MN The purpose of this study is to evaluate the ability of PET/MRI (Positron Emission Tomography/Magnetic Resonance Imaging) to give physicians preoperative information about specific sites in the body that the endometrial cancer may be present. If the PET/MRI is accurate and successful in providing this information, then women in the future may be able to have less extensive surgery for their endometrial cancer after evaluation with PET/MRI. - [Study of Adjuvant Regorafenib vs Placebo in Patients with Node Positive Esophageal Cancer who Completed Pre-operative Therapy](/research/clinical-trials/cls-20152538) Rochester, MN The purpose of this research study is to find out what effects, good and/or bad, the drug regorafenib has on stomach or esophagus cancer after completion standard chemotherapy, radiation therapy and surgery prescribed by your doctor. In this study the participant will either get regorafenib or a \"placebo\". - [Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma](/research/clinical-trials/cls-20486578) Jacksonville, FL The purpose of this study is to establish a recommended phase 3 dose (RP3D) and to evaluate the efficacy, PK, and safety of tazemetostat + doxorubicin vs placebo + doxorubicin in subjects with advanced epithelioid sarcoma (ES). This study will be conducted in 2 parts. - [A Study to Evaluate the Safety and Effectiveness of ALLO-501A CAR T Cell Therapy in Adults with Relapsed/ Refractory Large B Cell Lymphoma](/research/clinical-trials/cls-20510895) Scottsdale/Phoenix, AZ The primary purpose of this study is to assess the safety and effectiveness of ALLO-501A to treat patients with relapsed/refractory large B cell lymphoma (LBCL) to determine the maximum tolerated dose (MTD). - [Multi-epitope Folate Receptor Alpha Peptide Vaccine, Sargramostim, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer](/research/clinical-trials/cls-20366156) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate how well multi-epitope folate receptor alpha peptide vaccine, sargramostim, and cyclophosphamide work in treating patients with triple negative breast cancer. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving multi-epitope folate receptor alpha peptide vaccine, sargramostim, and Antigen-Directed for EBV the efficacy of autologous EBV-specific T-cells for the treatment of patients with aggressive EBV positive extranodal NK/T-cell lymphoma - [Mindfulness-Based Intervention in Breast Cancer Patients Undergoing Chemotherapy](/research/clinical-trials/cls-20139085) Rochester, MN There is evidence that mindfulness-based interventions (MBIs) such as meditation, mindfulness-based stress reduction (MBSR) and yoga might improve Quality of Life (QOL) and reduce stress in breast cancer survivors. These interventions are becoming increasingly popular in cancer survivors. However, little is known about the feasibility and effect of MBIs administered during the interval of time of chemotherapy, on QOL and stress. The investigators are planning a MBI intervention study developed specifically for breast cancer survivors receiving chemotherapy (usually 4-5 months) at the investigators institution, for at least 8 sessions combined with at least 8 weeks of home-practice, in 25 women ... - [Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Relapsed/Refractory Large B-cell Lymphoma](/research/clinical-trials/cls-20453739) Rochester, MN The purpose of this study is to evaluate the safety of axicabtagene ciloleucel in combination with utomilumab and to identify the most appropriate dose and timing of utomilumab to carry forward from Phase 1 into Phase 2, and to evaluate the effectiveness of axicabtagene ciloleucel and utomilumab in participants with refractory large B-cell lymphoma in Phase 2. - [A Study to Provide Access to CTL019 Out of Specification Managed Access Program (MAP) for ALL or DLBCL Patients](/research/clinical-trials/cls-20453747) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release. - [A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer](/research/clinical-trials/cls-20484365) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to evaluate the effectiveness of niraparib in combination with abiraterone acetate and prednisone (AA-P) compared to AA-P plus placebo. - [Open-label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety of CAR-BCMA T-cells (CT053) in Patients](/research/clinical-trials/cls-20472611) Scottsdale/Phoenix, AZ; Rochester, purpose of this study is to evaluate Chimeric Antigen Receptor T Cells targeting BCMA in patients with myeloma. - [A Study of T-VEC and Radiation to Treat Localized Soft Tissue Sarcoma](/research/clinical-trials/cls-20472680) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the side effects of talimogene laherparepvec and radiation therapy to see how well they work in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Radiation therapy uses high energy x-rays, photons. electrons, or protons to kill tumor cells and shrink tumors. Giving talimogene laherparepvec and radiation therapy may work better in treating patients with soft tissue sarcoma. - [Molecular Breast Imaging in Women with Atypia and LCIS](/research/clinical-trials/cls-20118285) Rochester, MN We aim to determine if Molecular Breast Imaging (a new nuclear medicine technique developed at Mayo) can identify malignant breast lesions in women who have atypical ductal hyperplasia, atypical lobular hyperplasia, or lobular carcinoma in [A Study to Establish a Living Breast Organoid Research](/research/clinical-trials/cls-20303251) Scottsdale/Phoenix, AZ; Jacksonville, FL; Researchers at Mayo Clinic are developing a Biobank of adult stem cell-rich breast organoids, a new research resource to facilitate normal and cancer stem cell research. Subjects in the Biobank will provide samples of excess breast tissue, complete a health questionnaire, and allow access to medical records now and in the future. The Biobank serves as a library for researchers; instead of having to look for volunteers for each new project, researchers can use samples from the Biobank as well as share information already collected. - [A Study to Evaluate the Effect of a Fasting Diet on Side Effects of Immunotherapy for Cancer Patients](/research/clinical-trials/cls-20533348) Jacksonville, FL The FMD-ICI study will utilize animal and human data that finds that fasting may promote survival mechanisms and stress resiliency. The study aims to assess the impact that a restrictive calorie diet, mostly of fat and complex carbohydrates, mimicking fasting and increasing resiliency will have in protecting patients from the adverse effects of certain cancer treatments (melanoma, lung, bladder and kidney cancer). By managing the adverse side effects of ICI treatments in select cancer patients, the study will assess the effect of immunotherapy plus the Xentigen fasting mimicking diet on adverse events rates, including immune-mediated colitis. Patients will be supplied with all their dietary ... - [A Study to Compare Venetoclax with Fulvestrant vs. Fulvestrant Alone in Women with Locally Advanced or Metastatic HER2-negative Cancer who Have Progressed or Recurred on a CDK4/6 Inhibitor](/research/clinical-trials/cls-20438535) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the efficacy of venetoclax in combination with fulvestrant compared with fulvestrant alone for HER2-negative breast cancer. - Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients with Stage IV Melanoma that Cannot be Removed by Surgery](/research/clinical-trials/cls-20115464) Rochester, MN; Scottsdale/Phoenix, AZ This randomized phase II paclitaxel albumin-stabilized nanoparticle formulation and bevacizumab or ipilimumab works as first-line therapy in treating patients with stage IV melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab and ipilimumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry ... - [Study Evaluating the Safety and Effectiveness of JCARH125 in Subjects with Relapsed and/or Refractory Multiple Myeloma (EVOLVE)](/research/clinical-trials/cls-20442762) Rochester, MN The purpose of this study is to determine the safety and effectiveness of JCARH125 in adult subjects with relapsed and/or refractory multiple myeloma. The study will include a Phase 1 part to determine the recommended dose of JCARH125 in subjects with relapsed and/or refractory multiple myeloma, followed by a Phase 2 part to further evaluate the safety and efficacy of JCARH125 at the recommended dose. - [A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide in Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20143946) Rochester, MN The purpose of this study is to compare the effectiveness of daratumumab when combined with lenalidomide and dexamethasone (DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple myeloma. - [A Study Evaluating the Safety and Effectiveness of JCAR017 to Treat Relapsed/Refractory Chronic Lymphocytic Leukemia Lymphoma (SLL)](/research/clinical-trials/cls-20467631) Jacksonville, FL; Rochester, MN The purpose of this study is to determine the effectiveness and safety of JCAR017 in adult subjects with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). The study will include a Phase 1 part to determine the recommended dose of JCAR017 monotherapy in subjects with relapsed or refractory CLL or SLL, followed by a Phase 2 part to further assess the effectiveness and safety of JCAR017 monotherapy treatment at the recommended dose. A separate Phase 1 cohort will assess the combination of JCAR017 and concurrent ibrutinib. In all subjects, the safety, efficacy, and pharmacokinetics (PK) of ... - MN A multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory large B-cell lymphoma. - [A Study of JNJ-68284528, a Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants with Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20467342) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of the study is to characterize the safety of JNJ-68284528 and establish the recommended Phase 2 dose (RP2D) (Phase 1b) and to evaluate the effectiveness of JNJ-68284528 (Phase 2). - [Kinetics of Troponin and BNP in Breast Cancer Chemotherapy with Adriamycin and Trastuzumab](/research/clinical-trials/cls-20119458) No Locations This pilot study involves very frequent monitoring of breast cancer patient blood levels of hs-cTnT Troponin and n-t-BNP (Brain Natriuretic Peptide) before and after initiation of chemotherapy with either adriamycin or trastuzumab in order to define the kinetics of both biomarkers during the first two cycles of chemotherapy. Cardiac troponins and BNP are frequently elevated after experimental chemotherapy in animal models. Their behavior in humans has been inconsistent, with occasional elevations seen, usually within 30 days of therapy. Assays for troponin with sensitivity into the pg/ml range have now been introduced. A majority of patients greater than age 50 have ... - [A Study to Evaluate Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Older Patients With Untreated Chronic Lymphocytic Leukemia](/research/clinical-trials/cls-20463113) La Crosse, WI; Mankato, MN; Scottsdale/Phoenix, AZ The purpose of this study is to evaluate how well ibrutinib and obinutuzumab with or without venetoclax works in treating older patients with untreated chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with obinutuzumab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from ... - [Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer](/research/clinical-trials/cls-20507128) La Crosse, WI This trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy, such as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving atezolizumab and radiation therapy ... - [A Study to Evaluate Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer](/research/clinical-trials/cls-20470676) La Crosse, WI The purpose of this study is to compare the effects of hormone therapy (androgen deprivation) and radiation therapy to the prostate gland and seminal vesicles with hormone therapy and radiation therapy to the whole pelvic body area in patients with prostate cancer to find out which is better. - [Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma](/research/clinical-trials/cls-20504165) Scottsdale/Phoenix, AZ; Rochester, MN the regimen of neoadjuvant cisplatin-pemetrexed-atezolizumab, surgery +/- radiation, then maintenance atezolizumab is feasible and safe (as defined in Section 11.1) for patients with resectable malignant pleural mesothelioma. a. To evaluate progression free survival (both by RECIST 1.1 and also using a Modified RECIST for Pleural Tumors) in patients with resectable malignant pleural mesothelioma treated with a regimen of neoadjuvant cisplatin-pemetrexed-atezolizumab, surgery +/- radiation, followed by one year of maintenance atezolizumab. b. To evaluate overall survival in patients with resectable malignant pleural mesothelioma treated with a regimen of neoadjuvant cisplatin-pemetrexed-atezolizumab, surgery +/- radiation, followed by one year of maintenance atezolizumab. c. ... - [Pembrolizumab, Dabrafenib, and Trametinib Before Surgery the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer](/research/clinical-trials/cls-20532371) Rochester, MN This phase II trial studies the effect of pembrolizumab, dabrafenib, and trametinib before surgery in treating patients with BRAF V600E-mutated anaplastic thyroid cancer. BRAF V600E is a specific mutation (change) in the BRAF gene, which makes a protein that is involved in sending signals in cells and in cell growth. It may increase the growth and spread of tumor cells. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with ... - [Isotretinoin With or Without Monoclonal Antibody Ch14.18, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma](/research/clinical-trials/cls-20112320) No Locations This partially randomized phase III trial studies isotretinoin with monoclonal antibody Ch14.18, aldesleukin, and sargramostim to see how well it works compared to isotretinoin alone following stem cell transplant in treating patients with neuroblastoma. Drugs used in chemotherapy, such as isotretinoin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as monoclonal antibody Ch14.18, can block tumor growth in different ways. Some block the ability of tumors to grow and spread. Others find tumor cells and help kill them or deliver tumor-killing substances to ... - [Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors](/research/clinical-trials/cls-20303248) Rochester, MN This randomized phase IIb trial studies how well low-dose carvedilol works in preventing heart failure in cancer survivors exposed to high dose anthracyclines for management of childhood cancer. Patients who received high-dose anthracycline chemotherapy are at a much greater risk for developing heart failure compared to survivors who didn't get any anthracycline chemotherapy. Heart failure happens when the heart muscle has been weakened and can't pump blood as well as it should. Carvedilol may help lower the risk of cardiovascular complications. - [A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma](/research/clinical-trials/cls-20435267) Rochester, MN The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM). - [Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa)](/research/clinical-trials/cls-20399424) Rochester, MN This is an open label, single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory multiple myeloma. A leukapheresis procedure will be performed to manufacture bb2121 chimeric antigen receptor (CAR) modified T cells. Prior to bb2121 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide. - [A Study to Evaluate Combined Durvalumab and Grid Therapy for Non Small Cell Lung Cancer](/research/clinical-trials/cls-20532723) Rochester, MN The purpose of this study is to determine whether combining grid therapy at the time of disease progression during durvalumab administration or shortly after durvalumab discontinuation may permit patients to continue on durvalumab which was otherwise effective at preventing polymetastatic disease. - [A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma](/research/clinical-trials/cls-20505057) Rochester, MN The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also compare the combination of rituximab and ibrutinib with the combination of rituximab and placebo to see which combination works better. - [Colorectal Cancer Screening in Black and Underserved Communities in the Phoenix Metro Area](/research/clinical-trials/cls-20532591) Scottsdale/Phoenix, AZ The aims of this study are to increase the number of Black consultants at MCA, make a meaningful impact on interactions among staff, leadership, and patients, and increase the number of Black staff in leadership roles beyond Diversity and Inclusion efforts. - [A Study of Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer](/research/clinical-trials/cls-20461213) Rochester, MN The purpose of this trial is to study how well tazemetostat works in treating patients with ovarian, primary peritoneal, or endometrial cancer that has come back. Drugs used in chemotherapy, such as tazemetostat, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. - [A Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age](/research/clinical-trials/cls-20470194) Rochester, MN The purpose of this study is to evaluate venetoclax, bendamustine and rituximab as induction therapy in eligible untreated patients. After 6 cycles, maintenance rituximab may be administered per physician discretion. Venetoclax is an oral Bcl-2 family protein inhibitor. It targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with mantle cell lymphoma. Venetoclax may make the cancer cells sensitive to chemotherapy. This may help to slow down the growth of cancer or may cause cancer cells to die. The purpose of this study is to see if venetoclax in combination with ... - [Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma](/research/clinical-trials/cls-20145294) Scottsdale/Phoenix, AZ; Rochester, randomized phase III trial studies ibrutinib and rituximab to see how well they work compared to fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab, interfere with the ability of cancer ... - [Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors](/research/clinical-trials/cls-20203301) Rochester, MN The goal of this clinical study is to learn how PLX3397 and paclitaxel work together to affect the growth of cancer cells in advanced solid tumors. - [Ga-DOTATATE PET for Localization of Phosphaturic Mesenchymal Tumors in Patients with Tumor Induced Osteomalacia](/research/clinical-trials/cls-20438425) Rochester, MN This study aims to identify cases of FGF23-mediated oncogenic osteoomalacia in which the underlying phosphaturic mesenchymal has not been found and perform 68Ga-DOTATATE PET in these patients to localize the tumor. - [Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia](/research/clinical-trials/cls-20111749) Scottsdale/Phoenix, AZ; Rochester, MN This randomized studies rituximab with bendamustine hydrochloride or ibrutinib to see how well they work compared to ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia. Monoclonal antibodies, such as rituximab, can block cancer growth in difference ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Ibrutinib ... - [A Study to Assess Multiparametric MR Elastography (MRE) in Diagnosing and Monitoring Cirrhosis or Hepatocellular Carcinoma (HCC) Patients](/research/clinical-trials/cls-20467515) Rochester, MN The primary purpose of this study is to is to develop an advanced multiparametric liver magnetic resonance elastography (MRE) imaging technology for early identification of hepatocellular carcinoma (HCC) involvement, differentiation, and risks of microvascular invasion. - [Molecularly Targeted Therapy in Treating Patients With Wild-type Melanoma That is Metastatic](/research/clinical-trials/cls-20145197) Scottsdale/Phoenix, AZ; Rochester, MN This phase II trial studies how well molecularly targeted therapy works in treating patients with melanoma that has spread to other parts of the body. Patients must have received or do not qualify for prior immunotherapy. Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. Molecularly targeted therapy works by treating patients with substances that kill cancer cells by targeting key molecules involved in cancer cell growth. - [A Study to Evaluate Encorafenib Plus AZ; Rochester, MN The purpose of this study is to evaluate whether encorafenib plus cetuximab (EC), alone or in combination with chemotherapy, can improve clinical outcomes relative to current standard of care chemotherapy in participants with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). - [Phase Chemotherapy +Various Proton Beam Therapy (PBT) Doses for Unresectable Cell Lung Cancer](/research/clinical-trials/cls-20338647) Scottsdale/Phoenix, AZ; Rochester, MN This study is being done to study which dose of proton beam therapy (PBT) for unresectable stage 2/3 Non-Small Cell Lung Cancer. - [Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer](/research/clinical-trials/cls-20151639) Jacksonville, FL; Rochester, MN This phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others ... - [(VOYAGER) Study of Avapritinib vs Regorafenib in GIST](/research/clinical-trials/cls-20438956) is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs. - [Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery](/research/clinical-trials/cls-20366150) Scottsdale/Phoenix, AZ This randomized phase II trial studies how well irinotecan and cetuximab with or without bevacizumab work in treating patients with RAS wild-type colorectal cancer that has spread to other places in the body and cannot be removed by surgery. Irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving irinotecan and cetuximab with or without bevacizumab may work betting in treating patients with colorectal cancer. - [A Study to Evaluate Wound Infiltration with Liposomal Bupivacaine in Laparotomy for Gynecological Malignancy](/research/clinical-trials/cls-20476554) Rochester, MN The purpose of this study is to determine whether or not there is a benefit to adding opioid injection around the spinal cord ( intrathecal) to incisional long-acting local anesthetic (liposomal bupivacaine) injection for pain management after abdominal surgery for gynecological cancer. - [Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma](/research/clinical-trials/cls-20115567) Rochester, MN RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as bendamustine hydrochloride, also work in different ways to kill cancer cells or stop them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of mantle cell lymphoma by blocking blood flow to the cancer. It is not yet known ... - [A Study of GDC-0199 with Plus Lymphocytic Leukemia](/research/clinical-trials/cls-20146632) Jacksonville, FL This open-label, randomized (GDC-0199+R) with bendamustine plus MabThera/Rituxan (Rituximab) (B+R) in patients with relapsed or resistant chronic lymphocytic leukemia. Patients will be randomized 1:1 into the two arms. Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on Day 1 of each 28-day cycle (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2). Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day ... - [Ruxolitinib Prior to Transplant in Patients With Myelofibrosis](/research/clinical-trials/cls-20111974) Scottsdale/Phoenix, AZ The purpose of this study is to find out if giving the study drug Ruxolitinib (INC424) prior to a combination of other chemotherapeutic drugs (Fludarabine and Busulfan) before infusing another person's hematopoietic stem cells (bone marrow transplantation) will be successful in people who have advanced primary as myelofibrosis (MF). MF is a disorder in which bone marrow tissue develops in abnormal sites because the bone marrow itself undergoes fibrosis or scarring. This study plans to evaluate whether adding the drug Ruxolitinib will further aid in reducing pre-transplant ... - [Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery](/research/clinical-trials/cls-20112272) Rochester, MN This pilot phase I trial studies the side effects and best way to give sirolimus, gemcitabine hydrochloride, and cisplatin in treating patients at high risk for cholangiocarcinoma recurrence after liver transplant or surgery. Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sirolimus with gemcitabine hydrochloride and cisplatin may be an effective treatment for patients with a high ... - [A Study to Evaluate Encorafenib AZ; Rochester, MN The purpose of this study is to evaluate whether encorafenib plus cetuximab (EC), alone or in combination with chemotherapy, can improve clinical outcomes relative to current standard of care chemotherapy in participants with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). - Melanoma That is Metastatic](/research/clinical-trials/cls-20145197) Scottsdale/Phoenix, AZ; Rochester, MN This phase II trial studies how well molecularly targeted therapy works in treating patients with melanoma that has spread to other parts of the body. Patients must have received or do not qualify for prior immunotherapy. Targeted therapy is a type of treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells. Molecularly targeted therapy works by treating patients with substances that kill cancer cells by targeting key molecules involved in cancer cell growth. - [Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery](/research/clinical-trials/cls-20366150) Scottsdale/Phoenix, AZ This randomized phase II trial studies how well irinotecan and cetuximab with or without bevacizumab work in treating patients with RAS wild-type colorectal cancer that has spread to other places in the body and cannot be removed by surgery. Irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. Giving irinotecan and cetuximab with or without bevacizumab may work betting in treating patients with colorectal cancer. - [Phase II Trial of Standard Chemotherapy +Various Proton Beam Therapy (PBT) Doses for Unresectable Cell Lung Cancer](/research/clinical-trials/cls-20338647) Scottsdale/Phoenix, AZ; Rochester, MN This study is being done to study which dose of proton beam therapy (PBT) for unresectable stage 2/3 Non-Small Cell Lung Cancer. - [Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer](/research/clinical-trials/cls-20151639) Jacksonville, FL; Rochester, MN This phase III clinical trial studies two different dose schedules of paclitaxel to see how well they work in combination with carboplatin with or without bevacizumab in treating patients with stage II, III or IV ovarian epithelial cancer, primary peritoneal cancer, or fallopian tube cancer. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others ... - [(VOYAGER) Study of Avapritinib vs Regorafenib in GIST](/research/clinical-trials/cls-20438956) is an open-label, randomized, Phase 3 study in patients with locally advanced unresectable or metastatic GIST (advanced GIST) of avapritinib (also known as BLU-285) versus regorafenib in patients previously treated with imatinib and 1 or 2 other TKIs. - [A Study to Evaluate Wound Infiltration with Liposomal Bupivacaine in Laparotomy for Gynecological Malignancy](/research/clinical-trials/cls-20476554) Rochester, MN The purpose of this study is to determine whether or not there is a benefit to adding opioid injection around the spinal cord ( intrathecal) to incisional long-acting local anesthetic (liposomal bupivacaine) injection for pain management after abdominal surgery for gynecological cancer. - [Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma](/research/clinical-trials/cls-20115567) Rochester, MN RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and help kill them or carry cancer-killing substances to them. Others interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as bendamustine hydrochloride, also work in different ways to kill cancer cells or stop them from dividing. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of mantle cell lymphoma by blocking blood flow to the cancer. It is not yet known ... - [A Study of GDC-0199 with Plus Lymphocytic Leukemia](/research/clinical-trials/cls-20146632) Jacksonville, FL This open-label, randomized (GDC-0199+R) with bendamustine plus MabThera/Rituxan (Rituximab) (B+R) in patients with relapsed or resistant chronic lymphocytic leukemia. Patients will be randomized 1:1 into the two arms. Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) on Day 1 of each 28-day cycle (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2). Patients randomized to B+R will receive 6 cycles of treatment consisting of a rituximab infusion (Cycle 1: 375 mg/m2; Cycles 2-6: 500 mg/m2) on Day ... - [Ruxolitinib Prior to Transplant in Patients With Myelofibrosis](/research/clinical-trials/cls-20111974) Scottsdale/Phoenix, AZ The purpose of this study is to find out if giving the study drug Ruxolitinib (INC424) prior to a combination of other chemotherapeutic drugs (Fludarabine and Busulfan) before infusing another person's hematopoietic stem cells (bone marrow transplantation) will be successful in people who have advanced primary as myelofibrosis (MF). MF is a disorder in which bone marrow tissue develops in abnormal sites because the bone marrow itself undergoes fibrosis or scarring. This study plans to evaluate whether adding the drug Ruxolitinib will further aid in reducing pre-transplant ... - [Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery](/research/clinical-trials/cls-20112272) Rochester, MN This pilot phase I trial studies the side effects and best way to give sirolimus, gemcitabine hydrochloride, and cisplatin in treating patients at high risk for cholangiocarcinoma recurrence after liver transplant or surgery. Sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sirolimus with gemcitabine hydrochloride and cisplatin may be an effective treatment for patients with a high ... - [Dasatinib and Bevacizumab in Treating Patients With Recurrent Glioma or Glioblastoma Multiforme](/research/clinical-trials/cls-20491212) Rochester, MN RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also block the growth of the tumor by blocking blood flow to the tumor. It is not yet known whether bevacizumab together with dasatinib are more effective than a placebo in treating patients with recurrent or progressive high-grade glioma or glioblastoma multiforme. ... - in Radiation-Induced Cancer Survivors](/research/clinical-trials/cls-20112263) Rochester, MN Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate may fight breast cancer by blocking the use of estrogen by the tumor cells This phase IIb trial studies how well low-dose tamoxifen citrate works in reducing breast cancer risk in radiation-induced cancer survivors. - [A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)](/research/clinical-trials/cls-20531308) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The primary objectives of this study are: Part A (Dose escalation): Part B (Cohort expansion): - To assess the efficacy of CTX130 as measured by objective response rate (ORR) in the following 2 expansion arms, according to Lugano response criteria (Cheson et al., 2014) or International Society for Cutaneous Lymphomas (ISCL) response criteria (Olsen et al., 2011) MF/SS (advanced and transformed) PTCL - [A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma](/research/clinical-trials/cls-20520963) Rochester, MN The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528. - [HPV Vaccine with or without Pembrolizumab for Human Papilloma Virus-related Cancer of the Head and Neck](/research/clinical-trials/cls-20526572) Rochester, MN Some patients with head and neck cancer caused by human papilloma virus have a higher risk of recurrence. We are proposing to treat these patients with HPV vaccine with or without pembrolizumab during the window prior to surgery, in hopes of stimulating an immune response. - [A Study to Evaluate the Safety and Tolerability of KTE-X19 in Adults with Relapsed/Refractory Chronic Small Lymphocytic Lymphoma](/research/clinical-trials/cls-20461784) Scottsdale/Phoenix, AZ; Rochester, MN The primary purpose of this study is to evaluate the safety and tolderability of KTE-X19 in adults with relapsed/refractory [An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are a PI and an IMiD](/research/clinical-trials/cls-20150042) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to evaluate the efficacy and safety of 2 daratumumab treatment regimens in participants with multiple myeloma who have received at least 3 prior lines of therapy (including a proteasome inhibitor [PI] and immunomodulatory drug [IMiD]) or are double refractory to a PI and an IMiD. - [A Study of the Effect of Using MRI and Mammography Before Surgery in Patients with Stage I-II Breast Cancer](/research/clinical-trials/cls-20193930) Rochester, MN The purpose of this study is to assess whether patients undergoing a breast MRI (magnetic resonance imaging) before breast surgery will have better results after the surgery. Breast tumors are routinely evaluated using mammograms and ultrasound before surgery. This study would like to find out if using MRI in addition to mammography before surgery improves the ability to evaluate tumors and decide what kind of surgery is best for the patient. - [A Study to Collect and Correlate the Data from Multiple Risk Assessments for Heart Toxicity in Patients Receiving Chemotherapy for Breast Cancer](/research/clinical-trials/cls-20235804) Rochester, MN The purpose of this study is to collect and correlate the data from various cardiovascular risk asessments to successfully measure the risk of heart toxicity in patients receiving chemotherapy for breast cancer. - [A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer](/research/clinical-trials/cls-20271977) Rochester, MN The purpose of this study is to evaluate the effectiveness of abemaciclib plus trastuzumab with or without fulvestrant or chemotherapy in women with hormone receptor positive (HR+), human epidermal growth factor receptor 2 positive (HER2+) locally advanced or metastatic breast cancer after prior exposure to at least two HER2-directed therapies for advanced disease. - [A Study to Analyze the Prevalence of Depression and Anxiety in Newly-diagnosed Breast Cancer Patients in a Community Hospital](/research/clinical-trials/cls-20477837) La Crosse, WI; Albert Lea, MN; Austin, MN; Eau Claire, WI; Rochester, MN The purpose of this study is to analyze the prevalence of mood disorders in newly-diagnosed breast cancer patients with use of specific questionnaires, aimed to diagnose clinically significant depression and anxiety, at a rural community hospital. - [A Study Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma](/research/clinical-trials/cls-20408127) Rochester, MN To evaluate the safety and tolerability of KITE-585, an autologous engineered CAR T-cell product targeting a protein commonly found on myeloma cells called BCMA. Patients will be given a 3 day course of chemotherapy followed by a single infusion of KITE-585. - [A Study to Test the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug for Genitourinary Tumors](/research/clinical-trials/cls-20467530) Eau Claire, WI; Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to assess how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that have spread to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib, nivolumab, and ipilimumab may work better in treating patients with genitourinary tumors that have no ... - [Study of HPN536 in Patients with Advanced Cancers With Mesothelin Expression](/research/clinical-trials/cls-20473923) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN To assess the safety and tolerability at increasing dose levels of HPN536 in successive cohorts of patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer to estimate the maximum tolerated dose (MTD) or maximum administered dose (MAD) and select the recommended Phase 2 dose (RP2D). - [Patient Survey of Molecular Breast Imaging](/research/clinical-trials/cls-20535716) Rochester, MN The purpose of this study is to gather qualitative information about patient comfort during MBI examinations. The primary aim is to assess patient comfort during MBI, relative to comfort during a mammogram. We also wish to identify factors that contribute to discomfort and patients' willingness to have MBI in the future. - [A Study to Evaluate Gevokizumab with Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers](/research/clinical-trials/cls-20469370) Scottsdale/Phoenix, AZ The purpose of this study is to determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose and preliminary effectiveness of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma. - [A Study of JNJ68284528 OutofSpecification (OOS) for Commercial Release in Patients with Multiple Myeloma](/research/clinical-trials/cls-20532048) Rochester, MN The purpose of this study is to evaluate the effectiveness of cilta-cel OOS based on overall response of partial response (PR) or better (overall response rate, ORR) to treat multiple myeloma. - [A Study to Evaluate M7824 with Concurrent Chemoradiation (cCRT) in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)](/research/clinical-trials/cls-20467886) Rochester, MN The primary purpose of this study is to evaluate safety and effectiveness in participants treated with concomitant chemoradiation therapy (cCRT) plus M7824 followed by M7824 compared to cCRT plus placebo followed by durvalumab. - [Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer](/research/clinical-trials/cls-20476148) La Crosse, WI; Albert Lea, MN; Eau Claire, WI; Mankato, MN; Rochester, MN The purpose of this study is to evaluate how well chemotherapy and radiation therapy (chemoradiation) with or without atezolizumab works in treating patients with limited stage small cell lung cancer. Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with ... - [An Effectiveness and Safety Study of Daratumumab in Relapsed/Resistant Mantle Cell Lymphoma, Diffuse Follicular Lymphoma](/research/clinical-trials/cls-20164357) Jacksonville, FL; Rochester, MN The purpose of this study is to assess overall response rate, including complete and partial response, of daratumumab in patients with relapsed or refractory mantle cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. - [A Study to Subjects with Relapsed or Refractory B-Cell Malignancies](/research/clinical-trials/cls-20490907) Jacksonville, FL The purpose of this study is to evaluate the safety and effectiveness CTX110 in subjects with relapsed or refractory B cell malignancies. - [Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma](/research/clinical-trials/cls-20304535) Rochester, MN This phase II trial studies how well ixazomib citrate, lenalidomide, dexamethasone, and daratumumab work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as daratumumab, may block cancer growth in different ways by targeting certain cells. Giving ixazomib citrate, With and Dexamethasone in Participants With Previously Untreated Multiple Myeloma](/research/clinical-trials/cls-20151076) Jacksonville, FL; Rochester, MN The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not candidates for high dose chemotherapy (treatment of disease, usually cancer, by chemical agents) and autologous stem cell transplant (ASCT). - [A Study to Compare Radiation Therapy + Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer](/research/clinical-trials/cls-20511390) Albert Lea, MN; Scottsdale/Phoenix, AZ; La Crosse, WI; Rochester, MN The purpose of this study is to compare the effect of adding radiation therapy to the usual maintenance therapy with atezolizumab versus atezolizumab alone in patients who have already received atezolizumab plus chemotherapy for the treatment of small cell lung cancer that has spread outside of the lung or to other parts of the body (extensive stage). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving radiation ... - [A Study of Using Palbociclib Combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive/ Human Epidermal Growth Factor Receptor 2 Negative Early Breast Cancer](/research/clinical-trials/cls-20199980) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the addition of 2 years of palbociclib to standard adjuvant endocrine therapy for patients with HR+ / HER2- early breast cancer to determine whether the addition of palbociclib will improve outcomes over endocrine therapy alone. - [A Study of Low Dose Tamoxifen for Patients at High Risk for Breast Cancer](/research/clinical-trials/cls-20467533) Jacksonville, FL; Rochester, MN The purpose of this study is to determine if counseling patients about low dose tamoxifen will influence the decision to take (or not take) preventive therapy among women at increased risk for breast cancer. - [A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer](/research/clinical-trials/cls-20511110) Rochester, MN This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan. It will also look at what side effects happen when these drugs are given together. A side effect is anything a drug does besides treating cancer. Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable). All participants will get both tucatinib and trastuzumab deruxtecan. - [A Study to Evaluate Lenalidomide and Dexamethasone, with or without Daratumumab, in Treating High-Risk Smoldering Myeloma Patients](/research/clinical-trials/cls-20467636) Albert Lea, MN; Eau Claire, WI; Rochester, MN The purpose of this study is to show how well lenalidomide and dexamethasone work with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients ... - [A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)](/research/clinical-trials/cls-20540545) Scottsdale/Phoenix, AZ The purpose of this study is to assess the effectiveness and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS). - [A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Impaired Renal Function](/research/clinical-trials/cls-20505898) Jacksonville, FL The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of with Relapsed/Refractory Multiple Myeloma (RRMM) who have had at least 3 lines of prior treatment and have either normal or impaired renal functions. Belantamab mafodotin (GSK2857916) is an antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and majority of MM participants either are at risk or already have renal dysfunction at initial diagnosis. - [EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx](/research/clinical-trials/cls-20337811) Rochester, MN; Scottsdale/Phoenix, AZ; Jacksonville, FL Advanced Accelerator Applications is currently pursuing marketing approval for 177Lu-DOTA0-Tyr3-Octreotate (Lutathera). This expanded access therapeutic protocol aims to allow patients suffering from inoperable, somatostatin receptor positive, neuroendocrine tumors, progressive under somatostatin analogue therapy to access the investigational product, 177Lu-DOTA0-Tyr3-Octreotate (Lutathera), prior to its commercial availability. - [An Extension Study MRI/US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue](/research/clinical-trials/cls-20490400) Rochester, MN To determine the efficacy of using MRI/US fusion imaging technology to direct focal ablation of prostate tissue using nanoparticle-directed laser irradiation. - [PET imaging with [18F]BF4](/research/clinical-trials/cls-20399897) Rochester, MN The objectives of the study are to determine the biodistribution of [18F]BF4 (TFB F 18 Injection) in patients with myeloma or endometrial cancer being treated with oncoviruses carrying the NIS reporter gene. - [Study of RP-6306 With FOLFIRI in Advanced Solid Tumors](/research/clinical-trials/cls-20532391) Scottsdale/Phoenix, AZ; Rochester, MN The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess preliminary anti-tumor activity. - [Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced With Gemcitabine and Nab-paclitaxel (PANOVA-3)](/research/clinical-trials/cls-20526477) Jacksonville, FL The purpose of this study is to test the effectiveness and safety of Tumor Treating Fields (TTFields), in combination with gemcitabine and nab-paclitaxel, for front line treatment of locally-advanced pancreatic denocarcinoma.The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields or TTF) to the region of the malignant tumor, by means of surface, insulated electrode arrays. - [A Study of Nab-Paclitaxel as Maintenance Treatment After Cisplatin-Based Chemotherapy and Surgery for Patients with High-Risk Bladder Cancer](/research/clinical-trials/cls-20199621) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate nab-paclitaxel as maintenance therapy after cisplatin-based chemotherapy and surgery in treating patients with high-risk bladder cancer. Maintenance therapy, such as paclitaxel albumin-stabilized nanoparticle formulation, can help keep cancer from coming back after it has disappeared following initial chemotherapy. - [Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST](/research/clinical-trials/cls-20482088) Jacksonville, FL; Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to provide patients who have locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST) and have received treatment with at least 2 prior Food and Drug Administration (FDA)-approved therapies early access to ripretinib until such time that ripretinib becomes commercially available or the Sponsor chooses to discontinue the program. - [A Study to Evaluate the Combination of Binimetinib and Palbociclib in Treating Patients with The of study is to determine how well binimetinib and palbociclib work compared to TAS-102 in treating patients with KRAS and NRAS mutation positive colorectal cancer that has spread to other places in the body or cannot be removed by surgery. Binimetinib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as TAS-102, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving binimetinib and palbociclib ... - [Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients with Locally Advanced Rectal Cancer Undergoing Surgery](/research/clinical-trials/cls-20154173) Eau Claire, WI The standard treatment for locally advanced rectal cancer involves chemotherapy and radiation, known as 5FUCMT, (the chemotherapy drugs 5-fluorouracil/capecitabine and radiation therapy) prior to surgery. Although radiation therapy to the pelvis has been a standard and important part of treatment for rectal cancer and has been shown to decrease the risk of the cancer coming back in the same area in the pelvis, some patients experience undesirable side effects from the radiation and there have been important advances in chemotherapy, surgery, and radiation which may be of benefit. The purpose of this study is to compare the effects, both good ... - [Testing Cabozantinib in Patients With FL; Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to see how well cabozantinib S-malate works compared with placebo in treating patients with neuroendocrine tumors previously treated with everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth. - [Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or In Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer](/research/clinical-trials/cls-20111946) Scottsdale/Phoenix, AZ This randomized phase II trial studies how well giving erlotinib hydrochloride and cabozantinib-s-malate alone or in combination works as second or third line therapy in treating patient with stage IV non-small cell lung cancer. Erlotinib hydrochloride and cabozantinib-s-malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving erlotinib hydrochloride together with cabozantinib-s-malate is more effective than erlotinib hydrochloride or cabozantinib-s-malate alone in treating non-small cell lung cancer. - [A Study to Assess the Effectiveness and Safety of Ublituximab in combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib Chronic Lymphocytic Leukemia (CLL)](/research/clinical-trials/cls-20467525) Jacksonville, FL; Rochester, MN The purpose of this study is to investigate the effectiveness and safety of ublituximab in combination with umbralisib and venetoclax compared to ublituximab and umbralisib in subjects with previously-treated chronic lymphocytic leukemia (CLL). - [A Study to Evaluate Acalabrutinib With or Without Obinutuzumab to Treat Early-Stage Jacksonville, FL; Rochester, MN This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating participants with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. - [Nilotinib and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Blastic Phase Chronic Myelogenous Leukemia](/research/clinical-trials/cls-20115488) Scottsdale/Phoenix, AZ; Rochester, MN In this study researchers want to find out more about the side effects of a new drug for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and chronic myelogenous leukemia (CML) blastic phase (BP) and if this disease will respond better to nilotinib combined with standard hyper-CVAD therapy rather than hyper-CVAD alone. Hyper-CVAD is (only for patients with cluster of differentiation [CD]20 positive disease). Researchers don't know all the ways that this drug may affect people - [Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Lymphoma](/research/clinical-trials/cls-20530470) Eau Claire, WI; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the effects of ibrutinib and rituximab with or without venetoclax in treating patients with previously untreated Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with may work better in treating patients with previously untreated Waldenstrom's macroglobulinemia than ... - [A Blanket Protocol to Study Oral Regorafenib in Patients with Selected Sarcoma Subtypes](/research/clinical-trials/cls-20111779) Jacksonville, FL; Rochester, MN Regorafenib might or might not slow down the growth of your tumor, or shrink your tumor. Regorafenib is approved in the United States to treat colon cancer and one form of sarcoma (GIST), but we do not know if regorafenib is useful to treat people with liposarcoma, osteosarcoma, and Ewing / Ewing-like sarcomas. One drug like regorafenib, called pazopanib, is approved to treat some sarcomas, but is not approved to treat liposarcoma, osteosarcoma. Since we do not know if any of these types of drugs help people with liposarcoma, osteosarcoma, or Ewing/Ewing-like sarcoma, our goal in - [Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma](/research/clinical-trials/cls-20143565) Jacksonville, FL; Rochester, MN The purpose of this study is to see whether a drug called regorafenib might be effective in treating angiosarcoma. This study is for patients who have angiosarcoma that has gotten worse after they received chemotherapy. Regorafenib is a type of drug called a kinase inhibitor. Regorafenib interferes with how some kinase proteins work. Some of these kinases in cancer cells might normally help the cancer cells grow or form new blood vessels that could feed a growing tumor. By blocking these proteins, regorafenib may help stop the growth of certain cancers. - [Combination Chemotherapy or 90-Yttrium Ibritumomab Tiuxetan and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Relapsed Diffuse Large B-cell Non-Hodgkin Lymphoma](/research/clinical-trials/cls-20164360) No Locations This randomized phase III trial studies 90-yttrium ibritumomab tiuxetan and combination chemotherapy compared with combination chemotherapy alone before stem cell transplant in treating patients with diffuse large b-cell non-Hodgkin lymphoma that has returned after a period of improvement. Radioactive substances linked to monoclonal antibodies, such as 90-yttrium ibritumomab tiuxetan, can bind to cancer cells and give off radiation which may help kill cancer cells. Drugs used in chemotherapy, such as carmustine, etoposide phosphate, cytarabine, and melphalan (BEAM), work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by ... - [A Study of to Evaluate Palbociclib in Combination With Letrozole HER2+ Breast Cancer](/research/clinical-trials/cls-20462051) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate combining endocrine therapy with CDK4/6 inhibition along with trastuzumab in ER+/ human epidermal growth factor receptor 2 (HER2)+ early stage breast cancer in order to influence estrogen receptor (ER) signaling. - [IRB#21-009968: Assessing the Sexual Health and Well-Being of Female Survivors of Pelvic Malignancies after Radiotherapy](/research/clinical-trials/cls-20529235) Rochester, MN The purpose of this study is to quantify the extent of sexual dysfunction in our patients to explore if there is a need for a prospective intervention, with the ultimate goal of improving the quality of life of our patients, with respect to sexual function. - [Fertility Outcomes in Lymphoma Patients](/research/clinical-trials/cls-20528671) Jacksonville, FL The objectives of this study are to analyze impact of radiation on fertility, to correlate the clinical outcome of fertility after chemotherapy and or radiation, and to evaluate the different modalities and cost/benefit of fertility preservation in lymphoma patients Lymphoma is a diversified disease with outcomes differing upon the types and subtypes of lymphoma as well as treatment modalities used. Fertility outcomes in patients treated with chemotherapy and/or radiation could vary and largely unknown. - [A Study to Evaluate Nutrition Therapy in Improving Immune System in Bladder Cancer Patients](/research/clinical-trials/cls-20462813) Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate how well nutrition therapy works in improving immune system in patients with bladder cancer that can be removed by surgery. Improving nutrition before and after surgery may reduce the infections and other problems that sometimes occur after surgery. - [A Study of Cabozantinib (XL184) vs Everolimus in Renal Cell Carcinoma](/research/clinical-trials/cls-20111986) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with Everolimus (Afinitor) on progression-free survival (PFS) and overall survival (OS) in subjects with advanced renal cell cancer that has progressed after prior VEGFR tyrosine kinase inhibitor therapy. - [A Phase I, Multi-Center, Open Label, Dose De-escalation and Expansion Study of Gemcitabine and Cisplatin with Pemigatinib for Advanced Cholangiocarcinoma](/research/clinical-trials/cls-20490398) Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the side effects and best dose of gemcitabine and cisplatin when given together with ivosidenib or pemigatinib in treating patients with cholangiocarcinoma that cannot be removed with surgery (unresectable) or has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ivosidenib and pemigatinib may stop the growth of tumor cells by blocking some of the enzymes needed for ... - [Rituximab, Romidepsin, and Lenalidomide in Scottsdale/Phoenix, AZ; Rochester, MN This phase I/II trial studies the side effects and best dose of romidepsin and lenalidomide when combined with rituximab and to see how well this combination works in treating patients with B-cell non-Hodgkin lymphoma that has returned (recurrent) or did not respond to treatment (refractory). Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Romidepsin and lenalidomide may stop the growth of cancer cells by blocking enzymes needed for cell growth. Giving rituximab together with romidepsin and lenalidomide may be a better treatment for B-cell non-Hodgkin lymphoma. - [Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer](/research/clinical-trials/cls-20111920) Jacksonville, FL; Rochester, MN This phase II trial studies how well cabozantinib-s-malate works in treating patients with thyroid cancer that does not respond to treatment. Cabozantinib-s-malate may stop the growth of thyroid cancer by blocking some of the enzymes needed for cell growth. Cabozantinib-s-malate may also stop the growth of thyroid cancer by blocking blood flow to the tumor. - [A Trial of RAdium-223 and SABR Versus SABR for oligomEtastatic Prostate caNcerS (RAVENS)](/research/clinical-trials/cls-20509425) Rochester, MN The primary purpose of this study is to assess progression-free survival of men who have oligometastatic prostate cancer after randomization to stereotactic ablative radiation therapy versus SABR and Radium-223. - [The Utility of 18F-DOPA-PET in the Treatment of Recurrent High-grade Glioma](/research/clinical-trials/cls-20366131) Rochester, MN This proposal is for a pilot study comparing volumes of 18F-DOPA-PET avidity with contrast enhancement and T2 FLAIR on MRI. We then plan to compare patterns of failure with target volumes, pre-treatment MRI changes and pre-treatment 18F-DOPA-PET. - [A Study to Explore Quality of Life According to Treatment Plan for Patients with Multiple Myeloma Following Autologous Stem Cell Transplant](/research/clinical-trials/cls-20271800) Rochester, MN The purpose of this study is to understand more about how multiple myeloma and its treatment affect day-to-day life for patients, with particular interest in how life is affected following stem cell transplant. - [A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM](/research/clinical-trials/cls-20425425) Rochester, MN A total of 207 subjects will be randomized into the study which will employ a double-blind placebo-controlled setting to assess the efficacy and safety of G-CSF + BL-8040 as compared to G-CSF + placebo. - [A Study to Evaluate Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC](/research/clinical-trials/cls-20459375) Scottsdale/Phoenix, AZ The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT. - [A Study to Evaluate Niraparib and TSR-042 data sequencing 3,000 patients with pancreatic cancer, approximately 3% of pancreatic cancer patients harbor germline mutations in DNA repair genes such as BRCA1/2 and PALB2, and are therefore potential candidates for PARP-inhibitor therapy. In addition, somatic mutations in Homologous Recombination Repair (HRR) genes can confer sensitivity as well, and have been reported to double the number of patients potentially eligible for such therapy. The Keynote-162 study of niraparib and pembrolizumab has validated this approach, with early reports of impressive efficacy. Although unselected trials in pancreatic cancer with immunotherapy alone have yet to be successful, we hypothesize that ... - [Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery](/research/clinical-trials/cls-20533408) Rochester, MN The purpose of this study is to anayze the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery. Immunotherapy with antibodies, such as nivolumab and ipilimumab, may remove the brake on the body's immune system and may interfere with the ability of tumor cells to grow and spread. Chemotherapy and radiation therapy may reduce the tumor size and the amount of normal tissue that needs to be removed during surgery. A combined treatment with nivolumab and ipilimumab, chemotherapy, and radiation therapy ... - [Neoadjuvant Combination Targeted and Immunotherapy for Patients With High-Risk Stage III Melanoma](/research/clinical-trials/cls-20437540) Rochester, MN; Jacksonville, FL The purpose of this early phase I pilot trial studies how well vemurafenib, cobimetinib, and atezolizumab work in treating participants with high-risk stage III melanoma. Vemurafenib and cobimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. Giving vemurafenib, cobimetinib, and atezolizumab may work better in treating high-risk stage III melanoma. A third cohort of patients (Arm C) will receive tiragolumab and atezolizumab for neoadjuvant therapy, and atezolizumab alone for adjuvant therapy. - [A Study to Test the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer](/research/clinical-trials/cls-20482105) Jacksonville, FL; Rochester, MN The purpose of this study is to determine how well cabozantinib, nivolumab, and ipilimumab work in treating patients with differentiated thyroid cancer that does not respond to radioactive iodine and that worsened after treatment with a drug targeting the vascular endothelial growth factor receptor (VEGFR), a protein needed to form blood vessels. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. ... - [A Study of Apalutamide in Participants With HighRisk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy](/research/clinical-trials/cls-20473400) Jacksonville, FL The purpose of this study is to determine if treatment with androgen deprivation therapy (ADT) plus apalutamide before and after radical prostatectomy in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS), as compared to ADT plus placebo. - [A Study to Evaluate Azacitidine Plus Venetoclax Induction Chemotherapy To Treat Acute Myeloid Leukemia Patients for T-cell Directed Immunotherapy](/research/clinical-trials/cls-20509427) Jacksonville, FL The purpose of this study is to evaluate immune profile of Acute Myeloid Leukemia (AML) patients receiving Venetoclax plus Azacitidine induction chemotherapy. - [Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients with Advanced Solid Tumors](/research/clinical-trials/cls-20511181) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to demonstrate the safety and tolerability of JAB-3312 in combination with anti-PD-1 mAb or MEKi or KRASi or EGFR-TKI in patients with advanced solid tumors. - [A Study to Evaluate CC-98633 to Treat Subjects with Relapsed and/or Refractory Multiple Myeloma](/research/clinical-trials/cls-20493136) Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this Phase 1 first-in human study is to evaluate the safety and preliminary efficacy of CC-98633 in adult subjects with relapsed and/or refractory MM. A challenge in CAR T-cell development is to generate a product that consistently expands, persists, and mediates durable antitumor responses after infusion. Multiple preclinical and translational studies have suggested that the differentiation state of adoptively transferred T cells can influence the ability of these cells to persist and promote durable antitumor immunity. Less differentiated T cells have shown an increased ability to proliferate, persist, and mediate responses in mouse tumor models compared to more differentiated effector memory cell subsets in certain studies. - [Nivolumab and Brentuximab Vedotin After Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Classical Hodgkin Lymphoma](/research/clinical-trials/cls-20391192) Rochester, MN This phase II trial studies how well nivolumab and brentuximab vedotin work after stem cell transplant in treating patients with high-risk classical Hodgkin lymphoma that has come back or does not respond to treatment. Monoclonal antibodies, such as nivolumab and brentuximab vedotin, may interfere with the ability of cancer cells to grow and spread. - [Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas](/research/clinical-trials/cls-20366134) Rochester, MN To investigate the efficacy of autologous Epstein-barr virus (EBV)-specific T cells for the treatment of EBV positive Diffuse Large B Cell Lymphoma (DLBCL), Hodgkin Lymphoma (HL) and Post-transplant Lymphoproliferative Disease (PTLD) after failing first line treatment. - [A Study to Assess CART19 for B Cell Malignancies](/research/clinical-trials/cls-20512716) Rochester, MN The purpose of this study is to find out more about the side effects of the CAR-T therapy called IC19/1563 and what dose of IC19/1563 is safe for patients. The therapy, IC19/1563, uses some of the patients own immune cells, called T cells, to kill cancer. T cells fight infections and, in some cases, can also kill cancer cells. In this study, some of the patient's T cells will be removed from their blood. In the laboratory, we will put a new gene into the T cells. This gene allows the T cells to recognize and possibly treat the cancer. The new modified ... - [A Study Comparing Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients with Chronic Lymphocytic Leukemia](/research/clinical-trials/cls-20463521) AZ; Rochester, MN The purpose of this trial is to evaluate how well ibrutinib and obinutuzumab with or without venetoclax work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or ... - [Estradiol in Treating Patients With ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer](/research/clinical-trials/cls-20458012) Jacksonville, FL; Rochester, MN The purpose of this trial is to determine how well estradiol works in treating patients with estrogen receptor beta (ER beta) positive, triple negative breast cancer that has spread to nearby tissue or lymph nodes (locally advanced) or other places in the body (metastatic). Hormone receptors like ER beta allow the body to respond appropriately to hormones. Triple negative means that the breast cancer does not express other hormone receptors called ER alpha, progesterone, and HER2. In some people with triple negative breast cancer, ER beta is overexpressed. Tumor cells that overexpress ER beta grow slower in the laboratory and ... - [Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery](/research/clinical-trials/cls-20417924) Albert Lea, MN; Mankato, MN; II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy and radiation therapy alone in treating patients with prostate cancer that has been removed by surgery. Androgen can cause the growth of prostate cells. Antihormone therapy may lessen the amount of androgen made by the body. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or ... - [A Study of Bladder Filling Variations During Radiation Therapy in Patients Undergoing Radiation Treatment for Prostate Cancer](/research/clinical-trials/cls-20359607) No Locations The purpose of this study is to examine bladder filling for radiation treatment to the prostate, and to evaluate how bladder fullness changes daily during radiation treatment. - [Radiation Therapy with Durvalumab or Cetuximab to Treat Patients with Locoregionally Advanced Head and Neck Cancer who Cannot Take Cisplatin](/research/clinical-trials/cls-20507611) Rochester, MN This phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with head and neck cancer that has spread to a local and/or regional area of the body who cannot take cisplatin. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as durvalumab or cetuximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not known if radiation therapy with durvalumab will work better than the usual therapy of radiation ... - [A Study to Compare Subcutaneous Daratumumab with Intravenous Daratumumab](/research/clinical-trials/cls-20509117) Rochester, MN The purpose of this study is to evaluate qualtiy of life (QOL) metrics while receiving subcutaneous (SQ) daratumumab, patient satisfaction, and patient preference for IV and/or SC therapies. - [NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS](/research/clinical-trials/cls-20539289) Jacksonville, FL The primary purpose of this study is to assess the safety and tolerability of NKX101 including dose-limiting toxicities (DLTs), and to identify the recommended Phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) of NKX101. - [A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent Breast Cancer](/research/clinical-trials/cls-20110794) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN This is a two arm Phase III trial in first and second-line HER2 negative patients with locally recurrent or metastatic breast cancer. The primary endpoint is overall survival (OS), and the objective is to test for the superiority of eribulin mesylate over standard weekly paclitaxel. Patients will be randomized between the experimental and control arm with equal allocation (1:1) within strata defined by prior adjuvant taxanes, hormone receptor status, and line of therapy. Subjects will continue protocol directed therapy until documentation of disease progression, development of unacceptable toxicity, or withdrawal of consent. Those who discontinue study treatment without radiological progression ... - [A Study to Compare the Effectiveness and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory FL; The study is designed to determine if JCAR017 is superior to current standard of care (SOC) therapy for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL). JCAR017 is a CAR-T therapy directed against CD19 (a cell surface protein on NHL cancer cells), meaning that a patient's own T-cells are collected from their blood, genetically modified to attack their cancer cells, then re-infused into their body. - [Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant](/research/clinical-trials/cls-20238952) Rochester, MN; Jacksonville, FL This phase II trial studies how well pembrolizumab, lenalidomide, and dexamethasone work in treating patients with newly diagnosed multiple myeloma that are eligible for stem cell transplant. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab, lenalidomide, and dexamethasone may work better in treating patients with multiple myeloma. - [Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer](/research/clinical-trials/cls-20315660) Jacksonville, FL This phase I/II trial studies the best dose of pembrolizumab and binimetinib and how well it works when giving together with pembrolizumab in treating patients with triple negative breast cancer that has spread to other parts of the body. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and binimetinib may work better in treating patients with triple negative breast cancer. - [Study of BN Brachyury and Radiation AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to determine if the combination of BN-Brachyury plus radiation therapy can induce objective radiographic response rate (ORR) in patients, using a Simon 2-stage optimal design. In stage 1, a minimum of threshold of activity will be needed to proceed to stage 2. - [A Study to Evaluate the Safety and Immunological Effect of in Resectable or Borderline Resectable Pancreatic Cancer](/research/clinical-trials/cls-20461992) Scottsdale/Phoenix, AZ The purpose this study is to investigate whether pembrolizumab (MK-3475 ) can be used safely during neoadjuvant treatment and can improve the body's immune response against pancreatic cancer. Pembrolizumab has been approved for treatment of patients with melanoma but has not been proven to be safe or helpful in patients with pancreatic cancer and is not approved by the U.S. Food and Drug Administration (FDA) for this purpose. - [A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relaped/Refractory Multiple Myeloma](/research/clinical-trials/cls-20507823) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate HPN217 as monotherapy to assess the safety, tolerability and pharmacokinetics in patients with relapsed/ refractory multiple myeloma. - [Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer](/research/clinical-trials/cls-20235636) Rochester, MN This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may be better in treating patients with breast cancer. - [PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer](/research/clinical-trials/cls-20111966) Scottsdale/Phoenix, AZ; Rochester, MN A Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER+ Human epidermal growth factor receptor 2 (HER2)- breast cancer, to investigate whether the combination of PD 0332991 and anastrozole is able to: 1) improve the pathologic complete response rate when compared to the historical control of single agent aromatase inhibitors, 2) result in fewer patients with on therapy Ki67>10% compared to historical control. - [Combination Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Young Patients with Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma](/research/clinical-trials/cls-20126460) Rochester, MN This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given before a peripheral stem cell transplant in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with a peripheral stem cell transplant may allow more chemotherapy to be given so that more tumor cells are killed. It is not yet known which ... - [Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Chronic Lymphocytic Leukemia or such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as pentostatin and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving rituximab together with combination chemotherapy and lenalidomide may kill more cancer cells. PURPOSE: ... - [Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma](/research/clinical-trials/cls-20492231) Rochester, MN; Scottsdale/Phoenix, AZ This randomized phase II trial studies how well rituximab and combination chemotherapy with or without lenalidomide work in treating patients with newly diagnosed stage II-IV diffuse large B cell lymphoma. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lenalidomide may stimulate the immune system in different ways and stop cancer cells ... - [Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, are distinct of B-cell NHL. Lenalidomide is an immunomodulatory agent with direct and immune-mediated mechanisms of action, as well as clinical activity in NHL. Recent studies in frontline and relapsed/refractory NHL show high activity for lenalidomide plus rituximab (R2), supporting further study of this combination. - [Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular may stimulate the immune system in different ways and stop cancer cells from growing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide together with rituximab and combination chemotherapy may kill more cancer cells. PURPOSE: ... - [Tucatinib With Trastuzumab and mFOLFOX6 Cancer](/research/clinical-trials/cls-20535897) Scottsdale/Phoenix, AZ; Rochester, MN The of this study is to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). - [XmAb\u00ae20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer](/research/clinical-trials/cls-20542043) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to investigate the safety and clinical activity of XmAb20717 alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have been treated with at least 2 prior lines of anticancer therapy. - [Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Recurrent or Refractory Multiple Myeloma](/research/clinical-trials/cls-20533789) Scottsdale/Phoenix, AZ Primary Goal: To determine the toxicity of in-house, manufactured MUC1-activated T cells in patients with relapsed/refractory MUC1-expressing multiple myeloma. The rationale for using MUC1-stimulated T-cells to treat multiple myeloma is twofold. The first is that T-cell therapies have been shown to be active in myeloma, making it an attractive disease model for the proposed study. The other is that we are expanding and using naturally occurring myeloma-fighting T-cells which may offer benefits, particularly with respect to longevity, as compared to the methods currently being employed using CAR-T and bispecific antibodies. This is highly significant as one of the ... - [Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer](/research/clinical-trials/cls-20438527) Scottsdale/Phoenix, AZ; Jacksonville, FL This II trial studies how well carboplatin and paclitaxel with or without atezolizumab before surgery works in treating patients with newly diagnosed, stage II-III triple negative breast cancer. Monoclonal antibodies, such as atezolizumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carboplatin and paclitaxel with or without atezolizumab before surgery may make the tumor smaller and reduce the ... - [Inolitazone Dihydrochloride and Paclitaxel in Treating Cancer](/research/clinical-trials/cls-20134474) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN how well inolitazone dihydrochloride (efatutazone dihydrochloride) and paclitaxel work in treating patients with anaplastic thyroid cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Drugs used in chemotherapy, such as efatutazone dihydrochloride and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. - [Use of Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy and Risk of Malignancy in Genetic Mutation Carriers](/research/clinical-trials/cls-20344120) Rochester, MN The purpose of this study is to determine if an increase risk of malignancy occurs in these patients if they use hormonal replacement therapies after a risk reducing salpingo-oophorectomy - [A Study to Evaluate Hyperthermic Intraperitoneal Chemotherapy to Treat Patients with Pancreatic Cancer and Peritoneal Metastasis](/research/clinical-trials/cls-20526066) Rochester, MN The primary purpose of this study is to assess short-term morbidity and disease-free survival outcomes for patients with pancreatic adenocarcinoma with limited low volume peritoneal metastasis or positive peritoneal cytology undergoing hyperthermic intraperitoneal chemotherapy. - [Lower or Standard Scottsdale/Phoenix, II trial studies how well lower-dose compared to standard dose regorafenib works in treating patients with colorectal cancer that has spread from the primary site (place where it started) to other places in the body and does not respond to treatment. Regorafenib may stop the growth of colorectal cancer by blocking the growth of new blood vessels necessary for tumor growth and by blocking some of the enzymes needed for cell growth. It is not yet known whether lower-dose or standard dose regorafenib is more effective in treating patients with colorectal cancer. Clobetasol propionate is a steroid ... - [Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer](/research/clinical-trials/cls-20520087) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to identify the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to treatment with drugs that contain the metal platinum but then comes back within a certain period (recurrent platinum-resistant). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them ... - [A Study to Investigate LYL797 in Adults With Solid Tumors](/research/clinical-trials/cls-20537302) Jacksonville, FL; Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the next part of the study, and will enroll TNBC patients only. The second part of the study will test that dose in additional TNBC patients and NSCLC patients. - [A Study of Ovarian Tissue Freezing for the Preservation of Fertility in Children](/research/clinical-trials/cls-20267872) Rochester, MN The purpose of this study is to offer ovarian tissue cryopreservation to female pediatric patients (birth-17 years of age) with fertility threatening medical diagnoses or facing surgery, chemotherapy or radiation therapy that may cause loss of reproductive potential. Since this procedure is currently considered experimental, the establishment of an IRB protocol under which this opportunity can be offered is needed. - [S1400 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer](/research/clinical-trials/cls-20145562) Rochester, MN This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid \"Master Protocol\" (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a \"non-match\" sub-study which will include ... - [Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for Transplant](/research/clinical-trials/cls-20304705) Jacksonville, FL This phase I/II trial studies the best dose and side effects of ibrutinib when given together with lenalidomide and dexamethasone and how well they work in treating patients with multiple myeloma that are not eligible for transplant. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib, lenalidomide, and dexamethasone may work better in ... - [A Study to Evaluate Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)](/research/clinical-trials/cls-20490567) Rochester, MN The purpose of tis study is to evaluate whether adding brentuximab vedotin helps two drugs work better to treat patients with diffuse large B-cell lymphoma (DLBCL). Participants in this study will have Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not gotten better with treatment. Patients will be randomly assigned to get either brentuximab vedotin or placebo. The placebo will look like brentuximab vedotin, but has no medicine in it. Since the study is \"blinded,\" patients and their doctors will not know whether a patient gets brentuximab vedotin or placebo. All patients in the study will get rituximab and ... - [Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia and FLT3 Mutation](/research/clinical-trials/cls-20192977) Rochester, MN This phase II trial studies how well midostaurin and decitabine work in treating older patients with newly diagnosed acute myeloid leukemia and fms-related tyrosine kinase 3 (FLT3) mutations. Midostaurin and decitabine may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. - [A Study to Evaluate Fractionated Radiation Therapy Utilizing GRID Therapy for Locally-advanced Bulky Tumors](/research/clinical-trials/cls-20491947) Rochester, MN; Jacksonville, FL The purpose of this research is to study radiographic control at the 3 month time-point, the side effects (good & bad), survival outcomes and proof of this idea in patients who have had grid therapy for locally advanced bulky tumors of the heat and neck, thorax, abdomen and extremities. - [Bevacizumab with or without Anti-Endoglin Monoclonal Antibody TRC105 in FL; Rochester, MN This partially randomized phase I/II trial studies the side effects and the best dose of anti-endoglin monoclonal antibody TRC105 when given together with bevacizumab and to see how well they work in treating patients with glioblastoma multiforme that has come back. Monoclonal antibodies, such as anti-endoglin monoclonal antibody TRC105 and bevacizumab, may find tumor cells and help kill them. Giving anti-endoglin monoclonal antibody TRC105 together with bevacizumab may be an effective treatment for glioblastoma multiforme. - [A Study to Evaluate the Safety and Immunological Effect of in Resectable or Borderline Resectable Pancreatic Cancer](/research/clinical-trials/cls-20461992) Scottsdale/Phoenix, AZ The purpose this study is to investigate whether pembrolizumab (MK-3475 ) can be used safely during neoadjuvant treatment and can improve the body's immune response against pancreatic cancer. Pembrolizumab has been approved for treatment of patients with melanoma but has not been proven to be safe or helpful in patients with pancreatic cancer and is not approved by the U.S. Food and Drug Administration (FDA) for this purpose. - [A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relaped/Refractory Multiple Myeloma](/research/clinical-trials/cls-20507823) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate HPN217 as monotherapy to assess the safety, tolerability and pharmacokinetics in patients with relapsed/ refractory multiple myeloma. - [Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast Cancer](/research/clinical-trials/cls-20235636) Rochester, MN This phase II trial studies how well alisertib with or without fulvestrant works in treating patients with endocrine-resistant breast cancer that has spread to other places in the body. Alisertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Hormone therapy using fulvestrant may fight breast cancer by blocking the use of estrogen by the tumor cells or reducing the amount of estrogen made by the body. Giving alisertib with or without fulvestrant may be better in treating patients with breast cancer. - [PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer](/research/clinical-trials/cls-20111966) Scottsdale/Phoenix, AZ; Rochester, MN A Phase II study to investigate the potential utility of PD 0332991 in the treatment of early stage ER+ Human epidermal growth factor receptor 2 (HER2)- breast cancer, to investigate whether the combination of PD 0332991 and anastrozole is able to: 1) improve the pathologic complete response rate when compared to the historical control of single agent aromatase inhibitors, 2) result in fewer patients with on therapy Ki67>10% compared to historical control. - [Combination Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Young Patients with Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma](/research/clinical-trials/cls-20126460) Rochester, MN This randomized phase III trial is studying two different combination chemotherapy regimens to compare how well they work when given before a peripheral stem cell transplant in treating young patients with newly diagnosed supratentorial primitive neuroectodermal tumors or high-risk medulloblastoma. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) together with a peripheral stem cell transplant may allow more chemotherapy to be given so that more tumor cells are killed. It is not yet known which ... - [Safety and Activity of MN This is a multicenter, open label, phase II trial to determine the safety, tolerability, and immunogenicity and initial clinical activity of the combination treatment of PolyPEPI1018 vaccine and atezolizumab in participants with MSS CRC who have progressed on 2 or 3 prior regimens. - [A Study to Evaluate Remote Monitoring in Cancer Care](/research/clinical-trials/cls-20517306) Rochester, MN The objectives of this study are to establish the validity for the use of wearable device for continuous, remote monitoring of physiologic parameters, to establish the validity for the use of wearable device for continuous, remote monitoring of physiologic parameters, and to develop patient-specific algorithms to predict the trajectory of CRS and or neurotoxicity and time to escalation of medical intervention is needed. - [A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers](/research/clinical-trials/cls-20509258) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety, tolerability, feasibility, and preliminary effectiveness of the administration of genetically-modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells). - [A Study to Evaluate Daratumumab and Ibrutinib to Treat Relapsed / Refractory Chronic Lymphocytic Leukemia Treatment (DIRECT)](/research/clinical-trials/cls-20476550) Jacksonville, FL For cohort 1: The primary goal is to the determine the overall response rate after 6 cycles of treatment with daratumumab in combination with ibrutinib in patients who are on/or are previously treated with ibrutinib. For Cohort 2: The primary goal is to determine the overall response rate after 6 cycles of treatment with daratumumab in combination with ibrutinib in patients who are naive to ibrutinib treatment. Secondary Goals: For Cohort 1 -Determine the best overall response rate to treatment with daratumumab plus ibrutinib at any time during the course of the therapy. -The overall incidence of MRD (minimal ... - [A Study of Daratumumab in Patients With Relapsed or Refractory Waldenstr\u00f6m Macroglobulinemia](/research/clinical-trials/cls-20429099) Rochester, MN This research study is studying Daratumumab as a possible treatment for Waldenstr\u00f6m Macroglobulinemia. - [Cyclophosphamide and Vaccine Therapy in Treating Patients with Stage II-III Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer](/research/clinical-trials/cls-20115989) Rochester, MN This study is being done to gather information. The study will provide important information related to the safety and the effect of the vaccine on a patient's immune system. What researchers learn from this study could possibly be used in the future to prevent or delay recurrence of breast or ovarian cancers. - [A Single Patient Study of Severe Fibrosis after Breast Radiation](/research/clinical-trials/cls-20302822) Rochester, MN This study is being performed to better understand the mechanisms behind severe radiation toxicity of a patient with severe fibrosis after breast radiation. - [Study of Encorafenib + Cetuximab or 3 study to evaluate encorafenib + cetuximab plus or minus binimetinib versus Investigator's choice of either irinotecan/cetuximab or FOLFIRI/cetuximab, as controls, in patients with BRAFV600E mCRC whose disease has progressed after 1 or 2 prior regimens in the metastatic setting. The study contains a Safety Lead-in Phase in which the safety and tolerability of encorafenib + binimetinib + cetuximab will be assessed prior to the Phase 3 portion of the study. - [Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer](/research/clinical-trials/cls-20151645) Mankato, MN RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Chemoradiotherapy (combining chemotherapy with radiation therapy) before surgery may shrink the tumor so that it can be removed. Giving chemotherapy after surgery may kill any remaining tumor cells. PURPOSE: This randomized phase II trial is studying two different regimens of neoadjuvant chemoradiotherapy and adjuvant chemotherapy and comparing how well they work in treating patients who are undergoing surgical resection for locally advanced rectal cancer. - [Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With in Previously Untreated Metastatic Colorectal Cancer](/research/clinical-trials/cls-20146660) Scottsdale/Phoenix, AZ This study seeks to evaluate the efficacy and tolerability of veliparib in combination with FOLFIRI +/- bevacizumab in untreated, metastatic adenocarcinoma of the colon or rectum. FOLFIRI is a chemotherapy regimen of fluorouracil, leucovorin and irinotecan. This is a blinded study such that the Investigator and Subject will be blinded but AbbVie will be unblinded. - [REFINE: Regorafenib Observational Study in Hepatocellular Carcinoma](/research/clinical-trials/cls-20417925) Rochester, MN The purpose of this observational study is to describe the safety and effectiveness of regorafenib in patients with uHCC under real world practice conditions. - [Erlotinib with or without Bevacizumab in Treating Patients with Stage IV Non-Small Cell Lung Cancer with EGFR Mutations](/research/clinical-trials/cls-20115807) Rochester, MN This randomized phase II trial studies how well giving erlotinib (Tarceva) with or without bevacizumab (Avastin) works in treating patients with stage IV non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Bevacizumab blocks the ability of tumors to grow new blood vessels and spread. It is not yet known whether erlotinib is more effective when given alone or with bevacizumab. - [Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Diagnosed and High Risk DLBCL Patients](/research/clinical-trials/cls-20520089) Rochester, MN; Jacksonville, FL The purpose of this study is to compare the effectiveness and safety of the humanized monoclonal anti CD19 antibody versus newly-diagnosed DLBCL. - [Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Active Multiple Myeloma](/research/clinical-trials/cls-20453012) Scottsdale/Phoenix, AZ; Rochester, MN RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Thalidomide may stop the growth of cancer cells by blocking blood flow to the tumor. Giving combination chemotherapy together with carfilzomib and thalidomide may kill more cancer cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of carfilzomib when given together with cyclophosphamide, thalidomide, and dexamethasone ... [A Study Mutated Acute Myeloid Leukemia](/research/clinical-trials/cls-20478567) Jacksonville, FL; Rochester, MN The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving standard combination chemotherapy for FLT3 AML. - [Rituximab Plus Lenalidomide for Indolent Lymphoma MN This double-blind randomized, parallel group study will evaluate the efficacy and safety of lenalidomide (Revlimid, CC-5013) in combination with rituximab (MabThera/Rituxan) in patients relapsed or refractory follicular lymphoma or marginal zone lymphoma. Patients will be randomized to receive either lenalidomide or placebo for twelve 28-day cycles in combination with rituximab. Anticipated time on study treatment is 1 year. - [A Study of R-ICE and Lenalidomide for Treating Patients with Refractory Diffuse Large B-Cell Lymphoma](/research/clinical-trials/cls-20214780) Rochester, MN; Jacksonville, FL The purpose of this study is to assess the side effects and best dose of lenalidomide when given together with rituximab-ifosfamide-carboplatin-etoposide (R-ICE) and how well they work in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement and that has not responded to previous treatment. Biological therapies, such as lenalidomide, may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as R-ICE, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or ... - [Erismodegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma](/research/clinical-trials/cls-20111944) Rochester, MN This phase II trial studies how well erismodegib and lenalidomide after stem cell transplant works in treating patients with multiple myeloma. Erismodegib and lenalidomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and may delay the recurrence of myeloma after a stem cell transplant. - [A Study Evaluating the Efficacy of Venetoclax Plus Ibrutinib in Subjects With T-cell Prolymphocytic Leukemia](/research/clinical-trials/cls-20484357) No Locations The purpose of this study is to evaluate the safety and effectiveness of venetoclax plus ibrutinib for participants with T-cell Prolymphocytic Leukemia (T-PLL) and follows a 2-stage design as follows: Stage 1: Enroll up to 14 participants and move to Stage 2 if 4 or more subjects meet protocol-specified response criteria. Response assessment will be performed on a continued basis until all 14 participants have enrolled into Stage 1 and have completed the Week 24 disease assessment. Stage 2: Enroll up to an additional 23 participants with previously untreated or relapsed or refractory T-PLL. - [DSC-MRI in Measuring Relative Cerebral Blood Volume for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma](/research/clinical-trials/cls-20423503) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient?s response to treatment. - [Study of Breast Cancer Risk Assessment in Female Patients with Benign Breast Disease](/research/clinical-trials/cls-20491945) Rochester, MN; Jacksonville, FL The purpose of this study is to to bring molecular risk prediction for breast cancer into the clinical arena through: the establishment of a large tissue repository from a retrospective cohort of women with benign breast disease with complete and long-term clinical follow-up to identify those who developed breast cancer (cases) and those who did not (controls); the application of potential biomarkers of risk to this archival tissue set; and, the discovery of new, potentially relevant biomarkers of risk in fresh and frozen specimens of benign breast disease. - [A Study to Evaluate Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer](/research/clinical-trials/cls-20470675) Eau Claire, WI The purpose of this study is to evaluate androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer. Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. - [Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer](/research/clinical-trials/cls-20470489) Rochester, MN RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective with or without androgen-deprivation therapy in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer. - [A Study to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma](/research/clinical-trials/cls-20507917) Rochester, MN This study aims to evaluate the safety and tolerability of CAR-CLDN18.2 T-cell therapy (CT041) in patients with advanced adenocarcinoma of stomach or gastroesophageal junction (STAD) or pancreatic adenocarcinoma (PAAD) and identify the maximum tolerated dose (MTD) and a recommended Phase 2 dose (RP2D) of CT041 therapy. - [A Study to Quantify Microvasculature Imaging for Breast Cancer Detection and Monitoring](/research/clinical-trials/cls-20460006) Rochester, MN The purpose of this study is to apply new microvasculature imaging for differentiation of breast lesions, and prediction of response to preoperative chemotherapy. - [A Study to Evaluate Abemaciclib for Surgically Chemotherapy-Resistant, Breast Cancer](/research/clinical-trials/cls-20462810) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The primary purpose of this study is to examine the effects of abemaciclib on the CD8/FOXP3 ratio in chemotherapy-resistant triple negative breast cancer (TNBC) patients following neoadjuvant chemotherapy. - [Study of Breast Cancer Risk Assessment in Female Patients with Benign Breast Disease](/research/clinical-trials/cls-20491945) Rochester, MN; Jacksonville, FL The purpose of this study is to to bring molecular risk prediction for breast cancer into the clinical arena through: the establishment of a large tissue repository from a retrospective cohort of women with benign breast disease with complete and long-term clinical follow-up to identify those who developed breast cancer (cases) and those who did not (controls); the application of potential biomarkers of risk to this archival tissue set; and, the discovery of new, potentially relevant biomarkers of risk in fresh and frozen specimens of benign breast disease. - [A Study to Evaluate Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer](/research/clinical-trials/cls-20470675) Eau Claire, WI The purpose of this study is to evaluate androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer. Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells. - [Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer](/research/clinical-trials/cls-20470489) Rochester, MN RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Androgens can cause the growth of prostate cancer cells. Androgen-deprivation therapy may lessen the amount of androgens made by the body. It is not yet known whether radiation therapy is more effective with or without androgen-deprivation therapy in treating patients with prostate cancer. PURPOSE: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with androgen-deprivation therapy in treating patients with prostate cancer. - [A Study to Evaluate the Safety and Efficacy of Autologous Claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Patients With Advanced Gastric or Pancreatic Adenocarcinoma](/research/clinical-trials/cls-20507917) Rochester, MN This study aims to evaluate the safety and tolerability of CAR-CLDN18.2 T-cell therapy (CT041) in patients with advanced adenocarcinoma of stomach or gastroesophageal junction (STAD) or pancreatic adenocarcinoma (PAAD) and identify the maximum tolerated dose (MTD) and a recommended Phase 2 dose (RP2D) of CT041 therapy. - [Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy ](/research/clinical-trials/cls-20519867) Rochester, MN This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such Rochester, trial studies how well atezolizumab and capecitabine with or without bevacizumab work in treating patients with colorectal cancer that is not responding to treatment and has spread to other places. Monoclonal antibodies, such as atezolizumab and bevacizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab with capecitabine and bevacizumab may be a better way in treating ... - [Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery](/research/clinical-trials/cls-20306547) Rochester, MN This phase II trial studies how well pembrolizumab and ibrutinib work in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Ibrutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and ibrutinib may work better in treating patients with melanoma. - [A Study Patients with Advanced HCC Undergoing Immunotherapy Through Novel 68Ga PSMA PET Imaging](/research/clinical-trials/cls-20523801) Rochester, MN The purpose of this study is to evaluate patient outcomes after undergoing 68Ga-PSMA PET/CT imaging prior to initiation of immunotherapy to identify PSMA PET/CT positive patients (estimated N=20) for long term follow up. In adult patients with advanced, pathologically confirmed HCC who are not amenable to curative restriction, transplantation or ablative therapies, and have radiographically measurable disease by RECIST; eligible for atezolizumab/bevacizumab front line therapy. - Specific Aim 1. To test the performance of novel biomarkers derived from PSMA PET/CT to measure response compared to RECIST criteria, in advanced HCC patients treated with immunotherapy. - Specific Aim 2. To identify precision ... - [Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome](/research/clinical-trials/cls-20425291) Rochester, MN This randomized phase II/III trial studies how well azacitidine with or without nivolumab or midostaurin, or decitabine and cytarabine alone work in treating older patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome. Drugs used in chemotherapy, such as azacitidine, decitabine, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as nivolumab, may interfere with the ability of cancer cells to grow and spread. Midostaurin may stop the growth of cancer cells by blocking some ... - [A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20424749) Jacksonville, FL The main purpose of this study is to assess the safety of the combination of JNJ-63723283 and daratumumab (Part 1); to compare the overall response rate (ORR) in participants treated with JNJ-63723283 in combination with daratumumab versus daratumumab alone (Part 2); and to compare progression-free survival (PFS) in participants treated with JNJ-63723283 in combination with daratumumab versus daratumumab alone (Part 3). - [A Study to Compare Tisagenlecleucel vs. Standard of Care in Adult Patients with Aggressive B-cell Non-Hodgkin Lymphoma](/research/clinical-trials/cls-20474784) Jacksonville, FL This is a randomized, open label, multicenter phase III trial to determine the efficacy and safety of tisagenlecleucel treatment strategy in adult patients with relapsed or refractory aggressive B-cell NHL after failure of rituximab and anthracycline containing frontline immunochemotherapy. - [Study of bb21217 Rochester, CRB-402 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb21217 in adults with relapsed/refractory multiple myeloma (MM). - [A Study to Compare Nivolumab or Brentuximab Vedotin Plus Combination Chemotherapy to Treat Patients with Newly-diagnosed Stage III-IV Classic Hodgkin Lymphoma](/research/clinical-trials/cls-20480302) Eau Claire, WI; Rochester, MN The purpose of this study is to compare immunotherapy drugs (nivolumab or brentuximab vedotin) when given with combination chemotherapy in treating patients with newly diagnosed stage III or IV classic Hodgkin lymphoma. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as doxorubicin, vinblastine, and dacarbazine, work Non-Hodgkin Lymphoma MN This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T Non-Hodgkin Lymphoma (NHL). [A Randomized Trial of & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity](/research/clinical-trials/cls-20360314) Jacksonville, FL This is an open-label, multi-institutional phase II randomized study neoadjuvant radiotherapy surgical resection to neoadjuvant pembrolizumab with concurrent radiotherapy, followed by surgical resection and adjuvant pembrolizumab. The total duration of pembrolizumab will be one year in the experimental arm. - [A Study to Evaluate APG2575 Combined with Novel Therapeutic Regimens To Treat Subjects with Relapsed or Refractory Multiple Myeloma and Immunoglobulin Light Chain Amyloidosis](/research/clinical-trials/cls-20514659) Jacksonville, FL The purpose of this study is to evaluate the safety and tolerability, identify dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD and recommended phase II dose (RP2D of APG2575 in combination with Pomalidomide/dexamethasone (Pd) in patients with relapsed/refractory (R/R) multiple myeloma (MM), or immunoglobulin light chain (AL) amyloidosis, and to evaluate the safety and tolerability, identify dose-limiting toxicities (DLT) and the maximum tolerated dose (MTD and recommended phase II dose (RP2D of APG2575 in combination with Daratumumab/Lenalidomide/dexamethasone (DRd) in patients with relapsed/refractory (R/R) multiple myeloma (MM). - [Treating Breast Cancer Patients Undergoing Trastuzumab Treatment with Carvedilol to Reduce Incidence of Heart Failure](/research/clinical-trials/cls-20469677) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate different strategies of cardiovascular therapy with Carvedilol, aiming to reduce the incidence of left ventricular ejection fraction (LVEF) decline and heart failure (HF) in patients undergoing curative intent Trastuzumab for breast cancer. . - [A Study to Evaluate the Impact of Non-invasive Tests for Bladder Cancer](/research/clinical-trials/cls-20510897) Rochester, MN Levels of bladder cancer-derived extracellular vesicles become undetectable after radical cystectomy in patients with localized bladder cancer. This study hopes to determine the levels of bladder cancer-derived extracellular vesicles pre- and post-RC. - [A Study Proton Therapy to Treat Low-Grade Glioma](/research/clinical-trials/cls-20509166) Rochester, MN The purpose of this study is to determine the feasibility of hippocampal-avoidance (HA) with proton therapy in suprasellar (LGGs). - [CT of the Breast: Feasibility and Comparison with MRI in Women with Breast Cancer](/research/clinical-trials/cls-20308688) No Locations The purpose of this study is to estimate the performance (sensitivity, specificity, accuracy) of dual-energy CT of the breast for detection of breast cancer in the ipsilateral and contralateral breast compared to standard multihance breast MR imaging. To determine the optimal workflow and images needed (multiplanar reconstructions, color maps, etc.) needed for routine interpretation of DE or quantitative CT imaging of contrast enhanced breast DECT. - [Parotidectomy QOL Score](/research/clinical-trials/cls-20531436) Rochester, MN The objectives of this study are to explore the quality of life value of various surgical and functional outcomes after parotidectomy from a patient-centered perspective, develop a comprehensive patient-centered outcome measure after parotidectomy using a patient survey, and to validate the content of the above survey. - [Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer](/research/clinical-trials/cls-20111990) Rochester, MN This randomized phase II trial studies how well cabozantinib-s-malate works compared to sunitinib malate in treating patients with previously untreated kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib-s-malate and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether cabozantinib-s-malate is more effective than sunitinib malate in treating patients with kidney cancer. - [Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib](/research/clinical-trials/cls-20115974) Rochester, MN The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib. - [Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma](/research/clinical-trials/cls-20145160) Scottsdale/Phoenix, AZ; Rochester, MN This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib or carfilzomib together with lenalidomide and dexamethasone may kill more cancer cells - [A Study to Analyze Hypofractionated Proton Therapy for Head and Neck Cancers](/research/clinical-trials/cls-20522381) Scottsdale/Phoenix, AZ; Rochester, MN This study utilizes a shorter course of radiotherapy for patients who need radiation after surgery or without surgery for head and neck cancers. Radiation is typically given in 6-7 weeks for head and neck cancer using X-ray therapy, but this study will administer treatment in approximately 3 weeks. To achieve this shorter course, proton therapy is used. This study aims to determine cancer control at 2 years after study registration. It also aims to determine the rate and duration of grade 3 or higher acute (defined from treatment start to 30 days from radiation completion date) adverse events ... - [A Study to Evaluate Tucatinib HER2+ Gastrointestinal Cancers](/research/clinical-trials/cls-20487854) Scottsdale/Phoenix, AZ The purpose of this study is to determine the recommended dose of tucatinib when combined with trastuzumab and modified FOLFOX7 (mFOLFOX7) or CAPOX in subjects with human epidermal growth factor receptor 2 (HER2)+ gastrointestinal cancers. - [Cell Saver During Tumor Resection](/research/clinical-trials/cls-20533940) Rochester, MN The aims of this study are to investigate the presence of tumor cells after filtration of autologous blood products by intraoperative cell saver, and to demonstrate the feasibility of intraoperative blood salvage during intralesional tumor resection. Intraoperative blood salvage is a relatively safe and cost-effective alternative to allogeneic blood transfusion during procedures with large volume blood loss. Salvaged blood products are washed and filtered before reinfusion into the patient. Given the theoretical risk of systemically re-infusing samples contaminated with tumor cells, many surgeons refrain from using intraoperative blood salvage. Aside from a few small studies, there is a ... - [A Study of Pembrolizumab (MK-3475) Versus Placebo in Combination with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer](/research/clinical-trials/cls-20467349) Rochester, MN The purpose of this study is to assess the effectiveness and safety of pembrolizumab (MK-3475) versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in the treatment of adults who have high-risk early-stage estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer. - [Eliminating Breast Cancer Surgery in Exceptional Responders with Neoadjuvant Systemic Therapy](/research/clinical-trials/cls-20438440) Rochester, MN The goal of this clinical research study is to learn how often breast cancer recurs (returns after treatment) in the breast in patients who have been treated with chemotherapy and have had follow-up radiation therapy (but not surgery) and are in complete remission (no evidence of disease). This is an investigational study. Radiation therapy is delivered using FDA-approved and commercially available methods. The study doctor can explain how radiation therapy is designed to work. About 120 participants will be enrolled on this multicenter study. Up to 90 may take part at MD Anderson. - [A Study of Pertuzumab Combined with High-Dose Trastuzumab for Patients who have Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer with Central Nervous System Progression After Radiation Therapy](/research/clinical-trials/cls-20260176) Jacksonville, FL This study will examine the safety and effectiveness of pertuzumab combined with high-dose trastuzumab in adult patients who have HER2-positive breast cancer that has spread to the central nervous system and the brain following radiation therapy. - [Olaparib and Atezolizumab Either Alone or in Combination in Treating Patients With Stage III-IV Triple Negative Breast Cancer](/research/clinical-trials/cls-20438526) Scottsdale/Phoenix, AZ; Rochester, MN This randomized phase II trial studies how well olaparib and atezolizumab work either alone or in combination in treating patients with stage III-IV triple negative breast cancer. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as atezolizumab, may interfere with the ability of tumor cells to grow and spread. It is not known whether giving olaparib and atezolizumab either alone or in combination would work better in patients with triple negative breast cancer. - [A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread](/research/clinical-trials/cls-20111756) Rochester, MN The treatment for postmenopausal women diagnosed with hormone receptor positive (HR+) metastatic breast cancer (mBr) includes endocrine therapy However, de novo or acquired resistance to endocrine therapy remains an important clinical problem. Many hormone receptor positive breast cancers demonstrate overexpression of cyclin D. Cyclin D interacts directly with cyclin-dependent kinases 4 and 6 (CDK4/6) in an active protein complex that promotes cell proliferation; and consequently, CDK4/6 represents a potential therapeutic target for HR+ breast cancers. LY2835219 represents a selective and potent small molecule inhibitor of CDK4/6. LY2835219 demonstrates suitable physical and pharmacokinetic (PK) properties, an acceptable toxicity profile in ... - [A Study of Niraparib Combined with Pembrolizumab (MK-3475) in Patients who have Triple-Negative Breast Cancer or Ovarian Cancer](/research/clinical-trials/cls-20238167) Rochester, MN; Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to evaluate the safety and effectiveness of combined treatment with niraparib and pembrolizumab (MK-3475) in patients who have triple-negative breast cancer that is advanced or has spread, or ovarian cancer that has returned after previous treatment. - [Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer](/research/clinical-trials/cls-20151641) Mankato, MN RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer. - [Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women](/research/clinical-trials/cls-20145186) Rochester, MN The purpose of the study is to determine whether treatment with a PI3K inhibitor plus letrozole leads to an increase in pathologic clinical response and Objective Response Rate compared to treatment with placebo plus letrozole in patients with Breast cancer - [Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients with Early-Stage Breast Cancer that was Removed by Surgery](/research/clinical-trials/cls-20116114) Scottsdale/Phoenix, AZ; Rochester, MN RATIONALE: It is not yet know whether higher per daily radiation therapy is equally as effective as standard per daily radiation therapy in treating breast cancer. PURPOSE: This randomized phase III trial studies how well an accelerated course of higher per daily radiation therapy with concomitant boost works compared to standard per daily radiation therapy with a sequential boost in treating patients with early-stage breast cancer that was removed by surgery. - [Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane with or without Chemotherapy in Treating Patients with Invasive RxPONDER Breast Cancer](/research/clinical-trials/cls-20115815) Jacksonville, FL; Rochester, MN This phase III clinical trial is studying how well giving tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy works in treating patients with invasive breast cancer. Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping ... - [Determining Molecular Drivers of Radiation Dermatitis](/research/clinical-trials/cls-20509173) Jacksonville, FL The purpose of this study is to collect (i) pre-treatment (at the time of breast cancer surgery) normal skin and (ii) on-treatment (around the third week of treatment with breast radiation) irradiated skin with clinical hallmarks of radiation dermatitis (erythema and/or dry desquamation, documented by a photograph and graded by clinical criteria). - [Breast-Conserving Surgery and Radiation Therapy in Patients with Multiple Ipsilateral Breast Cancer](/research/clinical-trials/cls-20115510) Rochester, MN RATIONALE: Breast-conserving surgery is a less invasive type of surgery for breast cancer and may have fewer side effects and improve recovery. Radiation therapy uses high-energy x rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial studies how well breast-conserving surgery and radiation therapy work in treating patients with multiple ipsilateral breast cancer - [Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Cancer: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial](/research/clinical-trials/cls-20492239) Rochester, MN A pragmatic randomized clinical trial of patients with locally advanced breast cancer randomized to either proton or photon therapy and followed longitudinally for cardiovascular morbidity and mortality, health-related quality of life, and cancer control outcomes. Quality of life is the outcome measure for the estimated primary completion date of November, 2020.\" - [Assessing the Accuracy of Tumor Biopsies After Chemotherapy to Determine if Patients Can Avoid Breast Surgery](/research/clinical-trials/cls-20343904) Rochester, MN This phase II trial studies how well biopsy of breast after chemotherapy works in predicting pathologic response in patients with stage II-IIIA breast cancer undergoing breast conserving surgery. Tumor tissue collected from biopsy before surgery may help to check if chemotherapy destroyed the breast cancer cells and may be compared to the tumor removed during surgery to check if they are the same. - [A Study of the Ability to Predict Lymphedema Development Following Axillary Surgery for Breast Cancer and Its Effects on Patient Survivorship](/research/clinical-trials/cls-20502537) Jacksonville, FL The purpose of this study is to better understand the anatomy of the lymphatic structure and the molecular process that leads to the over production of lymph fluid. This proposal will begin intense lymphedema screening and identify baseline characteristics potentially predisposing someone to lymphedema, and identify molecular markers that might be altered to prevent lymphedema. - [Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients with Early-Stage Breast Cancer that was Removed by Surgery](/research/clinical-trials/cls-20154150) Eau Claire, WI RATIONALE: It is not yet know whether higher per daily radiation therapy is equally as effective as standard per daily radiation therapy in treating breast cancer. PURPOSE: This randomized phase III trial studies how well an accelerated course of higher per daily radiation therapy with concomitant boost works compared to standard per daily radiation therapy with a sequential boost in treating patients with early-stage breast cancer that was removed by surgery. - [The Mayo Clinic Breast Disease Survivors Study](/research/clinical-trials/cls-20532531) Rochester, MN This study will recruit breast cancer patients and survivors to take part in an ongoing study of the issues and concerns surrounding breast cancer survivorship. We will recruit both newly diagnosed patients as well as patients diagnosed within the past 5 years. Those who consent to the study will be asked to provide a series of questionnaires and blood samples over time. These data/samples will create a repository that will enable us to address many specific hypotheses both now and in the future. As part of the study DNA samples will be genotyped for common genetic variants ... - [Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer](/research/clinical-trials/cls-20149934) Rochester, MN The objective of this study is to assess efficacy and safety of radium-223 dichloride in subjects with human epidermal growth factor receptor 2 negative (HER2 negative) hormone receptor positive breast cancer with bone metastases treated with hormonal treatment background therapy. - [A Study of Taxane, Trastuzumab, and Pertuzumab With or Without Atezolizumab in Treating Metastatic Breast Cancer Patients](/research/clinical-trials/cls-20468270) La Crosse, WI; Eau Claire, WI; Rochester, MN The purpose of this study is to evaluate how well paclitaxel, trastuzumab, and pertuzumab with or without atezolizumab works in treating patients with breast cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with trastuzumab, pertuzumab, and atezolizumab, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving ... - [A Study to Evaluate Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy](/research/clinical-trials/cls-20493189) Eau Claire, WI; Rochester, MN; La Crosse, WI This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of \"targeted therapy\" because they work by attaching themselves to specific molecules (receptors) on ... - [A Study of Hypofractionated Radiotherapy to the Whole Breast Alone Before Breast Conserving Surgery](/research/clinical-trials/cls-20447141) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this trial is to determine the patient's pathological response after hypofractionated radiotherapy to the whole breast based on a specimen after surgery. The analysis of tumor mutation may lead to a better understanding of the effect of radiotherapy in breast cancer. - [A2B101-101: Obtaining Primary Solid Tumor Tissue from Subjects Having Primary Surgical Resection for Certain Tumor Types and Leukapheresis for CAR T-cell Therapy Manufacturing](/research/clinical-trials/cls-20526322) Rochester, MN; Jacksonville, FL The primary objectives for this study are: - The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 6 months of undergoing leukapheresis. - The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 12 months of undergoing leukapheresis. - The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 18 months of undergoing leukapheresis. - The percentage of subjects who can enroll on an A2 CAR T-cell therapy study within approximately 24 months of undergoing leukapheresis. - Percentage of screened subjects experiencing loss of heterozygosity of HLA-A*02. - [Study to Evaluate Chemoembolization Combined with AZ; Rochester, MN; Jacksonville, FL The this global study is to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma. - [Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer](/research/clinical-trials/cls-20420888) Eau Claire, WI; Mankato, MN; Rochester, MN; Jacksonville, FL This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects. - [T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer](/research/clinical-trials/cls-20519839) Rochester, MN The purpose of this study is to determine if the invasive disease-free survival (iDFS) with T-DM1 and tucatinib is superior to the iDFS in the control arm (T-DM1 + placebo) when administered to high risk patients with HER2-positive breast cancer and residual disease after neoadjuvant HER2-directed therapy. - [S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer](/research/clinical-trials/cls-20145287) Mankato, MN RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer. PURPOSE: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus works in treating patients with breast cancer. - [Lobular Involution-Based Response to Antiendocrine Therapy for Women with Breast Atypical Hyperplasia](/research/clinical-trials/cls-20423497) Jacksonville, FL The goal of this study is to perform a quantitative measure of lobular involution (qLI) from breast biopsy samples obtained at baseline (surgery) and 12 months or at time of study discontinuation. The study will determine breast density (MMG) and correlate with qLI. The study will also determine the influence of chemoprevention therapies such as tamoxifen and letrozole on FL The optimal dose and fractionation regimen for whole breast irradiation, whole breast and regional nodal irradiation, and postmastectomy radiotherapy remains unknown. The goal of this phase II randomized controlled trial is to determine whether the hypofractionated proton regimens proposed are non-inferior compared with standard fractionated proton radiotherapy and therefore worthy of further investigation. - [Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma](/research/clinical-trials/cls-20307011) Rochester, MN This phase I/II trial studies the best dose and side effects of dendritic cell therapy, cryosurgery and pembrolizumab in treating patients with non-Hodgkin lymphoma. Vaccines, such as dendritic cell therapy made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving dendritic cell therapy, cryosurgery and pembrolizumab may work better at treating non-Hodgkin lymphoma. - [Study of Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer](/research/clinical-trials/cls-20446105) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the safety and effectiveness of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer. - [A Study Comparing Combinations of Chemotherapy for Treating Women who have Undergone Surgery for Node-Positive Breast Cancer](/research/clinical-trials/cls-20314045) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to compare three different combination chemotherapy regimens and evaluate how well they work in treating women who have undergone surgery for node-positive breast cancer. Drugs used in chemotherapy, such as docetaxel, doxorubicin, cyclophosphamide, paclitaxel, and gemcitabine work in different ways to stop tumor cells from dividing so they stop growing or die. Giving combination chemotherapy after surgery may kill any remaining tumor cells. - [Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Nab-Paclitaxel in Recurrent Metastatic Breast Cancer](/research/clinical-trials/cls-20149256) Scottsdale/Phoenix, AZ The purpose of this study is to assess safety of nab-paclitaxel based chemotherapy regimens administered prior to and/or in combination with nivolumab in Pancreatic Cancer, Non Small Cell Lung Cancer (NSCLC) and Metastatic Breast Cancer (mBC). - [ADVANCE 2: ADdressing Views of African AmericaNs on CancEr Screening](/research/clinical-trials/cls-20516796) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this research study is to understand the views and experiences of Non-Hispanic Black women with a diagnosis or who support a family member with breast or ovarian cancer. We also want to know participant thoughts on genetic testing for cancer risk and research participation. This is a qualitative interview study. Study participation involved talking on the phone or videoconference (e.g., Zoom) for about 1 - 1 1/2 hours with a researcher. - [S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer](/research/clinical-trials/cls-20474102) Rochester, MN RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer. PURPOSE: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer. - [Letrozole After Tamoxifen in Treating Women With Breast Cancer](/research/clinical-trials/cls-20154107) La Crosse, WI RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by reducing the production of estrogen. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works in treating women with breast cancer who have received tamoxifen for at least 5 years. - [A Study to Optimize Endocrine Therapy Through Motivational Interviewing and Text Interventions](/research/clinical-trials/cls-20512658) Albert Lea, MN This study aims to compare an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). - [Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy](/research/clinical-trials/cls-20111704) Jacksonville, FL; Rochester, MN; Albert Lea, MN; Mankato, MN This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate whether radiation therapy is as effective as lymph node dissection. - [Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery](/research/clinical-trials/cls-20379668) Rochester, MN This phase Ib/II trial studies how well dendritic cell therapy after cryosurgery in combination with pembrolizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Cryosurgery, also known as cryoablation or cryotherapy, kills tumor cells by freezing them. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving dendritic cell therapy after cryosurgery in combination with pembrolizumab may work better in treating patients ... - [Evaluating Surgical Treatment Related Differences in Patient Satisfaction and Health-related Quality of Life in Breast Cancer Survivors in the Long-term Survivorship Period](/research/clinical-trials/cls-20392182) Rochester, MN This study is being done to determine the long-term effects of different kinds of breast surgeries on women's health-related quality of life from the patient's perspective. The information will also provide information to assist in improving the quality of care given to patients. - [A Study to Compare Administering Olaparib Concurrently With Radiotherapy vs. Radiotherapy Alone in Treating Patients With Inflammatory Breast Cancer](/research/clinical-trials/cls-20455751) La Crosse, WI; Eau Claire, WI; Rochester, MN The purpose of this study is to evaluate how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer. - [Cancer Prevention: Stories for Change in Hispanic Community](/research/clinical-trials/cls-20541014) Rochester, MN This study is a process evaluation of a digital storytelling (DST) intervention. Because the DST intervention has not yet been developed, it is appropriate to use qualitative methods to assess the process. This study will recruit gifted storytellers for a digital storytelling intervention on breast, cervical, and colorectal cancer. A digital storytelling intervention will be developed to improve breast, cervical, and colorectal cancer screening rates among Hispanic, Spanish speaking individuals. Additionally, to conduct a qualitative assessment of the digital storytelling workshop. - [Letrozole in Treating Postmenopausal Women with Ductal Carcinoma in Situ](/research/clinical-trials/cls-20115515) Rochester, MN RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. PURPOSE: This phase II trial is studying how well letrozole works in treating women with ductal carcinoma in situ. - [Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer](/research/clinical-trials/cls-20151643) Eau Claire, WI RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer. - [Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer](/research/clinical-trials/cls-20319574) Rochester, MN Objective: To determine the Overall Response Rate (ORR) to Imprime PGG + pembrolizumab in subjects with advanced melanoma or TNBC Safety: To characterize the safety of Imprime PGG + pembrolizumab given in combination Hypothesis: Restore (for melanoma) or enhance (for TNBC) sensitivity to checkpoint inhibitors (CPI) by appropriate and effective stimulation of the subject's innate and adaptive immune systems in those subjects who have failed 1st line therapy The study will incorporate Simon's optimal 2-stage design with sample size fixed at 12 subjects each in Stage 1 for advanced melanoma and for Triple Negative Breast Cancer ... - [Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer](/research/clinical-trials/cls-20411286) Scottsdale/Phoenix, AZ; Rochester, MN The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer. - [A Study to Evaluate the Optune\u00ae (Tumor Treating Fields) Concomitant with RT & TMZ to Treat Newly-diagnosed Glioblastoma](/research/clinical-trials/cls-20515339) Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to test the effectiveness and safety of Optune\u00ae given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune\u00ae and maintenance temozolomide are continued following radiation therapy. - [AML: Treatment of Relapse after Transplant or Extended Maintenance of Remission - Investigational Study (ARTEMIS) Effectiveness of MT-401 in Patients with AML Following Stem Cell Transplant](/research/clinical-trials/cls-20532366) Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate safety and effectiveness of MT-401 administration to patients with AML, who have received their first allogeneic HSCT. - [Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant](/research/clinical-trials/cls-20115569) Rochester, MN This phase II trial studies how well carfilzomib and dexamethasone work in treating patients with multiple myeloma who previously underwent a stem cell transplant. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunosuppressive therapy, such as dexamethasone, may improve bone marrow function and increase blood cell counts. Giving carfilzomib together with dexamethasone may be an effective treatment for multiple myeloma. - [Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients with Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System](/research/clinical-trials/cls-20151153) Rochester, MN This phase III trial is studying giving combination chemotherapy together with 3-dimensional conformal radiation therapy and an autologous peripheral blood stem cell transplant to see how well it works in treating young patients with atypical teratoid/rhabdoid tumor of the central nervous system. Giving high-dose chemotherapy before an autologous peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored. Chemotherapy or radiation therapy is then given to prepare ... - [Effects of Cognitive Function, Post-op Fatigue and Quality of Life Comparing General vs Regional Anesthesia for Non-eloquent Brain Tumors Resection](/research/clinical-trials/cls-20541743) Jacksonville, FL The aim of the study is to create a registry to prospectively collect pre-operative, during surgery and post-operative data, questionaries will assess (at baseline before the surgery, 3-4 weeks, and at 3-6 months) cognitive function, assessed with a Mini-mental State Examination (MMSE), PROMIS Fatigue 7a form, quality of life (QoL), assessed using the SF-12 questionnaire, quality of sleep assessed using PROMIS Sleep disturbance 7a form (1 week after surgery). - [Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery](/research/clinical-trials/cls-20111970) Albert Lea, MN; Jacksonville, FL; La Crosse, WI; Mankato, MN; Rochester, MN This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer. - [A Study to See if Genetic Risk Estimation of Breast Cancer Influences the Use of Preventive Medication](/research/clinical-trials/cls-20273189) Rochester, MN The primary aim of this study is to determine if the addition of an individual polygenic risk score (PRS), in addition to the standard National Cancer Institute's Breast Cancer Risk Assessment Tool (BCRAT) or Tyrer-Cuzick (IBIS) score, will aid women at risk of breast cancer in making a decision to take (or not take) medications to prevent breast cancer. - [Survivorship Experiences Post Cancer Treatment](/research/clinical-trials/cls-20509058) Jacksonville, FL The purpose of this study is to evaluate sexual well-being in minority women who have been diagnosed with cancer, and their partners. - [A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer](/research/clinical-trials/cls-20151582) Rochester, MN The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women with breast cancer. - [A Study of Pembrolizumab and Ruxolitinib Phosphate for Treating Patients with Metastatic Stage IV Triple Negative Breast Cancer](/research/clinical-trials/cls-20307278) Scottsdale/Phoenix, AZ The purpose of this study is to assess the side effects and best dose of ruxolitinib phosphate when given together with pembrolizumab for treating patients with stage IV triple negative breast cancer that has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and ruxolitinib phosphate together may work better in treating patients with stage IV triple negative breast cancer. - [A Study of Nivolumab in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation](/research/clinical-trials/cls-20425087) Scottsdale/Phoenix, AZ This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence - [A Study to Evaluate ADP-A2M4 SPEAR T Cells in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma](/research/clinical-trials/cls-20477324) Jacksonville, FL The purpose of this study is to evaluate genetically-engineered ADP-A2M4 in HLA-A*02 subjects with metastatic Sarcoma or Myxoid/Round Cell Liposarcoma (MRCLS) who have received prior chemotherapy and whose tumor expresses the MAGE-A4 tumor antigen. - [Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)](/research/clinical-trials/cls-20541677) Rochester, MN The purpose of this study is to demonstrate that microwave ablation (MWA) of up to 3 hepatic metastases, each with a maximum diameter of 2.5 cm will result in a 2-year local progression free survival of at least 90%. This is a standard of care (SOC) study. - [A Study of the Reliability and Validity of Patient Reported Outcome Measures in Head and Neck Cancer](/research/clinical-trials/cls-20491136) Scottsdale/Phoenix, AZ; Rochester, MN This study will utilize Rasch analysis to study the construct validity and reliability of five shoulder-related patient-reported outcome measures in patients reporting shoulder impairment following surgery for head and neck cancer. - [A Study to Determine How BI 907828 is Taken up in the Tumor and to Determine the Highest Dose of BI 907828 That Could be Tolerated in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma](/research/clinical-trials/cls-20534429) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to examine the pharmacological effects of the compound BI 907828 on patient tumors at an early stage of drug development. - [A Study to Evaluate CHIP and Hematological Toxicity After PRRT Neuroendocrine Tumor Patients](/research/clinical-trials/cls-20490908) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to combine robust clinical data (e.g., prior chemotherapy or radiation exposure, cumulative Peptide Receptor Radionuclide Therapy (PRRT dose)) with genetic and clonal abnormalities (blood-based CHIP panel) in studying the predisposing risk factors for developing hematological toxicity including t-MN in PRRT-treated neuroendocrine tumor (NET) patients. - [Maintenance Chemotherapy With or Without Stereotactic Body Radiation Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer](/research/clinical-trials/cls-20417926) Scottsdale/Phoenix, AZ; Jacksonville, FL This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without stereotactic body radiation therapy works in treating patients with stage IV non-small cell lung cancer. Drugs used in maintenance chemotherapy, such as docetaxel, pemetrexed disodium, and gemcitabine work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Stereotactic body radiation therapy is a specialized radiation therapy that sends x-rays directly to the tumor using smaller doses over several days and may cause less damage to normal tissue. Giving maintenance ... - [A Study to Evaluate Gemcitabine, Cisplatin, and Nab-Paclitaxel to Treat Patients with High-Risk Liver Bile Duct Cancer Before Surgery](/research/clinical-trials/cls-20508607) Rochester, MN The purpose of this study is to evaluate how well gemcitabine, cisplatin, and nab-paclitaxel work before surgery in treating participants with high-risk bile duct cancer in the liver (intrahepatic cholangiocarcinoma). Drugs used in chemotherapy, such as nab-paclitaxel, cisplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. - [Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue](/research/clinical-trials/cls-20531157) Rochester, MN The purpose of this study is to determine the safety of the NanoKnife treatment in prostate cancer tissue when used in a low and intermediate risk patient population. - [Image-based Mapping of Brain Tumors](/research/clinical-trials/cls-20308051) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to combine MRI images with histologic and genetic analysis of cancer (from blood and tissue samples) to improve the overall accuracy of diagnosis and effectiveness of cancer treatment. - [MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer](/research/clinical-trials/cls-20112279) Rochester, MN This phase I/II trial studies the side effects and best dose of oncolytic measles virus encoding thyroidal sodium iodide symporter (MV-NIS) infected mesenchymal stem cells and to see how well it works in treating patients with recurrent ovarian cancer. Mesenchymal stem cells may be able to carry tumor-killing substances directly to ovarian cancer cells. - [A Study to Evaluate Stereotactic Radiosurgery Versus Hippocampal-Avoidant Whole Brain Radiotherapy for 10 or Fewer Brain Metastases from Small Cell Lung Cancer](/research/clinical-trials/cls-20525581) Scottsdale/Phoenix, AZ The primary objective of this study is to determine whether stereotactic radiosurgery (SRS) relative to whole brain radiotherapy with hippocampal avoidance (HA-WBRT) plus memantine for brain metastases from small cell lung cancer (SCLC) prevents cognitive function failure as measured by cognitive decline on a battery of tests: the Hopkins Verbal Learning Test - Revised (HVLT-R), Controled Oral Word Association (COWA) test, and the Trail Making Test (TMT). - [Randomized Control Trial for Awake vs. Asleep Craniotomy for Non-eloquent Gliomas](/research/clinical-trials/cls-20438468) Jacksonville, FL The purpose of this study is to compare local and general anesthesia (Awake vs. Asleep Craniotomy) in the removal of brain tumors that are in areas of the brain that do not directly control bodily functions (non-eloquent gliomas). - [A Study to Evaluate Radiotherapy to the Whole Breast or Post-mastectomy Chest Wall Including Regional Nodal Irradiation](/research/clinical-trials/cls-20492290) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to determine the safety of 5 fraction vs. 25 fraction radiation to the whole breast or post-mastectomy chest wall/reconstructed chest with regional nodal radiation. - [A Study to Compare Stereotactic Radiosurgery to Hippocampal-Avoidant Whole Brain Radiotherapy](/research/clinical-trials/cls-20440979) Jacksonville, FL; Rochester, MN The purpose of this study is to compare stereotactic radiosurgery (SRS) to whole brain radiotherapy (WBRT) in patients with 5 or more brain metastases. - [FRACTIONATE](/research/clinical-trials/cls-20528846) Rochester, MN; Scottsdale/Phoenix, AZ; Jacksonville, FL All lesions 4.0 cm to 6.0 cm will receive 32.5 Gy/5 fractions and will be analyzed separately. The portion of the trial is written as a phase II study without randomization noting the rarity of unresected brain metastasis of this size and the lack of comfort of treating radiation oncologist and neurosurgeons with single fraction SRS for tumors this large. However, noting the paucity of prospective data for this patient population enrolling patients on a clinical trial will provide a more accurate historical control for future trials. Although this cohort was enrolled on the prospective phase I trial from ... - [A Study to Compare Dual-Energy CT and Whole Body MRI for Monitoring of Bone Involvement in Multiple Myeloma Patients](/research/clinical-trials/cls-20502641) Rochester, MN The purpose of this study is to determine the performance of Dual-Energy CT (DECT) with Virtual Non-calcium (VNCa) and fat measurement in assessing multiple myeloma disease activity following treatment, with MRI and clinical/ laboratory parameters as reference standards. - [A Study to Assess Cisplatin and Combination Chemotherapy in Treating Children and Young Adults with Hepatoblastoma or Liver Cancer After Surgery](/research/clinical-trials/cls-20458953) Rochester, MN The purpose of this study is to determine how well cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or liver cancer after surgery. Drugs used in chemotherapy, such as cisplatin, doxorubicin, oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy after surgery may kill more tumor cells. - [Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma](/research/clinical-trials/cls-20349203) Rochester, MN For patients with this type of cancer, the standard of care is treatment with chemotherapy. Radiation therapy is typically not used. This is because radiation to the entire lining of the lung has many side effects that are often severe including damage to the lung (pneumonitis). There is a new radiation technique using Intensity Modulated Radiation Therapy (IMRT) that has been shown to reduce many of the side effects of standard radiation therapy. This type of radiation therapy specifically targets the lining of the lung, where you have your cancer, and reduces the risk of damaging the lung itself. The ... - [A Study to Evaluate Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant](/research/clinical-trials/cls-20469521) Scottsdale/Phoenix, AZ The purpose of this study is to provide ruxolitinib through an expanded access program for the treatment of graft-versus-host disease (GVHD) in United States to patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib in the treatment of GVHD. - [A Study Tacrolimus/Methotrexate Mofetil Non-Myeloablative/Reduced Stem Cell Transplantation](/research/clinical-trials/cls-20459862) Rochester, MN; Jacksonville, FL The primary purpose of this study is to compare 1 year graft-versus-host disease (GVHD)-free, graft relapse-free survival Randomized, Open-label Two-arm Phase Assessing the Role of Involved Mediastinal Radiotherapy after Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma](/research/clinical-trials/cls-20110048) Rochester, MN Primary mediastinal large B cell lymphoma is treated with a combination of chemotherapy and the monoclonal antibody rituximab (chemoimmunotherapy). Following chemoimmunotherapy patients receive radiation therapy if they have residues which may be active tumour. However at the end of chemoimmunotherapy the majority of patients show tissue scarring that is not necessarily active tumor. In recent years, PET/CT has proved to be a good tool to accurately identify active tumor from scar tissue in patients treated for mediastinal lymphoma.The purpose of this trial is to test whether radiation therapy is really necessary in patients where PET/CT has shown that the tumor is ... - [A Study to Evaluate Mindfulness Intervention During Radiotherapy](/research/clinical-trials/cls-20455889) Rochester, MN The purpose of this study is to evaluate the effectiveness of a mindfulness-based intervention (MBI) on subjective reports of wellness including emotional, physical, functional, and social domains during radiotherapy for the treatment of cancer. - [A Study to Evaluate Individualized Prehabilitation for People Undergoing and Lower Limb Soft-Tissue Sarcoma Surgery](/research/clinical-trials/cls-20533222) Scottsdale/Phoenix, AZ The primary objectives of this study are to determine if a tailored prehabilitation program focusing on functional optimization of spared limb tissue in two groups of patients with localized, lower extremity soft tissue sarcoma, one with prehabilitation and one with equal attention and informational support, improves functional outcome as measure by the Toronto Extremity Salvage Score (TESS), to identify the measures and metrics most responsive to the intervention using the (TESS), Six Minute Walk Test (6MWT)[5], wearable Heel2Toe sensor technology and daily step count, and to estimate recruitment, retention, adherence, and acceptability rates. - [Comparison of Axillary Lymph Node Dissection With Axillary Radiation for Patients With Node-Positive Breast Cancer Treated With Chemotherapy](/research/clinical-trials/cls-20502980) Mankato, MN This randomized phase III trial studies axillary lymph node dissection to see how well it works compared to axillary radiation therapy in treating patients with node-positive breast cancer treated with neoadjuvant chemotherapy followed by surgery. Lymph node dissection may remove cancer cells that have spread to nearby lymph nodes in patients with breast cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. This study will evaluate whether radiation therapy is as effective as lymph node dissection. - [Enhancing Facial Nerve Neuroprotection and Schwannoma Resection](/research/clinical-trials/cls-20523995) Rochester, MN The objectives of this study are to determine the impact of omega-3 supplementation on promoting facial nerve function recovery, and to determine the impact of omega-3 supplementation on Vestibular schwannoma (VS) tumor control. - [Efficacy of Electrical Stimulation for Dysphagia in Head & Neck Cancer Patients](/research/clinical-trials/cls-20478461) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of the investigation is to learn whether intense swallowing exercise or intense swallowing exercise coupled with electrical stimulation (E-Stim) helps patients who had head/neck cancer and currently have dysphagia swallow better. - [Density MATTERS [Molecular Breast Imaging (MBI) And Tomosynthesis To Eliminate the Reservoir]](/research/clinical-trials/cls-20310394) Rochester, MN; La Crosse, WI The significance of this study is that it will be the first prospective trial to compare MBI, a relatively low-cost functional breast imaging technique, to DBT, the new standard anatomic breast cancer screening technique in women with dense breasts. This study is also the first to evaluate two consecutive annual MBI scans to assess change in advanced cancer presentation after introduction of a functional imaging technique. These data will inform individualized decisions on supplemental screening and determine if a functional technique that is relatively low in cost and complexity of interpretation can eliminate the reservoir of clinically important breast cancers ... - [Radiation Therapy and Docetaxel in Oropharyngeal Cancer](/research/clinical-trials/cls-20134485) Scottsdale/Phoenix, AZ; Rochester, MN This phase II trial studies how well radiation therapy and docetaxel work in treating patients with human papillomavirus (HPV)-related oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy with docetaxel my kill more tumor cells. - [A Study to Investigate the Effects of GC4419 on Radiation-Induced Oral Mucositis in Patients With Head/Neck Cancer](/research/clinical-trials/cls-20467330) Jacksonville, FL The purpose of this study is to determine if GC4419, administered prior to intensity-modulated radiation therapy (IMRT), reduces the severity of radiation-induced oral mucositis in patients who have been diagnosed with locally advanced, non-metastatic squamous cell carcinoma of the head and neck. - [A Study of Heated Intra-peritoneal Chemotherapy (H.I.P.E.C.) with Doxorubicin and Cisplatin in Pediatric Patients with Pelvic and Abdominal Rhabdomyosarcoma](/research/clinical-trials/cls-20474322) Rochester, MN The primary purpose of this study is to assess the feasibility of heated intra-peritoneal chemotherapy (HIPEC) with doxorubicin (DOXO) and Cisplatin (CDDP) after surgical resection of pediatric pelvic and abdominal tumors, and to assess morbidity, hospital length of stay and peri-operative mortality outcomes for pediatric patients with intraperitoneal sarcoma undergoing hyperthermic intraperitoneal chemotherapy. - [A Study of Using Geometrically Accurate Functional MRI to Enable Personalized Radiotherapy of Glioblastoma](/research/clinical-trials/cls-20508795) Scottsdale/Phoenix, AZ The purpose of this study is to create a new Magnetic resonance imaging (MRI) technique with true contrast to the background reference points in functional MR images of individual patients. Functional MRI has been widely used in staging, grading and treatment response monitoring of glioblastoma. MRI has great soft tissue and tumor tissue contrast and can assist in outlining the target. It has proven able to offer functional information such as cell density, permeability of the micro-blood vessels, and the oxygen level of the tumor. - [Transoral Surgery Followed By Low-Dose or Standard-Dose Radiation Therapy With or Without Chemotherapy in Treating Patients With HPV Positive Stage III-IVA Oropharyngeal Cancer](/research/clinical-trials/cls-20111681) Scottsdale/Phoenix, AZ This randomized phase II trial how well transoral surgery followed by low-dose or standard-dose radiation therapy works in treating patients with human papilloma virus (HPV) positive stage III-IVA oropharyngeal cancer. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy with chemotherapy may kill any tumor cells that remain after surgery. It is not yet known how much extra treatment needs to be given after surgery. - [Hypofractionated Pre-Operative Radiation Therapy for Localized, Resectable Soft Tissue Sarcoma the Extremity or Superficial Trunk](/research/clinical-trials/cls-20507456) Rochester, MN; Scottsdale/Phoenix, AZ We propose conducting a single arm, prospective study to evaluate the efficacy and safety of a preoperative hypofractionated course, 42.75 Gy in 15 fractions, for localized, extremity and superficial trunk soft tissue sarcomas. The biologic equivalent dose of this regimen is 45.20 Gy10, similar to 43.83 Gy10 associated with conventionally fractionated 50 Gy in 25 fractions, to determine acute wound complications rates, analyze local failure rate, disease-free survival, overall survival, patterns of relapse, late toxicities, quality of life/patient-reported outcomes, and cost differences. We hypothesize a 15 fraction hypofractionated radiation therapy course will be associated with equivalent short term toxicity ... - [A Study to Collect Ovarian Tissue from Girls Undergoing Fertility-preserving Cryopreservation](/research/clinical-trials/cls-20492626) Rochester, MN The purpose of this study is to study the handling of ovarian tissue, cryopreservation technology, and oocyte maturation for female pediatric cancer patients and other female patients whose future fertility will be affected due to a disease or treatment. - [EORTC-1709-BTG_CCTG-CE.8: A Study to Compare Marizomib in Combination with Standard Radiochemotherapy vs. Radiochemotherapy Alone in with Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the safety and tolerability of marizomib in combination with Temozolomide-based radiochemotherapy versus standard Temozolomide-based radiochemotherapy alone in newly diagnosed glioblastoma patients. - [A Study to Evaluate Optune vs. Prophylactic Cranial Irradiation (PCI) in Non-Small Cell Lung Cancer Patients](/research/clinical-trials/cls-20508605) Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the safety and preliminary effectiveness of Optune\u00ae-Tumor Treating Fields (TTFields) therapy vs. Prophylactic Cranial Irradiation (PCI) in Small Cell Lung Cancer (SCLC), a common disease with a high propensity for brain metastases. Prophylactic cranial irradiation (PCI) is a standard therapy for reducing the risk of SCLC brain metastases. While PCI is associated with added survival benefit to patients with SCLC, the approach is associated with both acute and long-term toxicity. As an alternative treatment option, directed electrical fields to the brain using the Optune\u00ae device is associated with decreasing the risk of tumor progression ... - [Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma](/research/clinical-trials/cls-20536441) Rochester, MN The purpose of this study is to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC. The [68Ga]FAPI-46 PET scans will be acquired after initial staging using institutional standard methods. If the participant is prescribed neoadjuvant therapy, a second [68Ga]FAPI-46 PET scan will be performed within 21 days prior to planned surgical resection. - [Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma](/research/clinical-trials/cls-20115485) Jacksonville, FL; Rochester, MN This phase I/II trial studies the side effects and best dose of carfilzomib when given together with melphalan and to see how well they work in treating patients with multiple myeloma before stem cell transplant. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving carfilzomib together with melphalan may kill more cancer cells. - [Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes](/research/clinical-trials/cls-20326291) Rochester, MN The purpose of this study is to test whether adding certain genetic factors to the process of picking a stem cell donor can decrease the chances that the patient's leukemia will come back after bone marrow transplantation. Stem cell donors are \"matched\" based on genes called human leukocyte antigens (HLA). Currently, donors are selected largely on the basis of HLA gene typing alone. There is published data to show that donors with specific other genes called killer immunoglobulin-like receptors (KIR) may protect AML patients from having their leukemia return after a transplant. In this study, the best HLA matched donors will ... - [A Study to Evaluate Chemotherapy and Radiation Therapy With or Without Surgery to Treat Patients With Head and Neck Cancer](/research/clinical-trials/cls-20507131) Rochester, MN The purpose of this study is to determine whether intensification of radiation, relative to conventional fractionation plus cisplatin in the combined therapy setting can further improve the overall survival of patients with advanced HNSCC, to assess the actuarial local-regional control and disease-free rates of patients treated with the different regimens, to define the acute and late toxicity of each treatment regimen, to evaluate whether there are differences in patient's QOL, perception of side effects, and performance status between treatment arms, to establish whether EGFR and COX-2 expressions are independent prognostic markers for patients receiving concurrent chemoradiation. - [A Study to Evaluate 68Ga- PET/CT for Hepatocellular Carcinoma](/research/clinical-trials/cls-20508600) Rochester, MN The purpose of this study is to evaluate the feasibility and diagnostic performance of 68Ga PSMA-dual contrast PET/MRI for detection and staging of Hepatocellular Carcinoma (HCC), and to compare it with standard-of-care (SOC) imaging. Additionally, this study aims to identify the biologic correlates of biomarkers derived from 68Ga PSMA-dual PSMA immunostaining of HCC. - [International Registry for Men With Advanced Prostate Cancer (IRONMAN)](/research/clinical-trials/cls-20533339) Jacksonville, FL The purpose of this registry is to collect detailed clinical, epidemiological and biological information from 5,000 male patients with advanced prostate cancer. The objectives are to describe the practice patterns of therapeutic agents for treatment of advanced prostate cancer internationally; to assess whether specific treatment patterns are associated with clinically significant adverse events, and evaluate potential interactions with concomitant medications or demographic factors; to identify associations between treatment sequences or combinations and overall survival; to define the patient experience of men with advanced prostate cancer and identify unmet needs in their treatment; and to identify clinical and molecular disease subtypes that predict response to individual treatments, combinations, or sequences. - [18F-DOPA PET in Sarcoma Patients](/research/clinical-trials/cls-20531574) Jacksonville, FL The purpose of this study is to identify early response biomarkers from biological or functional imaging to better align with clinical trial endpoints and minimize sarcoma patient toxicities. - [A Study of Defitelio (Defibrotide) for the Prevention of Acute Graft-versus-Host-Disease (AGvHD)](/research/clinical-trials/cls-20461783) Jacksonville, FL The purpose of this study is to compare the defibrotide prophylaxis arm vs. standard of care arm for the prevention of aGvHD. - [A Study of Electron Beam Intraoperative Radiation Therapy Following Chemoradiation in Patients with Pancreatic Cancer with Vascular Involvement](/research/clinical-trials/cls-20469596) Rochester, MN; Jacksonville, FL The purpose of this study is to to evaluate the rate of overall survival (OS) at two years in patients with either borderline or locally advanced pancreatic cancer who receive electron beam intraoperative radiation therapy (IORT) following chemotherapy and radiation therapy. - [A Study to Assess the Effectiveness and Safety of Durvalumab Alone or Combined with Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment](/research/clinical-trials/cls-20472610) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to test the validity of durvalumab and VEGF inhibitor therapy to enhance anti-tumor immune responses to produce significant and consistent clinical benefit in patients with Hepatocellular Carcinoma (HCC) after curative hepatic resection or ablation. - [Hypofractionated Radiation Therapy in Treating Participants With Prostate Cancer High-Risk Features Following Radical Prostatectomy](/research/clinical-trials/cls-20426598) Scottsdale/Phoenix, AZ; Rochester, MN This phase II trial studies how well hypofractionated radiation therapy works in treating participants with prostate cancer high-risk features following radical prostatectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. - [A Study of Intratumoral Injection of Dendritic Cells after High-Dose Conformal External Beam Radiotherapy in Patients with Unresectable Liver Cancer](/research/clinical-trials/cls-20463508) Rochester, MN Group 1: The primary purpose of this study is to evaluate the safety and tolerability of an autologous dendritic cells (DC) vaccine delivered by intra-tumoral injection in patients with primary liver cancer treated with high-dose conformal external beam radiotherapy (EBRT). Group 2: The primary purpose of this study is to estimate the progression-free survival rate at 2 years post-registration to see if treatment is efficacious compared to historical data - [A Study to Assess Older Adults Applying Pre-transplant Comorbidity, Geriatric Assessment and Biomarkers to Transplant (CHARM)](/research/clinical-trials/cls-20467366) Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to determine the set of assessments and biomarkers that could together constitute a robust and valid composite health risk model for accurate personalized estimation of one year NRM. - [A Study to Develop Liquid Biopsy for Pediatric Brain Tumor Patients](/research/clinical-trials/cls-20471347) Rochester, MN The purpose of this study is to confirm detection of the H3K27M mutation in patient biofluids (CSF, blood, urine, saliva) and uncover the molecular histone (alkaline protein) profile of H3K trimethylation and H3S phosphorylation in the circulating nucleosomes isolated from the biofluids of patients with H3K27M tumors. - [Intervention for Children Undergoing Proton Radiation for Brain Cancer](/research/clinical-trials/cls-20541680) Rochester, MN The purpose of this study is to develop and pilot a novel early intervention program for children undergoing proton radiation thereapy (PRT) for brain tumors. Survivors of childhood brain cancers who undergo radiation therapy can have damage to normal brain tissue. Activities such as attention training and physical exercise can improve mental function in children with brain injury that is caused by the radiation therapy. Improvements in children's ability to learn, behavior and fitness will lead to a better developmental outcome and quality of life in the longer term. - [18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain ](/research/clinical-trials/cls-20488680) Jacksonville, FL The goal of this study is to further evaluate the ability of fluciclovine PET to discriminate between radiation necrosis and tumor progression in patients with previously irradiated intracranial metastatic disease. - [A (FLT3) Inhibitor Gilteritinib Administered as Maintenance Allogeneic Transplant for Patients With FLT3/Internal Tandem Leukemia (AML)](/research/clinical-trials/cls-20418900) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to compare relapse-free survival between participants with FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after the time of engraftment for a two year period. - [Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer](/research/clinical-trials/cls-20528748) Rochester, MN The purpose of this study is to to determine the effect to overall survival (OS) by adding GC4711 to SBRT following chemotherapy in patients with unresectable or borderline resectable nonmetastatic. - [A Study to Compare Memantine to Stereotactic Radiosurgery vs. Stereotactic Radiosurgery Alone to Treat Patients with Cancer That Has Spread to the Brain After Earlier Stereotactic Radiosurgery](/research/clinical-trials/cls-20525294) Jacksonville, FL The purpose of this study is to compare the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to the hippocampus, which is a brain structure that is important for memory. The medicine memantine is also often given with whole brain radiation therapy because it may decrease the risk of side effects of radiation on ... - [Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML](/research/clinical-trials/cls-20359599) Jacksonville, FL; Rochester, MN The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care. - [Ixazomib Citrate, Pomalidomide, Dexamethasone, and Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Multiple Myeloma](/research/clinical-trials/cls-20338653) Rochester, MN This phase II trial studies how well ixazomib citrate, pomalidomide, dexamethasone, and stem cell transplantation works in treating patients with multiple myeloma that has come back or does not respond to treatment. Giving chemotherapy, such as pomalidomide and dexamethasone, before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient?s bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem ... - [Combination Chemotherapy and Surgery in Treating Young Patients with Wilms Tumor](/research/clinical-trials/cls-20119661) Rochester, MN This phase III clinical trial is studying how well combination chemotherapy and surgery work in treating young patients with Bilateral Wilms tumor and children who are a special risk for forming tumors in both kidneys. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving it after surgery may ... - [Neoadjuvant Aliya PEF Soft Resectable NSCLC (VIGOR)](/research/clinical-trials/cls-20542402) Rochester, MN The purpose of this study is to evaluate the pathologic response of soft tissue ablated with Pulsed Electric Fields (PEF) in patients with non-small cell lung cancer (NSCLC) who may be candidates for resection following standard of care (SOC) neoadjuvant use of checkpoint inhibitor (nivolumab) treatment plus platinum doublet chemotherapy. - [A Multiple Myeloma](/research/clinical-trials/cls-20508587) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to compare the effectiveness of JNJ-68284528 with standard therapy, either Pomalidomide, for Lung Cancer](/research/clinical-trials/cls-20267558) Rochester, MN The purpose of this study is to determine if Stereotactic Ablative Radiotherapy improves survival over sublobar resaction in high risk operable stage I non-small cell lung cancer. - [Evaluating Mepitel in Post-mastectomy Patients and the Role of the Skin Microbiome in Radiation Dermatitis](/research/clinical-trials/cls-20398308) Eau Claire, WI; Rochester, MN The aim of this study is to examine alterations in the skin microbiome that occur during radiation therapy. The study design will examine changes secondary to ionizing radiation, and correlate these changes with the development and severity of radiation dermatitis. The goal is to improve understanding of the mechanism of radiation dermatitis. - [A Study to Assess Accelerated Resolution Therapy for Cancer Related Trauma and Distress](/research/clinical-trials/cls-20478277) Jacksonville, FL The purpose of this study is to quantitatively evaluate accelerated resolution therapy (ART) for treatment of cancer distress and psychological trauma. - [SBRT with Immunotherapy for Mesothelioma](/research/clinical-trials/cls-20514654) Rochester, MN The purpose of this study is to evaluate whether adding stereotactic body radiation therapy (SBRT) to immunotherapy as part of second line treatment for mesothelioma will improve the modest response rate of immunotherapy alone, provide local control/cytoreduction to sites of gross disease, and decrease symptomatic burden while improving outcomes. - [Ommaya Placement for Biomarker Collection](/research/clinical-trials/cls-20508001) Rochester, MN The purpose of this study is to determine the safety and feasibility of intra-operative Ommaya Reservoir placement during a clinically indicated tumor surgery in order to facilitate a longitudinal access to cerebrospinal fluid (CSF) for analysis of exploratory and future tumor biomarkers for individualized monitoring. - [BeWell360-CG Care Model: Health and Wellness Coaching to Support Caregivers of Patients Living With Advanced Lung Cancers](/research/clinical-trials/cls-20493094) Jacksonville, FL Piloting the BeWell360-CG model, in conjunction with usual care delivery for lung cancer patients in Palliative Care, will longitudinally improve the wellbeing and quality of life of care givers within and outside of clinical care settings, in such a way as to positively impact the quality of care of patients themselves. We hypothesize that PC staff trained in the BeWell360-CG will be able to identify the most common CG-centric needs and guide CGs to improve their QoL and personal wellbeing. In doing so, we further hypothesize that there will be an improvement in patient-reported and quality of care ... - [Oligomets pancreas SBRT](/research/clinical-trials/cls-20529231) Jacksonville, FL The primary endpoint for this study will compare PFS between SBRT + standard chemotherapy vs. standard chemotherapy alone in patients with oligometastatic pancreatic cancer. PFS is defined as the time from randomization to the first of either disease progression or death from any cause, where disease progression will be determined based on RECIST 1.1 criteria and will be documented at each enrolling site with no central review planned. - [SPORT-DMG](/research/clinical-trials/cls-20521956) Rochester, MN The purpose of this study is to evaluate the clinical outcomes of hypofractionation with planned courses of re-irradiation for patients with diffuse midline gliomas of the pons. Subjects will be screened by neurosurgery, radiation oncology, or pediatric oncology at outpatient clinic or by the multidisciplinary pediatric central nervous system tumor conference. Interested qualified patients and their families will be consented and offered participation in this study - [Study to Determine the Impact of Advanced Magnetic Resonance Imaging (MRI) Using 18F-DOPA (a chemical tracer that highlights certain cells during imaging) During Planning for Proton Beam Radiation Therapy.](/research/clinical-trials/cls-20446102) Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to utilize a novel approach of combining advanced radiation delivery with proton beam therapy with advanced tumor visualization with 18F-DOPA PET and MRI imaging. We will study the effectiveness and safety of this technique delivering the entire treatment over 1-2 weeks. - [A Study of Vaccine Therapy in Treating Patients With Recurrent Glioblastoma](/research/clinical-trials/cls-20387114) Rochester, MN The purpose of this study is to evaluate the side effects of vaccine therapy in treating patients with glioblastoma that has come back. Vaccines made from a person's white blood cells mixed with tumor proteins from another person's glioblastoma tumors may help the body build an effective immune response to kill tumor cells. Giving vaccine therapy may work better in treating patients with glioblastoma. - [A Study in Treating Patients With Kidney Cancer Undergoing Nephrectomy Comparing PERioperative Nivolumab vs. Observation](/research/clinical-trials/cls-20445695) Rochester, MN The purpose of this randomized phase III trial compares nephrectomy (surgery to remove a kidney or part of a kidney) with or without nivolumab in treating patients with kidney cancer that is limited to a certain part of the body (localized). Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving nivolumab before nephrectomy may make the tumor smaller and reduce the amount of normal tissue that needs to be removed, and after nephrectomy to increase survival. It is not yet known whether nivolumab and nephrectomy is more effective than nephrectomy alone ... - [Assessing the Psychosocial and Financial Impact CAR-T Survivors Caregivers](/research/clinical-trials/cls-20526690) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN Although survivorship recommendations have been developed in areas such as lymphoma and stem cell transplant, the long-term effects of CAR-T therapy are unknown. In addition, relatively little is known about the psychosocial impact of CAR-T on survivors and their caregivers. Due to the intensive nature of CAR-T treatment and its unique side effects, including neurotoxicity in the acute setting and infections and financial burden in the long-term setting, a longitudinal study that assesses these issues in a quantitative and qualitative fashion is required. Consideration of both patient and caregiver needs is important for the provision of appropriate and ... - [A Study to Evaluate the da Vinci\u00ae Xi Surgical System in Nipple Sparing Mastectomy (NSM) Procedures](/research/clinical-trials/cls-20520126) Rochester, MN; Jacksonville, FL The purpose of this study is to evaluate the safety and effectiveness of the da Vinci Xi Surgical System in Nipple Sparing Mastectomy procedures. - [A Study to Evaluate Quality of Life Over Time in Patients Treated with CAR-T Cell Therapy Compared with Stem Cell Transplantation in Hematologic Malignancies](/research/clinical-trials/cls-20436938) Rochester, MN The purpose of this study is to evaluate quality of life over time in patients treated with CAR-T therapy compared with autologous and allogeneic stem cell transplant. - [LS138D, Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Patients With Untreated Follicular Lymphoma](/research/clinical-trials/cls-20136422) Rochester, MN This randomized phase III trial studies rituximab and yttrium Y-90 ibritumomab tiuxetan to see how well they work compared to rituximab alone in treating patients with untreated follicular lymphoma. Monoclonal antibodies, such as rituximab, may find cancer cells and help kill them. Radioactive substances linked to monoclonal antibodies can bind to cancer cells and give off radiation which may help kill cancer cells. It is not yet known whether rituximab is more effective with or without yttrium Y-90 ibritumomab tiuxetan in treating follicular lymphoma. - of Multiple Myeloma with Antibody Therapy](/research/clinical-trials/cls-20439366) Jacksonville, FL The purpose of this study is to determine the overall response rate (ORR) of utilizing elotuzumab, pomalidomide and dexamethasone in patients with multiple myeloma resistant to daratumumab. - [Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival](/research/clinical-trials/cls-20318091) Rochester, MN; Jacksonville, FL This randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has spread to one or two locations in the body (limited metastatic) that are previously untreated. Standard of care therapy comprising chemotherapy, hormonal therapy, biological therapy, and others may help stop the spread of tumor cells. Radiation therapy and/or surgery is usually only given with standard of care therapy to relieve pain; however, in patients with limited metastatic breast cancer, stereotactic radiosurgery, also known as stereotactic ... - [A Study to Evaluate Mucosal Sparing Adjuvant Radiotherapy After Surgical Exploration In HPV Head And Neck Cancer](/research/clinical-trials/cls-20502724) Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to evaluate the clinical outcomes of de-intensified (mucosal sparing, possible ipsilateral neck) radiotherapy after surgical exploration of favorable risk HNCUP patients. evaluates the clinical outcomes of de-intensified (mucosal sparing, possible ipsilateral neck) radiotherapy after surgical exploration of favorable risk HNCUP patients. - [Study of NanoKnife for Ablation of Prostate Cancer in Low and Intermediate Risk Patients](/research/clinical-trials/cls-20491714) Rochester, MN The purpose of this study is to determine the safety of the NanoKnife treatment in prostate cancer tissue when used in a low and intermediate risk patient population. - [Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML](/research/clinical-trials/cls-20117948) Rochester, MN To determine if the addition of midostaurin (PKC412) to Standard of Care (SOC) therapy reduces relapse in FLT3-ITD mutated AML patients receiving an allogenetic hematopoietic stem cell transplant, - [A Study of Ruxolitinib for the Treatment of Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplant](/research/clinical-trials/cls-20467383) Rochester, MN The purpose of this study is to provide ruxolitinib through an expanded access program in the United States for the treatment of graft-versus-host disease (GVHD) in patients who are ineligible or unable to participate in any actively enrolling Incyte-sponsored clinical studies for ruxolitinib in the treatment of GVHD. - [A Study of Lutetium Lu 177 Dotatate (Lutathera\u00ae) in Patients with Inoperable, Progressive Meningioma after External Beam Radiation Therapy](/research/clinical-trials/cls-20467879) Rochester, MN The purpose of this study is to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 1 meningioma as measured by 6-month PFS rate, and to estimate the efficacy of LUTATHERA treatment in patients with recurrent grade 2 or 3 meningioma as measured by 6-month PFS rate. - [Preclinical investigation of immunotherapeutic efficacy and safety of a novel oncolytic vesicular stomatitis virus expressing extracellular matrix-destructing enzymes in combination with immune checkpoint inhibitors in pancreatic adenocarcinoma](/research/clinical-trials/cls-20515689) Jacksonville, FL The purpose of this study is to bioengineer a novel vesicular stomatitis virus (VSV) to express overcome pancreatic tumor microenvironment and assess the oncolytic virus (OVs') therapeutic safety and efficacy as monotherapy and in combination with immune checkpoint inhibitors (ICIs) in preclinical settings. This effectiveness will be investigated in vitro, ex vivo and in vivo. - [A Study of PY314 in Subjects With Advanced Solid Tumors](/research/clinical-trials/cls-20509859) AZ; Jacksonville, FL; Rochester, MN A Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY314 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors - [A Study to Predict Response to Virotherapy and Immunotherapy by Using an Ex-Vivo of Pediatric Urological Cancers](/research/clinical-trials/cls-20459863) Rochester, MN The purpose of this study is threefold: the first aim is to use patient-derived fresh tumor tissue to create cell lines and 3D tumor models (i.e. organoids) that preserve the characteristics of the original tumor. The preservation of the original tumor's drug resistance/response profile will be a major focus of this aim. The second aim is to conduct high-throughput testing of various drugs (e.g., virotherapy, immunotherapy) on these cell lines and 3D tumor models. The completion of the second aim is an important step towards developing a platform that can help guide treatment decisions for future patients, based on the drug ... - [Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery](/research/clinical-trials/cls-20111789) Rochester, MN This randomized phase II trial studies how well giving vaccine therapy with or without bevacizumab works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. Vaccines consisting of heat shock protein-peptide complexes made from a person's own tumor tissue may help the body build an effective immune response to kill tumor cells that may remain after surgery. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them. It is not yet known whether giving vaccine ... - [Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer](/research/clinical-trials/cls-20366151) Rochester, MN This phase II trial studies how well pembrolizumab, chemotherapy, and radiation therapy work with or without surgery in treating patients with anaplastic thyroid cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as docetaxel and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving pembrolizumab, chemotherapy, and radiation therapy with or without surgery ... - [Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index](/research/clinical-trials/cls-20151035) Rochester, MN Utilizing CellSearch\u00ae technology, the ability to both enumerate and reliably and reproducibly characterize circulating tumor cells (CTC) for tumor markers that predict endocrine sensitivity (estrogen receptor [ER] and Bcl-2) and resistance (HER2 and Ki67) has been demonstrated. An algorithm for a CTC-Endocrine Therapy Index (CTC-ETI) has been constructed that can be calculated for each patient using the CTC enumeration and marker results. The primary goal of this study is to determine a CTC-ETI in ER positive, HER2 negative metastatic breast cancer patients before the initiation of a new endocrine therapy for the identification of patients that will progress rapidly. - [A Consortium Trial to Evaluate Proton vs. Photon Therapy for Patients with Non-metastatic Breast Cancer](/research/clinical-trials/cls-20507924) Jacksonville, FL The purpose of this study to assess the effectiveness of proton vs. photon therapy in reducing major cardiovascular events (MCE), defined as atherosclerotic coronary heart disease or other heart disease death, myocardial infarction, coronary revascularization, or hospitalization for major cardiovascular event (heart failure, valvular disease, arrhythmia, or unstable angina or other major cardiovascular event) in patients with locally-advanced breast cancer. - [A Study to Evaluate the Feasibility of Daily, Long-Term, Intermittent Fasting for Men on PSA Surveillance Following Radical Prostatectomy](/research/clinical-trials/cls-20472026) Rochester, MN The purpose of this study is to determine whether men treated for localized prostate cancer adhere to a long-term (months-years) daily intermittent fasting regimen, and to measure the levels of metabolic and prostate-cancer derived microparticles in the serum of men that practice a daily intermittent fasting regimen after treatment for localized, high-risk prostate cancer. - [Open Nipple Sparing Mastectomy (NSM)](/research/clinical-trials/cls-20525895) Rochester, MN The purpose of this retrospective study is to evaluate the complication rate of prophylactic open NSM procedures through 42 days follow-up from retrospective chart review at the same investigators and institutions as those included under IDE Study protocol G190065/A001. - [Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant](/research/clinical-trials/cls-20426331) Rochester, MN This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM). Subjects will receive treatment in 3 phases - induction (6 cycles), consolidation (6 cycles), and maintenance (12 cycles). Each cycle is 28 days. - [A Study of Accelerated 3 Fraction Photon,Proton or Brachytherapy for Early Invasive and Noninvasive Breast Ca](/research/clinical-trials/cls-20146627) Rochester, MN; Scottsdale/Phoenix, AZ; Jacksonville, FL This is an open label phase II study to determine the safety and efficacy of a novel 3 fraction daily dosing regimen for accelerated partial breast irradiation (APBI) for early invasive and noninvasive breast cancer. The three techniques utilized are recognized as standard options for the delivery of APBI, and there is no evidence that either technique is superior or inferior to any other. The APBI technique utilized will be at the physician's discretion and will be based on technical considerations, availability at the treating radiation facility, insurance coverage, as well as patient preference. - [A Study to Evaluate Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maintenance for Multiple Myeloma with Minimal Residual Disease (MRD) to Direct Therapy Duration](/research/clinical-trials/cls-20477934) Eau Claire, WI; Rochester, MN; Scottsdale/Phoenix, AZ The primary purpose of this study is to compare overall survival between two treatment arms, with lenalidomide as the comparator arm and lenalidomide + daratumumab/rHuPH20 as the experimental arm, in post-autologous transplant multiple myeloma (MM) patients. - [A Study to Compare Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients](/research/clinical-trials/cls-20468475) Rochester, MN The purpose of this study is to evaluate the effectiveness and safety of durvalumab versus placebo following Stereotactic Body Radiation Therapy (SBRT) in patients with unresected clinical Stage I/II lymph node-negative Non-small Cell Lung Cancer (NSCLC). - [A Study to Evaluate Chemoradiotherapy with or without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer](/research/clinical-trials/cls-20467385) La Crosse, WI; Eau Claire, WI; Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to determine how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. - [A Study to Evaluate the Safety and Effectiveness of Axicabtagene Ciloleucel in Combination with Rituximab in Participants B-Cell Lymphoma (ZUMA-14)](/research/clinical-trials/cls-20475819) Jacksonville, FL; Rochester, MN The primary objective of this study is to estimate the safety and effectiveness of axicabtagene ciloleucel in combination with rituximab, as measured by assessment of response rates in adult participants with relapsed/refractory large B-cell lymphoma. - [A Study Stereotactic Radiosurgery with or without Ipilimumab Grade II-III Meningioma](/research/clinical-trials/cls-20462052) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to evaluate the side effects and best dose of nivolumab when given together with multi-fraction stereotactic radiosurgery and to see how well they work with or without ipilimumab in treating participants with grade II-III meningioma that has come back. Monoclonal antibodies, such as nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. It is not yet known whether giving nivolumab and multi-fraction ... - [A Study to Evaluate Left and Right Ventricular Function in Relation to Exercise Capacity in Breast Cancer Survivors](/research/clinical-trials/cls-20482116) Jacksonville, FL The purpose of this study is to determine if exercise improves cardiac remodeling as a way to mitigate the negative effects of chemotherapy and radiation therapy which lead to reduced exercise tolerance. - [Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)](/research/clinical-trials/cls-20542908) Rochester, MN The purpose of this trilal is to study a combination of neoadjuvant radiotherapy (RT), immunotherapy (pembrolizumab) and chemotherapy for lymph node-positive, triple negative (TN) or hormone receptor positive/HER2-negative breast cancer. - [ Understanding the Relationship Between Benign Breast Tissue, Benign Breast Disease, and Breast Cancer Development](/research/clinical-trials/cls-20464385) Jacksonville, FL The purpose of this study is to culture human mammary cells to identify cellular characteristics associated with lobular (MK-3475-B15/ KEYNOTE-B15 / EV-304)](/research/clinical-trials/cls-20519541) Scottsdale/Phoenix, AZ The purpose of this study is to assess the antitumor effectiveness and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy [gemcitabine plus cisplatin] and RC + PLND) for participants with MIBC who are cisplatin-eligible. The dual primary hypotheses are preoperative EV + pembrolizumab and RC + PLND (Arm A) will achieve superior pathologic complete response (pCR) rate and perioperative EV and pembrolizumab and RC + PLND (Arm A) will achieve superior event free survival (EFS) compared with neoadjuvant gemcitabine + cisplatin and ... - [Cisplatin, Intensity-Modulated Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma](/research/clinical-trials/cls-20318552) Rochester, MN This phase I trial studies the side effects and best dose of pembrolizumab when given together with cisplatin and intensity-modulated radiation therapy, in treating patients with stage III-IV squamous cell carcinoma of the head and neck. Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Intensity-modulated radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving ... - [ROR1771: A Prospective Observational Study of Proton Stereotactic Body Radiation Therapy and Immunotherapy for Head and Neck Cancer](/research/clinical-trials/cls-20417922) Scottsdale/Phoenix, AZ; Rochester, MN This study observes the clinical efficacy of combining proton SBRT with PD-1 blockade immunotherapy in both the locoregionally recurrent and metastatic settings. - [A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy](/research/clinical-trials/cls-20366141) Scottsdale/Phoenix, AZ; Rochester, III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy. - [A Study to Develop and Validate Hybrid Molecular Imaging to Transform the Care of Hepatocellular Carcinoma Patients](/research/clinical-trials/cls-20480314) Rochester, MN The primary purpose of this study is to evaluate diagnostic performance of 68Ga-PSMA-dual contrast (gadavist and gadoxetate) PET/MRI OR PET/CT (either resection, transplant or biopsy specimens) or LI-RADS\u00ae categorization as gold standard. - [Imaging Response to Immunotherapy and Radiation Therapy in Patients With Liver Metastases](/research/clinical-trials/cls-20383790) Rochester, MN Patients will be imaged with MRE at the time of the RT planning MRI, prior to the induction of RT and immunotherapy. Research imaging will be in addition to standard imaging studies performed at time points consistent with the standard of care (at the time of the RT planning MRI and the first clinical follow-up). An additional MRE exam will be performed at the end of treatment outside the standard of care imaging. - [Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction](/research/clinical-trials/cls-20122958) Rochester, MN Each year, the number of breast cancer survivors who choose post-mastectomy breast reconstruction keeps rising. Among women who elect to pursue breast reconstruction, approximately 75% will choose prosthetic breast reconstruction. Implant-based breast reconstruction is frequently achieved in two-stages. The first stage consists of the placement of a tissue expander after mastectomy. This is followed by a period of weekly tissue expansions that can last several months. In the second stage, the tissue expander is removed in a surgical procedure and replaced with a permanent breast implant. Tissue expansion is a well-established breast reconstruction technique characterized by high success rates and ... - [Inherited Breast Cancer Study](/research/clinical-trials/cls-20308210) Rochester, MN; Scottsdale/Phoenix, AZ; Jacksonville, FL The purpose of this study is to improve the interpretation of mutations in breast cancer predisposition genes. This will be accomplished by recruiting members of families found to carry deleterious (mainly protein truncating) mutations and evaluating co-segregation of the mutations with cancer within families. - [Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer](/research/clinical-trials/cls-20491454) Rochester, MN; Jacksonville, FL This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206 works in treating patients with previously treated prostate cancer. Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as bicalutamide, may lessen the amount of androgens made by the body. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether bicalutamide is more effective with or without Akt inhibitor MK2206 in treating prostate cancer. - [A Study to Evaluate Yttrium-90 Therapy for Radiation Lobectomy](/research/clinical-trials/cls-20527576) Jacksonville, FL The Patient Group 1 primary objective is to measure the distribution of 90Y glass microspheres throughout the tumor and non-tumor hepatic same day postradioembolization PET/CT scan. Correlate this measurement with mean lobar absorbed radiation dose and embolic load given to patients and time taken to achieve adequate Future Liver Remnant (> 40% of total liver volume) to determine if there is an optimal lobar dose and embolic load. The Patient Group 2 primary objectives are to assess the association of circulating and imaging biomarkers on Future Liver Remnant hypertrophy, and to assess progression-free survival between ... - [Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate Cancer](/research/clinical-trials/cls-20492219) Rochester, MN This phase I trial studies the side effects and the best dose of stereotactic body radiation therapy in treating patients with breast cancer, non-small cell lung cancer, or prostate cancer that has spread to other parts of the body. Stereotactic body radiation therapy delivers fewer, tightly-focused, high doses of radiation therapy to all known sites of cancer in the body while minimizing radiation exposure of surrounding normal tissue. - [A Study to Evaluate Daratumumab in Treating Transplant-Eligible Participants with Multiple Myeloma](/research/clinical-trials/cls-20419679) Jacksonville, FL To determine the percentage of patients achieving MRD negativity by MPF after autologous stem cell transplant (SCT) (at Day 100) using pre-SCT daratumumab consolidation. - [A Study to Evaluate the Safety of the Goldilocks Procedure with Implant-Based Reconstruction](/research/clinical-trials/cls-20471970) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to assess outcomes, satisfaction and aesthetics of two different breast reconstruction techniques (Goldilocks alone, and Goldilocks with Implant-Based Reconstruction) and compare its safety, patient satisfaction, aesthetic evaluation and complications. - [FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy](/research/clinical-trials/cls-20347030) Rochester, MN This phase II trial studies alpha-fluoroestradiol (FES) positron emission tomography (PET)/computed tomography (CT) in predicting response to endocrine therapy in patients with newly diagnosed breast cancer that has spread to other parts of the body. FES is a radioactive form of the hormone estrogen and may \"light up\" where cancer is in the body. Diagnostic procedures using FES, such as FES PET/CT, may help measure the FES and help doctors predict how well the cancer will respond to treatment. - [The NeoGlioma Study](/research/clinical-trials/cls-20519962) Jacksonville, FL This study aims to evaluate the safety of preoperative radiosurgery in the treatment of patients with biopsy-proven high grade glioma prior to conventional therapy. Safety is defined as any acute grade 3 (CTCAE v5.0) or greater unplanned adverse event from the time of enrollment until 4 weeks following postoperative radiotherapy. - FL; Rochester, MN The purpose of this study is to determine whether there is an increase in the time of a first occurrence of either: local recurrence, leptomeningeal disease, or symptomatic radiation brain necrosis in patients with brain metastases who receive SRS prior to surgery as compared to patients who receive surgery prior to SRS. - [A Study to Evaluate the Role of Gut Microbiome in Cancer Therapy](/research/clinical-trials/cls-20469367) Scottsdale/Phoenix, AZ; Jacksonville, FL; Rochester, MN The purpose of this study is to correlate gut microbiome with specific cancer diagnoses and the clinical response (effectiveness), and adverse effects of cancer therapy (single or multiple) and stem cell transplant. - [A Study to Compare Single Fraction Stereotactic Radiosurgery Compared with Fractionated Stereotactic Radiosurgery FL; Rochester, MN; Scottsdale/Phoenix, AZ The purpose of this study is to compare how well single fraction stereotactic radiosurgery works versus fractionated stereotactic radiosurgery in treating patients with cancer that has spread to the brain from other parts of the body and has been removed by surgery. Single fraction stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Fractionated stereotactic radiosurgery delivers multiple, smaller doses of radiation therapy over time. - [A Study of Massage Therapy Alone and in Combination with Acupuncture for Breast Cancer Patients Undergoing Autologous Tissue Reconstruction](/research/clinical-trials/cls-20304854) Rochester, MN The purpose of this study is to explore the effectiveness of massage therapy combined with acupuncture in breast cancer patients recovering from autologous tissue reconstruction with the hope that the combination will augment the benefit obtained by massage therapy alone. - [Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients With Non-Metastatic Breast Radiotherapy Effectiveness (RADCOMP) Consortium Trial](/research/clinical-trials/cls-20492222) Scottsdale/Phoenix, AZ A pragmatic randomized clinical trial of patients with locally advanced breast cancer randomized to either proton or photon therapy and followed longitudinally for cardiovascular morbidity and mortality, health-related quality of life, and cancer control outcomes. Quality of life is the outcome measure for the estimated primary completion date of November, 2020. - [Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radiation Injury After Treatment for Brain Metastases](/research/clinical-trials/cls-20308052) Rochester, MN This randomized phase II study aims to investigate whether the addition of bevacizumab to standard corticosteroid therapy results in greater improvement in symptoms and less treatment-induced symptoms compared with standard corticosteroid therapy for patients with symptomatic brain radionecrosis following radiosurgery. It is hypothesized that the addition of bevacizumab to standard care corticosteroids will reduce treatment-induced toxicities and improve neurologic impairments in patients with brain radionecrosis following radiosurgery for brain metastases. - [A Study to Determine the Effects of a Mechanical Device to Treat Swelling of the Face and Neck Following Treatment for Cancer.](/research/clinical-trials/cls-20536106) Scottsdale/Phoenix, AZ This study aims to assess the utility of pharyngeal manometry measures as a novel approach in quantifying internal lymphedema and compare success rates in reducing internal lymphedema using manual lymphatic drainage (MLD) versus use of a pneumatic compression device (PCD). It also aims to assess efficacy of PCD and MLD and assess compliance of treatment in both groups. Lastly, it aims to identify voice and swallowing changes in both groups. - [Comparison of Acute Toxicities Between Patients Treated With Protons or Intensity Modulated Radiation Therapy After Surgery for the Treatment of Endometrial or Cervical Cancer](/research/clinical-trials/cls-20503346) Scottsdale/Phoenix, AZ; Rochester, MN; Jacksonville, FL The purpose of this study is to evaluate whether proton radiation therapy (proton RT) reduces acute gastrointestinal toxicities at the end of treatment compared to intensity modulated radiation therapy (IMRT). - [Proton or Photon RT for Retroperitoneal Sarcomas](/research/clinical-trials/cls-20272702) Rochester, MN This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational intervention. Phase I studies also try to define the appropriate dose of the investigational therapy to use for further studies. \"Investigational\" means that the intervention is still being studied and that research doctors are trying to find out more about it. Retroperitoneal sarcomas are soft tissue tumors located at the far back of the abdomen. Typically, patients with retroperitoneal sarcomas either have surgery for the removal of their tumors alone, or have their tumors removed, followed by standard radiation therapy, ... - [A Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Unilateral Head and Neck Cancer](/research/clinical-trials/cls-20403515) Rochester, MN Compared to IMRT, PBRT is thought to give less radiation exposure to the surrounding healthy tissues. It is possible that side effect rates with PBRT will be lower or the same compared to IMRT, but this has not been well studied to date. Although both of these radiation therapies have been used in the past to treat head and neck cancer, this research study will compare the effects of these two different radiation treatment modalities with each other to see whether PBRT is better, the same or worse than IMRT. - [Estrogen Receptor Expression in Breast Cancer - Assessed With Positron Emission Mammography](/research/clinical-trials/cls-20398663) Rochester, MN The primary objective of this study is to determine the correlation between the distribution of F-18 FES within ER+ breast tumors as seen on Positron Emission Mammography (PEM) images of the breast, and the distribution of cells stained ER+ within the tumor by immunohistochemistry (IHC) measurements at surgical pathology. The secondary aim is to determine if the correlation (or lack of) between F-18 FES uptake and F-18 FDG uptake as imaged by PEM, is an accurate representation of the heterogeneity of ER expression in the tumor. - [A Study Using Gallium-68 PSMA-11 and C-11 Choline PET Imaging to Detect Metastatic Prostate Cancer in Patients](/research/clinical-trials/cls-20449461) Rochester, MN The purpose of this study is to examine PSMA and C-11 Choline PET in patients with suspected metastatic prostate cancer who have been imaged with 11C-Choline PET clinically and with PSMA PET (either Gallium-68 labeled HBED-CC PSMA (more commonly called 68Ga-PSMA-11) or F-18 PSMA 1007) in order to demonstrate their utility in detecting prostate cancer. - [A Study to Evaluate Cancer Patients' Experience with Bevacizumab- induced, Wound-healing Complications](/research/clinical-trials/cls-20467393) Rochester, MN The purpose of this study is to characterize the experiences and psychosocial impact of bevacizumab-wound-healing toxicities in cancer patients. - [Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma](/research/clinical-trials/cls-20314851) Rochester, MN This randomized phase III trial studies ibrutinib to see how well it works compared to placebo when given before and after stem cell transplant in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement (relapsed) or does not respond to treatment (refractory). Before transplant, stem cells are taken from patients and stored. Patients then receive high doses of chemotherapy to kill cancer cells and make room for healthy cells. After treatment, the stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Ibrutinib is a ... - [A Study to Evaluate Cancer Distress, Psychological Trauma, and Resiliency in Hospitalized Hematopoietic Stem Cell Transplant Patients](/research/clinical-trials/cls-20485244) Jacksonville, FL The purpose of this study is to better understand the distress experience of hospitalized patients undergoing hematopoietic stem cell transplant (HSCT), and to examine the relationship between cancer distress, psychological trauma, and resiliency over time. - [A Study to Collect Adipose Harvest for Mesenchymal Stem Cell Derivation in Patients with Head & Neck Cancer](/research/clinical-trials/cls-20515866) Rochester, MN The purpose of this study is to collect adiopose tissue to derive mesenchymal stem cells. - [A Study to Evaluate Software On Cross-sectional Imaging Evaluation of Microwave-ablated Liver Tumors](/research/clinical-trials/cls-20463719) Rochester, MN The primary purpose of this study is to assess the accuracy of the Philips High Precision 3D Ablation Solution software on cross-sectional imaging evaluation of microwave-ablated liver tumors, and to determine whether software accuracy varies based on patient, tumor, and technical procedural factors. - [Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma](/research/clinical-trials/cls-20463653) Scottsdale/Phoenix, AZ; Rochester, MN This randomized phase II well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as temozolomide, may make tumor cells more sensitive to radiation therapy. It is not yet known whether dose-escalated photon IMRT ... - [A Registry for Children Treated with Proton Radiation Therapy](/research/clinical-trials/cls-20267941) Rochester, MN The purpose of the Pediatric Proton Consortium Registry (PPCR) is to enroll children who have been treated with proton radiation in the United States in order to describe the population that currently receives protons and better evaluate its benefits over other therapies. The data collected from this study will help facilitate research on proton beam radiation therapy and allow for collaborative research. The PPCR will collect demographic and clinical data which many centers that deliver proton radiation therapy already collect in routine operations. - [Patient Outcomes after Hepatic Artery Infusion Pump Placement](/research/clinical-trials/cls-20534943) Rochester, MN The purpose of this study is to evaluate the short-term outcomes and the quality of life (QOL) after cholecystectomy and hepatic artery infusion pump placement for unresectable colorectal liver metastases (CRLM). - [Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (ReSPECT)](/research/clinical-trials/cls-20535254) Rochester, MN The primary objective of the United States Food and Drug Administration (FDA) for this study is to demonstrate non-inferiority in subjects who received an allogeneic BMT for subjects randomized to Rezafungin for Injection compared to subjects randomized to the standard antimicrobial regimen (SAR) for fungal-free survival at Day 90 (\u00b17 days). The primary objective of the European Medicines Agency (EMA) for this study is to demonstrate superiority in subjects who received an allogeneic BMT randomized to Rezafungin for Injection compared to subjects randomized to the SAR for fungal-free survival at Day 90 (\u00b17 days). - [A Study to Compare Standard-Dose Combination Chemotherapy with High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Resistant Germ Cell Tumors](/research/clinical-trials/cls-20204585) Rochester, MN The purpose of this study is to compare standard-dose combination chemotherapy to high-dose combination chemotherapy and stem cell transplant in treating patients with germ cell tumors that have returned after a period of improvement or did not respond to treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin, carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving ... - [Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission](/research/clinical-trials/cls-20391198) Rochester, MN; Jacksonville, FL This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient's bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. ... - [A Study of Photon and Proton Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to observe adverse events and effectiveness of hypofractionated concurrent chemoradiotherapy for the treatment of pancreatic cancer. - [A Study to Compare Optimal MRI Timing for Pre-surgical Planning to LINAC-based Therapy](/research/clinical-trials/cls-20509428) Rochester, MN The purpose of this research is to compare two different standard-of-care pre-surgical imaging methods. - [A Study to Evaluate Early Detection of SARS-CoV-2/COVID-19 in High Risk Radiation Oncology Patients](/research/clinical-trials/cls-20493290) Rochester, MN The purpose of this study is to develop algorithms that will enable earlier identification and testing triggers for COVID-19 in otherwise asymptomatic patients, and to identify baseline characteristics from patients who ultimately test positive for COVID-19 that may predict clinical trajectory during the evolution of disease. - [68GaFAPI-46 PET/CT for Pancreatic Ductal Adenocarcinoma](/research/clinical-trials/cls-20536444) Rochester, MN The purpose of this study is to examine the utility of 68GaFAPI-46 PET/CT imaging in adult patients with biopsy-proven Pancreatic Ductal Adenocarcinoma (PDA) who have no prior treatment for their PDA and who are expected to undergo surgical resection following NAT. - [A Study Comparing Proton and Photon Radiation Outcomes in Prostate Cancer Patients](/research/clinical-trials/cls-20452035) Eau Claire, WI; La Crosse, WI; Mankato, MN; Rochester, MN; Jacksonville, FL The purpose of this study is to determine if prostate cancer patients treated with proton therapy as compared to IMRT experience improved QOL (validated EPIC instrument measuring bowel, urinary, and sexual QOL). - [A Study to Compare Proton Therapy to Photon Radiation Therapy for Esophageal Cancer](/research/clinical-trials/cls-20461423) WI; Mankato, MN; Scottsdale/Phoenix, AZ; Rochester, MN The purpose of this study is to evaluate how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather than x-rays) to send radiation inside the body to the tumor without damaging much of the healthy tissue around it. Intensity modulated photon radiotherapy uses high-energy x-rays to deliver radiation directly to the tumor without damaging much of the healthy tissue around it. It is not yet known whether proton beam therapy or intensity modulated photon radiotherapy will work better in ... - [A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer](/research/clinical-trials/cls-20472608) Rochester, MN The purpose of this study is to assess late > grade 3 GI and/or GU toxicity of interest with the hypofractionated regimen with proton beam therapy or IMRT (late defined as 3 to 24 months after protocol RT). - [Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma](/research/clinical-trials/cls-20366154) Rochester, MN The purpose of this research study is to evaluate a treatment regimen called IRD which will be given to participants after their stem cell transplant in an effort to help prolong the amount of time the participants are disease-free after transplant. IRD is a three-drug regimen consisting of ixazomib, lenalidomide (also called Revlimid), and dexamethasone. After 4 cycles of IRD, the participants will be randomized to receive maintenance therapy either with ixazomib or lenalidomide. 09/23/2019: Upon review of the interim analysis that suggested inferior progression-free survival in the ixazomib maintenance arm, there will be no further randomizations into the ... - [A Study to Determine the Effects of COVID-19 in Cancer Patients](/research/clinical-trials/cls-20504261) Scottsdale/Phoenix, AZ; Mankato, MN; La Crosse, WI; Eau Claire, WI; Rochester, MN The study aims to characterize patient factors, such as pre-existing comorbidities, cancer type and treatment, and demographic factors, associated with short- and long-term outcomes of COVID-19, including severity and fatality, in cancer patients undergoing treatment. The study also is aimed to describe cancer treatment modifications made in response to COVID-19, including dose adjustments, changes in symptom management, or temporary or permanent cessation. Lastely, evaluate the association of COVID-19 with cancer outcomes in patient subgroups defined by clinico-pathologic characteristics. - [A Study to Evaluate Same Day Discharge Post-mastectomy with/without Alloplastic Breast Reconstruction](/research/clinical-trials/cls-20510373) Rochester, MN In the light of the pandemic, institutions have had to take greater precautions and instigate procedures to aim to improve safety and reduce risk for patients undergoing surgery. One intiative was designed to implement a same day discharge for patients undergoing mastectomy with or without alloplastic reconstruction. This study aims to evaluate the outcomes and patient satisfaction with same day mastectomy with or without alloplastic reconstruction following COVID-19 and compare satisfaction and outcomes (e.g complications) with patients pre-COVID 19. This is part of a quality improvement project. - [A Study to Evaluate Treating Post-Mastectomy Radiation Injury in Breast Cancer Patients with Adipose-Induced Regeneration of Breast Skin (AIR Breast)](/research/clinical-trials/cls-20462464) Jacksonville, FL The primary purpose of this study is to identify the therapeutic effect of Adipose-Induced Regeneration (AIR) in radiation-induced skin injury of post-mastectomy breast cancer patients. "}